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Summary 
In this thesis, we aimed to identify genetic factors that influence the risk of colorectal 
cancer (CRC). We also sought alleles that contribute to the likelihood of extreme 
adverse reactions to treatment. 
We validated five previously identified low penetrance variants using our training 
phase cohort, consisting of 2,186 advanced CRC (aCRC) from the COIN and COIN-
B trials and 2,176 geographically matched controls. Using this cohort we also 
identified a variant in RAD1 that was significantly associated with risk (X2=13.51, 
P=2x10-4). However, we failed to replicate these findings in an aCRC validation 
cohort consisting of 1,053 cases and 1,397 geographically matched controls 
(X2=2.76, P=0.1), potentially as a result of a lack of power due to insufficient sample 
numbers. 
We identified ten patients from the COIN trial with severe peripheral neuropathy 
associated with oxaliplatin (PNAO) treatment. Through exome resequencing we 
identified a novel stop gain variant (Ser613X) in the nucleotide excision repair gene 
(NER), ERCC4. Following analysis of 54 additional patients from the COIN trial with 
PNAO, we identified three rare nonsynonymous variants (Pro379Ser, Arg576Thr and 
Glu875Gly) that were predicted to interfere with protein function. Consistent with the 
rare variant hypothesis of common disease, two of these variants were seen to 
collectively contribute to the risk of the phenotype (7/63 [11.11%] of patients with 
PNAO compared to 86/1763 [4.88%] of patients without PNAO; X2=4.89, P=0.03).  
Using the fission yeast, Schizosaccharomyces pombe, we sought to elucidate 
functional effects of these variants in ERCC4 by creating a model system. Using cre 
recombinase mediated cassette exchange, we introduced the variants of interest into 
the ERCC4 homolog, rad16. Following treatment with a range of DNA damaging 
agents, we observed an increased sensitivity following introduction of the novel stop 
gain, indicating a defect in the NER pathway. Additionally, there was a clear pattern 
of oxaliplatin-specific sensitivity of strains with the introduced rare nonsynonymous 
variants, suggesting a defect of XPF in other repair processes associated with 
interstrand crosslinks. 
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Chapter One - Introduction 
1.1 Colorectal cancer  
 Colorectal cancer (CRC) is the fourth most common cancer in the UK, with 
over 40,000 cases diagnosed each year. The overall lifetime risk of developing CRC 
is around 5%, with 85% of diagnosed cases seen in people over the age of 60 
(Ballinger and Anggiansah, 2007). Despite advances in treatment and early 
screening methods dramatically reducing mortality rates by up to 50% in the last 40 
years, approximately 16,000 people still die in the UK each year from the disease 
(Cancer Research UK, Bowel cancer statistics, 2010). 
 The rate of development of colorectal adenomas (CRA) and CRC is 
determined by an individual’s exposure to a combination of environmental and 
genetic factors, although their influence on disease initiation and progression are not 
exclusive from one another (Kim and Milner, 2007). Current understanding 
surrounding environmental factors lists a diet high in heterocyclic amines from 
cooked red and processed meat (Martinez et al. 2007; Larsson and Wolk, 2006), 
obesity (Ning et al. 2010), sedentary lifestyle (Wolin et al. 2009), smoking (Liang et 
al. 2009) and alcohol intake (Giovannucci, 2004) as some of the risk factors. Many of 
these are considered to be part of an affluent Westernised lifestyle, the influence of 
which is mirrored in increased incidences in developing countries adopting said 
lifestyles (Curado et al. 2007). Inflammatory bowel diseases, including ulcerative 
colitis and Crohn’s disease, have been highlighted as risk factors, with a third of 
deaths related to ulcerative colitis due to the development of CRC (Itzkowitz and 
Hapraz, 2004). 
1.2 Inherited colorectal cancer  
The strong heritable component associated with CRC is highlighted by the 
identification of multiple genetic syndromes. Advances in genetics have led to a 
better understanding of the underlying molecular dysregulation associated with the 
phenotypes shown in such conditions, leading to improvements in treatment and 
increased surveillance for both patients and their family members (Lynch et al. 
2007). 
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 CRC is typically divided into two sub groups; sporadic and familial (Fig. 1.1). 
The vast majority of CRC cases are believed to be sporadic, with existing genetic 
understanding accounting for around 12%. However, the uncharacterised familial 
risk of CRC is illustrated by twin and sibling studies, which suggest that genetics 
could account for up to 35% of cases (Lichtenstein et al. 2000). The importance of 
familial contribution to disease burden is further illustrated by the fact that having a 
first degree relative with the disease increases relative risk two fold. The estimated 
risk rises further when multiple family members are affected (odds ratio [OR] =4.25) 
and when an early age of diagnosis is implicated (OR=3.87; Johns and Houlston, 
2001).  
 The so-called ‘L-shape’ distribution of allelic effects highlights the influence 
that certain variants have on complex traits such as CRC (Bost et al. 2001). The 
situation arises when a small number of variants with a relatively low minor allele 
frequency (MAF) have a dramatic effect on risk, whilst, on the contrary, a large 
number of variants with relatively large MAFs have a modest contribution. Hereditary 
CRC disorders, such as familial adenomatous polyposis (FAP) and hereditary non-
polyposis colorectal cancer (HNPCC), are known to be caused by high penetrance 
alleles. However, with the emergence of genome wide association studies (GWAS), 
multiple common low penetrance loci across the genome have been shown to be 
significantly associated with disease risk, albeit with a small effect size. 
1.2.1 High penetrance alleles 
 High penetrance is assigned to an allele if the presence of at least one of 
these alleles greatly increases the likelihood of a particular phenotype. These traits 
tend to be highly heritable and therefore easier to track and determine. In CRC, 
approximately 6% of all cases are attributable to these types of mutations 
(Jasperson et al. 2010; Patel and Ahnen, 2012; Table 1.1; Fig. 1.1). 
A large proportion of the high penetrance, hereditary CRC syndromes are a 
result of inactivating mutations in tumour suppressor genes. Most loss of function 
mutations of tumour suppressor genes are recessive, although dominant in nature, 
and require loss of the second allele in order for a cell to become cancerous. In  
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Disease 
Contribution to CRC 
incidence 
Gene Pathway 
Familial adenomatous 
polyposis (FAP) and 
attenuated FAP 
(AFAP) 
<1% APC Wnt signalling 
MUTYH-associated 
polyposis (MAP) 
<1% MUTYH BER 
Hereditary non-
polyposis colorectal 
cancer (HNPCC) 
2-6% 
MSH2; MLH1; 
MSH6; PMS1; 
PMS2; MLH3; 
EPCAM 
MMR 
 
Polymerase proof-
reading associated 
polyposis 
<1% POLD1/POLE 
Various DNA repair 
pathways 
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Peutz-Jeghers 
syndrome (PJS) 
<1% 
STKB11 mTOR 
Juvenilla polyposis 
syndrome (JPS) 
SMAD4 and 
BMPR1A 
TGFβ 
Cowden syndrome  PTEN P13K/Akt/mTOR 
Hereditary mixed 
polyposis syndrome 
(HMPS) 
GREM1 TGFβ 
 
Table 1.1 – High penetrance hereditary CRC syndromes and their associated genes and 
pathway (BER = Base excision repair; MMR = Mismatch repair; TGF-β = Transforming growth factor-
β; mTOR = Mammalian target of rapamycin). Polymerase proof reading associated polyposis is 
discussed in more detail in section 1.7.2.2. 
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Figure 1.1 - Percentage contribution of known hereditary CRC syndromes to the overall incidences of CRC. A large proportion of cases (~75%) are 
believed to be sporadic in nature. 
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accordance with Knudson’s two-hit hypothesis of tumour suppressor genes, an initial 
inherited mutation increases the likelihood of disease as a result of a greater 
probability of loss of the second allele in somatic cells (Knudson, 1971). In sporadic 
diseases, a somatic mutation on both alleles must occur (Fig. 1.2). 
  1.2.1.1 FAP  
Accounting for less than 1% of CRC incidence, FAP (OMIM #175100) is an 
autosomal dominant disease characterised by the formation of hundreds to 
thousands of variably sized CRAs. It affects 1 in 5,000-10,000 of the population 
(Nagy et al. 2004). Left untreated, it carries an almost 100% risk of CRC usually 
presenting by the fourth decade of life, with the most common form of treatment 
being a full colectomy (Thomson, 1990; Galiatsatos and Foulkes, 2006; Half et al. 
2009). FAP is also associated with allele dependant extra-colonic features, including 
congenital hypertrophy of the retinal pigment epithelium, dental abnormalities, 
epidermoid cysts and osteoma’s. Additionally, there is an increased risk of thyroid 
and other endocrine, desmoid, duodeum, brain, liver and pancreatic cancers (Groen 
et al. 2008).  
Attenuated familial adenomatous polyposis (AFAP) is a less aggressive form 
of the disease. It is characterised by the formation of tens to hundreds of CRAs, 69% 
risk of advancement to CRC, a later age of onset of CRC, and a lower burden of 
extra-colonic features (van der Luijt et al. 1995; Knudsen et al. 2003; Burt et 
al.2004).  
Both FAP and AFAP are caused by germline mutations in the adenomatous 
polyposis coli (APC) gene. Located on chromosome 5q21-22 (Bodmer et al. 1987), it 
consists of 21 alternatively spliced exons and encodes a 312kDa functional protein 
(Fearnhead et al. 2001). FAP and AFAP can be caused by more than 300 different 
mutations in APC. Although these vary in type, over 90% result in a truncated form of 
the protein (Miyoshi et al. 1992a; Half et al. 2009). A large proportion of these 
mutations are seen in exon 15, the largest exon that contributes over 75% of the 
coding sequence (Beroud and Soussi, 1996). APC mutations of these kinds carry an 
almost 100% penetrance in carriers. In contrast, a nonsynonymous variant, 
Ile1307Lys, which is relatively common in the Ashkenazi Jewish population (6%), is 
thought to carry only a 20% penetrance (Lynch and de la Chappelle, 2003). This 
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Figure 1.2 – Knudson’s two hit hypothesis for loss of tumour suppressor function in 
tumourigenesis. A) In inherited disease, a mutation of one allele is inherited in every cell, whilst the 
second allele mutation is acquired in one cell. B) In sporadic disease, two normal alleles are inherited 
in every cell. One allele is inactivated by sporadic mutation, followed by a second sporadic mutation of 
the other allele, leading to inactivation of the gene. Loss of tumour suppressor function leads to 
cellular growth advantage and tumour progression (Knudson, 1985) 
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variant has been shown to create a hypermutable tract in APC that predisposes to 
somatic mutations (Laken et al. 1997). Genetic analysis of families exhibiting AFAP 
revealed that they had mutations resulting in a truncated form of APC similar to that 
seen in classical FAP. However, the majority of these mutations were located in the 
extreme 5’ and 3’ regions of the gene (before codon158 or after codon 1595) – 
something which is not common in the classical form of the disease (Spirio et al. 
1993; Soravia et al. 1998). 
The exact nature of the somatic ‘second hit’ has been shown to be highly 
dependent upon the ‘first hit’ of germline APC allele mutations seen in FAP patients 
(Lamlum et al. 1999), suggesting that there is an ‘interdependence’ of APC 
mutations that results in a cellular growth advantage (Cheadle et al. 2002). Sixty 
percent of somatic APC mutations occur in the ‘mutation cluster region’ which 
resides between amino acid 1281 and 1556 of exon 15 (Miyoshi et al. 1992b; 
Cheadle et al. 2002).  
APC is a critical component of the Wnt signalling pathway, important for the 
intracellular control of cell growth and survival. Ultimately it is critical in the 
maintenance of the correct architecture of the colon via its regulation of key target 
genes (Bienz and Clevers, 2000). Following activation of the frizzled receptor by the 
Wnt ligand, inhibition of degradation of constitutively active β-catenin occurs as a 
result of phosphorylation and translocation of proteins key for its normal degradation 
(Klaus and Birchmeier, 2008). This allows for translocation of β-catenin to the 
nucleus and transcriptional activity of Wnt target genes to occur. In the absence of 
ligand, β-catenin degradation is controlled by phosphorylation of the protein by the 
so-called multi-protein ‘destruction complex’ of which APC plays a pivotal role 
(Huelsken and Behrens, 2002; Schneikert and Behrens, 2007). In situations where 
the destruction complex integrity is compromised, regardless of Wnt ligand binding, 
β-catenin is not degraded leading to excessive target gene activation (Morin et al. 
1997; Korinek et al. 1997; Mann et al. 1999).  
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  1.2.1.2 MUTYH-associated polyposis  
MUTYH-associated polyposis (MAP; OMIM #604933) is an autosomal 
recessive disease, characterised by CRA growth similar to that seen in mild FAP or 
AFAP (Sieber et al. 2003). The development of hundreds of adenomas throughout 
the colon puts sufferers at a greater risk of carcinoma (Sampson et al. 2003). MAP 
was first identified through somatic analysis of the APC gene in patients exhibiting 
multiple CRA without a germline APC mutation. It revealed an excessive proportion 
of G:C→T:A transversions, resulting in an elevated number of truncation mutations 
in tumours. Transversion mutations of this kind are commonly due to tautomeric 
changes that occur as a result of oxidative damage to guanine, which leads to the 
production of the highly mutagenic 8-oxo-7,8-dihydro-2’-deoxyguanosine (8-oxo-G); 
a stereometric alteration that readily misbinds with adenine. Guanine is at particular 
risk of oxidative damage due to its low redox potential (Neeley and Essigmann, 
2006). During the repair of oxidative damage by base excision repair (BER; 
discussed in section 1.3.2), it is typically the role of the DNA glycosylases, OGG1 
and MUTYH, to remove 8-oxo-G and the mispaired adenine, respectively. Germline 
screening of patients revealed biallelic mutations in MUTYH, in particular the function 
impairing nonsynonymous variants Tyr179Cys and Gly396Asp (Al-Tassan et al. 
2002; Jones et al. 2002).  
MUTYH is located on chromosome 1p34.1, consists of 16 exons and encodes 
a protein 535 amino acids in length. Tyr179Cys and Gly396Asp account for 
approximately 73% of all mutations seen in MAP (Cheadle and Sampson, 2007). 
Biallelic inactivation of MUTYH is the hallmark of MAP, increasing CRC risk by 93-
fold, with conflicting reports stating a modest, if any, increased risk observed in 
monoallelic carriers (Farrington et al. 2005; Balaguer et al. 2008).  
  1.2.1.3 HNPCC 
 HNPCC (OMIM #120435) is an autosomal dominant disease characterised 
by the formation of many different cancers. One of the most common sites of 
carcinoma is the colon, with an average age of cancer onset of 44 years (Lynch and 
de la Chapelle, 1999). Tumours occur more commonly in the proximal colon, can 
grow synchronously or metachronously and transform up to 7 years more rapidly 
than sporadic cancers (Jang and Chung, 2010). It carries an 80% risk of CRC in the 
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patient’s lifetime. Regular surveillance after partial colectomy is required since 
approximately 16% of patients that undergo the procedure will develop a secondary 
tumour within a ten year period (Nagengast et al. 2002). As the most common form 
of hereditary CRC, it accounts for approximately 2-6% of all CRC cases (Lynch et al. 
2006).  
Diagnosis of HNPCC in families can be subdivided into two catergories using 
the Amsterdam criteria (AC; Vasen et al. 1999); AC1, in which hereditary CRC is 
predominant and ACII, where multiple other cancer types are observed. These 
include endometrial, small bowel, renal pelvis and ureter cancers. A clinically distinct 
form of ACII, Muir Toirre syndrome, is characterised by an elevated risk of 
sebaceous skin cancers (Hall et al.1994). Additionally, Turcot syndrome is a variant 
associated with an increased risk of brain tumours, notably medullablastomas 
(Hamilton et al. 1995). 
Inherited defects in key genes in the mismatch repair (MMR; Section 1.3.1) 
pathway have been shown to be fundamentally responsible for HNPCC. Up to 90% 
of patients diagnosed have MSH2 or MLH1 inactivating mutations (Peltomäki, 2005). 
Also implicated in disease etiology are mutations in MSH6, PMS1, PMS2 and 
potentially MLH3, albeit at a lower frequency (Wu et al. 2001; Jasperson et al. 2010). 
Although the protein product is not involved in the MMR process, mutations in 
epithelial cell adhesion molecule (EPCAM) are thought to influence expression of 
MSH2 and have been proposed to have a role in less than 1% of cases (Ligtenberg 
et al. 2008; Kovacs et al. 2009).  
  1.2.1.4 Harmartomatous polyposis syndromes 
Harmartomatous polyps are benign malformations of the gastrointestinal tract 
(Calva and Howe, 2008). Although the cellular composition of the polyps is normal, 
the architecture is disordered and chaotic which results in the presence of a variety 
of different tissues. Although benign, these abnormalities increase the chance of 
malignancy in sufferers (Gammon et al. 2009). 
The harmartomatous polyposes are a heterogeneous group of inherited 
autosomal dominant conditions that are characterised by an abundance of 
harmartomatous polyps along the gastrointestinal tract and a marked increased risk 
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of CRC. Accounting for less than 1% of overall CRC cases, they are collectively rare 
(Zbuk and Eng, 2007). 
 1.2.1.4.1 Peutz Jegher syndrome 
Peutz Jegher syndrome (PJS; OMIM #175200) is an autosomal dominant 
disease that predisposes to hamartomatous polyps along the gastrointestinal tract. 
Approximately 30% of PJS sufferers will develop polyps in the colon, with an 
estimated relative risk of 84 for progression to carcinoma (Giardiello et al. 2000). 
Genetic studies have implicated the role of serine/threonine kinase 11 (STK11/LKB1) 
at chromosomal location 19q13.3 in the development of the disease. Germline 
mutations of the gene were identified in approximately 50-90% of patients with PJS. 
Approximately 70% are truncating or nonsynonymous variants, with the other 
proportion being attributed to large deletions (Aretz et al. 2005).  
There is dysregulation of the mammalian target of rapamycin (mTOR) 
pathway in PJS sufferers. Normally, STK11 phosphorylates AMP activated protein 
kinase (AMPK) in response to low energy levels. This protein is key in the activation 
of tuberin, which in turn inhibits mTOR, controlling cellular growth by reducing S6K 
and 4EBP1 phosphorylation (Corradetti et al. 2004). Additionally STK11 may play a 
role in p53 mediated cell cycle arrest, with low energy levels directly stalling cell 
cycle progression. The disordered architecture of the harmartomatous polyps seen in 
PJS supports this; patients with malfunctioning STK11 cannot reduce normal cell 
growth in reduced energy situations (Shaw, 2006). 
1.2.1.4.2 Juvenile polyposis syndrome 
Despite appearing outwardly similar to other harmartomatous polyps, juvenile 
polyposis syndrome (JPS; OMIM #174900) polyps are histologically very different, 
microscopically appearing as mucous filled glands. Almost all polyps occur in the 
colon or the rectum, with a 20% likelihood that these will progress to malignancy 
(Handra-Luca et al. 2005). 
Two genes from the transforming growth factor (TGFβ) pathway have been 
implicated in JPS; mothers against decapentaplegic, group 4 (SMAD4) at 18q21.1 
(Howe et al, 1998; Houlston et al, 1998) and bone morphogenetic protein receptor, 
type 1A (BMPR1A) at 10q22.3 (Howe et al. 2001). Both account for approximately 
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20% of cases each (Howe et al. 2004). The TGFβ pathway is important in the control 
of the cell cycle. Additionally mutations in endoglin (ENG) in the same pathway have 
been implicated in development of JPS in early childhood (Sweet et al. 2005), 
although its contribution towards disease aetiology is of debate (Howe et al. 2007). 
1.2.1.4.3 Cowden syndrome 
Cowden syndrome (OMIM #158350) is a rare autosomal dominant disease 
characterised by the formation of multiple harmartomatous polyps along the 
gastrointestinal tract, with colonic polyps present in up to 90% of cases. 
Cowden syndrome is caused by loss of function mutations in the tumour 
suppressor gene phosphatase and tensin homolog (PTEN) in up to 80% of cases. 
PTEN is a phosphatase protein involved in the regulation of many key signalling 
pathways through dephosphorylation of phosphatidylinositol-3,4,5-trisphosphate 
(PIP3; Blumenthal and Dennis, 2008). 
1.2.1.4.4 Hereditary mixed polyposis syndrome 
Hereditary mixed polyposis syndrome (HMPS, OMIM #601228) is associated 
with a predisposition to harmartomatous juvenile polyps. There is an elevated 
likelihood of CRA and CRC without any extra-colonic symptoms, something which is 
typically evident in other polyposis syndromes. In the molecular genetics of the 
disease, identification of a shared haplotype and a possible predisposition locus, so 
called colorectal adenoma and carcinoma (CRAC1) on chromosome 15, followed 
linkage analysis of two Jewish families (Tomlinson et al. 1999; Jaeger et al. 2003). 
Following fine mapping of the region in two families, three genes were identified; 
gremlin (GREM1), secretogranin (SGNE1) and formin (FMN1). Analysis of the region 
using a custom array identified a heterozygous, 40kb single copy duplication in all 
affected individuals. The duplication involves a region spanning the latter part of 
SGNE1 to just upstream of GREM1. Ectopic overexpression of GREM1 in colorectal 
crypt cells was observed, with significantly elevated expression of the duplicated 
allele (Jaeger et al. 2012). 
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1.2.2 Low penetrance allele 
 Since the majority of inherited CRC cases occur without any known 
underlying genetic reason, it was proposed that the remaining heritable component 
could be accounted for by common or rare, low penetrance variants (Fearnhead et 
al. 2005). Low penetrance is attributed to an allele if the effect on phenotype is small, 
although their contribution to disease burden could be substantial on account of their 
relative frequency in the general population.  
  1.2.2.1 ‘Common disease, common variant’ model 
 The ‘common disease, common variant’ model is one that helps to explain the 
variation that arises in many complex diseases such as CRC. In this model, the 
individual variant risk is relatively small; the OR seen are typically between 1.2 and 
1.5 (Bodmer and Bonilla, 2008). However, due to the fact that such alleles are 
usually relatively common in the population and can more than likely interact with 
one another in a polygenic manner, they have significant impact on disease 
likelihood.  
  1.2.2.1.1 GWAS 
The completion of the HapMap project meant that knowledge of linkage 
disequilibrium (LD) that captures variation across the genome has been made 
readily available (International HapMap Consortium, 2003). In addition to this, the 
production of large scale genotyping platforms means that a large number of variants 
can be screened in thousands of samples at an affordable cost, with quick 
turnaround. Ultimately, these large scale, hypothesis free, multi stage case control 
studies have directly identified 12 CRC susceptibility alleles to date.  
 GWAS are limited in their ability to detect novel variants by several 
constraints. Of most importance is the difficulty in acquiring the vast amount of 
samples needed to supply enough power to detect these modest effect sized 
variants. Pooling of data from multiple cohorts allows for increases in study power 
and such meta-analysis have identified 8 additional variants, bringing the total 
number of CRC susceptibility alleles to 20 in cohorts of European ancestry (Table 
1.2). Although all have modest contributions to overall risk, with OR ranging from 
1.07 to1.28 (Kilpivaara and Aaltonen, 2013), collectively they could account for up to 
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7% of the familial risk of CRC (Dunlop et al. 2012b). Additional problems of GWAS 
include the need to avoid population stratification by ruling out multiple ethnic 
groups, as well as the need for validation due to the high rate of false positive 
associations seen in such studies.  
1.2.2.2 ‘Common disease, rare variant’ model 
 Rare variants have been shown to play roles in the phenotype of complex 
diseases (Pritchard, 2001). Detection of rare variants is more commonly carried out 
through candidate searches of genes implicated in disease etiology. Research has 
indicated a role of rare variants in the Wnt signalling genes CTNNB1 and AXIN1, and 
the MMR genes MLH1 and MSH2 in the collective contribution to a modestly 
increased risk of CRA development (Fearnhead et al. 2004). Additionally, Azzopardi 
et al (2008) have shown that multiple rare but collectively common variants in APC 
contribute towards the development of CRA. Despite previous conflicting reports for 
the role of the nonsynonymous variant Glu1317Gln in APC in the predisposition to 
CRA, tumourigenesis and CRC (Frayling et al. 1998; Lamlum et al. 2000; Popat et 
al. 2000; Gismondi et al. 2002 Hahnloser et al. 2003;) researchers detected a role in 
CRA predisposition in patients characterised as ‘non-FAP, non-MAP’. Additionally 
they reported that, following exclusion of this variant as well as another low 
penetrance variant, Ile1307Lys in APC, significantly more of these patients carried 
various other rare nonsynonymous APC variants, suggesting a low penetrance effect 
of these rare alleles (Azzopardi et al, 2008). 
1.3 DNA repair and cancer 
 The ability of cells to repair DNA damage is crucial for the integrity and 
maintenance of genetic material in all organisms, and ultimately in survival. An 
individual cell is subjected to a plethora of DNA damaging events; up to a million 
events occur in a single cell each day (Lodish et al.2000). DNA damage has the 
ability to modify the coding sequence of DNA which, if not repaired, can lead to the 
development of cancer by mutational activation of proto-oncogenes and inactivation 
of tumour suppressor genes (Hoeijmakers, 2001).  
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Variant  Loci Gene Role/Pathway Reference 
rs6983267 8q24.21 MYC Wnt signalling  
(Tomlinson et al. 2007; 
Zanke et al. 2007) 
rs16969681/ 
rs11632715† 
15q13.3 GREM1 TGF-β signalling 
(Jaeger et al. 2008; 
Tomlinson et al. 2011) 
rs4939827 18q21 SMAD7 TGF-β signalling 
(Broderick et al. 2007; 
Tenesa et al. 2008) 
rs3802842 11q23   (Tenesa et al. 2008) 
rs16892766 8q23.3 EIF3H  
(Tomlinson et al. 
2008) 
rs10795668 10p14   
(Tomlinson et al. 
2008) 
rs4444235 14q22.2 BMP4 TGF-β signalling (Houlston et al. 2008) 
rs9929218 16q22.1 CDH1 Cell-cell adhesion (Houlston et al. 2008) 
rs10411210 19q13.1 RHPN2 TGF-β signalling (Houlston et al. 2008) 
rs961253 20p12.3 BMP2 TGF-β signalling  (Houlston et al. 2008) 
rs6691170/ 
rs6687758† 
1q41 DUSP10 MAPK signalling  (Houlston et al. 2010) 
rs10936599 3q26.2 MYNN  (Houlston et al. 2010) 
rs11169552/ 
rs7136702† 
12q13 LARP4  (Houlston et al. 2010) 
rs4925386 20q13.33 LAMA5 
Cell migration and 
localisation 
(Houlston et al. 2010) 
rs1321311 6p21 CDKN1A 
Cell cycle and 
apotosis 
(Dunlop et al. 2012a) 
rs3824999 11q13.3 POLD3 DNA repair  (Dunlop et al. 2012a) 
rs5934683 Xp22.2 SHROOM2  (Dunlop et al,.2012a) 
 
Table 1.2 – The 20 variants identified through GWAS at 17 genomic loci associated with CRC 
risk in Caucasian populations, with the respective genes and pathways (if applicable). †Two variants 
associated at locus.  
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 There are currently 168 known proteins that are involved in the various 
pathways of DNA repair (Wood, 2005). Each pathway consists of multiple steps, with 
specialised proteins involved in the diverse roles required for repair of the different 
forms of damage that can occur (Lindahl, 1993), although there is considerable 
overlap between proteins from different pathways. Mutations in DNA repair genes 
have been shown to have a role in various hereditary cancer predisposing 
syndromes, with multiple pathways shown to have a role in hereditary forms of CRC 
(Loeb, 2003; Milanowska et al. 2011; Negrini et al. 2010; Table 1.3). 
1.3.1 MMR pathway 
Microsatellites (also known as tandem simple sequence repeats) are short, 
repeating sequences that are between 1-6 nucleotides in length and found 
throughout the genome, though are more common in non-coding regions (Beckman 
and Weber, 1992). They are polymorphic in nature, variable in length between 
individuals, although are homogenous in all cells in an individual (Boland and Goel, 
2010). Microsatellite instability (MSI) is the result of increased variability in the length 
and frequency of microsatellite repeats throughout the genome commonly due to 
replication slippage as a result of inefficient binding of DNA polymerases during 
synthesis (Eisen, 1999; Kunkel, 2004). This results in the formation of insertion-
deletion loops (IDL) or base-base mismatches (Schlötterer and Harr, 2001), which 
broadly deems to have coding effects that can alter expression and/or function of a 
gene (Nelson and Warren, 1993). It is predominantly the role of the post-replicative 
MMR pathway to recognise and repair such damage. 
Recognition of damage occurs by two heterodimeric complexes consisting of 
MSH2-MSH6 (hMutSα) or MSH2-MSH3 (hMutSβ), with the former being primarily 
responsible for recognition of mismatches and single base IDL, and the latter for 
recognition of all IDLs (Li, 2008). A second heterodimeric complex (hMutL) has the 
ability to bind to the hMutS complexes in order to recognise damage as well as 
recruit additional machinery to the area of damage; either MLH1 and PMS2  
(hMutLα), MLH1 and PMS1 (hMutLβ) or MLH1 and MLH3 (hMutLγ; Jascur and 
Boland, 2006). MLH1 carries out incision of the damaged strand. Following 
recognition of damage, proliferating cell nuclear antigen (PCNA) is loaded onto the 
DNA by replication factor C (RFC). PCNA is responsible for recruiting exonuclease  
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Gene Pathway Disease (Cancer) 
ALKBH3 Direct reversal of damage Hereditary prostate cancer 
ATM HR 
Ataxia-telangiectasia (Lymphomas; 
leukaemia; breast cancer) 
BLM HR 
Bloom syndrome (Multiple; earlier age of 
onset) 
BRCA1, BRCA2, CHEK2 and 
RAD51 
HR 
Hereditary breast cancer; hereditary 
ovarian cancer; hereditary prostate cancer 
FANCA, -B, -C, -D1 (BRCA2), 
-D2, -E, -F, -G, -I, -J, -L, -M, -
N, -P and -Q 
ICL repair and HR Fanconi anaemia (Multiple) 
LIG4 NHEJ LIG4 syndrome (Leukaemia) 
MLH1, MLH3, MSH2, MSH3, 
MSH6, PMS1 and PMS2 
MMR 
HNPCC; Turcot syndrome; Muir Torre 
syndrome (CRC; Endometrial cancer; 
Small bowel cancer; Renal pelvis cancers; 
Uterine cancer; Brain cancer; Sebaceous 
skin cancers) 
MUTYH BER MAP 
NBN HR 
Nijmegen breakage syndrome (Non-
Hodgkin lymphoma; medulloblastoma; 
glioma; rhabdomyosarcoma) 
POLD1/POLE DNA repair and synthesis CRA and CRC 
POLH 
Translesion synthesis (after UV 
damage) 
Xeroderma pigmentosum, variant (Skin 
cancer) 
RECQL4 HR 
Rothmund-Thomson syndrome 
(Osteosarcoma; skin cancers) 
WRN Telomere maintenaince; HR Werner syndrome (Various cancers) 
XPA, -B, -C, -D, -E, -F, -G NER Xeroderma pigmentosum (Skin cancer) 
 
Table 1.3 – DNA repair genes, pathways they are involved in and associated hereditary 
cancer predisposition syndromes. Pathways associated with CRA and CRC syndromes are given in 
bold. (BER = Base excision repair; HR = Homologous recombination; ICL = Interstrand crosslinks; 
NER = Nucleotide excision repair; NHEJ = Non-homologous end joining; UV = Ultraviolet) 
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(EXO) to degrade the excised strand. Following this, polymerase δ (POLD) and DNA 
ligase I (LIG1) are recruited to accurately repair the excised strand and repair nicks 
once DNA synthesis has finished (Vilar and Gruber, 2010; Kunkel and Erie, 2005; 
Fig. 1.3) 
1.3.1.1 MMR gene mutations and cancer 
Deficiencies of the MMR system as a result of function impairing mutations 
predispose patients to various cancers (Lynch and Lynch, 1979; Section 1.2.1.3). 
HNPCC is a genetically heterogenous disease and multiple genes in the MMR 
pathway can be mutated. The majority of mutations seen in HNPCC syndromes are 
observed in MLH1 and MSH2, although many other genes from the MMR pathway 
have been implicated including MSH6, PMS1, PMS2 and MLH3 (Nicolaides et al. 
1994; Wu et al. 2001; Liu et al. 2003; Hendriks et al. 2004). Before the age of 70, 
overall risk of cancer in MMR gene mutation carriers is 91% for men and 69% for 
women. The frequency of different cancers differs between the sexes, with men at a 
much greater risk of developing CRC (Dunlop et al. 1997).  
In accordance with Knudson’s two-hit hypothesis, somatic inactivation of the 
second MMR allele in HNPCC patients leads to the formation of a mutator 
phenotype characterised by an increased rate of MSI; however this does not directly 
cause tumour growth (Parsons et al. 1993). Genes with repeat sequences are 
commonly affected by MSI in HNPCC patients (Duval and Hamelin, 2002). Such 
genes include TGFβ receptor 2 (TGFβR2), AXIN2, β-catenin, BCL2-associated X 
(BAX1), MSH3 and MSH6 (Wrana et al.1994; Lu et al. 1995; Malkhoysen et al. 1996; 
Rampino et al. 1997; Liu et al. 2000; Shitoh et al. 2001). 
The genetic and allelic heterogenity associated with HNPCC and the wide 
distribution of mutations throughout genes can make germline screening difficult 
(Peltomäki and Vasen, 1998). Over 90% of HNPCC patients display MSI, with 
somatic MSI status at particular repeat sequences commonly used in the diagnosis 
of germline mutations (Boland et al.1998; Lamberti et al. 1999). The Bethesde 
criteria form a comprehensive set of guidelines in the diagnosis of patients with 
expected HNPCC that should be sent for genetic MSI analysis (Umar et al. 2004). 
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Figure 1.3 – Involvement of the MMR pathway in the repair of various forms of DNA damage. 
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1.3.2 BER pathway 
DNA damage as a result of oxidative stress has been shown to have an 
important role in the development of degenerative syndromes, such as cancer and 
aging (Hoeijmakers, 2009). It has been proposed that oxidative stress could be 
responsible for up to half of all cancers (Beckman and Ames, 1997). The primary 
source of oxidative damage is from reactive oxygen species, created through both 
endogenous and exogenous sources (David et al. 2007). It is the role of the multi-
step BER pathway to remove and repair such damage, as well as repair other forms 
of damage such as abasic (AP) sites, alkylation and deamination to maintain the 
integrity of DNA (Lindahl and Wood, 1999). 
Following single base DNA damage, DNA glycosylases recognise and initiate 
repair by excising the damaged base. If monofunctional, the glycosylase removes 
the base through hydrolysis of the N-glycosidic bond. This results in an AP site, 
which is incised to form a single strand break (SSB) by apurinic/apyrimidinic 
endonuclease (APEX1). This leaves a 5’-deoxyribose 5’-phosphate residue (dRP) 
and a normal 3’hydroxyl (3’OH) group. DNA polymerase β (POLB) is involved in 
removal of the dRP overhang via the proteins integral lyase activity If bifunctional, 
the DNA glycosylase first removes the base and then incises the phosphodiester 
DNA backbone (Fromme et al. 2004). Depending on the glysocylase involved and 
the group left at the 3’ end of the break, either APEX1 or polynucleotide kinase 3’ 
phosphatase (PNKP) then processes the strand break (Wallace et al. 2012). In short 
patch repair, POLB repairs the damaged base (Matsumoto and Kim, 1995). X-ray 
repair cross complementing, 1 (XRCC1) acts as a scaffold protein for DNA ligase III 
(LIG3; Vidal et al. 2001), which then seals the SSB. In long patch repair, either 
POLB, POLD or polymerase ε (POLE) elongate 2-12 nucleotides from the 3’ incision 
site to create a flap (Dianov et al. 2003). Through the action of flap endonuclease 
(FEN1) this is removed (Liu et al. 2005) with the help of PCNA and poly (ADP ribose) 
polymerase (PARP1) to aid strand displacement. The strand is then ligated by LIG1 
(Fig. 1.4; Xu et al. 2008). 
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Figure 1.4 – The BER of DNA damage is initiated by the recognition and removal of the damaged base by either a monofunctional or bifunctional 
glycosylase to create an AP site. This can also occur spontaneously as a result of hydrolysis (Dianov et al. 2003). Either the long or short patch repair 
pathways will then repair the area, dependant on the type of damage and glycosylase recruited (adapted from Xu et al. 2008). 
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  1.3.2.1 BER gene mutations and cancer 
Biallelic mutations in the DNA glycosylase gene, MUTYH, have been shown 
to predispose to the familial CRA condition, MAP (Section 1.2.1.2). Over 30 different 
mutations of MUTYH have been observed in patients with MAP (Wallace et al. 
2012).  
1.3.3 NER pathway 
NER is involved in the removal of bulky adducts from DNA that cause 
distortion of the double helix, hindering replication and transcription. It is typically 
involved in the repair of ultraviolet B (UV) photoproducts in the forms of cyclobutane 
pyrimidine dimers (CPD) and 6-4 photoproducts (6-4,PP; Leibeling et al. 2006), 
although it is also involved in the repair of other forms of bulky adducts that occur as 
a result of exposure to a range of environmental and chemical sources (Gillet and 
Schärer, 2006). 
NER consists of two pathways that differ in the way that the DNA damage is 
recognised. If the region damaged is protein coding, transcription coupled (TC-NER) 
repair will occur when RNA polymerase II (RNA pol II) stalls at damaged regions. 
Cockayne syndrome group A and B (CSA and CSB) are recruited to the stall where 
they are involved in processing of the damage (Fousteri and Mullenders, 2008). If 
the damage occurs in a non-coding region of DNA, global genomic repair (GG-NER) 
is implemented via recognition by the xeroderma pigmentosum, group C (XPC) -
HR23B complex and the DNA damage binding proteins, 1 and 2 (DDB1 and DDB2). 
The proteins involved are dependent on the damage caused and the extent of the 
distortion of the DNA helix (Hanawalt, 2002; Diderich et al. 2011). It is the role of 
CSB and XPC-HR23B to recruit the ten sub-unit basal transcription factor complex 
(TFIIH) to the area of damage. This complex includes the helicases XPB and XPD, 
which facilitates DNA strand unwinding in the presence of ATP (Coin et al. 2007). 
This allows for binding of XPA, replication protein A (RPA) and XPG. XPA ensures 
the area is damaged, whilst also having roles alongside RPA in protecting the 
undamaged single stranded DNA and recruiting the XPF and excision repair cross 
complementing, group 1 (ERCC1) complex. This 5’ endonuclease complex 
functions, alongside the 3’ incision by XPG, to incise and release the damaged 
strand (Staresincic et al. 2009). This allows for recruitment of repair machinery to 
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Figure 1.5 – The two branches of the NER pathway. NER functions in the repair of helix distorting lesions. If in a coding region of the genome, TC-
NER will occur as a result of RNA pol II stalling. If elsewhere, helix distorting lesions are identified by XPC-HR23B, DDB1 and DDB2, dependent on the 
damage caused, as part of the GG-NER pathway. Following excision of the damaged strand, repair machinery is recruited. This includes POLD, POLE or 
polymerase κ (POLK; collectively POL in diagram; Ogi and Lehmann, 2006; Gillet and Scharer, 2006), as well as either XRCC1-LIG1 or LIG3 dependant on 
the stage of the cell cycle a cell is in, respectively (Moser et al. 2007). 
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the area of excised damage where it carries out repair and ligation, using the 
undamaged strand as a template (Fig. 1.5). 
1.3.3.1 NER gene mutations and cancer 
Xeroderma pigmentosum (XP) is an autosomal recessive disorder 
characterised by extreme sensitivity to UV light and a 1000 fold increased risk of skin 
cancers due to ineffective repair and accumulation of UV induced DNA damage 
(Kraemer et al. 1987). Skin cancers typically develop 50 years earlier than the 
general population, with commonly seen lesions including squamous and basal cell 
carcinomas, and melanomas (Kraemer, 1997). Internal cancer risk is also elevated, 
albeit to a lesser degree (Kraemer et al. 1984). There are currently 8 known 
complementation groups of XP, all exhibiting similar phenotypes but with varying 
degrees of sensitivity. Some complementation groups also exhibit signs of 
neurological degeneration, with 20-30% of all patients’ exhibiting symptoms (de Boer 
and Hoeijmaker, 2000; Anttinen et al. 2008). It is more common in Japanese 
populations, with approximately 1: 40,000 people affected compared to 1:1,000,000 
in Western populations (Bhutto and Kirk, 2008). 
Seven of the known complementation groups of XP (XPA through to XPG) are 
as a result of function impairing mutations in NER pathway genes, with the eighth 
complementation group, XPV, the result of mutations in the replicative bypass 
polymerase η (POLH). In XPV, the NER pathway performs normally; rather it is the 
inability to carry out DNA replication past regions with UV damage that results in the 
characteristic XP phenotype (Masutani et al. 1999).  
1.3.4 Double strand break repair 
One of the most detrimental forms of DNA damage are double strand breaks 
(DSB). DSB are formed following treatment with ionising radiation, X-ray or as a 
result of chemical damage. They are also formed following replication over a single 
stranded break, in the repair of interstrand crosslinks (ICL) and following collapse of 
stalled replication forks. Double strand ends that have become separated are liable 
to move away from one another. This can make repair difficult and also means there 
is the opportunity for recombination at other erroneous regions of the genome 
resulting in chromosome instability (Hoeijmakers, 2001). Chromosomal instability 
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formed in this way has been shown to be important in the early stages of 
tumourigenesis (Bartkova et al. 2005). There are two pathways involved in the repair 
of DSB; homologous recombination (HR) and non-homologous end joining (NHEJ).  
Which pathway acts to repair DSB is highly dependent on the nature of the 
break and at which cell cycle stage the affected cell is in. Whilst NHEJ is faster than 
HR and can occur throughout all stages of the cell cycle, it is a mutagenic process in 
which split ends are directly ligated (Mao et al. 2008; Takata et al. 1998). However, 
HR can only take place in cell cycle phases when the homologous chromosomes are 
in close proximity. In all other stages HR could lead to dangerous chromosomal 
translocation as a result of unsuitable selection of homologous regions within similar 
repetitive sequences in other chromosomes (Lieber et al. 2003). There is also a risk 
of loss of heterozygosity as a result of the HR process conferring mutations from the 
homologous chromosome (Alexander et al. 2001). 
1.3.4.1 HR 
HR functions in repairing DSB by conferring the correct genetic material from 
an undamaged strand with which it shares sequence homology, typically the 
homologous chromosome. It is considered an error free mechanism of DNA repair 
that occurs in the S and G1 phase of the cell cycle. Various proteins throughout the 
pathway help to regulate the cell cycle in order to ensure that HR only takes place 
during these phases to guarantee that repair is carried out safely (Lisby et al. 2004). 
In the main stages of HR, the meiotic recombination 11 (MRE11), nibrin (NBS1) and 
RAD50 (MRN) nuclease complex, the CTBP interacting protein (CtIP) nuclease, and 
the bloom syndrome protein (BLM) helicase, are directed to the area of damage 
(Sartori et al. 2007; Mimitou and Symington, 2009; Ouyang KJ et al. 2009). Together 
they process the ends of the DSB to expose the 3’ ends of the strands to create a 
single strand overlap for efficient recombination via strand cross-over (Wyman and 
Kanaar, 2006). During this time RAD51, with the aid of RAD52 and BRCA2, 
displaces RPA that has bound to single stranded DNA. RAD51 is a recombinase that 
is key in the identification of highly homologous sequences and in guidance of the 
exposed single strand (Baumann et al. 1996). The damaged strand is directed for 
exchange with a highly homologous sequence, forming a D loop, allowing for a 
polymerase to use the error free strand to replicate from the area of damage (Scully 
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et al.1997; Fig. 1.6). There are various alternative pathways from this point which 
include double strand break repair (DSBR) and synthesis-dependant strand 
annealing (SDSA). In DSBR, the second double strand end forms a Holliday 
junction. LIG1 then ligates the two ends and the Holliday junctions formed by 
crossover are cleaved (Holliday, 1964). In SDSA, the newly synthesised strand is 
displaced from cross over where it is re-ligated. This strand then acts as a template 
for synthesis and ligation of the other damaged strand (Sung and Klein, 2006). As 
well as the repair of DSBs, HR is also involved in telomere maintenance, cell cycle 
control, repair at stalled replication forks and control of meiotic chromosome 
segregation (Sung and Klein, 2006). 
1.3.4.2 NHEJ 
NHEJ is another DSB repair pathway in which breaks are simply ligated 
together; no information from the homologous chromosome is used to repair the 
break.  
The first step in NHEJ is recognition and binding of the Ku heterodimer, 
consisting of Ku70 and Ku80, onto both strands of DNA either side of the break. Ku 
helps to maintain the synapsis by keeping the DNA ends in close proximity (Walker 
et al. 2001). The DNA-PKcs-Artemis complex is then recruited to the area of damage 
where DNA-PKcs phosphorylates Artemis. The complex, via the nuclease activity of 
Artemis, resects 5’ overhangs to produce a blunt end (Ma et al. 2002). Recruitment 
of XLF (Gu et al. 2007), and the XRCC4-DNA ligase IV (LIG4) complex occurs 
(Chen et al. 2000), leading to repair and ligation of the separated strands (Fig. 1.6). 
1.3.4.3 DSB repair and cancer 
 1.3.4.3.1 Hereditary breast, ovarian and prostate cancers 
Heterozygous BRCA1 and BRCA2 mutations are linked to an increased risk 
of hereditary breast and ovarian cancers (Hall et al. 1990; Miki et al. 1994; Wooster 
et al. 1995, OMIM #114480). Both act as classical tumour suppressor genes, with a 
second somatic hit knocking out the genes function in DSB repair (Jasin, 2002; Sung 
and Klein, 2006). Genetic instability is a hallmark of BRCA1 and BRCA2 deficiency 
and cells display a heightened sensitivity to DNA damaging agents (Gretarsdottir  
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Figure 1.6 – DSB repair pathways. On the left is a schematic of NHEJ which involves simple re-
annealing of damaged strands. On the right is HR; the break is processed (A and B), the strand crosses 
over and the sister chromosome is used as a reference for strand re-synthesis and repair (C and D).  
5’ 
3’ 
3’ 
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et al. 1998; Moynahan et al. 2001). The overall risk of developing ovarian and/or 
breast cancer by the age of 70 in carriers of mutations in either gene is 
approximately 27% and 84%, respectively (Ford et al. 1998). Mutations of BRCA1 
and BRCA2 have also been linked to hereditary prostate cancers (Ford et al. 1994; 
Gayther et al. 2000; Tischkowitz and Eeles, 2003; Castro et al. 2013). 
In addition to the BRCA genes, other genes involved in HR have been 
implicated in hereditary breast cancers including checkpoint kinase 2 (CHEK2; 
Bernstein et al. 2006). CHEK2 is important in checkpoint signalling and control 
following DNA damage (Matsuoka et al. 1998). Upon activation by phosphorylation 
by ATM, CHEK2 phosphorylates and activates multiple downstream targets involved 
in DSB repair and checkpoint signalling, including BRCA1 (Bartek and Lukas, 2003). 
 1.3.4.3.2 Ataxia telangiectasia  
Ataxia telangiectasia (AT, OMIM #208900) is an autosomal recessive disorder 
that is caused by inactivation of ataxia telangiectasia mutated (ATM). Sufferers of AT 
are at a 100 fold greater risk of leukaemia and lymphoma than the general 
population, and ATM mutations have also been linked to breast cancer susceptibility 
in carriers (Athma et al. 1999; Gumy-Pause et al. 2004). AT cells show an elevated 
sensitivity to ionising radiation indicative of DSB repair failure (Meyn, 1995). ATM is 
a protein kinase that is activated following the formation of a DSB. It has many 
targets in the HR pathway and in checkpoint signalling (Morrison et al. 2000). 
 1.3.4.3.3 Bloom syndrome  
 Bloom syndrome (BS, OMIM #210900) is an autosomal recessive disease, 
caused by biallelic loss of function mutations in RECQL3 (BLM). Most of the 
mutations seen in BLM patients result in the production of a premature stop codon, 
leading to a truncated protein product (German et al. 2007). It predisposes sufferers 
to many different cancer types, with an early age of onset a hallmark of the disease 
(German, 1997). BS cells exhibit a high degree of chromosomal rearrangements 
between sister chromatids (Chaganti et al. 1974) which lead to an increased rate of 
loss of heterozygosity, chromosome rearrangements and deletions (Ouyang et al. 
2008). BLM is a DNA helicase that is critical in the repair of double strand breaks 
(Ellis et al. 1995). 
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 1.3.4.3.4 Nijmegen breakage syndrome 
Nijmegen breakage syndrome (NBS, OMIM #251260) is a rare autosomal 
recessive disease caused by at least 10 hypomorphic mutations in NBN (Weemaes 
et al. 1981; Varon et al. 1998; Carney et al. 1998). The most common cancer seen in 
patients is non-Hodgkins lymphoma, although other cancers include 
medulloblastoma, glioma and rhabdomyosarcoma (van der Burgt et al. 2005). NBN 
is a critical part of the MRN complex involved in the repair of DSBs. It is believed that 
its role in the complex is in the recruitment of checkpoint proteins and it therefore 
modulates DNA damage signalling pathways (Kobayashi et al. 2004). 
 1.3.4.3.5 Rothmund-Thomson syndrome 
Rothmund-Thomson syndrome (RTS, OMIM #268400) is an autosomal 
recessive disorder caused by biallelic mutations in RECQL4 (Taylor, 1957; Kitao et 
al. 1999). At least 39 different mutations have been associated with RTS (Reix et al. 
2007; Cabral et al. 2008; Siitonen et al. 2009; Debeljak et al. 2009). Sufferers are at 
a greater risk of osteosarcomas at a much younger age, with 32% of patients 
displaying symptoms. Additionally, approximately 5% of patients develop skin 
cancers later in life, with squamous cell carcinoma being the most common lesion 
seen (Wang et al. 2001). RECQL4 is a DNA helicase-like protein that is involved in 
recruitment of proteins at sites of single strand breaks following MRN processing of 
DSB (Petkovic et al. 2005; Singh et al. 2010). Additionally, interactions with proteins 
from multiple other DNA repair pathways have been reported, implicating a role in 
the repair of other forms of DNA damage (Woo et al. 2006; Fan and Luo, 2008; 
Schurman et al. 2009). 
 1.3.4.3.6 Werner syndrome 
Werner syndrome (WS; OMIM # 277700) is a rare autosomal recessive 
disorder. It is a result of biallelic loss of function mutations in RECQL2 (WRN) (Yu et 
al. 1996). There is an increased incidence of multiple cancers in carriers, with 
approximately 60% of cancers seen consisting of osteosarcomas, soft tissue 
sarcomas, thyroid cancers and melanomas (Goto et al. 1996). WS cells are prone to 
large deletions as well as other forms of cytogenetic abnormalities (Fukuchi et al. 
1989). WRN is a DNA helicase that functions in the ATP dependent unwinding of 
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DNA (Gray et al. 1997). In addition, WRN also possesses a 3’-5’ exonuclease 
domain (Huang et al.1998). In HR, WRN has the ability to localise with RPA, 
recognise branched structures, and dissociate branched recombination structures 
(Constantinou et al. 2000). Additionally, a role of WRN, in complex with BRCA1, has 
been suggested in the repair of interstrand crosslinks (ICLs; Cheng et al. 2006). 
 1.3.4.3.7 LIG4 syndrome 
LIG4 syndrome (OMIM # 606593) is a rare autosomal recessive disorder 
caused by mutations in LIG4. Mutations of these kind decrease the activity of the 
ligase in NHEJ (Girard et al. 2004) and are thought to be hypomorphic, since its 
knockout in mice is lethal (Frank et al. 2000). LIG4 syndrome predispose patients to 
acute leukaemias (Ben-Omran et al, 2005).  
 1.3.5 ICL repair 
 ICLs are highly toxic lesions due to the fact that, by binding and effectively 
joining opposite DNA strands together, they prevent strand separation, critical for 
replication and transcription (Dronkert and Kanaar, 2001). There are both exogenous 
and endogenous sources of ICLs but one of the best characterised is by-products of 
lipid peroxidation, such as malondialdehyde (Niedernhofer et al. 2003).  
 Due to the nature of ICLs, the lesions are only recognised in replicating cells, 
following stalling of DNA polymerases due to the inseparable DNA strands (Räschle 
et al. 2008). The stalled replication fork is recognised by the FANCM-FAAP24 
complex which recruits the Fanconi anaemia (FA) core complex, consisting of seven 
proteins. The core complex, notably FANCL, ubiquitylates the FANCD2-FANCI 
complex, leading to retention of the complex. FANCD2-FANCI is responsible for the 
recruitment of multiple repair enzymes to the area of damage. In addition, FANCM 
can effectively recruit the Bloom’s syndrome complex (BTR) which controls 
checkpoint activation via RPA and ATR triggered signalling cascades. The presence 
of RPA also triggers the localisation of HR pathway proteins, notably through 
BRCA2-FANCN. This allows for HR to control the stalled replication fork via the 
separation of DNA strands by the helicase activity of FANCJ (Li and Heyer, 2008).  
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  1.3.5.1 ICL repair and cancer 
 FA (OMIM #227650) is a group of recessive disorders, caused by mutations 
of one of fourteen different genes involved in the repair of ICLs. The inability of FA 
cells to repair ICL is highlighted by the severe sensitivity shown to agents that cause 
ICL (Auerbach, 1988). FA sufferers exhibit a heightened risk of cancer, in particular 
squamous cell carcinomas, acute myeloid leukaemia, head and neck, oesophageal 
and gynaecological cancers (Alter, 2003). However, the degree of cancer 
susceptibility varies between complementation groups (Faivre et al. 2000).  
All seven of the genes that form the core complex have been implicated in 
complementation groups of FA (FANCA, FANCB, FANCC, FANCE, FANCF, FANCG 
and FANCL), with over 90% of reported cases being the complementation groups 
FANCA, FANCC and FANCG (Deans and West, 2011). Notably, FANCD1 is caused 
by mutations in BRCA2, implicating its importance in multiple DNA repair pathways.  
1.4 Treatment of colorectal cancer 
The most important prognostic factor in CRC is tumour staging, for which 
treatment is highly dependent (Table 1.4). Five year survival rates drop to 
approximately 7% in patients presenting with stage IV CRC, in comparison to 93% in 
patients presenting with stage I (Cancer Research UK, Bowel cancer survival 
statistics, 2012). The most common form of curative treatment of stage I-III CRC is 
through surgery, with approximately 80% of patients undergoing surgical procedures. 
Adjuvant treatment with radiotherapy or chemotherapy is common. Unfortunately 
25% of people present with metastatic CRC and up to 50% of individuals progress to 
this stage, the treatment for which remains challenging (Van Cutsem and Oliveira, 
2009a). Only 20% of patients with hepatic metastasis are applicable for potentially 
curative surgery (Stangl et al. 1994). Chemotherapy therefore remains the mainstay 
in advanced CRC (aCRC) treatment. There are currently 8 agents that are approved 
by both the US food and drug administration (FDA) and European medicines agency 
(EMA) in the treatment of CRC. Additionally, regorafenib has recently received FDA 
approval, whilst aflibercept has recently received EMA approval following promising 
results (Table 1.5).  
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 TNM Staging  
Stage Tumour size (T) Lymph nodes (N) Metastasis (M) Description 
     
0 Tis N0 M0 
(Tis) Cancer in situ - confined to 
mucosa 
I T1 N0 M0 (T1) Tumour invade submucosa 
 T2 N0 M0 (T2) Tumour invades muscle layer 
II T3 N0 M0 
(T3) Tumour invades subserosa or 
beyond 
 T4 N0 M0 (T4) Tumour invades adjacent organs 
III T1-2 N1 M0 
(N1) Metastasis to 1-3 lymph nodes;  
(T1-2) either submucosa or muscle 
layer has been invaded 
 T3-4 N1 M0 
(N1) Metastasis to 1-3 lymph nodes; 
(T3-4) tumour goes beyond subserosa 
or to nearby organs 
 Any N2 M0 
(N2) Metastasis to 4 or more lymph 
nodes 
IV Any Any M1 (M1) Distant metastasis 
 
 Table 1.4 – Number stages and corresponding TNM staging of CRC with description of 
tumour growth given (adapted from Cancer Research UK, http://www.cancerresearchuk.org/cancer-
help/type/bowel-cancer/treatment/tnm-and-number-stages-of-bowel-cancer, 2011).  
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1.4.1 Fluoropyrimidines 
Fluoropyrimdines are central in the treatment of aCRC. Fluorouracil (5-FU, 
Efudex) has been used in the treatment of CRC for over 50 years. It is administered 
parenterally and, as an analogue of uracil, uses the same cellular transport systems 
to enter a cell. It can be considered a ‘fraudulent’ nucleotide; following conversion to 
flurodeoxyuridine monophosphate (fdUMP) it interacts, alongside reduced folate as a 
methyl donor (5,10-methylenetetrahydrofolate (MTHF)), and inhibits the action of 
thymidylate synthetase (TS) in the production of deoxythymine monophosphate, 
preventing DNA synthesis (Rang et al. 2007). It is often administered alongside the 
folate supplement leucovorin (5’-formyltetrahydrofolate, folonic acid). Leucovorin is 
anabolised to MTHF and has not only been shown to increase cellular levels of the 
donor but also to stabilise the TS-FdUMP complex (Radparvar et al. 1989). Studies 
have shown that administration alongside 5-FU results in clinical synergism, with 
double the response rate in aCRC (Advanced Colorectal Cancer Meta-Analysis 
Project, 1992). 
Capecitabine (CPB, Xeloda) is an oral fluropyrimidine which is readily 
absorbed through the gut wall and metabolised to 5-FU at a preferential rate in 
tumour cells (Miwa et al. 1998) reducing systemic exposure of 5-FU and thus 
reducing its associated toxicity (Schüller et al. 2000). A three step enzymatic reaction 
occurs to activate CPB; firstly it is converted by hepatic carboxylesterase to 5’-
deoxy-5-fluorocytidine and secondly to 5’deoxy-5-fluorouradine by cytidine 
deaminase. Finally, it is metabolised to the active metabolite 5-FU by thymidine 
phosphorylase, of which there is high activity in tumours leading to preferential 
accumulation (Ishikawa et al. 1998). In first line monotherapy treatment, response 
rates with CPB was significantly superior to those achieved with 5-FU and leucovorin 
(Van Cutsem et al. 2004). 
5-FU together with leucovorin, is currently approved for use in the clinic 
together with oxaliplatin as part of the FOLFOX regimen, whilst CPB is administered 
alongside oxaliplatin as part of the XELOX regimen. The FOLFOX regimen was 
shown to double response rates compared to the respective monotherapies, as well 
as increasing the time of progression free survival (PFS) in the treatment of aCRC  
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Year Therapy Advance 
1962 5-Fluorouracil  FDA approve 5-FU in the treatment of aCRC 
1990 Adjuvant therapy 
Chemotherapy becomes a mainstay as an adjuvant therapy 
following surgery; shown to improve survival following surgery by 
40% 
1996-1998 Irinotecan 
EMA and FDA approve use of irinotecan together with 5-FU and 
leucovorin (FOLFIRI) in the first line treatment or as second line 
monotherapy of aCRC 
1996-1999 Oxaliplatin 
EMA approval for the use of oxaliplatin together with 5-FU and 
leucovorin (FOLXFOX) in the second line treatment of aCRC 
2001-2004 Capecitabine 
EMA and FDA approval for the use of capecitabine, an oral 
fluoropyrimidine, in the treatment of aCRC together with 
oxaliplatin and irinotecan as part of the XELOX and XELIRI 
regimens, respectively. 
2002 Oxaliplatin 
FDA approve the use of oxaliplatin in the FOLFOX regimen in 
the second line treatment of aCRC 
2004-2005 Bevacizumab 
EMA and FDA approval for the use of bevacizumab in the 
treatment of aCRC together with FOLFIRI and XELIRI 
2004 Cetuximab 
EMA and FDA approval for the use of cetuximab in the treatment 
of aCRC alone or in combination therapy with irinotecan 
2006-2007 Panitumumab 
EMA and FDA approval for the use of panitumumab as a 
monotherapy, as first line treatment together with FOLFOX and 
as second line treatment together with FOLFIRI 
2008 Cetuximab 
Mutations in codon 12 and 13 of the EGFR pathway gene KRAS 
are shown to result in ineffectiveness of treatment (Karapetis et 
al. 2008). 
2009-2010 
Cetuximab and 
panitumumab 
EMA and FDA revise guidelines for EGFR inhibitors to take into 
consideration mutations of codon 12 and 13 of KRAS known to 
result in treatment failure 
2012 Regorafenib 
FDA approval for use of regorafenib in the treatment of aCRC 
refractory to other approved chemotherapeutics 
2013 Aflibercept 
EMA approval for the use of aflibercept in the treatment of aCRC 
that is refractory to oxaliplatin based treatment 
 
Table 1.5 – Main therapeutic advances in the treatment of CRC  
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 (de Gramont et al. 2000; Rothenberg et al. 2003; Saunders and Iveson, 2006). The 
FOLFOX and XELOX regimens have both been shown to be effective in the first line 
treatment of aCRC and as part of adjuvant therapy following surgery (Andre et al. 
2004; Goldberg et al. 2004; Cassidy et al. 2004; Twelves et al. 2005). Alternatively 
the two are administered alongside irinotecan as part of the FOLFIRI and XELIRI 
regimen, again for first and second line treatment of aCRC, although not as adjuvant 
therapy (Saltz et al. 2000; Bajetta et al. 2004; Grothey et al. 2004). Response rates 
of XELOX and XELIRI mirrored those of the FOLFOX regimen, verifying that both 
CPB and 5-FU can be used in various regimens for the effective treatment of aCRC 
(Grothey et al. 2004; Cassidy et al. 2004; Cassidy et al. 2008; Ducreux et al. 2011). 
1.4.2 Oxaliplatin 
Oxaliplatin (Eloxatin) is a third generation platinum compound that has been 
used in the treatment of CRC for over 15 years. It consists of a 1,2-
diaminocyclohexane (DACH) carrier ligand and a bidentate oxalate ligand (Kidani et 
al. 1978). Non-enzymatic displacement of the oxalate group following absorption 
allows for the formation of various reactive DACH intermediates that have the ability 
to react with DNA, notably to guanine and adenine bases. It acts as an alkylating 
agent of DNA, forming multiple crosslinks (Woynarowski et al. 2000). The production 
of these adducts, as well as secondary lesions that occur as a result of an 
accumulation of damage, ultimately results in apoptosis (Faivre et al. 2003). 
Approximately 90% of the lesions seen are intrastrand crosslinks, with 60% being 
between two adjacent guanine residues and the remaining 30% between adjacent 
guanine and adenine residues (Eastman, 1987). Other lesions observed include 
interstrand and DNA-protein crosslinks (Zwelling et al. 1979; Woynarowski et al, 
2000). Before the development of oxaliplatin, CRC was considered to have intrinsic 
resistance to other platinum treatments (Rixe et al. 1996).  
1.4.3 Irinotecan 
Irinotecan (Camptosar) is a plant alkaloid (from the Camptotheca acuminata 
tree) that functions as a topisomerase I inhibitor. Topisomerase I is involved in 
relaxing super-coiled DNA by creating transient nicks in single stranded DNA during 
repair and replication (Pommier, 2013). It is readily metabolised by both hepatic and 
intestinal carboxylesterases to form the active compound SN38 (Adeji, 1999). SN38 
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functions to stabilise the topisomerase-DNA complex after it has nicked DNA, thus 
preventing re-annealing. This leads to replication stalling and ultimately apoptosis 
(Hsaing et al. 1985; Kawato et al. 1991). As well as in first line combinational 
treatment regimens, irinotecan is useful as a monotherapy in second line therapy. 
1.4.4 Targeted therapies 
The rationale behind the stratified treatment of cancer has led to the 
development of therapies specifically targeted to redundancies or growth advantages 
displayed by cancer cells. The production of monoclonal antibodies, with epitopes 
that target cancer cells has increased treatment efficacy and reduced chemotherapy 
associated side effects. The problem lies with the cost; monoclonal antibodies still 
remain relatively expensive, meaning that discovering pharmacogenetic reasons for 
altered response between patients could be critical for adequate use. 
1.4.4.1 Cetuximab 
Cetuximab (Erbitux) is a chimeric IgG1 monoclonal antibody first approved in 
2004 after successful treatment of aCRC either alone or together with irinotecan 
(Saltz et al. 2004; Cunningham et al. 2004; Van Cutsem et al. 2009b). However, 
cetuximab was shown to be ineffective in the first line treatment of aCRC in 
oxaliplatin based regimens (Maughan et al. 2011; Tveit et al. 2012), despite some 
reports suggesting the contrary (Bokemeyer et al. 2011).  
The epidermal growth factor receptor (EGFR) is involved in regulation of 
transcription of nuclear targets involved in cell survival and growth through activation 
of signalling cascades including the Ras/Raf/MEK/MAPK and PI3K-Akt pathways 
(Krasinskas et al. 2011). Cetuximab selectively targets EGFR, competitively blocking 
ligand binding by EGF and TGFβ, preventing receptor activation (Mendelsohn and 
Baselga, 2003). Following binding to the extracellular domain of the EGFR receptor, 
apoptosis occurs as a result of cell cycle stalling in G1 (Huang et al. 1999). In 
addition to blocking ligand binding, as an IgG1 antibody it also has been shown to 
stimulate antibody-depedent cell-mediated cytotoxicity (ADCC) where the Fc region 
of the antibody is exposed, recognised as an antigen and the cancer cell targeted by 
the immune system (Iannello and Ahmad, 2005; Kawaguchi et al. 2007). 
Polymorphisms in receptors on killer cells required for antigen recognition have been 
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shown to alter the response of patients to cetuximab treatment, suggesting a role for 
ADCC in successful treatment (Zhang et al. 2007). 
1.4.4.2 Panitumumab 
As well as cetuximab, panitumumab (Vectibix) is also used in the selective 
targeting of the EGFR. A completely humanised IgG2 monoclonal antibody, it again 
targets the extracellular domain of the receptor. Mutational analysis of cetuximab 
resistant but panitumumab sensitive cell lines suggests that this may be through a 
slightly different epitope (Montagut et al. 2012; Mareike Voigt et al. 2012). It is 
effective as both a monotherapy and in combination with standard chemotherapeutic 
regimens in the treatment of aCRC (Van Cutsem et al. 2007; Hecht et al. 2007). It 
has been shown to be effective at increasing PFS in combination with FOLFOX in 
the first line treatment of aCRC (Douillard et al. 2010) and in combination with 
FOLFIRI (Berlin et al. 2007). In second line treatment with FOLFIRI an increase in 
response rate of 25% was observed. However, this was dependant entirely on a 
KRAS wild type status (Peeters et al. 2010; Section 1.6.4). 
1.4.4.3 Bevacizumab 
Bevacizumab (Avastin) is a humanised IgG1 monoclonal antibody specifically 
designed to target the VEGF-A ligand and prevent binding to the VEGF receptor. 
The VEGF system is chiefly involved in control of endothelial cell proliferation and 
promotion of angiogenesis, something which tumour cells rely on for sustenance, 
survival and growth (Kim et al. 1993; Lee et al. 2000; Ferrara et al. 2004). 
Normalisation of tumour vasculature in bevacizumab treatment is associated with an 
increase in tumour uptake of irinotecan (Wildiers et al. 2003) suggesting a 
synergistic action in CRC.  
Bevacizumab has shown to be effective in increasing overall survival and/or 
PFS in combination with fluoropyrimidine based treatment regimens (Kabbinavar et 
al. 2005; Hurwitz et al. 2005; Giantomio et al. 2007; Saltz et al. 2008; Van Cutsem et 
al. 2009c; Sobrero et al. 2009; Tsutsumi et al. 2012; Schmiegel et al. 2013; Beretta 
et al. 2013). 
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1.5 Side effects of CRC treatments (Table 1.6) 
 1.5.1 Fluoropyrimidines 
Infusion of 5-FU is better tolerated than bolus administration since the latter 
causes no extreme peaks in exposure to chemotherapy (Lokich et al. 1989; Hansen 
et al. 1996). Although the degree of toxicity profiles differs between regimens, the 
main side effects of 5-FU with leucovorin treatment are gastrointestinal epithelial 
damage resulting in diarrhoea, stomatis, nausea, vomiting and oral mucositis, hand-
foot syndrome and neutropaenia (Tsalic et al. 2003). In CPB treatment, similar side 
effects to 5-FU are observed, albeit at a reduced frequency (Cassidy et al. 2002; 
Schmoll et al. 2007). However, a hand-foot syndrome is seen at a greater rate. 
Hand-foot syndrome occurs in 50% of patients undergoing CPB treatment (Van 
Cutsem et al. 2000) and is characterised by erythema, dysthesia and, in extreme 
cases, swelling, ulceration and blistering of the skin, particularly on the hands and 
the feet (Barack and Burgdorf, 1991). Although rarely life threatening, it can be 
interfere with everyday life and compliance of patients undergoing treatment 
(Cassidy et al. 2002). One hypothesis for this increased prevalence is thought to be 
as a result of raised levels of the CPB metabolising enzyme, thymidine 
phosphorylase, in skin cells, resulting in an elevation of the metabolite (Asgari et al. 
1999).  
 1.5.2 Oxaliplatin 
Peripheral neuropathy is the most common dose limiting side effect 
associated with oxaliplatin treatment. An acute, dose dependant and reversible 
peripheral neuropathy is reported in 95% of patients undergoing treatment with 
oxaliplatin. The symptoms consist of parethesia, dysethesia and allodynia in the 
hands, feet and lips, as well as a laryngospasm or muscle cramps, which are 
exacerbated by exposure to low temperatures (Extra et al. 1998). Fortunately, the 
acute form appears to be reversible within hours or days (Argyriou et al. 2008).  
The mechanism of action by which acute neuropathy occurs is not completely 
understood, however it is thought that it is due to disruption of the voltage gated 
sodium channels indirectly as an extension of chelation of calcium ions by the 
oxaliplatin metabolite, oxalate (Grolleau et al. 2001). Oxalate is known for causing  
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Drug Side effect 
Fluoropyrimidines 
Gastointestinal epithelial damage; neutropenia; 
hand foot syndrome (greater incidence with 
capecitabine) 
Oxaliplatin Acute and chronic peripheral neuropathy 
Irinotecan 
Hyperstimulation of cholinergic system; 
neutropenia 
EGFR inhibitors 
(Cetuximab and 
panitumumab) 
Skin rash; trichomegaly; alopecia; hypersensitivity 
at injection site (with cetuximab) 
Bevazicumab Hypertension 
 
Table 1.6 – Main side effects associated with treatment of CRC 
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neurotoxic effects in ethylene glycol poisoning, with peripheral neuropathy a 
symptom (Baldwin and Sran, 2010).  
Chronic peripheral neuropathy is reported after several rounds of 
chemotherapy and has been shown to affect up to 50% of all patients undergoing 
treatment (Krishnan et al. 2006). Symptoms mimic that of cisplatin associated 
toxicity, consisting of a non-cold associated dysesthesia, paresthesia and sensory 
ataxia (Grothey, 2003), increasing in intensity following subsequent dosing. Although 
in 5% of patients symptoms appear to be irreversible following the cessation of 
treatment, in most cases there is an improvement of symptoms within 2 months (de 
Gramont et al. 2000; Alcindor and Beauger, 2011). It is believed to be due to direct 
toxicity of nerve cells via the accumulation of platinum adducts in the dorsal root 
ganglia, affecting DNA transcription and ultimately resulting in enhanced apoptosis in 
neuronal cells (Ta et al. 2006). There are no current treatments to alleviate the 
symptoms of peripheral neuropathy (Weickhardt et al. 2011). Since in most cases 
neuropathy is reversible, symptoms can be controlled with dose reductions and 
treatment modifications (de Gramont et al. 2000; de Gramont et al. 2004; Tournigand 
et al. 2006).  
In addition to peripheral neuropathy, an elevated degree of neutropenia, 
nausea and diarrhoea is associated with the FOLFOX regimen when compared to 5-
FU and leucovorin alone (Rothenberg et al. 2003). 
 1.5.3 Irinotecan 
Dose limiting side effects of irinotecan consists primarily of a delayed onset of 
diarrhoea, due to a high concentration of SN38 in the intestine following hepatic 
elimination (Hecht, 1998). In 40% of patients, the side effect is severe (Pitot et al. 
2000). Additionally, acute toxicites associated with hyperstimulation of the 
cholinergic system are commonly observed including emesis, diarrhoea, abdominal 
cramps, bradycardia and hypotension (Nicum et al. 2000; Tobin et al. 2004). 
Experiments in animals have indicated that irinotecan can effectively inhibit 
acetylcholinesterases, as well as effectively stimulating muscarinic receptors 
(Kawato et al. 1993). Severe neutropenia is also a commonly seen side effect. 
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The acute cholinergic symtoms respond well to the anti-cholinergic drug, 
atropine (Pitot et al. 2000; Fuchs et al. 2003), whilst the delayed onset diarrhoea has 
shown to be controlled by high dose loperamide (Abigerges et al. 1994). However, 
some patients do not respond and dose modifications or treatment cessation are 
required (Cunningham et al. 1998; Van Cutsem et al. 1999; Rothenberg, 2001) 
1.5.4 Targeted therapies  
1.5.4.1 Cetuximab 
One of the most common side effects, seen in 80% of patients treated, is the 
development of a skin reaction, most notably as an acnieform skin rash. The rash 
appears to be dose dependant and is seen most commonly on the face, neck, 
shoulders and chest (Segaert and Van Cutsem,2005). In up to 18% of cases it is 
severe. In addition, other common dermatological complaints include fissures on the 
hands and feet, xerosis and changes in hair growth (Agero et al. 2006). Other side 
effects of treatment include trichomegaly, alopecia, diarrhoea, hypomagnesmia and 
severe hypersensitivity at the site of infusion (Dueland et al. 2003; Chung et al. 
2008). 
In most cases treatment of skin rashes is necessary in order to ease 
discomfort and aid compliance. For acneiform skin rash, topical anti-acne medication 
or anti-inflammatory medication has been shown to be effective, although the choice 
of therapy is dependent on the location of rash. If xerosis is also present, a fine 
therapeutic balance must be struck between acneiform treatment and hydrating 
lotions, since either treatment can exacerbate the other symptom. In severe cases of 
acneiform skin rash, high dose oral anti-histamines are effective at reducing the 
reaction (Segaert and Van Cutsem, 2005).  
1.5.4.2 Panitumumab 
As an EGFR inhibitor, similar side effects to cetuximab are commonly seen 
with panitumumab treatment, with dermatological toxicities again being the most 
common (>90%). Additionally, fatigue, nausea, diarrhoea, hypomagnesmia and 
neutropeania are all commonly seen (Van Cutsem et al. 2007). However, 
hypersensitivity at the site of injection is rare due to the fact that, unlike cetuximab, 
panitumumab is a fully humanised antibody (Ranson, 2003). 
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1.5.4.3 Bevacizumab 
The most common side effect of bevacizumab treatment is severe 
hypertension. Approximately 23% of all patients undergoing treatment will suffer from 
the side effect, with 8% of these classified as severe (Ranpura et al. 2010). It is 
thought that inhibition of VEGF can lead to a reduced production of vasodilators, 
such as nitric oxide, lowering normal physiological levels and ultimately resulting in 
vasoconstriction (Olsson et al. 2006; Mourad et al. 2008). Additionally a reduced 
level of nitric oxide also leads to a reduced level of sodium excretion which in turn 
could contribute to hypertension as a result of water retention in the blood (Granger 
and Alexander, 2000). Other side effects associated with treatment include an 
increased risk of arterial and venous embolisms, proteinuria, bleeding, and in rare 
cases, poor wounding healing and gastrointestinal perforations (Hurwitz et al. 2004; 
Saltz et al. 2008). 
Hypertension can be treated by the administration of an angiotensin-
converting enzyme (ACE) inhibitor or other diuretic, calcium channel blockers, beta 
blockers or various other anti-hypertensive drugs (Motl, 2005; Pande et al. 2006; 
Saif, 2009). To minimise the chance of bleeding, problems with wound healing and 
gastrointestinal perforations, it is recommended that bevacizumab treatment as 
adjuvant to surgery is either discontinued or started at a time point suitable to allow 
for adequate healing of wounds (Shord et al. 2009). In severe cases of all side 
effects, dose modification and reduction can reduce the severity of the effect seen. 
1.6 Pharmacogenetics of CRC treatment 
 1.6.1 Fluoropyrimidines 
Several genetic factors have been attributed to varying response in treatment 
to the fluoropyrimidine agents in CRC. Polymorphisms in TS have been associated 
with altered expression of the protein, with increased expression being inversely 
linked to clinical outcome (Lurje et al. 2009). One such polymorphism consists of a 
28bp repeat sequence in the 5’ untranslated region (5’UTR) of the gene. Significantly 
higher expression of TS was associated with 3 such repeats when compared to 2 
repeats (Horie et al. 1995; Pullarkat et al. 2001). Expression was even higher when a 
G→C polymorphism in the second of the three repeats is present (Mandola et al. 
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2003). Conversely, a 6 base pairs deletion in the 3’UTR significantly decreased 
mRNA stability, influencing expression of TS (Mandola et al. 2004). In terms of side 
effects to treatment, individuals homozygous for the 2 repeat allele are over ten 
times more likely to suffer from greater than grade 3 toxicity than individuals 
homozygous for the 3 repeat allele (Lecomte et al. 2004). 
Another pharmacogenetic factor in fluoropyrimidine treatment consists of two 
common polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene. 
MTHFR is important in the production of reduced folate, critical for the action of 5-
FU. The polymorphisms Ala222Val and Glu429Ala have been shown to be 
associated with an increase in response to treatment (Little et al. 2003; Etienne-
Grimaldi et al. 2010). 
The main route of 5-FU metabolism is by the enzyme dihydropyrimidine 
dehydrogenase (DPYD), with up to 80% of the administrated dose degraded by the 
enzyme (Woodcock et al. 1980). Over 15 different polymorphisms correlate with 
altered DPYD activity, with lowered acivity being associated with a greater degree 
and a quicker rate of onset of 5-FU associated side effects (van Kuilenburg et al. 
2000; Collie-Duguid et al. 2000; Newton et al. 2012). An extreme toxicity phenotype 
is associated wih a splice site point mutation that results in a 165 base pair deletion 
consisting of an entire exon of the gene (Wei et al. 1996). Although rare in the 
Caucasian population (MAF <1%), up to 24% of patients with at least one copy of 
this allele exhibit grade 3 or greater toxicity (Raida et al. 2001). Additionally, a rare 
nonsynonymous variant at position 949, resulting in the subsitution of a valine for an 
aspartic acid residue has been shown to influence the enzymatic action of DPYD 
and cause 5-FU toxicity comparable to that seen with the exon skipping mutation 
(Morel et al. 2006). 
 1.6.2 Oxaliplatin 
The efficacy of oxaliplatin in the treatment of aCRC has been shown to be 
affected by variants in genes involved in its pharmacokinetic and cellular response 
pathway. For example, a coding variant in glutathione-S-transferase π (GSTP1), 
resulting in an isoleucine to valine substitution at codon 105 of the protein, increases 
survival in the treatment of aCRC (Stoehlmacher et al. 2002) although its reliability 
as a pharmacogenetic allele is of debate (Fariña Sarasqueta et al. 2011). GSTP1 is 
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involved in the detoxification of reactive intermediates of oxaliplatin by conjugation 
with glutathione.  
Altered expression of ERCC1, a gene integral to the NER of platinum 
adducts, has been shown to affect response to platinum treatment, with increased 
expression significantly increasing resistance to various treatment regimens in aCRC 
(Shirota et al. 2001; Arnould et al. 2003; Seetharam et al. 2010; Arora et al. 2010; 
Noda et al. 2012; Tentori et al. 2013). Concordant with this, increased expression of 
ERCC1 is commonly observed following oxaliplatin treatment (Baba et al. 2012). 
Clinical outcome of oxaliplatin treatment has also been associated with a C>T silent 
polymorphism, encoding Asn118. Homozygosity of the C allele has been shown to 
be positively correlated with outcome of treatment (Park et al. 2003), with presence 
of the T allele increasing mRNA levels and conferring resistance to treatment (Ruzzo 
et al. 2007).  
Another DNA repair gene that has been linked to clinical outcome is the BER 
gene XRCC1. The Arg399Gln polymorphism has been associated with an increased 
response to treatment (Stoehlmacher et al. 2001; Lv et al. 2013). 
With regards to side effects to treatment, a putative association between 
chronic peripheral neuropathy and Ile105Val in GSTP1 has been described (Grothey 
et al. 2005; Ruzzo et al. 2007; Peng et al. 2013), although the risk allele is of debate 
(Lecomte et al. 2006; Gamelin et al. 2007; Inada et al. 2010). Particular haplotypes 
of alanine glycoxylate transferase (AGXT), involved in oxalate metabolism, have 
been shown to predispose towards both acute and chronic forms of peripheral 
neuropathy (Gamelin et al. 2007). Additionally, the silent polymorphism encoding 
Asn118 in ERCC1 has been shown to be associated with an elevated rate of onset 
of peripheral neuropathy in the Japanese population (Inada et al. 2010; Oguri et al. 
2013). Oguri et al. also highlighted an association between rs17140129 in 
phenylalanyl-tRNA synthetase 2 (FARS2) and the severity of peripheral neuropathy, 
and rs10486003 in tachykinin (TAC1) and the rate of onset. Both of these variants 
are in non-coding regions and were originally associated with chronic peripheral 
neuropathy in a GWAS which also identified 7 other variants as associated with the 
side effect (Won et al. 2012). Also a nonsynonymous variant in sodium channel, 
voltage gated 10A (SCN10A; Leu1092Pro [rs12632942]) and an intronic variant 
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(rs2302237) in SCN4A have been shown, under an overdominant model, to increase 
the chance of acute peripheral neuropathy, with the latter also influencing the 
severity of the side effect (Argyriou et al. 2013). 
 1.6.3 Irinotecan 
There has been much research into the role of UDP-glucuronosyltransferase 
(UGT1A1) in response to treatment with irinotecan. UGT1A1 is important in the 
deactivation of the active metabolite, SN38 (Gupta et al. 1997). In patients 
homozygous for a [TA]7 repeat in the promoter region (referred to as UGT1A1*28) an 
increased degree of toxicity is observed, particularly diarrhoea and neutropeania 
(Ando et al. 2005; Hoskins et al. 2007). Additionally, patients with elevated bilirubin 
(another substrate of UGT1A1) or with inherited deficiencies in UGT1A1 (Gilberts 
syndrome; OMIM #143500) have also been shown to be at an elevated risk of 
irinotecan associated toxicities (Wasserman et al. 1997; Lankisch et al. 2008). 
 1.6.4 Cetuximab and panitumumab  
Mutations in a downstream effector of the EGFR associated pathway, kirsten 
rat sarcoma viral oncogene homolog (KRAS), are responsible for resistance to 
EGFR inhibitors. A lack of response in patients with KRAS mutations is seen in both 
monotherapy and combination therapies for both drugs (Lièvre et al. 2008; De Roock 
et al. 2008; Freeman et al. 2008; Amado et al. 2008; Bokemeyer et al. 2009; Van 
Custem et al. 2009b). Of note, it was shown that tumours with activating mutations in 
KRAS at codons 12 and 13 had significantly reduced response rates to cetuximab 
treatment; from 13% to 1.2% (Karapetis et al. 2008). Additionally, rarer activating 
mutations at codon 61 and 146 are associated with a similar lack of clinical response 
to treatment (Loupakis et al. 2009a). As KRAS mutations are seen in up to 40% of 
colorectal tumours, these activating mutations could have major implications in 
EGFR targeting treatment of CRC. 
Following the observation that up to 60% of KRAS wild type tumours are 
unresponsive to EGFR inhibitor treatment, it was proposed that other components of 
the EGFR pathway could be implicated in lack of response (Linardou et al. 2008). In 
addition to KRAS mutations, the presence of the activating v-raf murine sarcoma 
viral oncogene homolog B1 (BRAF) mutation, V600E, was seen to be associated 
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with a reduction in drug efficacy (Di Nicolantonio et al. 2008; Benvenuti et al. 2007). 
BRAF mutations are seen in approximately 10% of aCRC (Davies et al. 2002; 
Rajagopalan et al. 2002). Similarly, activating mutations in codon 61 of NRAS, 
another isoform of the Ras gene, reduces response rates by over 30% in carriers. 
Both BRAF and NRAS mutations are considered to be mutually exclusive to any 
KRAS mutation. In addition to this, oncogenic mutations of phosphatidylinositol-4,5-
bisphosphate 3-kinase (PI3KCA; De Roock et al. 2010; Laurent-Puig et al. 2009; 
André et al. 2013) and loss of expression of the PI3K pathway inhibitor and tumour 
suppressor, PTEN, are also associated with EGFR inhibitor treatment failure (Frattini 
et al. 2007; Perrone et al. 2009; Loupakis et al. 2009b; Sood et al. 2012). Both 
PI3KCA and PTEN mutations can co-occur with other mutations in the EGFR 
pathway (Sartore-Bianchi et al. 2009). 
Several studies have also reported a correlation between increased EGFR 
expression and response to treatment (Moroni et al. 2005; Sartore-Bianchi et al. 
2007; Heinemann et al. 2009), although the benefit of testing for overexpression as a 
biomarker of response is of debate. Recent evidence has emerged suggesting that 
an acquired mutation, Ser492Arg, found in the extracellular domain of the EGFR 
receptor could alter binding and therefore lessen effectiveness of treatment of 
cetuximab but not panitumumab (Montagut et al. 2012). Interestingly, the presence 
of a skin rash as a side effect in either drug treatment is positively correlated with 
overall response (Saltz et al. 2004; Jonker et al. 2008; Peeters et al. 2009). As 
EGFR is highly expressed on epidermal surfaces, the characteristic skin rash is 
thought to be due to direct inhibition of EGFR on the surface of the skin (Giovannini 
et al. 2009) 
1.7 Next generation sequencing  
Advances in next generation sequencing (NGS) have revolutionised genomics 
and our understanding of human disease. This ultimately can have implications in 
the diagnosis and treatment of patients (Gonzalez-Angulo et al. 2010). NGS utilises 
massively parallel sequencing to effectively amplify and sequence the genome 
reliably and at a low cost; the first genome to be sequenced using a NGS platform 
was done so at a significantly reduced cost compared to preceding methods (Levy et 
al. 2007; Wheeler et al. 2008; Shendure and Ji, 2008). To date, NGS has been used 
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in the identification of multiple casual alleles in multiple different diseases (Table 
1.7). 
1.7.1 General workflow  
NGS methods consist of three main stages, although the mechanism by 
which they are carried out can vary greatly depending on the data output desired and 
platform used (Metzker, 2010). These stages consist of initial sample preparation, 
massively parallel sequencing and imaging of sequence data, and data analysis. 
There are multiple NGS platforms currently available. Technologies vary in their 
amplification method, sequencing method and applications, each with their own 
advantages and disadvantages (Table 1.8). 
Despite 85% of disease causing mutations being located in protein coding 
regions, only 1% of the entire genome makes up the ‘exome’ (Ng et al. 2009; Choi et 
al. 2009). Considering the cost of whole exome sequencing (WES) is considerably 
less than whole genome sequencing (WGS) this makes it an appealing alternative 
when looking for mutations responsible for a given phenotype. In WES, an additional 
‘target capture’ step is carried out during sample preparation in order to select for the 
protein coding regions of DNA. Following sheering of the DNA, adaptors are ligated 
to the fragments and hybridisation assays are carried out to isolate the previously 
defined coding sequences (Pruitt et al. 2009). Common techniques include 
microarray-based (Albert et al. 2007; Okou et al. 2007) and solution based 
enrichment assays (Porreca et al. 2007). 
Following generation of sequencing reads, quality control of reads is carried 
out to remove errors that can occur during the sequencing process (Pabinger et al. 
2013). Following this, the reads are aligned with and compared to a reference 
sequence, ensuring that any differences between the two can be distinguished 
(Flicek and Birney, 2009). Multiple mapping algorithms for this purpose are available 
and the choice of tool is dependent on the original platform used and applications 
required (Bao et al. 2011). When analysing samples for variations in relation to the 
reference genome, multiple tools are available to aid annotation of variants 
(McKenna et al. 2010; Wang et al. 2010; Yandell et al. 2011). Some alignment tools, 
such as Mapping and Assembly with Quality (MAQ), have also been developed to 
also aid in the detection of variants (Li and Durbin, 2009). 
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Use of NGS technology Reference 
First genome sequenced by WGS Wheeler et al. (2008) 
First cancer genome (acute myeloid leukaemia) sequenced by 
WGS 
Ley et al. (2008) 
First 12 human exomes sequenced using targeted capture 
technology. Displayed that WES could be used to identify 
Mendelian disorders by studying four individuals with Freeman-
Sheldon syndrome (OMIM #193700) 
Ng et al. (2009) 
First diagnosis of a hereditary disease (congenital chloride losing 
diarrheao, OMIM #214700) with a previous diagnosis of Bartter 
syndrome using NGS 
Choi et al. (2009) 
First use of NGS in the discovery of alleles associated with a 
Mendelian disease trait; WES uncovered DHODH mutations in 
individuals with Miller syndrome by enriching for variants between 
two siblings and in two unrelated affected individuals (OMIM 
#263750) 
Ng et al. (2010) 
WES used to uncover the role of WDR62 mutations in patients with 
severe brain malformations 
Bilgüver et al. (2010) 
WES was used to uncover autosomal dominant mutations in 
SETBP1 in Schinzel-Giedon syndrome, that were shown to be de 
novo following Sanger sequencing of the patients parents 
Hoischen et al. (2010) 
WES used to uncover the role of MLL2 mutations in patients with 
Kabuki syndrome (OMIM #147920) 
Ng et al. (2010) 
WES used to identify de novo mutations in POP1 in two siblings 
with previously unclassified anauxetic dysplasia (OMIM #607095) 
Glazov et al. (2011) 
WES, together with linkage data, used in the discovery of variants 
in POLE and POLD (OMIM #615083, #612591, respectively) 
associated with predisposition to multiple CRA and CRC  
Palles et al. (2013) 
WES used to identify ERCC4 as a candidate gene for FA in one 
patient. Its role in an additional patient with previously unclassified 
FA symptoms was confirmed by Sanger sequencing of the gene 
(OMIM #615272) 
Bogliolo et al. (2013) 
WES used to uncover a role of STAMBP mutations in patients with 
microcephaly–capillary malformation syndrome (OMIM #614261) 
McDonell et al. (2013) 
NGS technologies used to identify driver mutations and pathways 
associated with oesphageal adenocarcinoma 
Dulak et al. (2013) 
WES of families with autism uncovers hypomorphic loci in genes 
implicated in other diseases 
Yu et al. (2013) 
 
Table 1.7 – A selection of developments and findings from NGS technology  
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Company Instrument (Base error rates) Amplification method Sequencing method Advantages Disadvantages 
Roche 
454 FLX Titanium/FLX Titanium +/ 
GS Jr. Titanium (All 1%) 
Emulsion PCR Pyrosequencing Long read lengths; fast 
Runs are expensive; 
problems with 
homopolymer repeats 
>8bp 
Illumina® 
GA II/HiSeq TM1000/Hiseq TM2000/ 
MiSeq /HiScanSQ (All 0.1%) 
Solid phase 'bridge' 
PCR 
Sequencing by 
synthesis 
Low running costs; 
widely used 
High start-up costs; 
difficult to multiplex 
samples; short read 
lengths 
Life 
technologiesTM 
SOLiD TM4 (0.06%)/SOLiD TMPI/ 
SOLiD TM4hq 
 (Both 0.01%) 
Emulsion PCR Sequencing by ligation 
Runs are inexpensive; 
highest accuracy 
Slow; short read 
lengths; high start-up 
costs 
Life 
technologiesTM 
Ion torrentTM PGMTM 314/316/318 
chip (All 1.2%) 
Emulsion PCR H+ detection synthesis 
Fast, platform is 
inexpensive 
Short read lengths; 
long sample 
preparation times 
Pacific 
bioscienceTM 
PacBio RS/RS II (13%) 
None - sequences 
single DNA molecules 
Real time 
Longest read lengths; 
runs are inexpensive 
High start-up costs; 
high error rates 
  
Table 1.8 – Summary of current available NGS technologies (Glenn, 2011; Henson et al. 2012; Liu et al. 2012) 
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1.7.2 Gene discovery strategies 
NGS has made substantial advances in determining the genetic architecture 
of many diseases, notably in the discovery of rare variants that previous studies did 
not have the power to detect (Table 1.7). However, the sheer amount of data 
produced with NGS can make finding disease-causing variants difficult; between 
20,000 and 50,000 variants in a single sample are typically identified through WES 
(Gilissen et al. 2012). This number grows considerably when variation in the whole 
genome is considered (Pabinger et al. 2013). Therefore, techniques to identify 
potential disease causing alleles are required (Cooper and Shendure, 2011). 
The selection of samples can aid greatly in the genetic enrichment process, 
and help to keep cost down. Two general strategies have been previously outlined; 
the sequencing of patients exhibiting extreme phenotypes (Li et al. 2011) and the 
sequencing of families. Sequencing of siblings, or other family members, with similar 
phenotypes can be useful in identifying a common causative allele (Gilissen et al. 
2012), whilst focusing of family trio’s can be helpful when investigating inheritance 
patterns or in the discovery of de novo mutations (Bamshad et al. 2011). 
Since the vast majority of known Mendelian disease-causing mutations are in 
protein coding regions, it is rational to consider protein coding variants to be the most 
deleterious. However, approximately 90% of coding variants identified are known 
polymorphisms (Robinson et al. 2011), and are therefore unlikely to be pathogenic. 
Filtering for novelty status or by rarity helps to focus the search whilst maintaining 
power to detect a casual variant. Both can be assessed by using online databases, 
such as dbSNP (NCBI Resource Coordinators, 2013), the 1000 genome project 
(1000 Genomes Project Consortium et al. 2010) and Ensembl (Flicek et al. 2013). 
Another approach involves assessing whether potential variants are predicted to be 
deleterious to protein function. For example, truncation, splice site, frameshifting 
insertions and deletions, and nonsynonymous variants are all likely to have 
functional implications. Multiple online tools are available to assess how a 
nonsynonymous variant may affect a proteins function, including SIFT (Ng and 
Henikoff, 2001), Align-GVGD (Tavtigian et al. 2006) and PolyPhen-2 (Adzhubei et al. 
2010). 
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Validation of variants identified is important. False positive can often arise as 
a result of poor mapping of reads or sequencing errors, whilst false negatives can 
occur as a result of poor coverage, poor calls of variants or poor capture of particular 
regions, particularly in WES (Majewski et al. 2011; Gilissen et al. 2012).  
1.7.2.1 Complex traits 
Complex traits with a known degree of heritability display high degrees of 
locus heterogeneity, with casual variants present in multiple different genes (Lander 
and Schork, 1994; Glazier et al. 2002). Previously, GWAS have made considerable 
headway in uncovering common loci that predispose to complex genetic traits 
(Hindorff et al. 2013). However, it has been suggested that additional rare variants 
could potentially further explain the percentage of heritable cases not explained by 
current genetic understanding; the so called ‘missing heritability’ (Manolio et al. 
2009).  
In the ‘common-disease-rare variant’ hypothesis, rare variants could 
potentially have a dramatic effect on overall risk (Pritchard, 2001; Bodmer and 
Bonilla, 2008). Typically, rare variants are not included on the large scale genotyping 
arrays used in GWAS. Also, due to the low frequency of such potential variants, 
GWAS are not powerful enough to detect linkage with such variation (McCarthy and 
Hirschhorn, 2008). Based on the observation that the vast majority of disease 
causing mutations affects protein coding regions, this suggests that WES could be a 
useful enrichment tool in rare variant discovery of complex disease (Kiezun et al. 
2012). 
Alternatively, it has been proposed that a low risk, common variant at a given 
loci uncovered by GWAS could be within haplotypes encompassing rarer variants 
that individually have a high effect on disease risk and are therefore likely to be the 
true casual variants (Dickson et al. 2010). This indirect association is referred to as 
synthetic association (Goldstein, 2009) and could be particularly helpful when 
considering regions of the genome to focus on in NGS. For example, following 
analysis of the region surrounding a GWAS locus for type 1 diabetes, four rare 
variants were discovered that were significantly associated with protection against 
the disease (Nejentsev et al. 2009). This highlights the validity of looking at GWA loci 
as an approach for rare variant discovery using NGS in complex disease. 
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1.7.2.2 Mendelian disorders 
NGS is also important in the diagnosis and discovery of the causes of 
Mendelian disorders that have previously been missed using traditional approaches 
(Bamshad et al. 2011). The use of NGS as a diagnostic tool was first displayed by 
Choi et al. (2009) who uncovered a homozygous missense variant in solute carrier 
member 26, member 3 (SLC26A3), known to cause congenital chloride diarrhoea, in 
patients previously diagnosed as having Bartter syndrome. 
NGS has also become a powerful tool in the discovery of Mendelian 
disorders. The first casual variant of a Mendelian disease trait to be uncovered by 
WES occurred in 2010 by Ng et al (2010); the researchers identified the underlying 
cause of previously undefined Millers syndrome in 6 kindred’s. Since then, WES has 
been used to uncover multiple underlying alleles associated with Mendelian 
disorders (Table 1.7). 
In hereditary CRC, Palles et al. (2013) used WGS, together with pre-existing 
linkage data, to examine 13 families with CRA and CRC without any known 
hereditary CRC gene mutations. They discovered a nonsynonymous variant, 
Leu424Val that falls within the catalytic subunit of the POLE complex; important in 
leading strand DNA synthesis during replication and repair. Additionally, the same 
research discovered a second predisposition allele in two different families, 
consisting of the nonsynonymous variant, Ser478Asn, seen in the catalytic subunit of 
POLD. Again, POLD is involved in DNA synthesis and repair but in the lagging 
strand. 
1.8 Genetic model systems of DNA repair 
 Adequate DNA repair mechanisms are critical for viable life (Alberts et al. 
2002). Chemically, the damage that arises in DNA is the same between organisms 
(Lindahl, 1993). Both prokaryotic and eukaryotic organisms are used as models for 
various DNA repair pathways and the degree of conservation shown highlights the 
importance in evolution. The use of genetic modelling systems is invaluable in 
gaining insight of how genetics influences protein function in a complex system in 
vivo (Table 1.9). The choice of model organism used for genetic manipulation relies  
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 Specie Advantages Disadvantages 
Escherichia coli (E.coli) 
Easy to genetically manipulate; 
cheap; genome well annotated; 
well-studied 
Not representative of a multicellular 
organisms; major difference with 
humans in most DNA repair 
pathways; prokaryote 
Saccharomyces 
cerevisiae (S.cerevisiae; 
also referred to as 
‘budding yeast’) 
Easy to genetically manipulate; 
cheap; genome well annotated; 
well-studied; pathways more 
similar to humans than E.coli; 
as a haploid organism it is 
useful for studying effects of 
recessive mutations 
Not representative of a multicellular 
organism; not a mammal; some 
differences in DNA repair pathways 
Schizosccharomyces 
pombe (S.pombe; ‘fission 
yeast’) 
Easy to genetically manipulate; 
cheap; genome well annotated; 
well-studied; pathways more 
similar to humans than E.coli; 
as a haploid organism it is 
useful for studying effects of 
recessive mutations; excises 
mammalian introns (unlike 
S.cerevisiae) 
Not representative of a multicellular 
organism; not a mammal; some 
differences in DNA repair pathways; 
alternative pathway for the repair of 
UV light 
Drosophilla melanogaster 
(fruit fly) 
Representative of a multicelluar 
organism; genome is well 
annotated; easy and cheap to 
use in the laboratory 
Differences between DNA repair 
pathways; not a mammal 
Caenorhabditis elegans 
(round worm) 
Representative of a 
multicellular organism; genome 
is well annotated; easy and 
cheap to use; easy to 
genetically manipulate 
Differences between DNA repair 
pathways; not a mammal 
Mus muscularis (mouse) 
Mammal; easy to genetically 
manipulate; genome is well 
annotated; large proportion of 
genome (>80%) homologous 
with humans 
Some differences in DNA repair 
pathways 
Table 1.9- Advantages and disadvantage of organisms commonly used as model systems i 
the study of human DNA repair pathways 
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heavily on the conservation of proteins and pathways. Also, particular organisms 
have ‘back up’ DNA repair pathways not seen in other organisms which need to be 
taken into account when choosing an organism for a genetic study. 
 1.8.1 MMR pathway 
 The MMR pathway has been well characterised in E.coli (Lahue et al. 1989). 
However, E.coli possess only three MMR exclusive proteins (MutS, MutL and MutH) 
whilst humans and other eukaroytes employ many more (Augusto-Pinto et al. 2003) 
all of which are homologs of MutS or MutL which are essential for MMR in all species 
(Kolodner, 1996). No homologs of MutH have been identified in humans.  
 The pathway has also been well studied in S.cerevisiae, S.pombe and 
C.elegans, and display more similarities to humans. For example, there are multiple 
homologs of both MutS and MutL involved in the pathway, though again none have 
MutH homologs (Harfe and Jinks-Robertson, 2000). There are far fewer MMR 
homologs present in D.melanogaster, although at least one of both MutS and MutL 
homologs are present (orthologs of MSH6, MLH1 and PMS1; Sekelsky et al. 2000). 
 1.8.2 BER pathway 
 The BER pathway is well conserved in most organisms, indicating its 
importance in survival. Studies of E.coli have been important in the understanding of 
mechanisms of repair, with most key proteins conserved from E.coli to eukaryotes 
(Robertson et al. 2009). Although most DNA glycosylases are conserved between 
species, there are some key differences of note. For example, there is no S.pombe 
homolog of OGG1 (Eisen and Hanawalt, 1999; Chang and Lu, 2005), however, it is 
conserved in S.cerevisiae, mice and various other organisms (Arai et al. 1997; 
Radicela et al. 1997). Also, the human glycosylase TDG is conserved in E.coli (Mug) 
but not in S.cerevisiae despite being conserved in S.pombe. One of the only major 
differences in D.melanogaster is the apparent lack of a POLB homolog (Sekelsky et 
al. 2000). The BER pathway is not well conserved in C.elegans, with homologs for 
only a couple of human DNA glycosylases (Eisen and Hanawalt, 1999; Leung et al. 
2008). All major components of the BER pathway are conserved in mice making it an 
excellent model organism of the pathway. 
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1.8.3 NER pathway 
 There are key differences in the repair of bulky, helix distorting adducts 
between E.coli and eukaryotes .Despite both being able to adequately excise bulky 
adducts such as those formed following UV treatment, the proteins involved vary 
greatly. E.coli uses a system known as the UvrABCD pathway, which functions in 
much the same way as the eukaryotic NER system (Hoeijmakers, 1993a; Truglio et 
al. 2006). However, there is little homology with those proteins involved in eukaryotic 
organisms. Also far fewer proteins are required in E.coli excision repair in 
comparison to eukaryotic repair (Prakash and Prakash, 2000; Cleaver et al. 2001).  
 S.cerevisiae is probably the best studied eukaryotic model organism of NER. 
There is a very high level of protein homology with humans (Hoeijmakers, 1993b; 
Prakash et al. 1993; Wood, 1997), although there are a few key differences in 
protein specificity between organisms (Eisen and Hanawalt, 1999). A similar degree 
of homology is observed in C.elegans, however no protein homologous to DDB2 or 
CSA have been identified (Lans and Vermeulen, 2011).  
S.pombe also displays a level of high conservation and homology with human 
NER proteins (Lehmann, 1996; Egel, 2004). However, S.pombe possesses a second 
UV damage repair pathway which was first recognised in NER knockouts when UV 
adducts were still repaired at a substantial rate (Birnboim and Nasim, 1975). 
Additionally S.pombe NER knockouts fail to display the same degree of sensitivity as 
the S.cerevisiae counterparts (Lehmann, 1996). The UV damaged DNA 
endonuclease (Uve1) –dependent excision repair pathway (UVER) has been shown 
to excise both 6-4,PPs and CPDs much more rapidly than the NER pathway 
(Yonemasu et al. 1997).  
D.melangoster appears to lack a TC-NER pathway, since no CSA or CSB 
homologs have been identified, and relies solely GG-NER (Keightley et al. 2009). In 
rodents, GG-NER of CPDs is significantly less efficient than in humans, due to a lack 
of p48 which is induced to upregulate NER (Tang et al. 2000). 
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1.8.4 DSB repair pathways 
 In E.coli, the only method for the repair of DSB is through HR. Although there 
is some degree of homology of the proteins involved, the main steps are carried out 
by proteins quite different to human HR proteins. One gene that maintains a high 
level of conservation throughout various species, is RAD51; a protein key in the 
recognition of homology between strands and for strand guidance. Its retention 
throughout evolution highlights its importance in the repair of DSB (Modesti and 
Kanaar, 2001). Similarly, there are at least five human homologs of the E.coli 
helicase, RecQ, with mutations in these causing WS, BS and RTS (Brosh and Bohr, 
2007).  
 There are many similarities in the DSB repair pathways between S.cerevisiae, 
S.pombe, C.elegans and D.melanogaster and these organisms have been 
invaluable in the study of both HR and NHEJ (Sekelsky et al. 2000; Krogh and 
Symington, 2004; Raji and Hartsuiker, 2006; Lemmens and Tijsterman, 2011). 
However, both yeast organisms only have one homolog of RecQ whilst 
D.melanogaster and C.elegans both have four (Sekelsky et al. 2000). 
The main difference in the repair of DSB in mammalian cells compared to 
yeast is that the majority of repair in mammalian cells occurs via the NHEJ pathway, 
whilst in yeast it is through HR (Eisen and Hanawalt, 1999). 
1.8.5 ICL repair pathway 
The repair of ICL in E.coli is predominantly carried out via incision of the 
damaged strand by the NER protein system UvrABC, as well as by the coordination 
of HR proteins. Similarly, an orchestration of multiple pathways is known to operate 
in ICL repair in yeast (McVey, 2010). 
 The main difference in mammalian cells is the presence of the FA pathway for 
ICL repair. Of the proteins involved, homologs for four have been identified in 
C.elegans and D.melanogaster indicating that the pathway may be important in 
these organisms (Youds et al. 2009; McVey, 2010). A high level of conservation of 
the pathway is observed in mice, in which they have been extensively studied with 
regards to the effects of mutations on the development of phenotypes of FA (Bakker 
et al. 2013). 
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1.9 Aims of this project 
 
1. To identify novel low penetrance alleles in DNA repair pathways that 
predispose to CRC. 
 
2. To utilise exome resequencing in the identification of alleles associated with 
severe forms of oxaliplatin induced peripheral neuropathy. To independently 
validate findings. 
 
3. To further examine identified variants and their associated genes genetically. 
 
4. To create a model system to investigate the functional effects of variants 
associated with oxaliplatin induced peripheral neuropathy. To further 
investigate phenotypes associated with the introduced variants. 
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Chapter Two - Materials and methods 
2.1 List of suppliers 
 Materials and equipment were purchased from the following companies: 
ABgene Ltd (Surrey, UK) 
Acros Organics (See Thermo Fisher Scientific) 
Agilent Technologies (Berkshire, UK) 
Anachem Ltd (Bedfordshire, UK) 
Applied Biosystems (Chesire, UK) 
Becton, Dickinson and Company (Oxford, UK) 
Bibby Sterlin (See Thermo Fisher Scientific) 
Bioquote (York, UK) 
Biorad (Hertfordshire, UK) 
Corning Incorporated (Flintshire, UK) 
Eurogentec (Hampshire, UK) 
Fisher Scientific (Leichestershire, UK) 
Formedium (Norfolk, UK) 
GE Healthcare (Buckinghamshire, UK) 
Illumina (California, USA) 
Invitrogen Life Technologies (Strathclyde, UK) 
Jencon (West Sussex, UK) 
Labtech International (East Sussex, UK) 
Melford (Suffolk, UK) 
Microzone (Haywards Heath, UK) 
Millipore (Hertfordshire, UK) 
MJ Research (Massachusetts, USA) 
Molecular Dynamics (See GE Healthcare) 
MWG Biotech (Buckinghamshire, UK) 
New England Biolabs (Hertfordshire, UK) 
Pharmacia Biotech (See GE Healthcare) 
Qiagen (West Sussex, UK) 
R&D Systems (Oxford, UK) 
Sigma-Aldrich Ltd (Dorset, UK) 
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Stratagene (California, USA) 
Thermo Fisher Scientific (Massachusetts, USA) 
Vector (Peterborough, UK) 
VWR International (Leicestershire, UK) 
 
2.2 Materials 
 
2.2.1 Chemicals 
Analytical grade chemicals were purchased from either Sigma-Aldrich Ltd or 
Fisher Scientific unless otherwise stated. 
2.2.2 Polymerase chain reaction (PCR) 
AmpliTaq Gold DNA polymerase along with appropriate buffer and MgCl2 
were purchased from Applied Biosciences. Deoxyribonucleotide triphosphates 
(dNTPs) were purchased from GE healthcare. All primers (unless otherwise stated) 
were purchased from Eurogentec. Dimethyl sulfoxide (DMSO) was purchased from 
Sigma Aldrich. Mega mix gold (MMG) was purchased from Microzone. 
2.2.3 PCR purification 
Exonuclease I (Exo) was purchased from New England Biolabs. Shrimp 
alkaline phosphatase (SAP) was purchased from GE healthcare. Millipore Montage 
SEQ96 sequencing reaction clean-up kits were purchased from Millipore. 
2.2.4 Electrophoresis 
Agarose was purchased from Eurogentec. Ethidium bromide was supplied by 
Sigma Aldrich. For the purpose of safe disposal of running buffer, ethidium bromide 
destaining bags from Fisher Scientific were utilised. 100bp DNA ladder was 
purchased from New England Biolabs and 1kb Plus DNA ladder from Invitrogen Life 
Sciences. 
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2.2.5 Sanger sequencing 
BigDye Terminator cycle sequencing kit v3.1, POP6 polymer and HiDi 
formamide were all purchased from Applied Biosystems. Capillary electrophoresis 
buffers were purchased from Sigma Aldrich. 
2.2.6 Sanger sequencing clean up 
For the isopropanol method, isopropanol was purchased from Fisher Scientific 
and HiDi formamide was purchased from Applied Biosystems. For the Montage 
SEQ96 sequencing reaction clean up, kits were purchased from Millipore. 
2.2.7 TaqMan single nucleotide polymorphism (SNP) genotyping 
All assays and TaqMan universal mastermix were purchased from Applied 
Biosystems. Predesigned assays were used for RAD1 – rs1805327 
(C_25617909_10), POLG – rs3087374 (C_15793548_10), REV1 – rs3087403 
(C_15793621_10), BRCA1 – rs799917 (C_2287943_10) and ERCC6 - rs2228527 
(C_935106_20). 
2.2.8 Gene expression analysis  
Expression of target genes was analysed using intron spanning primers. Both 
colon and kidney first strand cDNA was purchased from Stratagene. 
2.2.9 Clinical material 
All blood samples from COIN, COIN-B, FOCUS2, FOCUS3 and PICCOLO 
were obtained with patient consent and with ethical approval for bowel cancer 
research. 
2.2.10 Bacteria culture reagents and solutions 
All solutions were made using dH2O water and autoclaved on a liquid cycle at 
15lb/sq.in at 121°C for 20 minutes. 
Luria Bertani (LB) Culture Medium 
1% w/v tryptone, 0.5% w/v yeast extract (Both Becton, Dickinson) and 1% w/v 
NaCl in 1L dH2O 
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LB agar Medium 
1.5% w/v bacterial agar (Becton, Dickinson), 1% w/v tryptone, 0.5% w/v yeast 
extract and 10% w/vNaCl in 1L dH2O 
Ampicillin Stock Solution 
50mg/ml of ampicillin sodium salt (Melford) was dissolved in dH2O, filter 
sterilised and stored at -20°C 
Glycerol (BDH Laboratories) for long term storage 
50% glycerol for long term storage of bacterial cultures was made by diluting 
250ml of 100% glycerol with 250ml dH2O.  
SOC Medium (Invitrogen) 
2% w/v tryptone, 0.5% w/v yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM 
MgCl2, 10 mM MgSO4 and 20 mM glucose 
2.2.11 Plasmids 
pAW1 was first constructed by Watson et al (2008), and was generously 
provided by Oliver Fleck (Bangor University). pAW8-ccdB was constructed and 
generously provided by Edgar Hartsuiker (Bangor University). pGEM-T easy vector 
and system were purchased from Promega. 
2.2.12 Chemically competent cells 
JM109 chemically competent E.Coli cells were obtained from Promega. 
2.2.13 Plasmid extraction kit 
For small scale plasmid extraction, QIAprep mini-preparation (here after 
termed miniprep) plasmid kits (Qiagen) were used unless otherwise stated. 
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2.2.14 Cre Recombinase 
 Cre recombinase enzyme and respective buffer were purchased from New 
England Biolabs. 
2.2.15 Site directed mutagenesis (SDM) 
QuikChange Lightning site directed mutagenesis kits were purchased from 
Agilent Technologies. 
2.2.16 Restriction enzymes 
All restriction endonucleases were supplied with the appropriate buffer by 
New England Biolab. 
2.2.17 S.pombe reagents and solutions 
All solutions were made using dH2O water and autoclaved on the liquid cycle 
at 15lb/sq.in at 121°C for 20 minutes. 
Yeast extract liquid (YEL) and Yeast extract agar (YEA) 
For YEL, 0.5% w/v yeast extract and 3% w/v glucose is made up to 1L in 
dH2O. This was supplementated with 100mg/L of adenine, histidine, uracil (ura), 
lyseine and arginine (all Formedium). For YEA, in addition to this 1.6% w/v Bacto-
agar was added.  
Minimal media agar (MMA) 
0.17% w/v yeast nitrogen base, 1.8% w/v Bacto-agar, 0.5% ammonium 
sulphate, 1% glucose in 1L of dH2O to pH 6.5. Appropriate supplements to a 
concentration of 100mg/L were added when required. 
Edinburgh minimal media (EMM) 
14.7mM potassium hydrogen phthalate, 15.5mM disodium phosphate, 
93.5mM ammonium chloride, 2% w/v glucose and 2% w/v Bacto-agar.  
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Malt extract agar (MEA) 
 3% w/v Bacto-malt extract and 2% w/v Bacto-agar. Appropriate supplements 
to a concentration of 100mg/L were added as required. 
TE – 0.1M Lithium Acetate (LiAc) 
10mM Tris, 1mM  EDTA, 0.1M LiAc pH 8.0 
40% PEG 4000 with 0.1M LiAc in TE (pH8.0) 
40% PEG 4000, TE pH8.0/ 0.1M LiAC pH8.0. 
2.2.18 Yeast strains 
All strains of S.pombe were generously provided by Oliver Fleck. These 
included EH238 (smt-0 ura4 D18 leu1-32), J129 (h- uve1::LEU2 leu1-32 ura4-D18) 
and 503 (h+ leu1-32 ura4-D18 [ade6-704]). 
 
2.2.19 Extraction of S.pombe genomic DNA 
Lyticase, proteinase K and ribonuclease (RNase) were purchased from 
Sigma-Aldrich. Phenol chloroform isoamyl-alcohol (PCIA) was purchased from 
Fisher Scientific. 
2.2.20 Drugs for S.pombe treatments 
 Oxaliplatin was purchased from R&D systems; methyl methanesulfonate 
(MMS, 99%) was purchased from Acros Organics; hydroxyurea (HU, 1M) was 
purchased from Formedium. 
2.3 Equipment 
2.3.1 Plastics and glassware 
 Plastic eppendorf tubes (0.65ml, 1.5ml and 2ml) were purchased from 
Bioquote, whilst 1.5ml tubes were purchased from Sigma. Sterile pipette tips and tips 
for multi-channel pipettes were purchased from Anachem. Sterile stripettes were 
purchased from Corning Incorporated. Sterile universals were purchased from Bibby 
Sterilin. Fisher Scientific supplied 96 well Thermo-Fast PCR reaction plates, whilst 
4titude adhesive PCR sealing sheets were obtained from ABgene. 0.2ml plastic strip 
 63 
 
tubes were also obtained from ABgene. Glass flasks and beakers were obtained 
from Jencons or Fisher Scientific.  
2.3.2 Thermocycling 
Thermocycling was carried out using an MJ Research DNA engine tetrad 
PTC-225. 
2.3.3 Electrophoresis 
Electrophoresis was carried out in an AB gene AB0708 100V gel tank using a 
BioRad 200/2.0 power pack. Visualisation of ethidium bromide stained gels was 
achieved using a BioRad GelDoc XR transluminator. 
2.3.4 Taqman SNP genotyping  
Taqman SNP genotyping assays were analysed using either the Applied 
Biosystems 7900HT Real-Time PCR system (in Germany) or Applied Biosystems 
7500 Real-Time PCR system (in Cardiff). 
2.3.5 Sanger sequencing 
 Sanger sequencing was carried out on an ABI 3100 Genetic Analyser 
(Applied Biosystems). All data was analysed and annotated using Sequencer v4.2. 
Reference sequences were obtained from online databases, including NCBI and 
Ensembl. 
2.3.6 Quantification of nucleic acids 
To measure the concentration of DNA, either an UV spectrophometer 
(NanoDrop ND-800, Labtech International) or a Qubit® 2.0 Fluorometer (Life 
technologies) with appropriate buffers was used.  
 2.3.7 Transfer of S.pombe 
 Transfer of S.pombe was carried out using a replicating block and a sterile 
piece of velvet. 
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 2.3.8 UV treatment  
 S.pombe cells were treated with UV light using a Stratalinker (Stratagene). 
2.4 Bioinformatics and statistical software 
 Genetic statistical analyses were carried out using the online program PLINK 
v1.07 (Purcell et al, 2007; http://pngu.mgh.harvard.edu/purcell/plink/). All variants run 
through PLINK were tested for accordance with the Hardy-Weinberg equilibrium 
(HWE; Hardy, 1908). In addition to PLINKs meta-analysis application, meta-analysis 
was run using Comprehensive meta-analysis, v2.0 (Biostat; http://www.meta-
analysis.com/index.html). Other statistical software utilised included IBM SPSS 
statistics 20. All primers were designed using Primer 3 v0.4.0 
(http://frodo.wi.mit.edu/primer3/) and checked for sequence specificity using the 
online program Primer-BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-blast/).  
Illumina’s GenomeStudio v2009.1 was used to analyse results of Illumina 
genotyping and produce data plots. It was also used to create reports with specific 
variant information for analysis using PLINK. 
Species alignment of amino acid and nucleotide sequences was carried out 
using the online tool Clustal-Omega (Goujon et al. 2010; 
http://www.ebi.ac.uk/Tools/msa/clustalo/), with sequences obtained from NCBI.  
Restriction enzymes were chosen based on recognition sites in DNA 
sequences identified via the New England Biolab Cutter, v2.0 
(http://tools.neb.com/NEBcutter2/index.php). 
 In silico analysis of variants effect on protein function was determined using 
the online algorithm tools Align-Grantham Variation/Grantham Deviation (Align-
GVGD; http://agvgd.iarc.fr/agvgd_input.php), Polymorphism Phenotype v2 
(PolyPhen-2; http://genetics.bwh.harvard.edu/pph2/) and ‘Sorting intolerant from 
tolerant’ (SIFT; http://sift.jcvi.org). LD data was obtained using Haploview v4.2 
(Barrett et al. 2005). 
 In analysis of exome sequencing data, FASTQ files were processed using 
BWA, calibrated using GATK and annotated using ANNOVAR by Dr James Colley 
(Cardiff University). 
 65 
 
2.5 Methods 
2.5.1 General reagents 
10 x TAE Buffer (for electrophoresis); 
400mM Tris, 200mM Acetic acid, 10mM EDTA to pH 8.0 
10 x TBS Buffer 
 1.5M NaCl, 0.05M Tris, pH 7.6 
2.5.2 Quantification of nucleic acids 
To measure the concentration of DNA, an UV spectrophometer at 
wavelengths of 260nm and 280nm was used. An absorbance ratio of 1.8 at these 
wavelengths was considered an indicator of high sample purity. Alternatively, a 
Qubit®2.0 fluorometer was used, measuring DNA at a wavelength of 260nm. For 
samples predicted to have a concentration less than 100ng/μl, high specificity 
standards and buffers were utilised. For samples predicted to have concentrations 
up to 1000ng/μl, broad range standards and buffers were utilised. 
2.5.3 Primer design 
 All primers were designed using Primer 3, v0.4.0 (Rozen and Skaletsky, 
2000). Wherever possible, primers were designed between 18-25 nucleotides in 
length, had an annealing temperature within 2oC of the respective partner, and had 
low predicted dimerisation and secondary structure formation. All primers were 
checked for locus specificity by using the Primer-Blast software. 
2.5.4 PCR 
 PCR allows for rapid and accurate amplification of a chosen region of DNA in 
vitro. The exponential manner of DNA amplification allows for the production of 
several thousand copies of the region of interest.  
Initial stages involve heating the reaction mixture to a temperature sufficient to 
disrupt hydrogen bonds between opposite bases, resulting in separation of double 
stranded DNA. This separation and a cooling in temperature allow the binding of 
primers designed specifically to the region of interest. Upon the action of a 
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thermostable DNA polymerase, a new strand is synthesised from the primer by 
incorporating dNTPs. This results in the production of a complimentary strand of 
DNA. Repetition of this process, usually between 25-40 times, results in the 
production of a large amount of specific product (Mullis et al, 1986). 
 Unless otherwise stated, standard PCR reaction mixtures consisted of 0.2mM 
dNTPs, 10pmols forward and reverse primer, GeneAmp 10x buffer (added to a final 
concentration of 10mM Tris-HCl, 50mM KCl, 1.5mM MgCl2, 0.01% (w/v) gelatine, 
pH8.3), 1U AmpliTaq Gold DNA polymerase, 5% DMSO and 40ng of DNA (in a final 
volume of 25μl). Cycling conditions consisted of an initial denaturation step of 95oC 
for 2 minutes, followed by 35 cycles of 95oC for 30 seconds, annealing temperature 
of between 50-60oC for 30 seconds, elongation step of 72oC for 30 seconds, and a 
final elongation of 72oC for 10 minutes. 
 For PCR amplification that had previously failed using standard procedures, 
MMG was utilised. 25ng of template DNA was added to 25pmol of respective 
forward and reverse primers, with half the reaction mixture consisting of MMG 
reagent (Contents trade secret; CTS). 
2.5.5 Agarose gel electrophoresis 
 Agarose gel electrophoresis is a method used to separate DNA on the basis 
of size and shape. Agarose, when solid, forms a matrix with pores running through, 
the size of which is determined by the concentration of the gel. When an electrical 
charge is applied, negatively charged DNA and RNA fragments will move towards 
the positive (anode) electrode, pulling them through the agarose matrix. Shorter 
molecules and those of a smaller size and shape move faster through the matrix 
than larger, bulkier molecules, resulting in separation of the product (Sambrook et al. 
1989). The product can be visualised by the addition of ethidium bromide, an 
intercalating agents that sits between bases in DNA. The compound forms 
fluorescent complexes in this setting and these can be viewed under UV light at a 
wavelength of 300nm. 
 Agarose gels were made with 1XTAE buffer to a concentration of 0.8-2% 
(dependant on the size of the fragments to be separated). Conical flasks were 
heated to allow the agarose to melt, cooled slightly and 0.05µg/ml of ethidium 
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bromide was added in a fume hood. This was poured into a gel tank and allowed to 
cool until set. The gel was then completely submerged in 1xTAE buffer in an AB0708 
100V gel tank. 2µl of loading dye (15% w/v ficol, 10mM Tris pH 8, 1mM EDTA, 0.2% 
orange G) was added to 8µl of sample and the entire volume was loaded onto the 
gel. Gels were run at 100V for around 40 minutes with a 100bp or 1kb DNA ladder. 
UV visualisation was carried out following separation and photographed using Bio-
Rad XR system. Ethidium bromide destaining bags were added to running buffer for 
a minimum of 24 hours to remove the dye before disposal. 
2.5.6 ExoSAP PCR purification  
 ExoSAP degrades any excess primers, ssDNA and phosphate groups from 
dNTPs. Exo is a 3’-5’ exonuclease which degrades excess single stranded 
oligonucleotides from reactions containing double stranded products.  SAP is an 
alkaline phosphatase that removes 5’-phosphates from the PCR product. 1µl of 
ExoSAP is added directly to the PCR products. The sample is then incubated at 
37°C for 60 minutes, followed by an enzyme deactivating stage of 80°C for 15 
minutes. 
2.5.7 Sanger sequencing 
 Sanger sequencing utilises dideoxyribonucleotide triphosphates (ddNTPs), 
which lack the 3’hydroxyl group of the deoxyribose sugars, being incorporated into 
an emerging strand by DNA polymerase. As a result of the missing group, there is 
chain termination (Sanger et al. 1977). Each ddNTP is labelled with a different 
coloured fluorophore and capillary electrophoresis can detect nucleotides up to a 
sequence length of approximately 500bps. 
 DNA from a PCR product is denatured and a specific primer bound. The 
action of DNA polymerase extends the chain from the primer, incorporating dNTPs. 
However, it is the random insertion of a ddNTP that terminates further ssDNA strand 
elongation. Capillary electrophoresis separates the ssDNA through the polymer, 
POP-6, on the basis of size. Smaller products travel fastest, and subsequently pass 
through the laser beam first. This activates the fluorophore and causes the emission 
of light at a particular wavelength depending on the incorporated ddNTP. 
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 BigDye Terminator v3.1 Cycle Sequencing kit was used to sequence ExoSAP 
treated PCR products. A reaction mixture was used based on the manufacturer 
instructions; 5µl purified PCR product was added to 0.2% BigDye v3.1 (CTS), 
10pmol desired primer, 1x BigDye sequencing buffer (CTS) and made up to 10μl 
with dH2O. 
 Cycling conditions consisted of 25 cycles of 96°C for 10 seconds, 50°C for 5 
seconds and finally 60°C for 3 minutes and 30 seconds 
 Products of BigDye termination sequencing reactions were subsequently 
cleaned of all unincorporated nucleotides and dyes by either the isopropanol method 
or using Montage SEQ Sequencing Reaction Clean-up kits. 
2.5.8  Isopropanol clean up method 
 In the isopropanol clean up method, 40µl of 75% isopropanol was added to 
10µl BigDye reaction mixture and left to incubate at room temperature for 30 
minutes. Samples were then centrifuged at 4000rpm for 45 minutes and inverted on 
absorbent paper to remove all isopropanol. Samples were then spun inverted at 
500rpm for 30 seconds and air dried in a dark place for 10 minutes to evaporate any 
residual liquid. The pellet was resuspended in 10µl of HiDi formamide. 
2.5.9 Montage SEQ96 sequencing clean up 
 Millipore Montage SEQ96 sequencing reaction clean-up kits provide an 
efficient way to remove salts and dye terminators from Big Dye v3.0 reactions in a 
similar manner to the isopropanol method. They employ size exclusion technology 
via a filter at the bottom of each well to retain sequencing products. 20µl of injection 
solution (CTS) was added to 10µl Big Dye product and the entire volume was 
transferred to a Millipore clean up plate. Suction was applied to the bottom of the 
plate for 6 minutes, which was then removed and blotted onto absorbent tissue. 25µl 
of fresh injection solution was added to the wells and suction was applied for another 
6 minutes. Once blotted again, 20µl of fresh injection solution was added to the wells 
and the plate placed on a microplate shaker for 6 minutes. 10µl was transferred from 
the clean up plate to a 96 well plate to be sequenced.  
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 Following both clean-up methods, samples were analysed using an ABI 3100 
analyser. Chromatograms were visualized and analysed using Sequencher v4.2. 
2.5.10 TaqMan SNP genotyping 
 TaqMan SNP genotyping assays make use of specific primer and probe sets 
in order to successfully assay for SNPs. During thermal cycling, allele specific 
probes labelled with different dyes (namely VIC and FAM dyes) are allowed to 
selectively bind to single stranded DNA. AmpliTaq Gold DNA polymerase extends 
from the primer, and due to the 5’ exonuclease activity of DNA polymerase, breaks 
down any probe that is bound. This results in the release of the allele specific dye 
from the immediate proximity of a quencher, leading to a measurable emission. 
 Reaction mixture was made containing 1 x Taqman Universal Mastermix 
(CTS), 1 x Taqman assay and a minimum of 10ng of DNA, to a final volume of either 
5µl (Applied Biosystems 7900HT Real-Time PCR system) or 25µl (Applied 
Biosystems 7500 Real-Time PCR system). A pre-read run was performed to 
determine any baseline fluorescence. PCR was then carried out in the real time 
machine with thermal cycling conditions consisting of an initial denaturation of 95°C 
for 10 minutes followed by 40 cycles of 92°C for 15 seconds and 60°C for 1 minute. 
Following amplification, a post read run using the original pre read document was 
carried out to subtract the baseline fluorescence. The sequence detection system 
(SDS) software was used to plot the result of the allelic discrimination run on a 
scatter plot of allele X versus allele Y. 
2.5.11 Gene expression analysis 
 Tissue specific expression of genes of interest was analysed by amplification 
with intron spanning primers using first strand colon and kidney cDNA as a template. 
Two sets of primers for each gene were utilised to gauge expression. Primer for β-
actin from the supplier was used as a positive control. PCR conditions consisted of 
an initial denaturation of 95°C for 2 minutes, followed by 40 cycles of 95°C for 1 
minute, 55°C for 1 minute and 72°C for 2 minutes, with a final elongation of 72°C for 
10 minutes. 
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2.5.12 Bacterial techniques 
2.5.12.1 General growth of bacteria 
 All glassware, equipment and reagents used were autoclaved before use. All 
bacterial work was carried out in sterile conditions. Cultures were incubated at either 
30°C or 37°C in line with optimum conditions for the plasmid used (pAW8 and p-
GEM T easy vector, respectively). 
2.5.12.2 Preparation of LB and LB-agar 
 LB and LB-agar were made up as described in section 2.2.10, adjusted to pH 
7 and autoclaved on a liquid cycle. In the case of LB-agar, solution was cooled to 
50°C and ampicillin added to the appropriate concentration. Where appropriate, 
0.5mM of isopropyl-β-D-thio-galactopyranoside (IPTG) and 80µg/ml of 5-bromo-4-
chloro-3-inodyl-D-galactoside (X-gal; both Sigma-Aldrich) were also added. 
Approximately 20ml was poured into the bottom of an 80mm petri dish and allowed 
to cool. All plates were stored at 4°C. 
2.5.12.3 Set up of starter cultures 
 For each culture, 5ml of LB was added to a universal along with the 
appropriate concentration of antibiotic. A sterile pipette tip was used to isolate and 
remove colonies from LB-agar plates and transferred to a universal. Cultures were 
left on an orbital shaker for 14-18 hours at either 30°C or 37°C at 200rpm. 
2.5.12.4 Long term storage of bacteria 
 For storage at -80°C, 500µl of 50% glycerol was added to 500µl of starter 
colonies. The solution was vortexed gently to mix and stored at -80°C. 
 Recovery of bacteria was carried out by thawing on ice, vortexing to mix and 
using a sterile loop to streak out the glycerol stock onto LB agar plates with 
ampicillin. Plates were incubated at either 30°C or 37°C overnight. 
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2.5.12.5 Ligation reaction 
 Purified PCR products were ligated into the pGEM-T easy vector system 
(Promega). The amount of PCR product required was calculated as follows; 
𝐼𝑛𝑠𝑒𝑟𝑡 (𝑛𝑔) =  
𝑉𝑒𝑐𝑡𝑜𝑟 (𝑛𝑔)𝑥 𝑆𝑖𝑧𝑒 𝑜𝑓 𝑖𝑛𝑠𝑒𝑟𝑡(𝑘𝑏)
𝑆𝑖𝑧𝑒 𝑜𝑓 𝑣𝑒𝑐𝑡𝑜𝑟 (𝑘𝑏)
 × 𝑖𝑛𝑠𝑒𝑟𝑡: 𝑣𝑒𝑐𝑡𝑜𝑟 𝑚𝑜𝑙𝑎𝑟 𝑟𝑎𝑡𝑖𝑜 
A reaction mixture consisting of 3 units of T4 DNA ligase, 1x T4 DNA ligase 
rapid ligation buffer, 50ng pGEM-T easy vector and the desired amount of PCR 
product. Ligation was carried out either at room temperature for 1 hour or at 4°C 
overnight. 
 2.5.12.6 Transformation of JM109 competent cells 
Transformation of JM109 was carried out via heat shock. This process results 
in semi-permeabilisation of the cell membrane, allowing for uptake of ‘naked’ DNA 
molecules into the cell. JM109 cells were thawed on ice and mixed gently by flicking. 
Two microliters of each ligation reaction and 50µl of cells were placed into eppendorf 
tubes on ice for 20 minutes.  Samples were heat shocked by placing on a 42°C heat 
block for 50 seconds, followed by immediately incubating on ice for 2 minutes. Each 
reaction was added to 950µl of SOC medium and incubated at 37°C with agitation 
for 1.5 hours, following which 100µl was spread onto LB agar plates containing 
ampicillin, X-gal and IPTG. Plates were incubated at 37°C for 16-18 hours. The 
pGEM-T vector carries the LacZ gene which encodes β-galactosidase; an enzyme 
which breaks down X-gal, resulting in the production of blue colonies. If the insert 
had been correctly taken up into the vector, there is disruption of the LacZ gene, 
resulting in no X-gal breakdown and colonies appear white in colour. This allows for 
easy selection of colonies with successful uptake of the vector and insert ligation 
product. 
2.5.12.7 Small scale purification of plasmids 
 All small scale plasmid purifications were carried out using QIAgen miniprep 
kit unless otherwise stated and following the manufacturer’s protocol. Extraction 
involves alkaline lysis of cells accompanied by gentle mixing; releasing DNA and 
denaturing proteins. By the addition of a neutralisation agent and adjustment of salt 
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levels, binding of DNA to a silica column and precipitation of proteins and other cell 
debris is facilitated.  
5ml starter cultures were harvested by centrifuging for 1 minute at 13,000rpm. 
Supernatant was discarded and the pellet re-suspended in 250µl of buffer P1, 
containing RNase (100µg/ml), 50mM Tris/HCl, 10mM EDTA. Following this, 250µl of 
lysis buffer (buffer P2; 200mM NaOH, 1% SDS) was added and the tube inverted 8-
10 times to mix, resulting in lysis of the bacterial cells. After approximately 1 minute 
(no longer than 5 minutes) 350µl of neutralisation buffer (buffer N3; 3M potassium 
acetate) was added and inverted 8-10 times to prevent the reaction going any 
further. The tube was centrifuged for 10 minutes at 13,000rpm. A P1000 pipette was 
used to transfer supernatant to a spin column. This was centrifuged for 1 minute at 
13,000rpm and the flow through discarded. A wash step was carried out by adding 
750µl of buffer PE, containing ethanol, and centrifuged for 1 minute at 13,000rpm to 
remove any salt. The flow was discarded, the tube was twisted slightly and 
centrifuged for 1 minute at 13,000rpm to ensure that all wash buffer had been 
removed since ethanol could interfere with some downstream applications. The 
QIAprep column was placed in a clean 1.5ml microcentrifuge tube and 50µl of dH2O 
added to the centre of each membrane, left for 1 minute on the bench and then 
centrifuged at 13,000rpm for 1 minute. 
2.5.12.8 Cre recombinase reaction 
Cre recombinase is a topoisomerase enzyme which catalyses both the in vitro 
and in vivo homologous recombination of DNA between lox sites allowing for site 
specific recombination. Lox sites are 34 base pair sequences consisting of 13 base 
pair inverted repeat sequences with a central 8 base pair spacer region. The 
efficiency of recombination can be altered by mutating nucleotides in the spacer 
region on the lox sites. By flanking cassette regions with two varying lox sites which 
display inefficient recombination with one another (in this study loxP and loxM3), we 
can efficiently and precisely carry out a double recombination at a particular locus 
(Hoess et al, 1986; Langer et al, 2002).  
Molar ratios of plasmid to insert were calculated depending on the size of 
each to calculate the concentration of insert that was required. A total concentration 
of 250ng of DNA was required for optimal recombination.  
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Standard reaction mixture consisted of appropriate volumes of insert and 
vector, 1xCre recombinase reaction buffer (33mM NaCl, 10mM MgCl2, 50mM Tris-
HCl, pH 7.5), 1U Cre recombinase and 5% PEG 8000, made up to a final volume of 
10µl. Solution was mixed thoroughly and incubated at 37°C for 30 minutes, followed 
by 70°C for 10 minutes to inactivate the enzyme. 
2.5.12.9 SDM  
 SDM is a technique used to introduce mutations of interest into plasmids. 
Mutant strand synthesis is carried out using primers designed with the mutation of 
interest incorporated. Using these primers on a suitable template, thermal cycling is 
carried out using a high fidelity PfuI enzyme. Following this, the paternal strand 
(which does not contain the mutation) is digested using DpnI; an endonuclease that 
degrades methylated and hemi-methylated DNA (Fig. 2.1). DNA that has been 
isolated from E.Coli is dam methylated and susceptible to this degradation. Finally, 
the mutated plasmid is transferred into competent cells (Kunkel, 1985). 
 All reactions were carried out using the QuikChange Lightning SDM kit, 
following manufacturers’ protocol. Primers consisting of between 30-37 base pairs 
with the mutation incorporated into both complementary pairs were used. PCR 
reaction mixture containing 2x QuikChange lightning buffer (CTS), 1.25pmol of both 
primers, 10mmol dNTPs, 6% QuikSolution reagent, 2.5U of PfuUltra HF DNA 
polymerase and 10ng of target plasmid  was made up to a final volume of 50µl with 
dH2O. Thermal cycling conditions for all reactions consisted of an initial denaturation 
of 95°C for 1 minute followed by 18 cycles of 95°C for 50 seconds, 60°C for 50 
seconds and 68°C for 1 minute/kb in size. An elongation step of 68°C for 7 minutes 
finished the cycle and all reactions were placed on ice for 2 minutes to cool the 
reaction below 37°C. Degradation of the paternal DNA was carried out by adding 1µl 
of DpnI directly to the reaction mixture and mixing thoroughly by pipetting up and 
down. Products were incubated in a water bath at 37°C for 1 hour 
For the transformation, XL-10 Gold ultracompetent cells were thawed on ice. 
Once thawed cells were mixed by gently flicking the tube and 45µl was pipetted into 
pre-chilled microcentrifuge tubes. To each reaction 2µl of XL-10 Gold β-
mercaptoethanol mix was added, pipetted up and down to mix and left on ice for 10  
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Figure 2.1 – SDM utilising QuikChange lightning SDM kit (M = mutation of 
interest) 
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minutes, swirling gently every 2 minutes. 2µl of DpnI treated product was added to 
each aliquot of cells and vortexed slightly to mix, incubating on ice for 30 seconds. 
To heat pulse, all tubes were placed on a heat block at 42°C for 30 seconds and 
immediately transferred to ice for 2 minutes. 500µl of preheated (42°C) SOC media 
was added to each reaction tube and incubated for 1 hour at 37°C on an orbital 
shaker at 225rpm. After this period 250µl was pipetted onto a LB agar plate with 
ampicillin incorporated and spread using a sterile spreader. Plates were incubated 
for 16-18 hours at 30°C (in order to suppress unwanted recombination between the 
lox sites of pAW8-ccdB) and successful colonies harvested. 
2.5.12.10 Electroporation  
Electroporation is a technique used to electrically induce pores in the cell 
membrane of bacteria, allowing the passage of solutions which otherwise could not 
cross the phospholipid bilayer (Neumann et al. 1982). 
All curvettes and microcentrifgue tubes were placed on ice 5 minute prior to 
experimentation. DH5α electrocompetant bacterial cells were thawed on ice and 
mixed by flicking the bottom of the tube. In a cold microcentrifuge tube, 25µl of cells 
were mixed with 1µl of DNA and stored on ice. Cells were transferred to 2mm 
curvettes, the outside dried carefully and placed in the micropulser. Following the 
application of 250 volts, 975µl of SOC medium was added immediately to the cells 
and transferred to a clean microcentrifuge tube. This was incubated for 2 hours with 
shaking at 180rpm. 100µl was subsequently pipetted and spread onto pre-warmed 
plates with selective antibody. 
2.5.13 S.pombe techniques 
2.5.13.1 Growth of S.pombe 
All glassware, equipment and reagents used were autoclaved before use. All 
cultures were incubated at 30°C. 
2.5.13.2 Preparation of EMM, MMA, MEA, YEA and YEL 
 EMM, MMA, MEA, YEA and YEL were made up as described in section 
2.2.17 and autoclaved on a liquid cycle. In the case of EMM, MMA, MEA and YEA, 
the solution was cooled to an appropriate temperature and appropriate supplements 
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and/or drug treatments being used were added. Approximately 25ml was 
subsequently poured into a petri dish whilst still in liquid form and allowed to set 
completely. 
When screening selectively for strains without functional orotidine 5'-
phosphate decarboxylase (ura4-), 0.1% w/v of 5-fluoroorotic acid (5-FOA; Melford) 
was added to YEA whilst still in liquid form and approximately 25ml poured into a 
petri dish before setting completely. 5-FOA, otherwise non-toxic to S.pombe, is 
converted to the toxic form 5-fluorouracil by Ura4, resulting in positive selection for 
ura4- strains. With regards to MMA plates, where in vivo Cre recombinase was 
required via controlled expression of Cre recombinase from pAW8, thiamine (thi, 
Acros Organics) was added to a final concentration of 15μM. Approximately 25ml 
was poured into the bottom of an 80mm petri dish and allowed to cool. All plates 
were stored at room temperature. 
2.5.13.3 Starter cultures 
 For each culture, 2ml of YEL was added to a sterile glass tube. A sterile loop 
was used to swab colonies from growing plates and transferred to the glass tube. 
Cultures were left on an orbital shaker for 18-24 hours at 30°C at 180rpm. 
2.5.13.4 Long term storage of S.pombe 
Long term storage of S.pombe was achieved by mixing 600µl of glycerol with 
400µl of overnight culture in YEL and freezing to -80°C. Cultures were restored by 
freeze thawing on ice, vortexing briefly and streaking onto YEA plates before 
incubating at 30°C. 
2.5.13.5 Colony PCR 
 A small amount of appropriate colony was taken from plates using a pipette 
tip and suspended in 25µl of dH2O. Samples were heated to 100°C for 5 minutes 
using a PCR machine to break down cell walls and membranes, following which they 
were centrifuged briefly and placed on ice. Standard Ampli-Taq PCR reaction 
mixture was added to a final volume of 25µl and placed on the thermal cycler. 
Thermal cycling conditions consisted of an initial denaturation of 95°C for 30 
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seconds, followed by 40 cycles of 95°C for 30 seconds, 50°C for 30 seconds and 
68°C for 1 minute. A final elongation of 68°C for 5 minutes completed the cycle. 
2.5.13.6 Extraction of genomic DNA - PCIA (25:24:1, pH 8)  
 The extraction of genomic DNA free of excess salts and other impurities was 
required for downstream applications such as sequencing. A small swab of culture 
was added to 2ml YEL and left to grow at 30°C with shaking at 180rpm for 
approximately 16-18 hours until in stationary phase. The culture was centrifuged for 
1 minute at 13,000rpm and supernatant disposed of. The pellet was resuspended in 
1 ml of solution A (1.2M sorbitol, 40mM EDTA, 20mM citric acid 20mM Na2HPO4, 
adjusted to pH5.6) with 500 units lyticase and incubated at 37°C for 90 minutes. This 
process acts to breakdown the yeast cell wall and after this time cultures were 
checked under the microscope to check for disruption.  
 The reaction was centrifuged for 30 seconds at 13,000rpm and the pellet 
suspended in 250µl of solution B (50mM Tris-HCl pH 7.5, 50mM EDTA and 1% 
SDS) and incubated at 65°C for 10 minutes, following which 250µl of solution C 
(50mM Tris-HCl pH 7.5, 50mM EDTA and 0.2mg proteinase K) was added. The 
whole reaction mixture was incubated for 90 minutes at 37°C. 
 1ml of PCIA (Fisher Scientific) was added to each reaction mixture in a fume 
hood. The reaction was mixed and centrifuged for 10 minutes at 13,000rpm. The 
aqueous phase was removed with a pipette and added to a clean eppendorf tube.  
 DNA was the precipitated by adding approximately 45µl of sodium acetate 
(NaAc) with 0.9ml of absolute ethanol and mixed. The reaction was left at room 
temperature for 10 minutes, following which DNA was precipitated by centrifuging for 
10 minutes at 13,000rpm. The supernatant was removed and left to air dry for 10 
minutes at room temperature. The pellet was re-suspended in 200µl of TE (pH 7.5). 
 Subsequently, 5µl RNase (10mg/ml; Sigma Aldrich) was added and the 
reaction incubated for 60 minutes at 37°C. 0.4ml of PCIA was added, mixed and 
centrifuged for 10 minutes at 13,000rpm. The aqueous phase was removed and 
transferred to a new eppendorf tube. DNA was precipitated again by adding 15µl 
NaAc alongside 400µl of absolute ethanol and incubating for 10 minutes at room 
temperature. The reaction mixture was centrifuged for 10 minutes at 13,000rpm and 
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supernatant discarded. The pellet was washed of excessive salt by addition of 1ml of 
70% ethanol and centrifuged for a further 5 minutes at 13,000rpm. The supernatant 
was removed and any excess ethanol was removed by tapping the inverted 
eppendorf on absorbent paper and air drying the pellet at room temperature for 10 
minutes. The pellet was re-suspended in 50µl of TE (pH7.5).  
 Extracted genomic DNA was quantified on a Qubit® 2.0 Fluorometer using 
high specificity buffers and standards. 
2.5.13.7 Lithium acetate (LiAc) plasmid transformation 
 The LiAc method of plasmid transformation allows for adequate 
permeabilisation of the cell wall of yeast cells through actions of lithium cations to 
allow for the uptake of plasmid DNA (Ito et al. 1983).  
Pre-cultures were made by adding a small amount of growing colony from 
plates to 5ml of YEL and incubating for 16-18 hours at 30°C with shaking at 180rpm. 
Between 75-150µl of the pre-culture was added to 50ml of YEL and incubated for 16-
18 hours at 30°C with shaking to a titre of 1-2 x 107 cells/ml. 
 10ml of culture was added to a clean test tube and centrifuged for 5 minutes 
at 2,800rpm. The supernatant was removed and the pellet suspended in 20ml dH2O 
to wash. A further centrifugation of 5 minutes at 2,800rpm was carried out. The 
supernatant was removed and the pellet suspended in 5ml TE pH 8.0/0.1M LiAc, 
and centrifuged for 5 minutes at 2,800rpm. The pellet was resuspended in 100µl TE 
pH8.0/ 0.1M LiAc, approximately 55μl of DNA sample added and incubated at 30°C 
for 30 minutes with soft shaking. 
 Following this, 0.7ml of 40% PEG 4000 and 100µl of TE with 0.1M LiAc 
(pH8.0) was added and incubated for 60 minutes at 30°C without shaking. 100µl 
DMSO was added and placed in a water bath at 45°C for 10 minutes to heat shock. 
This was followed by centrifugation at 2,800rpm for 5 minutes. The supernatant was 
carefully removed and the pellet was resuspended in 250µl dH2O. Volumes of 50µl 
and 200µl were pipetted onto the centre of a selective medium plate and spread 
sterilely over the plate. Plates were left to air dry in the hood and then placed at 30°C 
for incubation. 
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2.5.13.8 Spot test assays – production of plates 
Spot test experiments were carried out for MMS, HU and UV treatment. MMS 
is an alkylating agent that adds methyl groups to nitrogen atoms in purines. HU 
prevents the production of new nucleotides by inhibiting ribonucleotide reductase. It 
therefore inhibits DNA synthesis and repair by depleting the dNTP pool.  
 Approximately 25ml of heated liquid YEA was aliquoted into falcon tubes and 
allowed to cool to around 50°C. In the case of MMS and HU, appropriate volumes of 
drug were added to desired concentration and poured into petri dishes. All were 
allowed to cool and stored at room temperature for 2 days before use. 
 
  
 80 
 
Chapter Three – Identifying novel low penetrance alleles in DNA repair genes 
that predispose to CRC 
 
3.1 Introduction 
Despite evidence to suggest that up to a third of all CRC cases could be due 
to underlying genetics, only a proportion are explained by current understanding. 
Approximately 6% of CRC cases can be explained by rare, high penetrance variants. 
These include inherited mutations in APC (which cause FAP; Fearnhead et al. 
2001), MUTYH (MAP; Al-Tassan et al. 2002), SMAD4/BMP1R1A (JPS; Howe et al. 
1998; Howe et al. 2002), STK1/LTB1 (PJS; Aretz et al. 2005), POLE and POLD1 
(Palles et al. 2013), and various MMR genes (HNPCC; Peltomaki, 2001; as 
discussed in sections 1.2.1 and 1.7.2.2). It has been proposed that some of the 
remaining genetic risk could be due to the combined effect of multiple rare, low 
penetrance alleles; the so-called ‘common disease-rare variant’ hypothesis (Bodmer 
and Bonilla, 2008). Previous research has highlighted the role of rare variants in 
APC, CTNNB1, AXIN1 from the Wnt signalling pathway and MSH2 and MLH1 from 
the MMR pathway as collectively contributing to an increased risk of CRA 
(Fearnhead et al. 2004; Azzopardi et al. 2008; Section 1.2.2.2). In addition to these, 
GWAS have uncovered common, low penetrance variants that significantly 
contribute to CRC risk. In total, 20 alleles have been associated with CRC, and 
despite individual variant risk being relatively low, they are likely to act in concert to 
significantly alter disease likelihood (Section 1.2.2.1). 
Previous research has implicated the importance of DNA damage repair in the 
development of hereditary cancer syndromes (Section 1.3). With regards to CRC, 
conditions such as MAP and HNPCC are caused by underlying deficiencies in DNA 
repair pathways. In addition to the association between hereditary CRC and DNA 
repair, inactivation of the MMR gene, MLH1, has been shown to cause sporadic 
forms of CRC in up to 12% of cases as a result of the formation of a mutator 
phenotype (Ionov et al. 1993). This is due to epigenetic silencing of MLH1 via 
biallelic hypermethylation of CpG islands in the promoter region (Kane et al. 1997; 
Toyota et al. 1999). 
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Using a candidate gene approach to focus on genes in the DNA repair 
pathways, we sought novel associations between low penetrance variants and CRC 
risk. To do this, we attempted to genotype every nonsynonymous variant with a MAF 
≥4% in DNA repair gene in large case control cohorts. 
3.2 Materials and methods 
3.2.1 Samples 
3.2.1.1 Training phase – aCRC cases and controls 
We analysed 2,186 blood DNA samples from unrelated patients with aCRC 
from COIN (2,073 patients) and COIN-B (113 patients). COIN is a phase III trial, 
comparing two experimental arms with the control arm of oxaliplatin plus 
fluoropyrimidine chemotherapy in first line treatment. COIN-B is a phase II trial 
examining intermittent chemotherapy plus cetuximab. All patients gave fully informed 
consent for their samples to be used for bowel cancer research. We also analysed 
2,176 blood DNA samples from healthy controls from the UK Blood Services 
collection of Common Controls (UKBS collection; Wellcome Trust Case Control 
Consortium 2007, Wellcome Trust Case Control Consortium and Australo-Anglo-
American Spondylitis Consortium 2007). These samples were selected from a total 
of 3,092 samples within the UKBS collection that best matched the patients with 
aCRC in terms of place of residence within the UK (Table 3.1).  
3.2.1.2 Validation phase – aCRC cases and controls 
We analysed 1,053 blood DNA samples from unrelated patients with aCRC 
from COIN (10 patients that were not used in the training phase), COIN-B (85 
patients that were not used in the training phase), FOCUS2 (361 patients), FOCUS3 
(221 patients) and PICCOLO (376 patients that were not recruited into COIN or 
COIN-B). FOCUS2 is a trial for patients with unpretreated aCRC judged unfit for full-
dose combination chemotherapy. FOCUS3 is a trial to determine the feasibility of 
molecular selection of therapy using KRAS, BRAF and topoisomerase-1. PICCOLO 
is a trial for the treatment for fluorouracil-resistant aCRC. We also analysed 1,397 
blood DNA samples from unrelated healthy Caucasian controls from the UKBS 
collection (917 samples that were not used in the training phase) and from the  
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 Training phase 
 
aCRC cases (n=2,186) 
Controls 
(n=2,176) 
 
COIN 
(%) 
n=2,073 
 
COIN-B 
(%) 
n=113 
 
UKBS 
(%) 
n=2,176 
     
Age at diagnosis 
(aCRC)/sampling 
(controls) 
 
 
 
Mean 61.5 61.2 43.7 
<20 1 (0.0) 0 64 (2.9) 
20-49 232 (11.2) 13 (11.5) 1,317 (60.2) 
50-59 549 (26.5) 27 (23.9) 602 (27.7) 
60-69 845 (40.8) 49 (43.4) 193 (8.9) 
70-79 435 (21.0) 22 (19.5) 0 
80-89 9 (0.1) 2 (1.8) 0 
Missing 2 (0.1) 0 0 
Sex 
 
Female 698 (33.7) 48 (42.5) 1,074 (49.4) 
Male 1,375 (66.3) 65 (57.5) 1,102 (50.6) 
WHO-PS 
 
0 969 (46.7) 58 (51.3) - 
1 951 (45.9) 46 (40.7) - 
2 153 (7.4) 9 (8.0) - 
Primary Site 
 
Colon 1,119 (54.0) 37 (32.7) - 
Rectum 653 (31.5) 32 (28.3) - 
 
Table 3.1 – Clinicopathological data for patient/samples in COIN, COIN-B and the UKBS 
collection used as part of the training phase cohort 
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human randomised control (HRC) collection from the Health Protection Agency (480 
samples; Table 3.2). 
3.2.1.3 Population based analyses 
We analysed 2,169 DNA samples from unrelated CRC patients from the 
POPGEN cohort based in Kiel, Germany. These were in comparison to 2,968 DNA 
samples from either the POPGEN (n=604) or Study of Health in Pomerania (SHIP; 
n=2,364) cohorts, based in Kiel or Greifswald, Germany respectively. These samples 
acted as geographically -matched healthy controls (Table 3.3). Both trials were 
population-based biobank projects. 
In addition, we used publicly available data from another population based 
cohort consisting of 2,575 CRC cases (1,101 females and 1,474 males; mean age of 
diagnosis 59 years) recruited through the Institute of Cancer Research/Royal 
Marsden Hospital NHS Trust (RMHNHST) and 2,707 healthy UK controls (1,871 
females and 836 males; mean age at sampling 59 years) recruited as part of the 
National Cancer Research Network genetic epidemiological studies (n=1,075), the 
Royal Marsden Hospital Trust/Institute of Cancer Research Family History and DNA 
Registry (n=1,033) and the UK Study of Breast Cancer Genetics (n= 599; Webb et 
al. 2006).  
3.2.2 Genotyping of training phase cohort 
Genotyping of the training phase cohort was carried out using Illumina’s Fast-
Track Genotyping Services (San Diego, CA), using their high throughput 
BeadArrayTM technology on the GoldenGate® platform. Data was analysed and 
plotted using Illumina GenomeStudio v1.1. 
Genes were selected from a comprehensive list of  DNA repair genes 
(http://sciencepark.mdanderson.org/labs/wood/DNA_Repair_Genes.html) and were 
involved in BER, MMR, NER, HR, NHEJ, ICL repair (ICLR) or other DNA repair 
pathways (ODRP; Wood et al. 2005). Nonsynonymous variants with a MAF ≥4% 
were chosen through dbSNP (build version 129) or through additional literature 
reviews. Variant were identified by Christopher Smith and James Colley (Cardiff 
University; Table 3.4).  
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 Validation Phase 
 
aCRC cases (n= 1,053) Controls (n= 1,397) 
 
COIN 
(%) 
n=10 
COIN-B 
(%) 
n=85 
FOCUS2 
(%) 
n=361 
FOCUS3 
(%) 
n=221 
PICCOLO 
(%) 
n=376 
UKBS Controls 
(%) 
n=917 
HRC Controls 
(%) 
n=480 
          
Age at 
diagnosis 
(aCRC)/ 
sampling 
(controls) 
Mean 63 62.6 - - - 41.3 38.6 
<20 0 0 - - - 24 (2.6) 0 
20-49 0 13 (15.3) - - - 567 (61.8) 103 (21.4) 
50-59 2 (20) 16 (25.6) - - - 253 (27.6) 13 (2.7) 
60-69 8 (80) 29 (34.1) - - - 72 (7.9) 1 (0.2) 
70-79 0 24 (28.2) - - - 0 0 
80-89 0 3 (3.5) - - - 0 0 
Missing 0 0 - - - 1 (0.1) 358 (74.5) 
Sex 
Female 5 (50) 38 (44.7) - - - 477 (52) 249 (53.9) 
Male 5 (50) 47 (55.3) - - - 440 (48) 230 (47.9) 
Missing 0 0 - - - 0 1 (0.2) 
WHO PS 0 3 (30) 38 (44.7) - - - - - 
 1 7 (70) 41 (48.2) - - - - - 
 2 0 6 (7.1) - - - - - 
Primary Site Colon 3 (30) 55 (64.7) - - - - - 
 Rectum 7 (70) 30 (35.3) - - - - - 
 
Table 3.2 – Clinicopathological data for patient/samples in COIN, COIN-B, UKBS and HRC 
collections used as part of the validation phase cohort. Clinicopathological data for FOCUS2, 
FOCUS3 and PICCOLO trials were not available. 
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Population based cohort 
Cases (n=2,169) Controls (n=2,968) 
POPGEN 
(%) 
n=2,169 
SHIP 
(%) 
n=2,364 
POPGEN 
(%) 
n=604 
     
Age at 
diagnosis 
(CRC)/ 
sampling 
(controls) 
Mean  65.5 61.5 63.4 
<20  0 0 0 
20-49  
 
 
 
 
 
 
 
 
 
 
179 (8.3) 
469 (21.6) 
1,066 (49.1) 
182 (8.3) 
46 (2.1) 
1 (0.04) 
1,080 (49.8) 
1,089 (50.2) 
1,008 (46.4) 
904 (41.6) 
257 (11.8) 
302 (12.8) 1 (0.2) 
50-59 675 (28.6) 172 (28.5) 
60-69 761 (32.2) 235 (38.9) 
70-79 585 (24.7) 121 (20) 
80-89 41 (1.7) 0 
Missing 0 75(12.4) 
Sex 
Female 1,212 (51.3) 285 (47.2) 
Male 1,152 (48.7) 319 (52.8) 
Primary Site 
Colon -  
Rectum -  
Missing -  
 
Table 3.3 – Clinicopathological data for the patients/samples used in the POPGEN and SHIP 
population based collections 
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Gene Pathway Role in pathway Variants analysed  
ATM ODRP Essential kinase  rs1800058 [Leu1420Phe]; rs1801516 
[Asp1853Asn]; rs35813135 [Thr935Ala] 
ATR ODRP Essential kinase rs2227928 [Met211Thr]; rs2229032 
[Arg2425Gln]; rs34124242 [Ile1526Val] 
BRCA1 HR Nuclear 
phosphoprotein 
rs16942 [Lys1183Arg]; rs1799950 [Gln356Arg]; 
rs1799966 [Ser1613Gly]; rs28897674 
[Ser153Arg]; rs28897687 [Asn1236Lys]; 
rs4986850 [Asp693Asn]; rs799917 [Pro871Leu]; 
rs4986852 [Ser1040Asn] 
BRCA2 HR Involved in 
RAD51 loading 
onto DNA 
rs144848 [Asn372His]; rs28897708 [Ile505Thr]; 
rs28897727 [Asp1420Tyr]; rs28897729 
[Val1542Met]; rs28897731 [Val1643Ala]; 
rs28897758 [Leu3101Arg]; rs1046984 
[Ser599Phe]; rs28897743 [Arg2336Gln] 
BRIP1 HR Helicase with 
interactions with 
BRCA1 
rs4986764 [Ser919Pro] 
C19orf40 ICLR Role in the repair 
of inter-strand 
cross links 
rs2304103 [Ser158Leu]; rs3816032 [Ile192Thr] 
CHAF1A ODRP Chromatin 
assembly 
rs8100525 [Lys850Arg]; rs9352 [Ala923Val] 
CHEK1 ODRP Effector kinase rs506504 [Ile471Val] 
DCLRE1A ODRP DNA crosslink 
repair 
rs3750898 [Asp317His] 
DCLRE1B ODRP DNA crosslink 
repair 
rs12022378 [His61Tyr] 
DCLRE1C NHEJ Nuclease rs12768894 [His243Arg] 
EME1 HR Sub-unit of 
nuclease 
rs12450550 [Ile350Thr]; rs17714854 [Phe63Leu] 
ERCC2 NER 5’ to 3’ DNA 
helicase 
rs13181 [Lys751Gln], rs1799792 [His201Tyr] 
ERCC4 NER 5’  incision 
catalytic sub-unit 
rs1800067 [Arg415Gln] 
ERCC5 NER 3’ incision DNA 
binding sub-unit 
rs17655 [Asp1104His]; rs2227869 [Cys529Ser] 
ERCC6 NER Distortion 
recognition in 
transcription 
coupled repair 
rs2228527 [Arg1213Gly]; rs2228528 
[Gly399Asp]; rs2228529 [Gln1413Arg]; 
rs2228526 [Met1097Val] 
EXO1 ODRP 5’ exonuclease rs12122770 [Ser610Gly]; rs1776148 
[Glu670Gly]; rs4149963 [Thr439Met]; rs735943 
[His354Arg]; rs9350 [Pro757Leu] 
FANCA ICLR Part of FA core 
complex 
rs2239359 [Gly501Ser]; rs7190823 [Thr266Ala]; 
rs1800282 [Val6Asp]; rs11646374 [Ala412Val]; 
rs7195066 [Gly809Asp]; rs9282681 [Thr1328Ala] 
FANCD2 ICLR Protein 
recruitment 
 
rs3864017 [Pro714Leu] 
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Gene Pathway Role in pathway Variants analysed 
FANCE ICLR Part of FA core 
complex 
 
rs7761870 [Ser204Leu]; rs9462088 [Ala502Thr] 
FANCM ICLR Multiple roles in 
repair of ICL  
 
rs1367580 [Val878Leu]; rs3736772 [Pro1812Ala] 
FLJ35220 ODRP Incision 3' of 
hypoxanthine and 
uracil in DNA; 
inosine in RNA 
rs34933300 [Arg112Gln]; rs35549084 [Val29Ile] 
HEL308 ODRP DNA Helicase rs1494961 [Val306Ile] 
LIG1 BER and 
MMR 
DNA ligase – 
repairs nicks in 
ssDNA 
rs3730947 [Val349Met] 
LIG4 NHEJ DNA ligase – 
repairs nicks in 
ssDNA 
rs1805388 [Thr9Ile] 
MDC1 ODRP Recruitment of 
proteins to areas 
of damage  
rs9262152 [Arg268Lys] 
MGMT ODRP Methyltransferase 
that directly 
repairs DNA 
damage 
rs12917 [Leu84Phe]; rs2308321 [Ile143Val] 
MLH1 MMR Part of mismatch 
and loop 
recognition 
heterocomplex 
MutL 
rs1799977 [Ile219Val] 
MLH3 MMR  Part of loop 
recognition 
heterocomplex 
MutL 
rs175080 [Pro844Leu]; rs28756982 [Val420Ile]; 
rs17782839 [Ser966Pro] 
MMS19 NER Roles in 
stabilising and 
recruiting proteins 
rs29001285 [Val197Ile]; rs3740526 [Gly790Asp] 
MSH3 MMR Part of loop 
recognition 
heterocomplex 
MutS 
rs184967 [Gln949Arg]; rs26279 [Ala145Thr]; 
rs1650697 [Ile79Leu] 
MSH4 MMR MutS homolog rs5745459 [Tyr589Cys]; rs5745549 [Ser914Asn]; 
rs5745325 [Ala97Thr] 
MSH5 MMR MutS homolog rs1802127 [Pro786Ser]; rs28381349 [Leu85Phe] 
MUS81 HR Subunit of a 
structure specific 
nuclease 
 
rs13817 [Arg37His]; rs545500 [Arg180Pro] 
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Gene Pathway Role in pathway Variants analysed  
MUTYH BER DNA glycosylase rs3219484 [Val22Met]; rs3219489 [Gln335His] 
NBN HR Acts in complex 
to repair double 
strand breaks 
rs1805794 [Glu103Gln] 
NEIL3 BER DNA glycosylase rs13112390 [Gln471His]; rs1876268 
[Gly520Arg]; rs34193982 [His286Arg]; 
rs7689099 [Pro177Arg] 
OGG1 BER DNA glycosylase rs1052133 [Ser326Cys]; rs17050550 [Ala85Ser] 
PARP1 ODRP Poly-ADP-
ribosylation 
protein 
rs1136410 [Val762Ala] 
PARP2 ODRP Poly-ADP-
ribosylation 
protein 
rs3093921 [Asp186Gly]; rs3093926 [Arg247Gln] 
PMS2 MMR Part of mismatch 
recognition 
heterocomplex 
MutL 
rs2228006 [Lys541Glu]; rs1805321 [Pro470Ser] 
POLE NER, 
MMR 
DNA polymerase rs5744934 [Asn1396Ser]; rs5744751 [Ala252Val] 
POLG BER DNA polymerase 
in mitochondrial 
DNA 
rs3087374 [Gln1236His] 
POLI ODRP DNA polymerase 
involved in lesion 
bypass 
rs8305 [Ala706Thr] 
POLL NHEJ Gap filling DNA 
polymerase 
rs3730463 [Thr221Pro]; rs3730477 [Arg438Trp] 
POLM NHEJ Gap filling DNA 
polymerase 
rs28382644 [Gly220Ala] 
POLN ODRP DNA polymerase rs10011549 [Gly336Ser]; rs11725880 
[Pro315Ser]; rs2353552 [Gln121His]; rs9328764 
[Arg425Cys] 
POLQ  ODRP DNA polymerase rs1381057 [Gln2513Arg]; rs3218634 
[Leu2538Val]; rs3218649 [Thr982Arg]; 
rs3218651 [His1201Arg]; rs487848 [Ala581Val]; 
rs532411 [Ala2304Val] 
PRKDC NHEJ Catalytic subunit 
of a DNA kinase 
rs8178017 [Met333Ile] 
RAD1 BER 
 
Sub-unit of 9-1-1 
complex DNA 
damage sensor 
rs1805327 [Glu281Gly] 
RAD17 ODRP DNA damage 
sensor 
rs1045051 [Leu546Arg] 
RAD18 ODRP Ubiquitin ligase 
 
rs373572 [Arg302Gln] 
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Gene Pathway Role in pathway Variants analysed  
RAD23B NER Recognise DNA 
distortion  
rs1805329 [Ala249Val] 
RAD51L1 ODRP Involved in 
recruitment of 
proteins 
rs34594234 [Lys243Arg] 
RAD51L3 HR Role in early 
stages of DNA 
strand pairing 
rs4796033 [Arg165Gln] 
RAD52 HR Accessory factor 
in recombination 
rs7487683 [Gly180Arg] 
RDM1 HR Repair of double 
strand breaks 
rs2251660 [Cys127Trp] 
RECQL5 HR, 
ODRP 
DNA helicase rs820196 [Asp453Gly] 
REV1 ODRP Scaffold for DNA 
polymerases  
rs3087386 [Phe257Ser]; rs3087399 
[Asn373Ser]; rs3087403 [Val138Met] 
REV3L ODRP Catalytic subunit 
of POLZ 
rs3204953 [Val2986Ile]; rs458017 [Tyr1078Cys]; 
rs462779 [Thr1146Ile] 
RPA1 NER Pre-incision 
complex 
rs5030755 [Thr351Ala] 
TDG BER DNA glycosylase rs2888805 [Val367Leu] 
TDP1 ODRP Repair of DNA 
topisomerase 
cross links 
rs28365054 [Ala134Thr] 
TP53 ODRP Critical in 
regulation of cell 
cycle 
rs1042522 [Pro72Arg] 
WRN HR,  Helicase and 3’-
exonuclease 
rs1346044 [Cys1367Arg]; rs1800391 
[Met387Ile]; rs2230009 [Val114Ile]; rs2725362 
[Leu1074Phe] 
XPC BER Recognise DNA 
distortion 
rs2228000 [Arg500Trp]; rs2228001 [Gln940Lys] 
XRCC1 BER Scaffold protein 
for LIG3 
rs1799782 [Arg194Trp]; rs25487 [Gln399Arg] 
XRCC2 HR DNA cross link 
and break repair 
rs3218536 [Arg188His] 
XRCC3 HR DNA cross link 
and break repair 
rs861539 [Thr241Met] 
XRCC4 NHEJ Ligase accessory 
factor 
rs28360135 [Ile134Thr] 
 
Table 3.4 –DNA repair genes with nonsynonymous variants with a MAF ≥4% assayed in the 
training phase cohort. Variants in each gene shown with rs numbers, followed by the amino acid 
substitution (in parentheses). Those highlighted in red failed genotyping on the GoldenGate platform 
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Genotyping of TTC23LHis22Arg (rs6451173) in the training phase cohort was 
carried out using KASPar technology by KBioscience (Hoddesdon, Hertfordshire, 
UK) 
3.2.3 Genotyping of validation phase cohort 
Genotyping of RAD1Glu281Gly (rs1805327), polymerase γ (POLG)Gln1236His 
(rs3087374) and REV1 Val138Met (rs3087403) in the validation phase cohort was 
carried out using KASPar technology. 
3.2.4 Genotyping of POPGEN samples 
 Genotyping of RAD1Glu281Gly, POLGGln1236His, REV1Val138Met, 
BRCA1Leu871Pro (rs799917) and ERCC6Arg1213Gly (rs2228527) in the population cohort 
was carried out using Taqman genotyping assays. Assays were analysed using 
either the Applied Biosystems 7900HT Real-Time PCR system (Germany) or Applied 
Biosystems 7500 Real-Time PCR system (Cardiff) and data was analysed using 
Applied Biosystems Sequence Detection Software (SDS) Software v2.3.  
3.2.5 PCR and Sanger sequencing 
The entire open reading frame (ORF), flanking intronic sequences and the 
5’UTR of RAD1, tetratricopeptide repeat protein 23-like (TTC23L), DnaJ homolog, 
subfamily C, member 21 (DNAJC21) and ribosome genesis protein (BRIX1) were 
amplified by PCR. PCR, verification by agarose gel electrophoresis, product 
purification, Sanger sequencing and sequencing clean up were carried out as 
described in sections 2.5.4 to 2.5.9. Sequences were analysed using Sequencer 
v4.6. All primers used are given in Appendices 1-4. 
3.2.6 Real time PCR 
We carried out real time PCR (RT-PCR) of alanine--glyoxylate 
aminotransferase 2 (AGXT2), BRIX1, DNAJC21, RAD1 and TTC23L using colon and 
kidney first strand cDNA. Two set of intron spanning primers for each gene were 
utilised to gauge expression (Appendix 5; Fig. 3.1). Primers for β-actin from 
Stratagene were used as a positive control. PCR (Section 2.5.4) was carried out with 
conditions consisting of an initial denaturation of 95°C for 2 minutes, followed by 40  
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Figure 3.1 – Schematic to demonstrate approximate size and structure of genes analysed with intron spanning primers to assay for gene expression 
in colonic and renal cDNA. Blue arrow represents forward primers and red arrow represents reverse primers. Closed boxes represent ORF, whilst open boxes 
represent non-coding exonic regions and horizontal line represents intronic regions 
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cycles of 95°C for 1 minute, 55°C for 1 minute and 72°C for 2 minutes, with a final 
elongation of 72°C for 10 minutes. Products were analysed on 1.5% agarose gels 
(Section 2.5.5). 
3.2.7 In silico analysis of variants 
LD between variants was assessed using Haploview v4.2. Species alignment 
of all mammals listed on NCBI was carried out using Clustal Omega. A list of 
common specie names are given in Appendix 20. Prediction of the damaging effects 
of coding variants on protein function was carried out using SIFT, Polyphen and 
Align-GVGD. 
3.2.8 Statistical analyses 
Single marker association analyses and meta-analyses were performed using 
PLINK v1.07 (Purcell et al. 2007). Meta-analysis was also performed using 
Comprehensive Meta-Analysis program (Biostat). Variants were analysed using 
Pearsons Chi square (X2) test for association under an allelic model (1 degree of 
freedom [d.f]), dominant (1d.f), recessive (1d.f) and genotypic model (2d.f). Violation 
of the HWE was also assessed. Correction for multiple testing was carried out using 
the Bonferroni test. Logistic regression was used to analyse data dependant on sex 
and age for the training phase cohort only since inadequate data was available for 
validation phase cohort. 
3.2.9 Exclusion criteria for samples 
Following review of patient notes and medical records, 40 patients of a non-
Caucasian background in the training phase cohort were identified and subsequently 
removed to avoid population stratification. 
3.3 Results 
3.3.1 Utility of the training phase cohort to identify CRC susceptibility 
alleles 
Our training phase cohort of 2,186 unrelated British patients with aCRC and 
2,176 geographically-matched unrelated healthy British Caucasian controls has 
recently been used to help identify and validate novel CRC-susceptibility loci 
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(Houlston et al. 2010; Dunlop et al. 2012a). To further demonstrate the utility of this 
cohort to identify CRC-susceptibility alleles, we assayed a single genome-wide 
significant variant from ten of the known loci identified from GWAS of CRC risk 
alleles. Any cases identified as being of non-Caucasian origin (n=40) were excluded 
from this analyses. Genotyping concordance rates for duplicate samples (n=55) in 
the Golden Gate assay were 100% (550/550 genotypes were concordant) and 
GenTrain scores for the ten variants analysed ranged from 0.68-0.91. The overall 
genotyping success rate was 98.5% (42,982/43,620 genotypes called successfully; 
Fig. 3.2).  
We independently validated five of these loci using the training phase 
samples (Table 3.5). The OR observed in this study were all in the same direction to 
those given in Houlston et al. (2008). 
3.3.2 Identifying novel variants associated with CRC – Training phase 
cohort 
We attempted to assay every nonsynonymous variant with a MAF ≥4% in the 
training phase cohort in every DNA repair gene in the human genome (Wood et al. 
2005). Based on the number of samples in our training phase cohort, we had 72% 
power to detect a variant with a MAF of at least 4%, with an OR of 1.3 (with 5% 
significance levels). This effect size was chosen to calculate power because the 
largest OR seen from current GWAS for CRC was 1.28. We excluded samples 
known at the time to be of non-Caucasian ethnicity (n=40).  
We identified 180 nonsynonymous variants with a MAF ≥4% in DNA repair 
genes. Of these, 36 failed in silico locus conversion. Accordingly, 144 variants were 
genotyped representing 71 genes, of which 17 failed genotyping, meaning that we 
successfully genotyped 127 variants representing 68 genes. Genotyping 
concordance rates for duplicate samples (n=55) was 100% (6,985/6,985 genotypes 
were concordant), GenTrain scores ranged from 0.47 to 0.97 and the overall 
genotyping success rate was 99.73% (556,037/557,530 genotypes were called 
successfully). 
Three variants were in violation of HWE (rs175080, rs34193982 and 
rs34594234 at P=0.05). However, when corrected for multiple testing using the
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    Cases Controls       
Variant Chr 
Minor 
allele 
(A) 
Major 
allele 
(B) 
AA AB BB MAF AA AB BB MAF 
Dom  
X2  
P 
Rec  
X2  
P 
Geno  
X2  
P 
Allelic 
X2 
P OR L95 U95 
rs4939827 18q21 C T 419 1062 661 0.44 504 1113 558 0.49 1.4x10-4 3.8x10-3 1.6x10-4 16.85 4.04x10-5 0.84 (0.85) 0.77 0.91 
rs16892766 8q23 C A 13 389 1742 0.10 14 299 1862 0.08 1.1x10-4 0.88 4.1x10-4 12.8 3.39x10-4 1.32 (1.32) 1.13 1.53 
rs4779584 15q13 T C 113 715 1316 0.22 81 677 1413 0.19 1.5x10-2 1.1x10-2 8.3x10-3 9.06 2.61x10-3 1.17 (1.19) 1.06 1.3 
rs10795668 10p14 A G 194 904 957 0.31 226 968 889 0.34 1.1x10-2 0.13 3.1x10-2 6.59 1.02x10-2 0.89 (0.89) 0.81 0.97 
rs6983267 8q24 T G 435 1029 675 0.44 483 1067 617 0.47 2.7x10-2 0.12 6.0x10-2 5.5 1.9x10-2 0.90 (0.83) 0.83 0.98 
rs961253 20p12 A C 303 1019 821 0.38 281 1008 886 0.36 0.1 0.24 0.21 3.08 0.08 1.08 (1.13) 0.99 1.18 
rs9929218 16q22 A G 172 865 1105 0.28 181 930 1064 0.30 0.08 0.73 0.21 2.3 0.13 0.93 (0.88) 0.85 1.02 
rs4444235 14q22 C T 507 1044 589 0.48 459 1105 611 0.47 0.68 0.04 0.12 2.16 0.14 1.07 (1.12) 0.98 1.16 
rs3802842 11q23 C A 218 899 1027 0.31 216 874 1085 0.30 0.19 0.8 0.42 1.25 0.26 1.05 (1.21) 0.96 1.15 
rs10411210 19q13 T C 18 362 1764 0.09 23 356 1795 0.09 0.8 0.46 0.7 0.003 0.95 1.00 (0.79) 0.87 1.16 
 
Table 3.5 – Training phase data for variants and chromosomal position (chr) previously identified through GWAS. Variants were analysed using the 
Chi square test under dominant (dom), recessive (rec), genotypic (geno) and allelic models. Minor allele frequency (MAF), P values (P), odds ratios (OR) and 
lower (L95) and upper (U95) 95% confidence intervals (CI) were all calculated. Non-Caucasian samples were removed from analysis (n=40). OR from 
Houlston et al. (2008) shown in parentheses. 
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Figure 3.2 – Examples of genotype cluster plots for variants genotyped in the training phase cohort which had previously been identified as alleles 
associated with CRC risk through GWAS. Plotted using data generated from Illumina GenomeStudio v1.1. Blue are samples identified as AA, red as AB and 
green as BB. 
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Bonferroni technique, all variants were within HWE. Under an allelic model, we found 
that 9 variants, representing 7 genes, were significantly over-represented at the 5% 
level (genotyping plots given in Fig. 3.3). Only RAD1Glu281Gly (rs1805327) remained 
significant after Bonferroni correction for multiple testing (P= 0.03). 
LD was assessed between the variants in ERCC6 (rs2228527 and 
rs2228529) and BRCA1 (rs16942, rs799917 and rs1799966) using Haploview. High 
LD (r2 and/or D’ >0.8) was observed between the two variants in ERCC6 (r2=0.99, 
D’=1.0), as well as between the three variants in BRCA1 (rs1799966-rs799917, 
r2=0.88, D’=0.97; rs1799966-rs16942, r2=0.99, D’ = 0.99; rs16942-rs1799917, 
r2=0.9, D’=0.98).  
Variants in RAD1, POLG, REV1 and FANCA were all over-represented in 
controls suggesting a protective effect, whereas variants in BRCA1 and ERCC6 
were over-represented in cases. 
 Following adjustment by logistic regression for sex and age, REV1Val138Met, 
ERCC6Arg1213Gly, ERCC6Gln1413Arg, BRCA1Pro871Leu, BRCA1Lys1183Arg and 
BRCA1Ser1613Gly remained significant. However, following Bonferroni correction for 
multiple testing, none remained significant. 
3.3.3 Identifying novel variants associated with CRC – Validation phase 
cohort 
We screened our validation phase cohort for the most significant variant 
identified in the training phase cohort (RAD1Glu281Gly). We also genotyped 
POLGGln1236His and REV1Val138Met  in 846 aCRC patients from this cohort due to less 
available PICOLLO samples at the time of genotyping (all controls from the 
validation cohort were genotyped for these variants). Genotyping was carried out 
using KBiosciences KASPar technology and data was subsequently analysed using 
PLINK. Genotyping concordance rates for duplicate samples was 100% (66/66 
genotypes were concordant), and overall genotyping success rate was 93.9% 
(5,756/6,132 genotypes were called successfully). For RAD1Glu281Gly (Fig. 3.4), 102 
samples failed genotyping using KASPar technology. We therefore determined the 
genotypes of these samples by directly amplifying the target region by PCR and  
 
 97 
 
 
     Cases Controls      
Variant Gene 
Amino acid 
change 
Minor 
allele 
(A) 
Major 
allele 
(B) 
AA AB BB MAF AA AB BB MAF 
Dom  
X2  
P 
Rec 
X2  
P 
Geno  
X2  
P 
Allelic 
X2 
P OR L95 U95 
rs1805327 RAD1 Glu281Gly G A 10 245 1887 0.06 9 340 1825 0.08 8.6x10-5 0.79 2.9x10-4 13.51 2x10-4 0.73 0.62 0.87 
rs3087374 POLG Gln1236His A C 13 286 1844 0.07 15 350 1810 0.09 0.001 0.73 0.04 6.21 0.01 0.82 0.70 0.96 
rs3087403 REV1 Val138Met A G 151 842 1149 0.27 172 918 1085 0.29 0.01 0.28 0.04 5.72 0.02 0.89 0.81 0.98 
rs2228527 ERCC6† Arg1213Gly G A 92 666 1385 0.2 81 624 1470 0.18 0.04 0.34 0.11 4.37 0.04 1.12 1.01 1.25 
rs799917 BRCA1‡ Pro871Leu A G 243 975 925 0.34 237 917 1021 0.32 0.01 0.64 0.04 4.35 0.04 1.10 1.01 1.20 
rs16942 BRCA1‡ Lys1183Arg G A 228 968 945 0.33 222 913 1040 0.31 0.02 0.63 0.05 4.19 0.04 1.10 1 1.20 
rs1800282 FANCA Val6Asp A T 10 353 1779 0.09 25 384 1766 0.10 0.11 0.01 0.02 4.11 0.04 0.86 0.74 1.00 
rs2228529 ERCC6† Gln1413Arg G A 92 664 1386 0.20 81 626 1468 0.18 0.05 0.34 0.14 3.97 0.05 1.12 1.00 1.24 
rs1799966 BRCA1‡ Ser1613Gly G A 230 971 942 0.33 225 916 1034 0.31 0.02 0.68 0.06 3.89 0.05 1.10 1.00 1.20 
 
Table 3.6 - Most significant low penetrance DNA repair variants in the training cohort, analysed under dominant, recessive, genotypic and allelic 
models. A common key is given in table 3.5. † Strong LD was seen between two variants in ERCC6 (r2=0.99, D’=1.0). ‡ Strong LD was seen between three 
variants in BRCA1 (rs1799966-rs799917, r2=0.88, D’=0.97; rs1799966-rs16942. r2=0.99, D’ = 0.99; rs16942-rs1799917, r2=0.9, D’=0.98) 
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Figure 3.3 – Genotype cluster plots for most significant low penetrance DNA repair variants in the training phase cohort. Plotted using data generated 
from Illumina GenomeStudios v1.1. A common key is given in figure 3.2.
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Sanger sequencing in house. Of the 102 samples analysed, we were able to 
successfully amplify, sequence and genotype 56. 
All variants were within HWE. All were over-represented in controls, 
concordant with the training phase cohort. However, none reached statistical 
significance under an allelic model (Table 3.7). We were unable to adjust for sex and 
age due to insufficient data for cases in this cohort to carry out the analysis.  
3.3.4 Population based cohorts – POPGEN and RMHNHST  
 3.3.4.1 POPGEN 
 Using TaqMan SNP genotyping assays, we genotyped the POPGEN cohort 
for the most significant variants from the training phase cohort. These included 
RAD1Glu281Gly, POLGGln1236His and REV1Val138Met. In addition, we also genotyped 
BRCA1Pro871Leu and ERCC6Arg1213Gly, as these variants were the most significant of 
the tagging variants in their respective genes.  
Taqman assays for REV1Val138Met and POLGGln1236His were first set up in 
Cardiff to gauge the robustness of the technology. A selection of COIN samples from 
the training phase were chosen based on known genotypes (n=101 for POLG; 
n=105 for REV1). All Taqman genotype data was 100% concordant for each variant 
with the Illumina GoldenGate data. 
Genotyping of the POPGEN cohort was carried out in Germany by myself. 
Overall genotyping success rate was 89.2% (22,923/25,685 genotypes were called 
correctly). All variants were in accordance with HWE. All variants were more frequent 
in controls, which was concordant with the training cohort for the variants in POLG, 
REV1 and RAD1 but not for the variants in ERCC6 and BRCA1. POLGGln1236His was 
the only variant that was statistically significant under an allelic model (Table 3.8). 
3.3.4.2 RMHNHST  
 Publicly available data for 2,575 CRC cases and 2,707 healthy controls was 
examined for variants identified as over-represented in the training cohort. In this 
published study, low penetrance susceptibility alleles were sought by assaying 
 100 
 
 
     Cases Controls       
Variant Gene 
Amino 
acid 
change 
Minor 
allele 
(A) 
Major 
allele 
(B) 
AA AB BB MAF AA AB BB MAF 
Dom 
X2 
P 
Rec 
X2 
P 
Geno 
X2 
P 
Allelic 
X2 
P OR L95 U95 
rs1805327 RAD1 Glu281Gly G A 2 132 900 0.07 13 189 1169 0.08 N/A N/A N/A 2.76 0.1 0.83 0.66 1.03 
rs3087374 POLG Gln1236His A C 1 108 702 0.07 8 198 1071 0.08 N/A N/A N/A 3.54 0.06 0.8 0.63 1.01 
rs3087403 REV1 Val138Met A G 55 319 437 0.27 107 562 700 0.28 0.37 0.21 0.4 1.83 0.18 0.91 0.79 1.04 
 
Table 3.7 - Results of genotyping three variants in the validation cohort, analysed under dominant, recessive, genotypic and allelic models, where 
applicable. A common key is given in table 3.5. 
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Figure 3.4 – Genotype cluster plot from KASPar genotyping of RADGlu281Gly (rs1805327) 
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     Cases Controls       
Variant Gene 
Amino 
acid 
change 
Minor 
allele 
(A) 
Major 
allele 
(B) 
AA AB BB MAF AA AB BB MAF 
Dom 
X2 
P 
Rec 
X2 
P 
Geno 
X2 
P 
Allelic 
X2 
P OR L95 U95 
rs1805327 RAD1 Glu281Gly G A 13 283 1776 0.08 24 361 2313 0.08 0.99 0.31 0.57 0.05 0.82 0.98 0.84 1.15 
rs3087374 POLG Gln1236His A C 8 291 1813 0.07 22 412 2279 0.08 0.08 0.06 0.06 4.21 0.04 0.85 0.73 0.99 
rs3087403 REV1 Val138Met A G 155 777 1187 0.26 182 1094 1445 0.27 0.04 0.39 0.04 1.61 0.21 0.94 0.86 1.03 
rs2228527 ERCC6 Arg1213Gly G A 106 725 1261 0.22 160 960 1609 0.24 0.36 0.23 0.41 1.49 0.22 0.94 0.86 1.03 
rs799917 BRCA1 Pro871Leu A G 221 906 977 0.32 303 1200 1222 0.33 0.27 0.5 0.51 1.32 0.25 0.95 0.87 1.04 
 
Table 3.8 - Results of genotyping of variants in the POPGEN cohort, analysed under dominant, recessive, genotypic and allelic models. A common 
key is given in table 3.5. 
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nonsynonymous variants that were predicted to be deleterious to protein function 
using the predicted impact of coding variants (PICS) database, PolyPhen and SIFT. 
Genotyping was carried out by customised Illumina Sentrix bead array assays. In 
total, 1,467 variants were submitted for genotyping and 1,218 variants were 
successfully genotyped and analysed. Six variants previously identified in the 
training phase cohort were analysed (RAD1Glu281Gly, REV1Val138Met, BRCA1Lys1183Arg, 
BRCA1Ser1613Gly, ERCC6Arg1213Gly and ERCC6Gln1413Arg), which included two variants 
in both BRCA1 and ERCC6 previously shown to be in LD with each other. No 
variants were over-represented in this cohort (Table 3.9).  
 3.3.5 Meta-analysis 
 To enhance the power to detect an association between variants and CRC 
risk we conducted a meta-analysis of various cohorts for RAD1Glu281Gly, 
POLGGln1236His and REV1Val138Met. For each meta-analysis carried out, Cochran’s Q 
statistic to test for heterogeneity (Q) was used and the I2 statistic was calculated to 
determine the proportion of variation due to heterogeneity. A large degree of 
heterogeneity is typically indicated be an I2≥75% and in situations where this arises, 
a random effects model is typically considered. We observed no significant 
heterogeneity in any of the meta-analysis carried out and a fixed effects model was 
used for all. 
3.3.5.1 RAD1Glu281Gly 
Pooling the data from the four cohorts analysed suggested that RAD1Glu281Gly 
was associated with CRC risk (P=2x10-3). A separate analysis of aCRC cohorts only 
revealed an association between the variant and risk (P=8.2x10-5). However, there 
was no association following the pooling of data from early stage CRC cohorts only 
(P=0.43; Fig. 3.5A). 
3.3.5.2 POLGGln1236His 
Pooling the data from the three cohorts analysed suggested that 
POLGGln1236His  was associated with CRC risk (P=1.9x10-3). A separate analysis of 
aCRC cohorts only revealed an association between the variant and risk    
(P=2.2x10-4; Fig. 3.5B). 
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     Cases Controls       
Variant Gene 
Amino 
acid 
change 
Minor 
allele 
(A) 
Major 
allele 
(B) 
AA AB BB MAF AA AB BB MAF 
Dom 
X2 
P 
Rec 
X2 
P 
Geno 
X2 
P 
Allelic 
X2 
P OR L95 U95 
rs1805327 RAD1 Glu281Gly G A 10 328 2223 0.07 13 363 2314 0.07 0.41 0.61 0.66 0.76 0.38 0.94 0.81 1.09 
rs3087403 REV1 Val138Met A G 189 1008 1364 0.27 222 1085 1385 0.28 0.19 0.24 0.3 2.35 0.13 0.94 0.86 1.02 
rs2228527 ERCC6 Arg1213Gly G A 88 847 1624 0.2 113 862 1718 0.2 0.8 0.15 0.29 0.07 0.79 0.99 0.9 1.08 
rs16942 BRCA1 Lys1183Arg A G 253 1138 1166 0.32 273 1193 1229 0.32 0.98 0.84 0.98 0.02 0.9 0.99 0.92 1.08 
rs2228529 ERCC6 Gln1413Arg G A 87 846 1624 0.2 113 861 1721 0.2 0.79 0.13 0.26 0.08 0.78 0.99 0.9 1.09 
rs1799966 BRCA1 Ser1613Gly G A 256 1141 1160 0.32 277 1196 1222 0.33 0.99 0.81 0.97 0.03 0.87 0.99 0.92 1.08 
 
Table 3.9 – RMHNHST genotyping data available online (ICR - SNPlink database; 
http://www.icr.ac.uk/research/team_leaders/Houlston_Richard/Houlston_Richard_RES/SNPLINK/index.shtml) from a population based cohort, analysed 
under dominant, recessive, genotypic and allelic models. A common key is given in table 3.5. 
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3.3.5.3 REV1Val138Met 
Pooling of the data from the four cohorts analysed suggested that 
REV1Val138Met was associated with CRC risk (P=1x10-3). A separate analysis of aCRC 
cohorts only revealed an association between the variant and risk (P=6.2x10-3). 
When data from early stage CRC cohorts was pooled, a borderline significant 
association was observed (P=0.05; Fig. 3.5C). 
3.3.6 In silico analysis 
The glutamic acid at residue position 281 in RAD1 was conserved in multiple 
species (Appendix 21), although conservation throughout species was not complete. 
In silico analyses suggest that the glycine substitution has an effect on function with 
a PolyPhen score of 1.586 (possibly damaging), an Align-GVGD score of C65 (GD 
97.85) (likely to interfere with function) and a SIFT score of 0.03 (affects protein 
function).  
The glutamine at residue position 1236 in POLG was conserved in multiple 
species (Appendix 22), although conservation throughout species was not complete. 
However, in silico analyses suggest that the histidine substitution is unlikely to affect 
function, with a PolyPhen score of 0.80 (possibly damaging), an Align-GVGD score 
of C15 (less likely to interfere with function) and a SIFT score of 0.12 (tolerated). 
The valine at residue position 138 in REV1 was conserved in multiple species 
(Appendix 23) although conservation throughout species was not complete. 
However, in silico analysis suggests that the methionine substitution is unlikely to 
affect function, with a PolyPhen score of 0.019 (benign), an Align-GVGD score of 
C15 (less likely to interfere with function) and a SIFT score of 0.11 (tolerated). 
3.3.7 Sequencing of RAD1 
 In order to seek potential casual variants that may be in LD with RAD1Glu281Gly, 
we sequenced the entire ORF, flanking intronic regions and 5’UTR of RAD1 in 
twenty five aCRC patients carrying the risk allele. Ten of the patients carried alleles  
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A. 
 
B. 
 
C. 
 
 Figure 3.5 – Forest plots of effect size associated with various cohorts and in meta-
analyses for A) RAD1Glu281Gly B) POLGGln1236His C) REV1Val138Met. Closed boxes represent odds ratios 
(OR) with horizontal lines displaying lower (L95) and upper (U95) confidence intervals (CI) with P 
values for meta-analysis calculated under a fixed effects model.  
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encoding Gly/Gly and fifteen carried alleles encoding Glu/Gly. Sample numbers were 
based on 95% power to detect a variant with a MAF in controls of 8%.  
 We found two nonsynonymous variants in RAD1 (Gly114Asp [rs2308957, 
MAF in dbSNP = 0.5%] and Thr104Ser [rs1805328, MAF in dbSNP = 1.2%]), each in 
a single sample. 
3.3.8 Analyses of genes tagged by RAD1Glu281Gly 
RAD1Glu281Gly lies in a 62kb LD block that encompasses four other genes 
(BRIX1, DNAJC21, TTC23L and AGXT2). We considered whether tagging variants 
within these genes might be responsible for the association seen for RAD1Glu281Gly. 
Firstly, we sought expression of these genes within the colon. We observed 
expression of RAD1, BRIX1, DNAJC21 and TTC23L, but not AGXT2, within the 
colon. All five were expressed within the kidney.  
Secondly, we sought potential causal variants within BRIX1, DNAJC21 and 
TTC23L that might be in LD with RAD1Glu281Gly, by direct sequencing of their entire 
ORFs, flanking intronic sequences and 5’UTR in twenty five aCRC patients carrying 
the risk allele.  
We found two variants in BRIX1 that were not likely to affect function (a 
synonymous variant Thr35 [rs2069465, MAF in dbSNP = 6.6%] and a variant 281bp 
upstream of exon 1 [rs2069469, MAF in dbSNP = 6.6%]). In DNAJC21,  we found 
two synonymous variants that were not likely to affect function (Pro378 [rs17304200, 
MAF in dbSNP = 7.1%] and Val482 [rs17244979, MAF in dbSNP = 9.3%], and a 
private nonsynonymous variant Asn561Ser [rs35999194, MAF in dbSNP = 1.4%]). In 
TTC23L, we found four variants (a synonymous variant Thr137 [rs3906383, MAF in 
dbSNP = 3.4%], one novel variant 452bp upstream of exon 1, one variant 157bp 
upstream of exon 1 [rs336484, MAF in dbSNP = 41%], and a nonsynonymous 
variant, His22Arg [rs6451173, MAF in dbSNP = 43%]). 
Since there was a high level of LD between TTC23LHiss22Arg and RAD1Glu281Gly 
in the samples analysed (r2=1.0, D’=1.0), the entire training phase cohort was 
genotyped for this variant using KASPar genotyping. No association with CRC risk 
was observed (X2=0.24, P=0.63). 
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3.4 Discussion 
3.4.1 The training phase cohort 
Recently, GWAS has uncovered multiple common variants that have a 
modest contribution to CRC risk. Our training phase cohort has recently been used 
in the identification and validation of novel CRC susceptibility alleles (Houlston et al. 
2010; Dunlop et al. 2012a). We sought to further demonstrate the ability of the 
training phase cohort to uncover predisposition alleles by validating alleles previously 
discovered by GWAS. We successfully validated 5 of these loci. The failure to 
validate the remaining 5 loci could be due to a lack of power to detect small effect 
sizes as a result of sample size in the training phase cohort. 
3.4.2 Known biological effects of validated variants 
 A major problem with the interpretation of GWAS results is that the variants 
discovered rarely appear to be the true casual variants. Steps have been taken to 
examine GWAS loci in more depth and uncover the underlying biological 
mechanisms associated with risk loci. Four of the five loci validated by the training 
phase cohort here have been investigated further, allowing for the biological bases of 
disease to be alluded to. The variant rs10795668 at the remaining locus, 10p14, 
appears to be in a region that has no predicted to be protein coding genes. 
  3.4.2.1 – 18q21 – rs4939827 
In the original GWAS carried out by Broderick and colleagues, three variants 
at the 18q21 locus were identified as being significantly associated with risk of CRC 
(rs4939827, rs12953717 and rs4464148). The OR for rs4939827 (OR=0.85) given in 
this study mirrored those seen in the COIN cohort. Association between rs4939827 
and CRC risk was replicated in three independent studies (Tenesa et al. 2008; Curtin 
et al. 2009; Slattery et al. 2010). This variant maps to a distinct LD block in intron 3 
of SMAD7. Further investigation of this 17kb LD block uncovered a common 
(MAF=47%) novel variant located in an enhancer element, shown to reduce 
expression of SMAD7 by 11%, suggesting it was the true contributor to CRC risk 
(Pittman et al. 2009). SMAD7 is a negative regulator of the TGFβ signalling pathway. 
The TGFβ pathway is involved in the development, prognosis and progression of 
both hereditary and sporadic forms of CRC, suggesting that the pathway has a key 
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role in disease aetiology. Upon activation of the TGFβ receptor, SMAD7 binds to the 
receptor intracellularly and, together with Smurf1, ubiquinates and breakdowns the 
receptor complex, halting any downstream signalling transduction (Ebisawa et al. 
2001; Serra, 2002). The TGFβ pathway controls key biological functions that could 
implicate it in cancer development and progression, such as inflammation, apoptosis, 
differentiation and cellular adhesion, therefore suggesting that SMAD7 is the most 
likely candidate gene for CRC at this locus (Shi and Massagué, 2003). 
3.4.2.2 – 15q13 – rs4779584 
In addition to SMAD7, several other components of the TGFβ pathway have 
been shown to house genetic variants that are significantly associated with CRC risk. 
This includes the locus validated here, rs4779584, which is seen in the region just 
upstream of GREM1. In the original study, an OR of 1.35 did not meet formal 
significance after correction for multiple testing. However, following genotyping in 
three additional cohorts, a meta-analysis revealed that there was an association 
between the locus and CRC (OR=1.26), similar to the OR reported here (Jaeger et 
al. 2008). A synthetic association of rs4779584 is assumed due to the fact that it tags 
two functional variants, rs16969681 and rs11632715, which were subsequently 
shown to also be significantly over-represented in CRC cases (Tomlinson et al. 
2011). Interestingly, GREM1 has recently been shown to be associated with the 
Mendelian colorectal polyposis syndrome HMPS and the two GWAS variants fall 
within the region duplicated in this condition (Jaeger et al. 2012; Section 1.2.1.4.4). 
GREM1 operates in the bone morphogenetic protein (BMP) pathway. It acts 
extracellularly on BMP receptors as an antagonist of the signal transduction 
molecules, BMP2 and BMP4, and therefore reduces signalling. 
3.4.2.3 – 8q24 – rs6983267 
We also validated the variant rs6983267 at 8q24 originally identified by 
Tomlinson et al. (2007) to be associated with an elevated risk of CRC and CRA 
(OR=1.21 and 1.22, respectively). An oncogenic mechanism was suggested for the 
risk allele (G) when it was shown to be amplified in CRC tumours (Tuupanen et al. 
2008). Following confirmation that the region has a high level of species 
conservation and contains potential enhancer elements, researchers proposed that 
the variant could play a role in gene regulation (Yeager et al. 2008). Although in a 
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relative ‘gene desert’, interestingly the nearest coding gene (>300kb away) to the 
variant is MYC; a proto-oncogene key in the Wnt signalling pathway. It was shown 
that the rs6983267 directly affects the rate of binding of the Wnt related transcription 
factor, T cell factor 4 (TCF4). In fact, the presence of the causative G allele leads to 
a 1.5 fold increase in the degree of Wnt signalling response compared to the T allele 
(Tuupanen et al. 2009).  
In support of this was the finding that a physical interaction between the risk 
region and the first half and promoter region of MYC occurs in CRC cell lines 
(Pomerantz et al. 2009). The formation with either allele of a chromosomal loop 
demonstrated that, despite the large genomic distance between the two regions, an 
interaction is seen. This was supported by Wright and colleagues, who also showed 
for the first time that the presence of the G allele conferred an increase in MYC 
expression; approximately 2 fold that of the T allele (Wright et al. 2012). 
Recently, the expression of MYC by TCF4 was shown to be positively 
regulated by a non-coding RNA transcript, colon cancer associated transcript 2 
(CCAT2). CCAT2 lies in the region of the rs6983267, with the presence of the G 
allele increasing the transcription rate. It was shown to be over-expressed in CRC, 
with expression negatively associated with MSI and associated with an increased 
rate of metastasis (Ling et al. 2013).  
3.4.2.4 – 8q23.3 – rs16892766 
The variant rs16892766 tags a possible causative gene, eukaryotic translation 
initiation factor 3, H (EIF3H). In order to assess the risk associated with rs16892766, 
a region of LD was investigated further and a tagging variant, rs16888589, was 
found to be associated with an increase in expression of EIF3H (Pittman et al. 2010). 
EIF3H has previously been shown to increase growth and survival, with over 
expression linked to other cancer types (Savinainen et al. 2006). Additionally, an in 
silico analysis of the region also indicated that rs16888589, in addition to two other 
variants, were significantly associated with transcript levels of UTP23, suggesting 
that this was the true target of the functional effect of the locus association (Carvajal-
Carmona et al. 2011). 
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3.4.3 DNA repair genes and cancer 
Inherited and acquired deficiencies in DNA repair pathway genes have 
previously been shown as important contributors in the development of multiple 
cancer types, including CRC (Section 1. 3). We attempted to assay for common 
(MAF≥4%) nonsynonymous variants in DNA repair genes from multiple pathways in 
the training phase cohort. We identified one variant, RAD1Glu281Gly, which remained 
statistically significant after correction for multiple testing in the training phase cohort. 
Despite initial associations in this cohort we failed to replicate findings in an aCRC 
setting. 
3.4.4 Failure to replicate association observed in the training phase 
3.4.4.1 The ‘winner’s curse’  
 The theory behind the phenomenon of the ‘winner’s curse’ could explain an 
elevation of the OR seen in our training phase cohort. Winner’s curse describes how 
the effect size of exploratory studies is elevated, conditional on that study being the 
first to show such an effect (Zöllner and Pritchard, 2007). It is commonly seen in 
large scale GWAS due to an inability to correct for the large amount of variants 
tested in a cohort in one go, resulting in a high false positive rate. Similarly, the 
winner’s curse has also been shown to have a role in inconsistencies between 
candidate gene studies (Ioannidis et al. 2001). Consequently, the initial first positive 
result seen cannot be given as an accurate representation of the true population 
effect.  
With regards to RAD1Glu281Gly, based on a MAF in controls of 8% at the OR 
seen in the training phase cohort, we had 66% power to detect the same effect size 
in our validation phase cohort of 1,053 cases and 1,397 controls. However, in order 
to compensate for a potential over-estimation in the initial effect size, we would 
require the validation cohort to be a lot larger. For example, using a more 
conservative OR of 1.1, we would require over 11,000 cases and controls in order to 
achieve 80% power at a 5% significance level (Table 3.10). 
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OR 
Power with current 
validation cohort 
(cases n=1,053; 
controls n=1,397) 
Number of both 
cases and controls 
required for 80% 
power 
1.27 66% 1,697 
1.25 59.70% 1,960 
1.2 43.10% 2,971 
1.15 27.03% 5,237 
1.1 14.80% 11,331 
 
 Table 3.10 – Sample numbers required in the validation phase cohort to overcome 
possible elevation in initial effect size of RAD1Glu281Gly due to the ‘winner’s curse’. Sample 
numbers for a given odds ratio (OR) were calculated based on a MAF of 8% in controls at a 
5% significance level with 80% power 
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3.4.4.2 Population stratification 
 Different subpopulations often display different allele frequencies, normally as 
a result of different ancestral routes. Differences in allele frequencies that occur 
because of underlying genetic drift are often referred to as population stratification. 
Population stratification can cause falsely significant results in case control studies of 
disease when population homogeneity is incorrectly assumed (Freedman et al. 
2004). As a UK based drug trial, the COIN and COIN-B trials consisted of mostly 
patients with a known Caucasian background. Despite this we endeavoured to 
gauge as much information regarding samples as possible before the analysis, using 
medical records and other notes to rule out any confounding factors of population 
stratification on the analysis. We identified and removed 40 samples known to be of 
a non-Caucasian background.  
 In retrospect of our failure to replicate findings in the validation phase cohort, 
Fay Hoskins (ICR, London) performed a principal component analysis (PCA) 
following genotyping of over 280,000 variants on all patients from COIN and COIN-B. 
It showed that there were 125 COIN or COIN-B patients from a non-Caucasian 
background. Of these, 37 had previously been identified by us. In total, 128 samples 
were deemed to be from a non-Caucasian background. Upon removing these from 
the analysis, we observed very subtle effects on the association in the training phase 
cohort for RAD1Glu281Gly (X2=13.57, P=2x10-4; MAF cases=6%, controls=8%) 
  3.4.4.3 Linkage disequilibrium 
Failure to replicate initial findings could be due to the identified variant being 
in LD with another true casual variant, meaning that the variant identified is not 
responsible for the association observed at a locus; there is indirect association 
(Hirschhorn et al. 2002). In order to assess the likelihood that RAD1Glu281Gly is in LD 
with another true casual variant we sequenced the entire ORF, flanking regions and 
5’UTR of RAD1, as well as three tagging genes within the identified LD block 
(BRIX1, DNAJC21 and TTC23L). We identified one nonsynonymous variant, 
TTC23LHis22Arg, which displayed high LD with RAD1Glu281Gly in the patients assayed. 
However, we failed to observe an association in the training phase cohort. Together, 
these data suggest that RAD1Glu281Gly itself is likely to be responsible for the 
observed association. 
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3.4.4.4 Meta-analysis 
Following rigorous correction for multiple testing, only the Glu281Gly variant in 
RAD1 remained significant in our training phase cohort. However, conducting a 
meta-analysis allowed us to increase the power to assess variants by increasing the 
sample size. As well as pooling data from all cohorts in meta-analysis for each 
variant, we also endeavoured to stratify by CRC stage by analysing population 
based, early stage CRC cohorts (POPGEN and RMHNHST) and aCRC cohorts 
(training and validation phase cohorts) in separate meta-analysis. 
3.4.4.4.1 RAD1Glu281Gly 
We observed, when analysed together under meta-analysis, a positive 
association between RAD1Glu281Gly and aCRC. Similarly, meta-analysis of all cohorts 
revealed a positive association. However, since no association was observed in the 
other cohorts assessed, it would appear that both meta-analysis results are primarily 
driven by the original association from the training phase cohort. Since no 
association was observed in the meta-analysis of early stage CRC cohorts, this 
suggests that any association may be specific to aCRC. We do not have enough 
evidence to support a role for RAD1Glu281Gly in aCRC predisposition and it warrants 
further investigation.  
3.4.4.4.2 POLGGln1236His 
We observed, when all cohorts were analysed together in meta-analysis, a 
positive association between POLGGln1236His and CRC. Similarly, an association was 
observed when data from aCRC cohorts was pooled. Again, since there was little or 
no association seen in the other cohorts, we feel that the meta-analysis association 
is again driven by the association from the training phase cohort. 
3.4.4.4.3 REV1Val138Met 
We observed, when analysed together under meta-analysis, a positive 
association between REV1Val138Met and aCRC. Additionally, an association was 
observed when all cohorts were analysed together. Again, since there was little or no 
association seen in the other cohorts, we feel that both meta-analysis associations 
are driven by the association from the original training phase cohort. No association 
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was observed in the meta-analysis of early stage CRC, suggesting the association 
may be specific to aCRC. 
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Chapter Four – Identifying genes associated with oxaliplatin-induced 
peripheral neuropathy in the treatment of aCRC 
 
4.1 Introduction 
Oxaliplatin (Eloxatin®) is a third generation platinum compound first approved 
for the treatment of CRC in the EU in 1996. It is commonly used as part of the 
chemotherapeutic regimens FOLFOX and XELOX (Section 1.4.2). Before the 
development of oxaliplatin, a proportion of patients with CRC were considered to 
have an intrinsic resistance to platinum treatments (Kemeny et al. 1990; Loehrer et 
al. 1988; Fink et al. 1998; Rixe et al. 1996). Despite showing different patterns of 
cancer specific resistance, the platinum drugs are believed to share a common 
mechanism of action and metabolism. The correct cellular response and 
pharmacokinetic profile of oxaliplatin is critical for the adequate action of the drug in 
the treatment of CRC. 
4.1.1 Pharmacokinetics of oxaliplatin 
Oxaliplatin consists of a central platinum atom, with a DACH carrier ligand 
and bidentate oxalate ligand (Kidani et al. 1978). Oxaliplatin is administered 
intravenously at a dose of 85mg/m2 once every two weeks in the first line treatment 
or 130mg/m2 once every three weeks in the second line treatment in combination 
with fluoropyrimidines over the course of 2-6 hours to achieve sufficient plasma Cmax 
(Culy et al. 2000).  
4.1.1.1 Absorption 
Upon initial absorption, the oxaliplatin prodrug is non-enzymatically 
hydrolysed by displacement of the oxalate group by H2O and chloride ions. This 
forms the reactive intermediates monochloro-, dichloro- and diaquo-DACH platinum 
(Desoize and Madoulet, 2002) which bind to amino groups in DNA, RNA and 
proteins, as well as biotransformation via irreversibly binding to sulphur groups in 
cysteine, glutathione and methionine (Luo et al. 1999). 
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After a direct 2 hour infusion with oxaliplatin, over 70% of these metabolites 
will bind irreversibly to plasma proteins, predominantly albumin and erythrocytes, 
rendering the drug unavailable (Pendyala and Creaven, 1993; Culy et al. 2000). 
4.1.1.2 Distribution 
The DACH compound of oxaliplatin is highly lipophilic and readily distributes 
from the plasma throughout the body. The high level of distribution is aided by the 
ability to readily bind to proteins, macromolecules and DNA (Graham et al. 2000). 
4.1.1.3 Metabolism 
Oxalate is produced as a metabolite of oxaliplatin following non-enzymatic 
displacement by H2O or chlorine ions. As a chelator of calcium it is thought that 
oxalate may have an acute role in neuropathy seen in oxaliplatin treatment (Grolleau 
et al. 2001). The metabolism of oxalate is similar to that of glycoxylate, a by-product 
of amino acid metabolism. Glycoxylate is detoxified and metabolised by AGXT and 
glyoxylate reductase-hydroxypyruvate reductase (GRHPR) respectively (Holmes and 
Assimos, 1998). 
4.1.1.4 Elimination and excretion 
It is believed that renal elimination is the main course of excretion of unbound 
oxaliplatin, accounting for around 50% of the free concentration. Renal excretion has 
been shown to occur at a rate of approximately 121ml/min (Kern et al. 1999). The 
proportion of oxaliplatin bound to erythrocytes (approximately 37%) is eliminated 
from circulation at a rate that is in accordance with the cells half-life (Levi et al. 
2000).  
4.1.2 Cellular processing of platinum agents  
4.1.2.1 Cellular influx  
The primary mechanism of uptake is passive diffusion; however, several 
transporter proteins have been implicated in platinum uptake. The copper transporter 
protein 1 (CTR1; Song et al. 2004; Holzer et al. 2006) and both organic cation 
transporters (OCT1 and OCT2) have been shown to increase cellular accumulation 
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of oxaliplatin (Zhang et al. 2006). Knockout of Oct2 in mice has been linked to an 
increased rate of oxaliplatin-induced neurotoxicity (Sprowl et al. 2013).  
4.1.2.2 Trafficking and localisation 
Other members of the copper transport system have previously been 
recognised as having a role in the control of localisation of cellular platinum 
compounds (Safaei et al. 2004). Copper chaperones bind to and distribute platinum 
drugs throughout the cell. The human antioxidant homologue 1 (HAH1) shuttles 
platinum compounds to the copper transporting P-type adenosine triphosphatase 7A 
and 7B (ATP7A and ATP7B) in the Golgi apparatus. Trafficking of both proteins to 
the plasma membrane is thought to play a role in efflux from the cell (Katano et al. 
2002). Alternatively, other copper charperones, namely cytochrome C oxidase 
(COX17) and copper chaperone for superoxide dismutase (CCS), escort platinum 
compounds to the mitochondria and cytoplasmic superoxide dismutase (SOD), 
respectively (Plasencia et al. 2006). 
4.1.2.3 Detoxification 
Detoxification of platinum compounds has profound effects on the amount of 
active drug free to interact with DNA. Direct biotransformation by complex formation 
with reducing agents rich in thiol groups, such as L-cysteine, L-methionine and 
glutathione (forming Pt(DACH)(Cys)2, Pt(DACH)Met and Pt(DACH)(GSH)2, 
respectively) results in unreactive species (Luo et al. 1999; Levi et al. 2000). 
Conjugation results in cellular efflux of the platinum, protecting the DNA from 
damage (Siddick, 2003). Glutathione conjugation is catalysed by GST, a phase II 
metabolic enzyme. Although many subclasses of GST exist, only a handful have 
been implicated in platinum detoxification, in particular, GSTP1, GST-τ (GSTT1) and 
GST-µ (GSTM1) (Stoehlmacher et al. 2002; Medeiros et al. 2003). 
Platinum detoxification is also carried out by metallothioneins (MT); low 
molecular weight proteins, consisting of mainly cysteine residues. Intrinsically, MT is 
thought to be important in controlling the exposure of heavy metals, as well as 
copper. Cancers exhibiting high levels of MT1A and MT2A have been shown to 
exhibit a reduced response to platinum treatments (Siegsmund et al. 1999; Toyoda 
et al. 2000). 
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4.1.2.4 Efflux 
One of the key mechanisms of cellular efflux of platinum compounds is via the 
ATP7A and ATP7B copper export proteins. Additionally, there are reports of the role 
of the ATP-binding cassette, subfamily B (ABCB1), ABCG2, ABCC1, ABCC2, 
ABCC3 and ABCC5 as platinum efflux proteins. Overexpression of several of these 
has been associated with outcome of platinum treatment (Liedart et al. 2003; Oguri 
et al. 2000; Ceckova et al. 2008; Theile et al. 2009; Pham et al. 2012).  
4.1.3 Pharmacodynamics of platinum drugs 
 The anti-neoplastic properties of all of the platinum compounds are 
based predominantly on their ability to form platinum-DNA adducts in nuclear DNA 
(Brabec and Kasparkova, 2005). The formation of cross links stalls DNA synthesis 
(Raymond et al. 1998) impairing both replication and transcription and ultimately 
triggering apoptosis (Faivre et al. 2003; Cepeda et al. 2007). 
Oxaliplatin and cisplatin appear to have similar sequence and regional 
localisation of DNA damage (Woynarowski et al. 1998). Oxaliplatin is believed to 
form fewer adducts than cisplatin at equimolar concentrations but, in part due to 
gross modifications of the DNA helix on account of the bulky DACH group, inhibits 
DNA synthesis at a greater efficiency (Saris et al. 1996).  
Initially, monoadducts between the platinum adduct and DNA form. However, 
these adducts are not considered to be integrally damaging (Zwelling et al. 1979). It 
is only following the formation of biadducts that the cytotoxic effects of platinum 
treatments are evident. It seems that the predominant lesion, constituting about 60% 
of those seen, consist of intrastrand crosslinks between two guanine residues. 
Similarly, intrastrand crosslinks between guanine and adenine contribute to around 
30% of the lesions (Eastman, 1987; Woynarowski et al. 1998). Other DNA adducts 
include ICLs (Woynarowski et al, 2000). Although rare, DNA-protein cross links are 
also seen (Zwelling et al. 1979). 
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4.1.4 Apoptosis 
Following exposure of cells to platinum treatment, cell cycle arrest and 
intrinsic signalling cascades indicative of that of apoptosis occurs within the first 24 
hours of treatment. In response to regulation by p53, a marked increase in BAX 
leads to the release of cytochrome C from the mitochondria and activation of 
apoptotic peptidase activating factor 1 (APAF1). This activates the aspartate specific 
proteases, the caspases. Upstream effector caspase 9 (CASP9) activates CASP3 
and CASP7 (Donzelli et al. 2004), leading to apoptosis as a result of cleavage of 
cellular proteins (Arango et al. 2004). 
4.1.4.1 Cell checkpoints 
The process of cell cycle arrest in G2 is critical for the action of platinum drugs 
by engaging cell death. Cell division cycle 25 (CDC25C) is phosphorylated by the 
checkpoint kinase proteins, CHEK1 and CHEK2, as part of the DNA damage sensor 
signalling pathway involving ATM and ataxia telangiectasia and Rad3 related (ATR). 
Ultimately, the initiator of G2 stalling is in response to an elevation in cell division 
cycle 2 (CDC2), following translocation from phosphorylated CDC25C (Wang and 
Lippard, 2005). 
4.1.4.2 Damage recognition and cellular transduction 
The formation of a shallow but wide structural distortion of the minor groove 
allows recognition of intrastrand DNA adducts. Initially, as well as other DNA repair 
proteins, distortion caused by platinum drug treatments is recognised via the binding 
of high mobility group (HMG) box protein 1 (Wozniak and Blasiak, 2002) and 
structure specific recognition protein (SSRP1; Yarnell et al. 2001). 
The role of HMGB proteins is wide in the response to damage, including 
stimulating site-directed recombination by cleavage of the recombination activating 
genes 1 and 2 (RAG1/2; van Gent et al. 1997), binding and enhancing structural 
changes of the nucleosome and directly interacting with components of the MMR 
pathway to stimulate repair (Yuan et al. 2004), as well as shielding areas of damage 
from other repair processes (Huang et al. 1994).  
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HMGB1 directly interacts and localises p53 (Jayaraman et al.1998), a crucial 
component of apotosis and cell cycle arrest triggered by platinum DNA damage. A 
role for p53 in DNA repair of platinum damage has also been proposed due to 
interactions with XPC, TFIIH and RPA in the NER process (Dutta et al. 1993; Wang 
et al.1995; McKay et al. 1999). 
Alternatively, SSRP1 binds to suppressor of Ty 16 homolog (SPT16) forming 
the facilitates chromatin transcription (FACT) complex. The complex recognises 1,2-
intrastrand platinum damage and via its HMG domain, recruits the protein to areas of 
damage (Yarnell et al. 2001). 
Signal transduction from the nucleus to the cytosol is a key part of the 
response of a cell to DNA damage in order to control checkpoint progression or 
trigger apotosis. C-ABL is a nuclear tyrosine kinase that has been shown to be 
stimulated by platinum drug DNA damage to regulate apoptosis by interactions via a 
HMG domain. Prevention of this signalling cascade can be controlled by the tumour 
suppressor retinoblastoma 1 (RB1), which binds to C-ABL and prevents kinase 
activity following DNA damage signalling. In addition to p53, another pro-apoptotic 
downstream target of C-ABL, p73, has been shown to be key in response to 
platinum treatment in MMR-proficient cells only (Shaul, 2000). Since the proficiency 
of MMR has no effect on oxaliplatin response, this is thought to be specific to 
cisplatin adducts (Nehmé et al. 1999).  
C-ABL is also key in activating other protein kinases in response to platinum 
damage. Firstly, p38-MAPK, important in controlling gene expression and the 
chromatin environment, had been shown to be activated in platinum treated cells via 
the mitogen activated protein kinase kinases, MKK3 and MKK6. Downstream target 
mitogen and stress activated protein kinase 1 (MSK1) phosphoylates histone H3 in 
response to platinum damage (Wang and Lippard, 2005). Secondly, extracellular 
signal regulated kinase (ERK) activation following phosphorylation by the mitogen 
activated protein kinases, MEK1 and MEK2 in response to platinum treatment could 
have a role in response. Thirdly, a role of the c-Jun N terminal kinase (JNK) 
signalling cascade (following MKK4/MKK7 mediated phosphorylation) has also been 
proposed due to observations that activation leads to an increase in cell death 
following platinum drug treatment (Pandey et al. 1996).  
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However, there are also survival pathways that are key in platinum drug 
damage. The AKT-pathway is one such example;  a part of the PI3K signalling 
cascade. AKT is activated by the direct binding of PI3K-generated phospholipids and 
has several anti-apoptotic actions. Firstly, phosphorylation of X-linked inhibitor of 
apoptosis (XIAP) stabilises the protein and prevents breakdown following platinum 
drug DNA damage, ultimately resulting in a decrease in activation of apoptotic 
pathways (Dan et al. 2004). Additionally, AKT also prevents apoptosis in response to 
platinum damage by phosphorylating and increasing activation of nuclear factor kB 
(NF-kB), inhibition of which has been shown to increase efficacy of platinum 
compounds (Mabuchi et al. 2004). 
Additionally, increase in survival following platinum treatment has been linked 
to MAP kinase phosphatase (MKP1) which inhibits both JNK and p38MAPK 
activation (Wang and Lippard, 2005). 
4.1.5 DNA repair of platinum induced damage 
4.1.5.1 NER pathway 
The NER pathway is important in the repair of bulky adducts that alter the 
helical formation of DNA and cross linking agents, such as those formed in platinum 
drug treatment (Section 1.3.3).  
4.1.5.2 MMR pathway 
In platinum treatment, the formation of adducts leads to strand contortion in 
DNA which the MMR pathway (Section 1.3.1) plays a role in repairing. However, it is 
the adduct that is recognised by MMR proteins and, as a by-product of this, shielded 
and protected from other DNA repair processes. Ultimately this results in the removal 
of the contorted strand and retention of DNA adducts. This process, known as ‘futile 
cycling’, was first proposed by Goldmacher in 1986 and helps to explain why MMR 
deficiency increases resistance to platinum treatments (Goldmacher et al. 1986). 
It is interesting to note that MMR deficiencies confer resistance to cisplatin 
and carboplatin but not oxaliplatin (Fink et al. 1996). This is particularly important in 
the treatment of CRC, since approximately 15% have MMR deficiencies. The 
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reasons for the differences between platinum treatments is believed to be as a result 
of differences in adduct specificity of the MMR pathway (Martin et al. 2008). 
4.1.5.3 BER pathway 
The BER pathway is involved in the removal of non-helix distorting DNA 
damage (Section 1.3.2). The type of DNA damage caused by platinum drugs means 
that BER is not thought to be the main mechanism of repair. Despite this, certain 
BER proteins have been linked to platinum treatment outcome (Stoehlmacher et al. 
2001; Lv et al. 2013). 
4.1.5.4 ICL repair  
Approximately 5% of the lesions seen in platinum treatment consist of ICL as 
a result of platinum adducts binding to bases in opposing strands. It is role of the FA 
pathway to repair these lesions (Section 1.3.5). 
4.1.5.5 Replicative bypass 
The ability of certain polymerases to skip platinum DNA damage during 
replication means that there is an opportunity for platinum adducts to accumulate 
and potential tolerance to develop. Polymerases that have been previously 
implicated in platinum treatment or could play a role include REV3L, POLB, POLH 
and POLM (Rabik and Dolan, 2007).  
4.1.6 Side effects of oxaliplatin treatment – peripheral neuropathy 
As the main dose limiting side effect of oxaliplatin treatment, peripheral 
neuropathy is a major problem in treatment (O' Dwyer et al. 2000). It is more often 
severe peripheral neuropathy that results in the removal from treatment than disease 
progression. Additionally, peripheral neuropathy associated with oxaliplatin (PNAO) 
is not correlated with response to treatment and is therefore considered an avoidable 
malady (Whinney et al. 2009). There are no current treatments to alleviate the 
symptoms associated with PNAO (Wolf et al. 2008). Two clinically distinct forms of 
neuropathy have been reported and are believed to arise through different 
pathophysiological mechanisms. An acute form is due to disruption of voltage gated 
sodium channels indirectly as an extension of chelation of calcium ions by the 
oxaliplatin metabolite, oxalate (Grolleau et al. 2001). The chronic form is due to 
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direct toxicity of nerve cells via the accumulation of platinum adducts in the dorsal 
root ganglia (Ta et al. 2006). 
There is little knowledge surrounding possible risk factors or genetic 
predisposition to PNAO. Previously, a putative association between chronic PNAO 
and a coding variant in GSTP1, resulting in an isoleucine to valine substitution at 
codon 105 of the protein, has been described (Grothey et al. 2005; Ruzzo et al. 
2007; Peng et al. 2013), although the risk allele is of debate (Lecomte et al. 2006; 
Gamelin et al. 2007; Inada et al. 2010). Also, particular haplotypes of AGXT have 
been shown to predispose towards both acute and chronic forms of PNAO (Gamelin 
et al. 2007). Additionally, a silent polymorphism which falls within an aspartic acid 
residue at position 118 of the NER gene ERCC1 has been associated with an 
increased rate of onset of chronic PNAO in a Japanese population (Inada et al. 
2010; Oguri et al. 2013). Mutations in genes involved in neuronal function have also 
been suggested to predispose to PNAO. A nonsynonymous variant in SCN10A 
(Leu1092Pro [rs12632942]) has been shown, under an overdominant model, to 
increase the chance of acute PNAO (Argyriou et al. 2013). 
Here, we sought to identify the underlying genetic causes of PNAO in patients 
exhibiting the most severe phenotypes using exome resequencing. In order to 
assess the sequencing data, we applied two analysis strategies; 
1. Analysis of variants in genes involved in the pharmacokinetics and 
cellular response to oxaliplatin 
2. Analysis of novel variants in genes involved in neuronal function 
and/or peripheral neuropathy 
4.2 Materials and methods 
 4.2.1 Patient selection 
Patients were selected from 2,445 individuals undergoing treatment with 5-
fluorouracil or capecitabine, oxaliplatin and potentially cetuximab as part of the COIN 
trial. PNAO with a grade 3 or greater was observed in 23% of patients with 5-
fluorouracil based regimens and 16% of those with capecitabine based regimens 
over the entire trial period (Maughan et al. 2011). Assessment of PNAO was carried 
out every 6 weeks following the initiation of treatment. The recording of PNAO grade 
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was carried out by a consultant and clinical nurse using the Common Terminology 
Criteria for Adverse Effects v3.0 (CTCAE; National Cancer Institute common toxicity 
criteria for adverse events, Accessed June 19, 2013; Table 4.1). Additionally, 
patients who reported at least grade 3 neuropathy carried out a Quality of life 
Questionnaire (QLQ C30) which supported evidence of severe PNAO.  
4.2.2 Oxaliplatin administration as part of the COIN trial 
With capecitabine, oxaliplatin was given intravenously at 130mg/m2 over a 
period of 2 hours at 3 weekly intervals. Capecitabine was given orally twice a day for 
the three weeks prior to oxaliplatin administration. Initially it was given at 1000mg/m2 
but was reduced to 850mg/m2 following evidence that there was elevated toxic 
effects in patients from Arm B of the trial (Adams et al. 2009). 
With 5-fluorouracil and folinic acid, oxaliplatin was given intravenously at 
85mg/m2 over a period of 2 hours at 2 weekly intervals. This was followed by a bolus 
injection of 400mg/m2 of 5-fluorouracil, with a 46 hour infusion of 2400mg/m2 of the 
drug. Either 175mg of L-folinic acid or 350mg of D,L-folinic acid was given 
intravenously over a 2 hour period concurrent to oxaliplatin treatment (Maughan et 
al. 2011). 
4.2.3 Exclusion of known neuropathies 
Exclusion of known neuropathies in the ten patients sent for exome 
resequencing was carried out by multiplex ligation-dependant probe amplification 
(MLPA) at Bristol Genetics laboratory. Samples were analysed with the SALSA® 
MLPA® kit using the P033-B2 probe mix (Appendix 6; MRC Holland, Amsterdam), 
following the manufacturer’s instructions. Sample were analysed on a Beckman 
Coulter CEQ 8000 capillary analyser and with the GeneMarker software package. 
Additionally, exome resequencing data of all genes associated with known 
neuropathies was examined in all ten patients. 
4.2.4 MUTYH analysis 
Patient 1 was shown previously to carry potentially biallelic mutations in 
MUTYH (Gly396Asp and Arg426Leu). Cloning was carried out by Christopher Smith  
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 Grade 1 Grade 2 Grade 3 Grade 4  Grade 5 
Peripheral 
sensory 
neuropathy 
Loss of 
deep tendon 
reflexes; 
Paresthesia 
that does 
not affect 
function 
Sensory 
alteration or 
parasthesia; 
interfering 
with 
function but 
not with 
ADL 
Sensory 
alteration or 
paresthesia 
interfering 
with ADL 
Disabling Death 
 
Table 4.1 – Grading criteria for symptoms of PNAO in accordance with 
CTCAE v3.0 (ADL – activities of daily living) 
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to determine if these variants were on the same or opposite strands. Exon 13 was 
amplified by PCR (Forward primer - 5’-AGGGCAGTGGCATGAGTAAC-3’; Reverse 
primer – 5’-GGCTATTCCGCTGCTCACTT-3’; Section 2.5.4) followed by verification 
by agarose gel electrophoresis and PCR purification (Sections 2.5.5 and 2.5.6). 
Ligation into the pGEM-T easy vector, transformation and plasmid extraction were 
carried out (Sections 2.5.12.5 - 2.5.12.7). Following PCR and clean up, amplification 
products were sequenced and cleaned up (Sections 2.5.7 and 2.5.9). Sequences 
were viewed with Sequencher v4.2. 
4.2.5 The platinum pharmacokinetic and cellular response pathway 
In order to analyse the exome resequencing data, a pathway approach was 
initially taken. We concentrated on genes involved in platinum drug 
pharmacokinetics and cellular response (Sections 4.1.1-4.1.5). Genes were found 
via literature reviews of platinum pathways and exome resequencing data was 
filtered accordingly. In total, we identified 104 genes that may play a role including 
four genes involved in drug influx (OCT1, OCT2, CTR1 and hMATE1), three genes 
involved in trafficking (CCS, COX17 and SOD1), seven genes involved in 
detoxification (MT1A, MT2A, NQO1, GSTT1, GSTP1, GSTM1 and MPO), two genes 
involved in oxalate metabolism (AGXT and GRHPR), three genes involved in 
sequestration (ATP7A, ATP7B and HAH1), thirty two genes involved in DNA damage 
response and subsequent signalling pathways (SPT16, SSRP1, HMGB1, RAG1, 
RAG2, ABL1, RB1, p53, p73, AURKA, CCNG2, p38MAPK, MSK1, MKK3, MKK6, 
Histone H3, ERK, MEK1, MEK2, JNK, MKK4, MKK7, MPK1, AKT, NF-kB, XIAP, 
Bax, APAF1, CYC, CASP3,6 and 9), forty six genes involved in DNA damage repair 
and the associated response pathways (POLB, POLH, POLM, REV3L, FANCA, 
FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, 
FANCN, FAAP100, RM1, FAN1, MLH1, MSH2, MSH6, PMS2, ATM, ATR, CHEK1, 
CHEK2, BRCA1, BRCA2, GADD45, DDB2, CDC25C, CDC2, CSA, HR23B, 
RNApolII, RPA1, ERCC1-6, XPA, XRCC1, XRCC3 and MGMT), and seven genes 
involved in drug efflux (ABCC1-5, ABCB1 and ABCG2; Fig.4.1). 
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Figure 4.1 – Proteins implicated in the cellular pharmacokinetics and response pathways to platinum drugs. 
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4.2.6 Exome resequencing 
Exome resequencing, read alignment and variant calling was carried out by 
James Colley. Library fragments containing exomic DNA from our 10 patients with 
PNAO were collected using the Roche Nimblegen SeqCap EZ Exome Library v2.0 
solution-based method. Massively parallel sequencing was performed on the 
Illumina Genome Analyser at the University of North Carolina. Fastq files were 
processed through a sequence analysis pipeline using BWA (Li and Durbin, 2009) 
for sequence alignment and modules from the Broad Institute’s Genome analysis 
Toolkit (GATK) (McKenna et al. 2010) to recalibrate quality scores, refine alignments 
around potential insertion or deletions (indels), eliminate duplicate reads, call indel 
and SNP genotypes, generate QC metrics, and apply quality filters to the genotype 
calls. SNP calls were annotated using the Analysis package ANNOVAR (Wang et al. 
2010). 
4.2.7 Analysis of genes involved in neuronal function or peripheral 
neuropathy 
Literature reviews of gene of interest were carried out by searching for a role 
with ‘neurons’ or ‘peripheral neuropathy’ via NCBI and other internet search engines. 
4.2.8 PCR and Sanger sequencing 
All variants of interest from exome resequencing were validated by Sanger 
sequencing of an independent PCR product. PCR of specific regions, verification by 
agarose gel electrophoresis, product purification, Sanger sequencing and 
sequencing clean up were carried out as described in sections 2.5.4 to 2.5.8. 
Sequences were analysed using Sequencer v4.6. Primers are given in Appendix 7. 
4.3 Results 
4.3.1 Patient selection 
Nine patients from COIN were identified as having severe PNAO that required 
removal from treatment within the first 7 weeks. A tenth patient was identified as 
having PNAO whilst receiving therapy from Professor Timothy Maughan, stopping 
treatment at the end of the first cycle on account of severe toxicity. This patient was 
recruited into this COIN Trial Management approved translational project. 
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4.3.2 MUTYH analysis 
Cloning and Sanger sequencing of exon 13 of MUTYH revealed that Patient 1 
was compound heterozygous for the variants Gly396Asp and Arg426Leu. The 
patient had ‘multiple colorectal polyps’. 
4.3.3 Exclusion of known hereditary neuropathies 
We carried out MLPA of PMP22 on all ten patients but did not find gene 
dosage abnormalities. We also examined exome resequencing data in the ten 
patients with PNAO for mutations in PMP22 and the other genes associated with 
rare inherited neuropathies such as MPZ/PO, SIMPLE/LITAF, EGR2, NEFL, 
GJB1/CX32, PRPS1, DNM2, YARS, MFN2, RAB7, GARS, HSPB1 (HSP27), HSPB8 
(HSP22), GDAP1, LMNA, MED25, MTMR2, SBF2/MTMR13, KIAA1985 (SH3TC2), 
NDRG1, PRX, FGD4, FIG4, BSCL2, DCTN1, SPTLC1 and IGHMBP2. At 20-fold 
coverage, on average, we covered >50% of the ORF of 85% of these genes. 
Additionally, 38% of genes had, on average, greater than 90% of the ORF covered. 
However, 15% of the genes had less than 5% of the ORF covered on average 
(Table 4.2).  
We failed to find any stop-gain mutations or truncating indels in these genes 
in our 10 patients with PNAO. Although we did find various nonsynonymous variants 
in IGHMBP2, these variants were also found in dbSNP at a similar or greater 
frequency (Thr879Lys [rs17612126; MAF=15% in patients with PNAO compared to 
30% in Caucasians in dbSNP]; Ile275Val [rs10896380; 25% compared to 30%]; 
Arg694Trp [rs2236654; 25% compared to 30%]; Leu201Ser [rs560096; 15% 
compared to 11%]; Thr671Ala [rs622082; 40% compared to 30%]) and were 
therefore considered to be benign polymorphisms. Therefore, we excluded all known 
genes associated with inherited neuropathies as the likely cause of PNAO. 
4.3.4 Exclusion of other known causes of PNAO 
 4.3.4.1 GSTP1 
We examined exome resequencing data for a nonsynonymous variant in 
GSTP1 that had previously been associated with PNAO (Grothey et al. 2005; Ruzzo 
et al. 2007; Peng et al. 2013).The variant consisted of an isoleucine to valine  
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 Patient ID  
Gene 1 2 3 4 5 6 7 8 9 10 Average 
BSCL2 70 79 85 78 74 77 86 74 75 77 77 
DCTN1 47 68 77 80 57 69 65 61 72 73 67 
DNM2 66 80 81 81 76 81 81 81 83 81 79 
EGR2 50 65 82 78 66 71 68 69 71 72 69 
FGD4 93 92 96 97 95 98 99 95 97 96 96 
FIG4 82 76 96 95 79 85 98 84 85 97 88 
GARS 0 0 0 0 0 0 0 0 0 0 0 
GDAP1 92 78 100 100 92 98 100 98 100 100 96 
GJB1 87 86 88 94 82 91 82 90 97 91 89 
HSPB1 0 0 9 0 0 0 4 0 0 3 2 
HSPB8 41 18 68 83 68 47 63 54 52 62 55 
IGHMBP2 59 82 92 93 71 88 89 77 90 85 83 
LITAF 100 96 100 100 100 100 100 100 100 100 100 
LMNA 35 73 76 79 56 77 65 58 71 73 66 
MED25 27 44 47 50 33 48 52 37 44 44 43 
MFN2 91 100 100 100 98 99 100 99 98 100 99 
MPZ 69 87 84 77 68 93 83 77 86 76 80 
MTMR2 84 82 96 96 88 93 96 96 92 96 92 
NDRG1 80 98 97 92 79 97 92 85 96 88 90 
NEFL 0 0 0 0 0 0 0 0 0 0 0 
PRPS1 92 75 100 100 85 84 91 95 93 100 92 
PRX 3 4 5 5 5 5 5 5 5 5 5 
SBF2 92 84 98 98 89 97 98 94 89 98 94 
SH3TC2 64 82 88 94 66 90 90 69 88 88 82 
SPTLC1 96 92 96 96 91 96 96 95 96 96 95 
YARS 88 93 100 100 91 100 100 98 99 100 97 
 
Table 4.2 – Percentage of the ORF covered (at 20-fold coverage) of genes 
previously implicated in hereditary neuropathies. Shades from red through to green 
represents no to complete coverage, respectively. 
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substitution at position 105 (rs1695). We found two patients homozygous for the 
variant (MAF=20% in patients with PNAO compared to 38% in dbSNP). 
 4.3.4.2 AGXT haplotype 
We examined exome resequencing data for a particular haplotype in AGXT 
that consisted of two nonsynonymous variants; Pro11Leu and Ile340Met 
(rs34116584 and rs4426527, respectively). This particular haplotype, in either the 
heterozygous or homozygous form, has previously been associated with PNAO 
(Gamelin et al. 2007). We found three patients heterozygous for both variants and 
another patient heterozygous for just Pro11Leu (Pro11Leu [MAF=20% in both 
patients with PNAO and dbSNP] and Ile340Met [MAF=15% in both patients with 
PNAO and dbSNP]). 
 4.3.4.3 ERCC1 
We examined exome resequencing data for a synonymous variant in ERCC1 
that had previously been associated with rate of onset of PNAO (Asp118 [rs11615] 
Inada et al. 2010; Oguri et al. 2013). We found five patients heterozygous for the 
variant (MAF=25% in patients with PNAO compared with 35% in dbSNP).  
 4.3.4.4 SCN10A 
We examined exome resequencing data for a nonsynonymous variant 
(Leu1092Pro [rs12632942]) that had previously been associated with risk of PNAO 
(Argyriou et al. 2013). We found four patients heterozygous and one patient 
homozygous for the variant (MAF=30% in patients with PNAO compared with 24% 
in dbSNP). 
4.3.5 Exome resequencing results 
On average, across the entire coding genome, we had 54.7% (range 45.7-
59.9%) coverage of the ORF at 20-fold coverage. We identified on average 48.9 
(range 40-57) stop gains and 87.7 indels predicted to result in frameshift mutations 
(range 73-111) per patient exome. Variants not present in dbSNP v132 (deemed 
‘novel’) were considered to be the most likely to cause PNAO and warranted further 
investigation. We identified on average 8 (range 2-11) and 28.2 (range 16-57) novel 
stop gains and frame shifting indels, respectively, per patient (Table 4.3).  
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 Patient 1 2 3 4 5 6 7 8 9 10 
            
S
to
p
 G
a
in
s
 
Total  
 
43 51 46 40 56 52 51 48 45 57 
Novel  
 
2 10 6 7 10 10 11 8 6 10 
Oxaliplatin 
pathway 
 
1 1 1 2 1 1 1 2 1 2 
Novel and in 
the oxaliplatin 
pathway 
 
0 0 0 0 0 0 0 1 0 0 
            
In
d
e
ls
 
Total  
 
73 111 80 86 85 99 91 77 93 82 
Novel  
 
16 57 21 20 16 41 28 18 39 26 
Oxaliplatin 
pathway  
 
2 1 1 1 1 0 3 0 0 0 
Novel and in 
the oxaliplatin 
pathway  
 
0 0 0 0 0 0 0 0 0 0 
 
 Table 4.3 – Number of stop gain and frameshifting indels identified from 
exome resequencing in each patient analysed. Variants were filtered based on 
novelty status, as well as for variants in genes involved in the platinum pathway 
(Table 4.4). 
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 1 2 3 4 5 6 7 8 9 10 
Stop 
Gains 
MKK3 - 
Gly102X 
(rs55796947) 
MKK3 - 
Gly102X 
(rs55796947) 
MKK3 - 
Gly102X 
(rs55796947) 
MKK3 - 
Gly102X 
(rs55796947); 
BRCA2 - 
Lys3326X 
(rs11571833) 
MKK3 - 
Gly102X 
(rs55796947) 
MKK3 - 
Gly102X 
(rs55796947) 
MKK3 - 
Gly102X 
(rs55796947) 
MKK3 - 
Gly102X 
(rs55796947); 
ERCC4 - 
Ser613X 
MKK3 - 
Gly102X 
(rs55796947) 
MKK3 - 
Gly102X 
(rs55796947); 
BRCA2 - 
Lys3326X 
(rs11571833) 
Indels 
CASP9 - 
Val448fs 
(rs2234723); 
OCT1 - 
Pro425fs 
(rs113569197) 
OCT1 - 
Pro425fs 
(rs113569197) 
OCT1 - 
Pro425fs 
(rs113569197) 
CASP9 - 
Val448fs 
(rs2234723) 
POLM - 
Arg108fs 
(rs28382645) 
 
CASP9 - 
Val448fs 
(rs2234723); 
OCT1 - 
Pro425fs 
(rs113569197); 
POLM - 
Arg108fs 
(rs28382645) 
   
 
 Table 4.4 – Stop gain and frameshifting indels in genes in the platinum pathway. Novel variants are highlighted in red. 
Variants validated by Sanger sequencing of an independent PCR product are in bold font. 
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4.3.6 Analysis strategy 1 – Analysis of genes in the platinum pathway 
 We analysed exome resequencing data for the 104 genes identified as 
important in the platinum pharmacokinetic and cellular response pathways. On 
average, we covered 74% of the ORF in all of the genes of interest at 20-fold 
coverage. In addition, over 74% of the genes in the pathway had at least 70% of 
their ORF covered at this depth, with 32% of genes with at least 90% of the ORF 
covered. However, 6% of the genes were not covered (Table 4.5). 
4.3.6.1 Stop gain mutations 
We identified Gly102X in MKK3 at the same frequency to that reported in 
dbSNP (rs55796947, MAF=50%) and was therefore considered likely to be a 
common benign polymorphism. 
A stop-gain in BRCA2 (Lys3326X, rs11571833; MAF in dbSNP=0.1%) was 
found in two patients and was verified by Sanger sequencing of an independent PCR 
products.  
We identified a single patient (Patient 8) with a novel stop gain Ser613X in 
exon 9 of ERCC4 which was verified by Sanger sequencing of an independent PCR 
product.  
 4.3.6.2 Frameshifting indels 
We identified one frameshifting deletion (Pro425fs; rs113569197) in OCT1 in 
four samples. However, the variant was not confirmed in any of the samples upon 
Sanger sequencing of independent PCR products, suggesting that it was an artefact. 
We also discovered Val448fs in CASP9 in multiple patients with a frequency 
similar to that reported in dbSNP (rs2234723, MAF in dbSNP=19.60%) and was 
therefore considered likely to be a common benign polymorphism. Additionally, 
Arg108fs in POLM was observed in two patients and in dbSNP (rs28382645, MAF in 
dbSNP=2.3%) but was in a transcript associated with nonsense mediated decay so 
was not considered functional. 
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Table 4.5 – Percentage of the ORF covered (at 20-fold coverage) of genes implicated in the 
platinum pharmacokinetic and cellular response pathways. A common key is given in table 4.2. 
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4.3.7 Analysis strategy 2 – Analysis of genes involved in neuronal 
function and/or peripheral neuropathy 
 4.3.7.1 Stop gain mutations 
We considered whether stop gains in genes involved in nerve function and/or 
peripheral neuropathy might also be responsible for PNAO. Therefore, every gene 
predicted to carry a novel stop gain variant (n=52) from the whole exome analyses 
was assessed in the literature for a potential role in neuronal function. Literature 
searches were carried out as described in section 4.2.7. 
We identified 2 genes as potentially relevant; stomatin like 3 (STOML3) and 
annexin (ANXA7) A stop gain variant in STOML3 (Arg164X), identified in a single 
patient and absent from dbSNP, was confirmed in an independent PCR product. 
However the variant Tyr54X in ANXA7 was not confirmed upon sequencing of an 
independent PCR product from the relevant patients genomic DNA and was 
therefore excluded.  
 4.3.7.2 Frameshifting indels 
We identified 204 novel frameshifting indels from the exome analysis of ten 
patients with PNAO and every gene was assessed in the literature for a potential role 
in neuronal function. We identified 5 genes that potentially had a role in peripheral 
neuropathy; adapter protein containing PH domain (APPL1 ; Phe472fs), 
neurofilament, medium (NEFM; Tyr63fs), neuropilin 2 (NRP2; Ser904fs and 
Cys907fs), semaphorin-4C (SEMA4C; Gly648fs) and protein phosphatase 1 
(PPP1R13L; Pro562fs). We attempted to validate by carrying out Sanger sequencing 
of independent PCR products from the relevant patients; only the deletion in NRP2 
was present in two samples. The rest were considered artefacts. 
The variant identified in NRP2 consisted of a CGCA deletion resulting in a 
frameshift (Ser904fs), as well as an insertion of a single adenine (Cys907fs). One 
patient was homozygous; another was heterozygous for both variants. Upon 
sequencing, both were validated in the relevant samples. 
 
 
 139 
 
4.4 Discussion 
4.4.1 Identification of MAP in Patient 1 
 By cloning and sequencing of exon 13 of MUTYH of Patient 1, we identified 
that the patient was compound heterozygous for the variants Gly396Asp and 
Arg426Leu. Biallelic mutations of this kind have previously been associated with the 
inherited CRC condition MAP (Section 1.2.1.2). The patient had ‘multiple colorectal 
polyps’, consistent with MAP. There has been no association between peripheral 
neuropathy and MAP previously made. 
4.4.2 Exclusion of hereditary neuropathies  
We first attempted to rule out inherited forms of peripheral neuropathy. 
Charcot-marie tooth syndrome (CMT; also known as hereditary motor and sensory 
neuropathy [HMSN]) comprises both a clinically and genetically heterogeneous 
group of disorders. Individual’s exhibit distal sensory loss, weakness and wasting of 
the muscles (Reilly et al. 2011). As the most common form of inherited neuropathy, it 
has an overall population prevalence of 1 in 2,500. Over sixty genes encoding 
proteins with different cellular functions and localisation have been associated with 
the disease, accounting for 50% of all cases (Rossor et al. 2013). Approximately 
75% of patients with CMT1 have a 1.4mb duplication in peripheral myelin protein 22 
(PMP22). No dosage abnormalities were found following MLPA analysis of PMP22 in 
the ten patients with PNAO. Five nonsynonymous variants in IGHMBP2 (previously 
associated with hereditary neuropathies), were identified following analysis of exome 
resequencing data. However, all were seen at similar frequencies to that reported in 
dbSNP. Therefore, we ruled out all inherited forms neuropathy in our ten patients. 
4.4.3 Exclusion of known causes of PNAO 
 Secondly, we investigated coding variants previously associated with PNAO. 
These included GSTP1Ile105Val, AGXTPro11Leu and AGXTIle340Met, ERCC1Asp118 and 
SCN10ALeu1092Pro. All variants were observed in the ten patients with PNAO at a 
lesser or similar frequency to that documented in dbSNP suggesting that they did not 
contribute to PNAO. 
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4.4.4 Exome resequencing 
NGS has allowed researchers to adequately assess large regions of the 
genome to help identify the underlying causes for disease phenotypes (Section 1.7). 
Exome resequencing allows researchers to target the protein coding regions of the 
genome. However, only the regions captured by the exome targeted platform will be 
sequenced. Here we used the Roche Nimblegen SeqCap EZ Exome Library v2.0 
solution-based method for exome enrichment. This capture kit targets 89.8% of the 
exome annotated in CCDS (Parla et al. 2011). We analysed coverage of the ORF of 
genes involved in hereditary neuropathies and the platinum pathway at 20-fold 
coverage. We observed that over 90% of the ORFs were covered on average for 
38% and 32% of these genes, respectively. Furthermore, two of the genes involved 
in hereditary neuropathies (GARS and NEFL) and six of the genes involved in the 
platinum pathway (ATP7B, HAH1, MT2A, GSTP1, MKK7 and ABCC1) had no 
coverage in the ten patients. We speculated that this could be as a result of these 
genomic regions not being well represented by the probes. Analysis of the 
annotation files of the genomic regions covered by the platform (available online at 
http://www.nimblegen.com/products/seqcap/ez/v2/index.html#annotation) revealed 
that all of these genes had probes to cover 100% of their ORFs. We suggest that this 
could be due to a lack of specificity of probes in some of the earlier capture kits. This 
could ultimately result in false negative results. Later capture kits have taken steps to 
overcome this, such as improving probe specificity and increasing probe numbers to 
cover areas with poor capture. 
Here we present the results from the analysis of exome resequencing data of 
ten patients exhibiting PNAO. We sought to identify variants by taking two analytical 
approaches; analysis of variants in genes in the platinum pathway and analysis of 
variants in genes involved in neuronal function or peripheral neuropathy. Variants 
predicted to be most detrimental to protein function (stop gains and frameshifting 
indels) were focused on. We identified four genes with a potential role in the 
development of PNAO (analysed further in Chapter 5). 
 4.4.4.1 BRCA2 
BRCA2 is a tumour suppressor gene which functions to repair DSBs as part 
of the HR pathway (Roy et al. 2011) as well as having roles in the repair of ICLs 
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(Cipak et al. 2006; Section 1.3.4 and 1.3.5). Although DNA repair is critical in the 
maintenance of neuronal homeostasis (McMurray et al. 2005), no previous link of 
BRCA2 with peripheral neuropathy has previously been established. 
 4.4.4.2 ERCC4 
ERCC4 encodes the structure specific 5’ endonuclease protein XPF which, in 
complex with ERCC1 (van Vuuren et al. 1993; Park et al. 1995), plays a role in the 
NER pathway, the main DNA repair pathway involved in the removal of bulky and 
DNA distorting adducts (Section 1.3.3), such as those formed by oxaliplatin 
(Reardon et al. 1999). XPF is the catalytic sub-unit of the complex (Enzlin and 
Schärer, 2002). The complex has also been implicated in ICL repair (Kuraoka et al. 
2000) and repair of DSBs (Sargent et al. 1997; Niedernhofer LJ et al. 2004; Ahmad 
et al. 2008; Al-Minawi et al. 2009).  
4.4.4.3 STOML3 
STOML3 encodes a mechanosensory channel, stomatin like protein. It is 
expressed in the primary sensory neurons in the dorsal root ganglion in mice 
(Mannsfeldt et al. 1999). Deletion of STOML3 leads to loss of mechanoreceptor 
function and loss of mechanosensitive currents in isolated neurons from mice 
(Wetzel et al. 2007). 
4.4.4.4 NRP2 
NRP2 has been shown to have a crucial role in the signalling responsible for 
peripheral nervous system axonal guidance (Schwarz et al. 2009; Roffers-Agarwal 
and Gammill, 2009). A putative association between variants in NRP2 has previously 
been seen with regards to chronic PNAO in GWAS of 96 CRC patients (Lee et al. 
2010) 
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Chapter Five – Analysis of candidate genes responsible for PNAO 
 
5.1 Introduction 
 In Chapter 4, we attempted to uncover a genetic basis for a predisposition to 
PNAO via exome resequencing of ten patients with extreme forms of the phenotype. 
By focusing on novel stop gain variants and frameshifting indels involved in the 
platinum pathway and in neuronal function and/or peripheral neuropathy, we 
uncovered variants in four candidate genes that potentially had a role in PNAO. Two 
of those genes are involved in neuronal function. NRP2 has a crucial role in the 
signalling responsible for peripheral nervous system axonal guidance (Roffers-
Agarwal and Gammill, 2009) and STOML3 encodes a mechanosensory channel 
(Wetzel et al. 2007). The two proteins encoded by genes involved in the platinum 
pathway are both involved in DNA repair; BRCA2 is involved in the repair of DSBs 
and ICLs and XPF (encoded by ERCC4) is involved in NER, DSB and ICL repair. 
 Here, we studied these variants and their associated genes to prove a casual 
role in PNAO, by using a combination of strategies; 
1. Analysing control samples. 
2. Assaying for additional variants in more patients with PNAO. 
3. Analysing functionally related genes. 
5.2 Materials and methods 
 5.2.1 Patient selection 
 Selection of additional patients with PNAO within the first 12 weeks of 
treatment was carried out as described in section 4.2.1.  
 5.2.2 Control samples 
We used panels of either 47 or 190 UKBS healthy control subjects to assay 
for variants in order to assess their frequency in the normal population. 
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 5.2.3 Correlating variants with PNAO 
 In order to correlate variants with the risk of PNAO, we obtained clinical data 
regarding the maximum grade of PNAO after 12 weeks of treatment for the entire 
COIN cohort. We termed ‘PNAO’ as ≥ grade 3 or removed from treatment within the 
first 12 weeks, whilst patients graded 0 and 1 were grouped as not suffering from 
PNAO. Grade 2 patients were not included in any analysis to allow for better 
discrimination between patients with and without PNAO. 
5.2.4 PCR and Sanger sequencing 
PCR, verification by agarose gel electrophoresis, product purification, Sanger 
sequencing and sequencing clean up were carried out as described in sections 2.5.4 
to 2.5.8. Sequences were analysed using Sequencer v4.6. All primers used for PCR 
and Sanger sequencing are given in Appendices 8-11. Primers used for the 
validation of nonsynonymous variants in NER genes identified by exome 
resequencing are given in Appendix 7. 
5.2.5 Genotyping 
Genotyping of Arg415Gln (rs1800067) in ERCC4, Asp118 (rs11615) in 
ERCC1, Lys3326X (rs11571833) in BRCA2 and Gly399Asp (rs2228528), 
Arg1213Gly (rs2228527) and Gln1413Arg (rs2228529) in ERCC6 was carried out 
with Illumina’s Fast-Track Genotyping Service using their high throughput 
GoldenGate technology. Genotyping of Pro379Ser (rs1799802), Arg576Thr 
(rs1800068), His466Gln (novel), Glu875Gly (rs1800124) and rs1799800 in ERCC4, 
and Asp425Ala (rs4253046), Gly446Asp (rs4253047), Pro694Leu (rs114852424), 
Ser797Cys (rs146043988), Gly929Arg (novel), Phe1217Cys (rs61760166), 
Arg1230Pro (rs4253211), Ala1296Thr (rs139509516), Thr1441Ile (rs4253230) and 
Phe1437Ile (novel) in ERCC6 was carried out by KBiosciences using their KASPar 
technology. 
5.2.6 In silico analysis of variants 
LD between variants was assessed using Haploview v4.2. Species alignment 
of all mammals listed on NCBI was carried out using Clustal Omega. A list of 
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common species names is given in Appendix 20. The functional consequences of 
amino acid changes on protein function were determined using Align-GVGD. 
5.2.7 Statistical analysis 
Differences between patients with and without PNAO and variant status was 
determined using the Pearsons Chi square test (X2) or the Fisher exact test if cell 
counts were <5. 
5.3 Results 
5.3.1 Patient selection 
A second panel of samples, consisting of 54 patients with extreme and dose 
limiting PNAO after 12 weeks of treatment was selected following review of their 
toxicity data. 
5.3.2 Further analysis of genes implicated in PNAO 
  5.3.2.1 NRP2 analysis  
We screened for the CGCA deletion resulting in a frameshift (Ser904fs), as 
well as an insertion of a single adenine (Cys907ins) in NRP2 in a panel of 47 healthy 
UKBS control subjects. We amplified the region by PCR and carried out Sanger 
sequencing using primers previously used for validation in Appendix 7. We identified 
both variants in 3 of the 47 samples; one sample was homozygous and two were 
heterozygous (2/64 [3.1%] of patients with PNAO compared to 3/47 [4.3%] of healthy 
controls [P=0.65])  
5.3.2.2 STOML3 analysis 
 We carried out PCR and Sanger sequencing to screen the entire ORF, 
flanking regions and 5’UTR of STOML3 in 54 additional patients with PNAO. No 
coding variants were found and intronic variants were observed at frequencies 
similar to those found in dbSNP (rs9548577 - MAF=0.8% in patients with PNAO 
compared to 0.8% in dbSNP; rs9574474 - MAF=10.9% compared to 18.1%).  
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5.3.2.3 BRCA2 analysis  
 We assayed for Lys3326X (rs11571833) in BRCA2 in all other available cases 
from COIN. Genotyping was performed using Illumina’s Fast-Track Genotyping 
Services (San Diego, CA) utilising their high throughput GoldenGate technology. In 
total, 2,060 samples were genotyped or sequenced successfully. Overall, we found 
similar proportions of cases with (2/64; 3.1% of patients) and without (36/1,752; 
2.1%) PNAO harbouring this variant (X2=0.35, P=0.56).  
5.3.2.4 ERCC4 analysis  
 5.3.2.4.1 Phenotype of patient 8 
Through exome resequencing and Sanger sequencing of an independent 
PCR product, we identified and validated a novel stop gain in ERCC4 in one patient 
with PNAO (Patient 8; Chapter 4). We amplified and sequenced the entire ORF and 
flanking regions of ERCC4 in this patient and did not find any other coding variants. 
The patient was a 79 year old female at the time of undergoing oxaliplatin 
therapy. She had been diagnosed with metastatic CRC following an ultrasound scan 
on her liver in March 2006. She had originally presented with right upper quadrant 
pain and two months of intermittent diarrhoea. Her carcinoembryonic antigen had 
been 130µg/L following testing, and a computerised tomography scan revealed 
multiple metastases throughout the liver, as well as a large caecal mass. A biopsy of 
the liver provided histological diagnosis of adenocarcinoma from a synchronous 
colonic primary cancer. The patients past medical history included a tubular 
adenoma which had been excised in 2001, peri-orbital rosacea diagnosed in 2003, 
excision of a seborrhoeic wart, moderate macular degeneration consistent with her 
age group and mild osteoarthritis. Allergy skin tests at this time had suggested nickel 
sensitivity and she was allergic to lidocaine. There was no past medical history of 
skin cancers, no immunodeficiency disorders or related diseases, no ataxia, memory 
loss or muscle weakness.  
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 5.3.2.4.2 Analysis of ERCC4 in additional patients with PNAO 
We carried out Sanger sequencing of amplified PCR products of the entire 
ORF, flanking regions and 5’UTR of ERCC4 in 54 additional patients with PNAO. We 
identified five nonsynonymous variants: Pro379Ser was found in 3 patients 
(MAF=4.69%) and was previously documented in dbSNP (rs1799802); Arg415Gln in 
9 patients (MAF=14.1%) and in dbSNP (rs1800067); His466Gln in a single patient 
and not in dbSNP; Arg576Thr in a single patient and in dbSNP (rs1800068) and 
Glu875Gly in 4 patients (MAF=6.25%) and in dbSNP (rs1800124). Apart from one 
case that carried both Arg576Thr and Glu875Gly all other cases carried a single 
ERCC4 nonsynonymous variant in a heterozygous state.  
We also identified 3 synonymous variants (Ala11 [rs3136042], Ser835 
[rs1799801] and Thr885 [rs16963255]) and three variants in the 5’UTR (-30T>A 
[rs1799797], -356C>A [rs6498486] and -69G>C [novel]), all of which were 
considered unlikely to affect function (Fig. 5.1). 
5.3.2.4.3 In silico analysis of nonsynonymous variants in ERCC4 
 We used Align-GVGD to gauge the potential impact on function of the five 
nonsynonymous variants identified. Pro379Ser, Arg576Thr and Glu875Gly were all 
predicted to interfere with function (a score of C65). Arg415Gln was less likely to 
interfere with function (Class C35) and His466Gln was not predicted to interfere with 
function (Class C15). 
Alignment of all mammalian sequences available on NCBI was carried out 
using Clustal Omega, revealing that XPF was well conserved across several 
species. Conservation was seen in all species analysed for Pro379, Arg415, Arg576, 
Ser613 and Glu875. Although some conservation was observed, His466 was not 
well conserved (Appendix 24). 
We analysed the 5’UTR of ERCC4 for potential transcription factor binding 
sites. Although the 5’UTR of ERCC4 lacks common consensus sequences, there is 
a TTCGGC(T/C) heptamer repeated ten times within 300bps immediately upstream 
of the translation start site. This heptamer is moderately conserved between several 
species potentially validating a regulatory role (Appendix 25). Rs1799797 
(MAF=24.4% in patients with PNAO compared to 25% in dbSNP) is seen in the last  
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base of the penultimate repeat before the start of exon one and is in high LD with the 
synonymous variant Ser835 and another variant located in the 5’UTR, rs6498486 
(both r2=1.0, D’=1.0). 
5.3.2.4.4 Correlating variants in ERCC4 with PNAO 
We genotyped Pro379Ser, His466Gln, Arg576Thr and Glu875Gly in the 2,186 
available cases from COIN and COINB using KBiosciences KASPar technology. We 
also used the same technology to genotype the intronic variant rs1799800 (in strong 
LD with -356C>A, -30T>A and Ser835; all r2=1.0, D’=1.0) which has previously been 
linked with an increased risk of bortezomib induced peripheral neuropathy in the 
treatment of multiple melanoma (Broyl et al. 2010). Arg415Gln was genotyped using 
Illumina’s GoldenGate technology.  
For KASPar genotyping of ERCC4 variants, the overall genotyping success 
rate was 98.1% (11,075/11,290 genotypes were called successfully) and 
concordance rate for duplicated samples (n=63) was 100% (315/315 genotypes 
were concordant). All samples deemed to be heterozygous and homozygous for 
their respective variant were validated in house via Sanger sequencing (n=33 for 
rs1799802; n=5 for rs1800068; n=73 for rs1800124). Samples that failed genotyping 
were Sanger sequenced to determine their genotype (n=26 for rs1799802; n=28 for 
rs1800068; n=10 for rs1800124). Additionally, following plotting of genotyping data, 
outliers were identified and sequenced to verify robustness of technology (n=4 for 
rs1799802; n=1 for rs1800068; n=9 for rs1800124; 100% concordance). In the 
genotyping of Arg415Gln using Illumina’s GoldenGate  technology, overall 
genotyping success rate was 99.95% (2,069/2,070 genotypes were called 
successfully) and concordance rate for duplicated samples (n=63) was 100% (Fig. 
5.2) 
We compared the frequencies of individual variants, and variants grouped by 
their likely effect on function as determined by Align-GVGD, in patients with and 
without PNAO. Variants predicted to affect protein function included Pro379Ser; 
Arg576Thr; Glu875Gly. Although each of these rare variants was found more 
frequently in cases with PNAO as compared to those without (Pro379Ser was in 
4.76% cases with PNAO compared with 1.53% of cases without PNAO, Arg576Thr 
was in 1.59% compared with 0.22%, and Glu875Gly was in 6.35% compared with 
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3.41%, respectively), none were individually significantly over-represented when 
analysed using Fishers exact test. However, combined, we found that more patients 
with PNAO carried a potentially function impairing variant (7/63, 11.11%) as 
compared to patients without PNAO (90/1,762, 5.11%; X2=4.23, P=0.04). However, 
there is a potential for novel or private variants in small cohorts to skew the data and 
therefore we removed Arg576Thr from the analysis. Statistically more patients with 
PNAO carried Pro379Ser and Glu875Gly than patients without PNAO (7/63, 11.11% 
compared to 86/1763, 4.88%; X2=4.89, P=0.03). 
Arg415Gln, which was predicted by Align-GVGD to be less likely to interfere 
with function, was found in similar proportions of patients with (9/63, 14.29%) and 
without (260/1,754, 14.8%) PNAO (P=0.91). The novel variant His466Gln was not 
seen in any further samples and was considered to be private (Table 5.1). 
Rs1799800 was not in association with PNAO (24/63, 38.1% of patients with 
PNAO carried this variant as compared to 834/1,736, 48% without, P=0.121). 
 5.3.3 Analysis of other genes in the NER pathway 
  5.3.3.1 Analysis of ERCC1 
Since XPF and ERCC1 function together to form a 5’ incision complex (van 
Vuuren et al. 1993; Park et al. 1995), we sought likely causal variants in ERCC1 via 
amplification and Sanger sequencing of the ORF, intronic boundaries and 5’UTR in 
all 64 patients with PNAO. We found three synonymous variants (Thr75 [rs3212947], 
Asn118 [rs11615], Pro128 [rs139827427]) and five variants in the 5’UTR (-96T>G 
[rs2298881]; -230C>A [rs41559012]; -303C>T [rs41540513]; -495C>A [rs3212931]; -
790T>C [rs3212930]; Fig 5.3). 
Rs11615 has previously been associated with response to treatment and, 
more recently, rate of onset of PNAO in a Japanese population (Ruzzo et al. 2007; 
Inada et al. 2010; Oguri et al 2013). Therefore, we genotyped the COIN cohort for 
this variant. Overall, we found similar proportions of cases with (38/64, 59.4% of 
patients) and without (1,063/1,717, 61.9%) PNAO harbouring this variant, thereby 
failing to support a casual role (X2=0.168, P=0.682). 
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  Variant rs # 
Frequency in patients (%) 
X2 P OR (L95-U95) 
+ PNAO - PNAO 
        
Predicted 
to affect 
function 
(C65) 
Pro379Ser rs1799802 3/63 (4.76%) 27/1,763 (1.53%) N/A 0.08  
Arg576Thr rs1800068 1/63 (1.59%) 4/1,762 (0.22%) N/A 0.16  
Ser613X Novel 1/63 (1.59%) - - -  
Glu875Gly rs1800124 4/63 (6.35%) 60/1,763 (3.41%) N/A 0.28  
Total (No 
private 
variants) 
 7/63 (11.11%) 86/1,763 (4.88%) 4.89 0.03 2.44 (1.08-5.51) 
Less 
likely to 
affect 
function 
(C15-35) 
Arg415Gln rs1800067 9/63 (14.1%) 260/1,754(14.8%) 0.014 0.91  
His466Gln Novel 1/63 (1.59%) 0/1,677 (0%) N/A 0.04 - 
 
Table 5.1 – Nonsynonymous and stop gain variants identified in ERCC4 in patients with and 
without PNAO analysed with respect to their potential effect on function. Ser613X was not included to 
determine the total numbers since it was only assayed for in cases with PNAO. Variants seen in more 
than one PNAO sample (highlighted in bold and shaded) were analysed in a combined analysis 
(total). We did not include the private variant Arg576Thr in the combined analysis due to the potential 
to skew the data. Patient 1C (a patient with PNAO) was not included in the analysis since they were 
not part of the original COIN trial. One patient with PNAO carried both Arg576Thr and Glu875Gly. 
Another patient without PNAO carried both Pro379Ser and Glu875Gly. Values in the total column 
reflect the number of patients genotyped. The Chi square (X2) test was used to test significance or 
Fishers exact test when values in cells were <5, and respective P value (P) given alongside odd’s 
ratios (OR) with 95% confidence intervals (L95 and U95). 
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Figure 5.2 – Genotyping cluster plots of A. rs1799800, B. Arg576Thr (rs1800068), C. Glu875Gly (rs1800124) and D. Arg415Gln (rs1800067). Figures 
A-C were generated through plotting data generated through KASPar technology; Figure D was generated through plotting genotyping data from Illuminas 
GoldenGate platform. Differential genotype groupings (circled) are due to variance of values as a result of genotyping samples in various batches-this is not 
outlying data.
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5.3.3.2 Variants in other ERCC homologs 
We examined the exome resequencing data for variants in ERCC2, ERCC3, 
ERCC5, ERCC6 and ERCC8. We did not find any variants of interest in ERCC2, 
ERCC5 or ERCC8. However, we identified one novel nonsynonymous variant in 
ERCC3 (XPB [Arg283Cys]) and three novel nonsynonymous variants in ERCC6 
(CSB [Ser797Cys, Gly929Arg and Phe1437Ile]). All were validated by Sanger 
sequencing of an independent PCR product.  
 5.3.3.2.1 ERCC3 
The region containing Arg283Cys was amplified and Sanger sequenced in 
190 UKBS controls. Of the samples successfully sequenced, we discovered that the 
variant was present in 1 out of 167 control subjects, suggesting that this variant was 
a low frequency variant. 
 5.3.3.2.2 ERCC6 
The regions containing Ser797Cys, Gly929Arg and Phe1437Ile were 
amplified and Sanger sequenced in 190 UKBS controls. Of the samples successfully 
sequenced, we discovered that Ser797Cys was present in 1 out of 155 subjects, 
suggesting that this variant was a low frequency variant. Neither Gly929Arg nor 
Phe1437Ile in ERCC6 were seen in the controls studied. We therefore amplified and 
sequenced the 5’UTR, ORF and flanking regions of ERCC6 in the 64 patients with 
PNAO. 
We identified 12 additional nonsynonymous variants; six of these were rare 
(MAF≤1%) and six were common (MAF >1%). Four of the rare variants identified had 
a higher MAF in patients with PNAO than that given in dbSNP (Table 5.2). We also 
identified two synonymous variants (Leu45 [rs2228524] and Gly917 [rs2229760]) 
and one variant in the 5’UTR (-466G>C), all of which were unlikely to affect function 
5.3.3.2.2.1 In silico analysis of nonsynonymous variants  
Gly399Asp, Asp425Ala, Gly446Asp, Pro694Leu, Ser797Cys, Arg1215Gly, 
Phe1217Cys, Arg1230Pro and Thr1441Ile were all predicted to interfere with 
function (Class C65). Ala1296Thr was predicted as likely to interfere with function  
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Align GVGD 
classification 
Exon 
Amino acid change 
MAF in 
cases 
with 
PNAO 
MAF in 
dbSNP 
[variant ID] 
Rare 
variants 
(MAF 
≤1%) 
N/A 
Transcript 2 
– Exon 6 
Gly929Arg [Novel] 0.80% Novel 
Class C15 21 Phe1437Ile [Novel] 0.80% Novel 
Class C55 19 Ala1296Thr [rs139509516] 0.80% 0% 
Class C65 
5 Asp425Ala [rs4253046] 2.40% 0.10% 
10 Pro694Leu [rs114852424] 0.80% 0.50% 
13 Ser797Cys [rs146043988] 1.60% 0.10% 
18 Phe1217Cys [rs61760166] 0.80% 0.10% 
21 Thr1441Ile[rs4253230] 1.60% 1.30% 
 
Common 
variants 
(MAF 
>1%) 
Class C15 18 Met1097Val [rs2228526] † 20.50% 20% 
Class C35 21 Gln1413Arg [rs2228529] † 21.40% 20% 
Class C65 
5 Gly399Asp [rs2228528] 15.10% 16.10% 
5 Gly446Asp [rs4253047] 2.40% 3.10% 
18 Arg1215Gly [rs2228527] † 21.40% 20% 
18 Arg1230Pro [rs4253211] 11.40% 10.80% 
 
Table 5.2 – All nonsynonymous variants identified in ERCC6. Shaded are rare variants that 
appear to be more common in patients with PNAO compared to the frequency data given in dbSNP. † 
Variants seen in high LD with each other  
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 (Class C55). Gln1413Arg was less likely to interfere with function (Class C35), and 
Met1097Val and Phe1437Ile were not predicted to interfere with function (Class 
C15). We were unable to assess the novel variant Gly929Arg due to it being located 
in an alternative transcript for which the protein sequence was not available.  
 5.3.3.2.2.2 Correlating variants in ERCC6 with PNAO 
Following the identification of 14 nonsynonymous variants in ERCC6 we 
genotyped the 2,186 available cases from COIN and COIN-B. Gly399Asp, 
Arg1215Gly and Gln1413Arg were genotyped using Illumina’s GoldenGate platform; 
Asp425Ala, Gly446Asp, Pro694Leu, Ser797Cys, Gly929Arg, Phe1217Cys, 
Arg1230Pro, Ala1296Thr, Thr1441Ile and Phe1437Ile were genotyped using 
KBioscience KASPar technology. We did not genotype Met1097Val since this variant 
was in high LD with Gly399Asp and Arg1215Gly ([Met1097Val-Arg1213Gly; r2 = 
0.99, D’ = 1.0], [Met1097Val-Gln1413Arg; r2 = 1.0, D’ = 1.0], [Arg1213Gly-
Gln1413Arg; r2 = 0.99, D’ = 1.0]). 
For KASPar genotyping, the overall genotyping success rate was 97% 
(22,340/23,020 genotypes were called successfully) and concordance rate for 
duplicated samples (n=63) was 99.2% (625/630 genotypes were concordant). For 
Illumina genotyping, the overall genotyping success rate was 99.85% (6548/6558 
genotypes were called successfully) and concordance rate for duplicated samples 
(n=63) was 100% (189/189 genotypes were concordant).  
Of the rare variants that were predicted to be damaging, we found that 
Asp425Ala, Pro694Leu and Ser797Cys were individually statistically 
overrepresented in patients with PNAO (Asp425Ala, 4.76% in patients with PNAO 
compared to 0.86% in patients without PNAO, P=0.02; Pro694Leu, 1.59% and not 
present in patients without PNAO, P=0.04; Ser797Cys, 3.29% compared to 0.17%, 
P=0.01). One patient with PNAO was heterozygous for both Asp425Ala and 
Ser797Cys. 
Combined we found that these five rare variants were statistically associated 
with PNAO (11.11% compared to 1.47%, P=1.7x10-8). However, there is a potential 
for novel and private variants in small cohorts to skew associations. Therefore, we 
conducted the combined analysis without Pro694Leu, Phe1217Cys and Thr1441Ile. 
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We observed a statistically significant over representation of Asp425Ala and 
Ser797Cys in patients with PNAO (6.78% compared to 1.04%, P=6x10-3). 
The novel nonsynonymous variants from exome resequencing, Glu929Arg 
and Phe1437Ile, were seen in patients without PNAO. Neither were individually 
associated with risk of PNAO (Glu929Arg, 1.59% compared to 0.23%, P=0.16; 
Phe1437Ile, 1.59% compared to 0.06%, P=0.07). Also, the rare variant not predicted 
to be damaging, Ala1296Thr, was not associated with PNAO risk (1.59% compared 
to 0.17%; P=0.13; Table 5.3).  
None of the common variants predicted to affect function were statistically 
associated with PNAO (Gly399Asp, 28.57% compared to 30.65%, P=0.73; 
Gly446Asp, 4.76% compared to 3.1%, P=0.32; Arg1215Gly, 36.51% compared to 
34.61%, P=0.76; Arg1230Pro, 20.63% compared to 19.13%, P=0.77). Similarly, the 
common variant predicted to be less likely to affect function, Gln1413Arg, was not 
associated with PNAO risk (36.51% compared to 34.46%, P=0.74; Table 5.4) 
5.3.3.2.2.3 Combined analysis of ERCC4 and ERCC6 rare variants 
 We carried out a combined analysis for the two rare variants from ERCC4 
(Pro379Ser and Glu875Gly) and the two rare variants in ERCC6 (Asp425Ala and 
Ser797Cys) shown to be associated with PNAO risk. We found that significantly 
more patients with PNAO had one of these rare variants in ERCC4 or ERCC6 in 
comparison to those without PNAO (11/63 [17.46%] compared to 103/1742 [5.97%]; 
X2=13.5, P=2.4x10-4; Table 5.5). 
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 Variant rs # 
Frequency in patients (%) 
P OR (L95-U95) 
+ PNAO - PNAO 
       
Predicted to 
affect function 
(C65) 
Asp425Ala rs4253046 3/63 (4.76%) 15/1,756 (0.86%) 0.02 5.80 (1.64-20.58) 
Pro694Leu rs114852424 1/63 (1.59%) 0/1,761 0.04 84.55 (3.41-2096.37) 
Ser797Cys rs146043988 2/63 (3.29%) 3/1,754 (0.17%) 0.01 19.14 (3.14-116.62) 
Phe1217Cys rs61760166 1/63 (1.59%) 3/1,738 (0.17%) 0.13  
Thr1441Ile rs4253230 1/63 (1.59%) 4/1,745 (0.22%) 0.16  
Total 
(No private 
variants) 
 4/63 (6.78%) 18/1,748 (1.04%) 6.10E-03 39.44 (8.63-180.18) 
Less likely to 
affect function 
(C15-C55) 
Ala1296Thr rs139509516 1/63 (1.59%) 3/1,748 (0.17%) 0.13  
Phe1437Ile Novel 1/63 (1.59%) 4/1,752 (0.23%) 0.16  
No information Glu929Arg Novel 1/63 (1.59%) 1/1,752 (0.06%) 0.07  
 
Table 5.3 – Rare nonsynonymous variants identified in ERCC6 in patients with and without PNAO analysed with respect to their potential effect on 
function. Patient 1C (a patient with PNAO) was not included in the analysis since they were not part of the original COIN trial. One patient with PNAO carried 
two of the predicted to be functional rare nonsynonymous variants (Asp425Ala and Ser797Cys). Variants seen in more than one PNAO sample (highlighted in 
bold and shaded) were analysed in a combined analysis (total). Fishers exact test was used and respective P value (P) given alongside odd’s ratios (OR) with 
95% confidence intervals (L95 and U95) 
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  Variant rs # 
Frequency in patients (%) 
X2 P 
+ PNAO - PNAO 
       
Predicted to 
affect 
function 
(C65) 
Gly399Asp rs2228528 18/63 (28.57%) 536/1,749 (30.65%) 0.12 0.73 
Gly446Asp rs4253047 3/63 (4.76%) 54/1,756 (3.1%) N/A 0.32 
Arg1215Gly rs2228527 23/63 (36.51%) 607/1,754 (34.61%) 0.1 0.76 
Arg1230Pro rs4253211 13/63 (20.63%) 335/1,751 (19.13%) 0.09 0.77 
       
Less likely to 
affect 
function 
(C35) 
Gln1413Arg rs2228529 23/63 (36.51%) 604/1,753 (34.46%) 0.11 0.74 
 
 Table 5.4 – Common nonsynonymous variants identified in ERCC6 in patients with and 
without PNAO analysed with respect to their potential effect on function. Patient 1C (a patient with 
PNAO) was not included in the analysis since they were not part of the original COIN trial. The Chi 
square (X2) test was used to test significance and P values (P) are given.
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 Frequency in patients (%) 
X2 P OR (L95-U95) 
  Variants + PNAO - PNAO 
ERCC6 
Asp425Ala, 
Ser797Cys 
4/63 (6.78%) 18/1,748 (1.04%) N/A 6.1x10-3 39.44 (8.63-180.18) 
ERCC4 
Pro379Ser, 
Glu875Gly 
7/63 (11.11%) 86/1,763 (4.88%) 4.89 0.03 2.44 (1.08-5.51) 
  Total 11/63 (17.46%) 104/1,743 (5.97%) 13.5 2.4x10-4 3.33 (1.69-6.68) 
 
Table 5.5 – Combined analysis of four rare, predicted to be damaging, nonsynonymous 
variants in ERCC4 and ERCC6. Novel and private variants (seen in one patient with PNAO) were not 
included due to the potential of such variants to skew analyses.
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5.4 Discussion 
5.4.1 Excluding roles of NRP2, STOML3 and BRCA2 in PNAO 
Two frameshifting indels in NRP2 originally seen in two patients with PNAO 
were also identified in 3 UKBS healthy control samples, suggesting these variants 
were common polymorphisms. We therefore ruled NRP2 out of future analysis. 
Following the identification of a novel stop gain variant in STOML3 in one 
patient with PNAO, we attempted to find further rare variants in additional patients 
with PNAO by sequencing the ORF, flanking region and 5’UTR of STOML3. We 
failed to find any other coding variants to support a role for STOML3 in PNAO. 
We identified a known stop gain variant, Lys3326X, in two patients with PNAO 
in BRCA2. Following genotyping and analysis of this variant in the COIN cohort, we 
failed to find an association between the variant and PNAO risk. We therefore ruled it 
out of future analysis. 
5.4.2 ERCC4 
5.4.2.1 Hereditary disease associated with ERCC4 
Biallelic mutations in ERCC4 are known to cause the autosomal recessive UV 
sensitivity disorder XP, group F (XPF; OMIM #278760) characterised by an elevated 
risk of cancer, in particular skin and oral cancers (Section 1.3.3.1; Matsumura et al. 
1998; Lehmann et al. 2011). In these patients, expression of XPF is reduced to 
approximately 5% of that seen in normal cells (Brookman et al. 1996). However, in 
comparison to other XP complementation groups, the XPF phenotype is considered 
mild, with the majority of cases seen in Japanese patients (Gregg et al. 2011). 
Recently, biallelic mutations in ERCC4 have also been attributable to the 
development of FA (OMIM #615272; Bogliolo et al. 2013), Cockayne syndrome (CS) 
and an XP-CS-FA phenotype (Kasiyama et al. 2013). FA is characterised by an 
increased risk of various cancers and bone marrow failure (Section 1.3.5.1). CS 
sufferers exhibit growth retardation, photosensitivity and impairment of the nervous 
system. Additionally, homozygosity of the Arg153Pro allele has been shown to cause 
XPF-ERCC1 (XFE) progeroid syndrome (OMIM #610965), characterised by 
moderate UV sensitivity and an accelerated rate of aging (Niedernhofer et al. 2006).  
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 5.4.2.2 ERCC4 and Patient 8 
A stop gain (Ser613X) in ERCC4 was identified in one patient with PNAO. 
After reviewing this patient’s medical record, we found no indication of XP. We 
assayed for a mutation in the second ERCC4 allele in the patient by Sanger 
sequencing of amplified products of their entire ORF and flanking intronic 
sequences. We failed to find any other coding variants, indicating that the patient 
was haploinsufficient for a mutant allele. 
5.4.2.3 Variants identified in ERCC4 
We identified five nonsynonymous variants in ERCC4 in patients with PNAO. 
Two of these variants, which were individually rare and predicted to be damaging 
(Pro379Ser and Glu875Gly), were shown to collectively contribute to the 
development of PNAO. 
In addition, we also identified two variants in the 5’UTR of ERCC4. Although 
the 5’UTR of ERCC4 lacks common consensus sequences, there is a heptamer 
repeat with mild species conservation. Rs1799797 is seen in the last base of the 
penultimate repeat before the ORF and is in high LD with the synonymous variant 
Ser835 and another variant located in the 5’UTR, rs6498486. However, since it was 
seen to be at a similar frequency in patients with PNAO to that reported in dbSNP, it 
was considered to be a benign polymorphism.  
5.4.2.4 ERCC4 in chemotherapy induced peripheral neuropathy 
The role of XPF in chemotherapy induced peripheral neuropathy was 
explored in more detail in the bortezimab treatment of multiple myeloma. Patients 
carrying the intronic variant rs1799800 and the silent polymorphism Ser835 in 
ERCC4, were at a 2.74 and 2.48-fold greater risk, respectively, of developing late 
onset peripheral neuropathy after treatment with bortezimab (Broyl et al. 2010). 
These two variants were shown to be in high LD with one another. We genotyped 
rs1799800 but found no association with PNAO. 
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5.4.3 Other ERCC family members 
5.4.3.1 ERCC1 
XPF functions in a complex with ERCC1 (van Vuuren et al. 1993; Park et al. 
1995). ERCC1 has roles in binding to single stranded DNA and localising the 
complex to the area of DNA damage (Tsodikov et al. 2005; Tripsianes et al. 2005). 
The complex structure formation is critical since either subunit requires the other for 
stabilisation, although it is thought this is more crucial for XPF protein stability (de 
Laat et al. 1998; Arora et al. 2010). Biallelic mutations in ERCC1 have been shown 
to cause XP (Gregg et al. 2011), CS (Kasiyama et al. 2013) and cerebro-oculo-facio-
skeletal syndrome (COFS; OMIM #610758). COFS represents a moderate sensitivity 
to UV light but with a severe growth failure (Jaspers et al. 2007). 
Here we investigated a role of ERCC1 in PNAO by amplifying and Sanger 
sequencing the 5’UTR, ORF and flanking regions in all patients identified with the 
phenotype. We identified five variants in the 5’UTR, all of which were unlikely to 
affect function. We also identified three synonymous variants. Despite these variants 
being unlikely to affect protein function, researchers have previously found a 
correlation between the silent polymorphism, ERCC1Asn118, and rate of onset of 
PNAO in a Japanese population (Inada et al. 2010; Oguri et al. 2013). In chapter 4, 
we observed the variant at a reduced frequency in the initial ten PNAO patients in 
comparison to dbSNP. Here we sought and failed to find an association between the 
variant and PNAO, confirming that it is unlikely to have an effect on Caucasian 
populations. 
5.4.3.2 ERCC6 
ERCC6 encodes CSB, a SWI/SNF DNA-dependent related ATPase (Troelstra 
et al. 1992). It is recruited to areas of damage following stalling of RNApolII at DNA 
lesions and has multiple roles including chromatin remodelling (Citterio et al. 2000) 
and recruitment of other NER proteins (Fousteri et al. 2006). Inactivating mutations 
have been shown to predispose patients to CS, group B (CSB, OMIM #133540; 
Mallery et al. 1998) characterised by physical and mental retardation, premature 
aging, neurological abnormalities, retinal degeneration, hearing loss and sensitivity 
to UV light (Nance and Berry, 1992).  
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 We identified fourteen nonsynonymous variants in ERCC6, five of which were 
rare and predicted to be detrimental to protein function. After exclusion of private 
variants, we have shown that two of these variants (Asp425Ala and Ser797Cys) 
collectively contribute to the likelihood of PNAO. These variants have not previously 
been linked to CSB. 
5.4.4 Rare variant hypothesis 
When analysed together we observed a collective contribution of two rare 
variants in ERCC4 seen in more than one patient (Pro379Ser and Glu875Gly) and 
two rare variants in ERCC6 (Asp425Ala and Ser797Cys) in PNAO patients. Although 
private and novel variants were identified in both genes, we did not include such 
variants in this analysis as there is a potential for such variants in a small cohort to 
skew the data and bias the statistics.  
The ‘rare variant hypothesis’ has previously been used to explain how 
individually rare but collectively common variants could contribute to disease 
etiology. For example, multiple rare nonsynonymous variants in three genes 
(ABCA1, APOA1 and LCAT) have been shown to be associated with low levels of 
HDL-cholesterol (HDL-C); a risk factor of artherosclerosis (Cohen et al. 2004). 
Similarly, rare nonsynonymous mutation in Wnt signalling genes (APC, AXIN and 
CTNNB1), and mismatch repair genes (MSH2 and MLH1) have been shown to 
collectively contribute to an increased predisposition risk to CRA (Fearnhead et al. 
2004; Azzopardi et al. 2008). The data presented here suggests that variants from 
multiple genes in the NER pathway could be contributing to the risk of PNAO. 
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Chapter Six – Construction of a model system to test the functionality of 
variants identified in ERCC4  
 
6.1 Introduction 
 The ability of oxaliplatin to form DNA crosslinks is critical for the drugs 
function as a chemotherapeutic in the treatment of CRC (Brabec and Kasparkova, 
2005). It is primarily the role of the NER pathway to remove bulky intrastrand 
adducts, the predominant lesion formed following oxaliplatin treatment (Reardon et 
al. 1999). The XPF (encoded by ERCC4) and ERCC1 complex is primarily involved 
in the 5’ incision of DNA during NER of such damage, although the complex also has 
roles in the repair of ICL and DSBs (Sections 1.3.3 and 4.4.4.2).  
In Chapter 4, we identified a novel truncation mutation in ERCC4 in one 
patient with PNAO. In Chapter 5, we subsequently characterised two rare 
nonsynonymous variants in ERCC4 in seven other patients with PNAO that 
collectively significantly altered the risk of developing this side effect. Typically, it is 
desirable to validate biomarker findings in a validation cohort. However, since the 
variants observed were rare (collective MAF in controls was 2.4%) we would require 
a very large cohort of patients in order to observe the effect size seen in COIN 
(OR=2.44). In COIN, we had approximately 60% power at a 5% significance level to 
detect this OR. In addition to this, the phenonomen of the ‘winners curse’ could 
mean that this OR was elevated. Therefore, if we consider a more modest OR of 1.8, 
with 75% power at a 5% significance level, we would require in excess of 250 
samples with PNAO and 7000 samples without PNAO to validate our findings. Since 
all other trials utilising oxaliplatin as part of the treatment regimen consisted of far 
fewer patients (n<1000), this was not possible. 
Since we cannot easily validate our findings in an independent cohort, we 
modeled our variants in the organism S.pombe in order to gauge their effects on 
function. S.pombe was the organism of choice as it is a simple, eukaryotic model, 
with a well annotated genome (Section 1.8). In addition to roles in NER, intrastrand 
crosslink repair, ICL repair and HR, the XPF S.pombe homolog, Rad16, has also 
been shown to play a role in checkpoint signalling and MMR independent from 
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typical MMR pathway proteins (Carr et al. 1994; Fleck et al. 1999; Prudden et al. 
2003; Bøe et al. 2012).  
In an attempt to develop a model system to test the effect of residue changes 
on the function of XPF, we genetically manipulated rad16 using Cre recombinase 
mediated cassette exchange (RMCE). We sought to initially knock out rad16 in the 
creation of a rad16 base strain, followed by restoration of wild type rad16 with 
flanking lox sites in order to test functionality. Mutations of interest were created by 
SDM on a constructed vector and RMCE was used to introduce the mutated 
cassettes into the rad16 base strain. 
6.2 Materials and methods 
6.2.1 Construction of the rad16 deletion base strain (Fig. 6.1) 
6.2.1.1 Construction of loxP-ura4+-loxM3 PCR product 
 For the construction of a rad16 deletion (rad16Δ) base strain, we used PCR 
with primers that incorporated a 100bp region upstream and downstream of the 
genomic rad16 locus. The 3’ ends of the primers were also designed to incorporate a 
20 nucleotide region in pAW1 (Appendix 12; Bähler et al.1998), in order for 
amplification of the ura4+ gene with flanking lox sites (so called ura4+F and ura4+R – 
Appendix 13; Appendix 14 for lox sites), as described by Watson et al. (2008). 
Primers with HPLC purity were purchased from MWG. PCR was carried out on 
lineralised pAW1 as the target using MMG® (Section 2.5.4). PCR conditions 
consisted of an initial denaturisation of 95˚C for 2 minutes, followed by 30 cycles of 
95˚C for 20 seconds, 55˚C for 30 seconds and 72˚C for 90 seconds. This was 
followed by a final elongation step of 72˚C for 10 minutes. Reaction mixtures from 
two identical PCRs were pooled and ethanol precipitation carried out. The pellet was 
dissolved in dH2O and an aliquot run on 1.5% agarose gel (Section 2.5.5). The PCR 
product consisted of ura4+ with flanking lox sites and with a 100bp sequence specific 
to the rad16 genomic region at the 5’ and 3’ ends (hereafter loxP-ura4+-loxM3). 
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  6.2.1.2 Lineralisation of pAW1 
Lineralisation of pAW1 was carried out in order to achieve a more efficient 
PCR reaction. 40ng of pAW1 was lineralised with 1 unit of AccI (New England 
Biolabs) in supplied buffer at 37˚C for 2 hours.  
 6.2.1.3 Transformation of loxP-ura4+- loxM3  
We transformed the loxP-ura4+- loxM3 PCR product into a wild type strain of 
S.pombe in order to knock out rad16 and incorporate lox sites at the locus to allow 
for ease of future recombination events. For homologous integration of the loxP-
ura4+- loxM3 PCR product at the rad16 genomic locus in the EH238 wild type strain 
(ura4-D18, leu1-32), the LiAc method of transformation was utilised (Section 
2.5.13.7). LiAc reaction product was plated onto MMA supplemented with leucine 
(MMA +leu) and allowed to grow for 5-7 days. Following this, successfully growing 
colonies were streaked out onto a MMA+leu master plate and left to grow for 5-7 
days.  
 6.2.1.4 Enrichment by UV sensitivity 
Rad16 plays a crucial role in the repair of DNA intrastrand cross links created 
by UV damage (McCready et al. 1993). Enrichment of UV sensitive colonies was an 
easy way to screen for either knock out or insertion of rad16. Oliver Fleck (Bangor 
University) carried out the enrichment process. Replica plates of the potential 
transformants were created by transfer using a replicating block covered with sterile 
velvet onto a YEA plate. A rad13Δ (homologous to human ERCC5/XPG; Rad13 is 
another important component in the repair of UV induced intrastrand crosslinks as 
part of the NER pathway; McCready et al. 1993) base strain was streaked onto the 
plates, as well as the unaltered EH238 wild type strain to act as controls. 
Transformants and controls were tested for UV sensitivity by treatment with 50-
100J/m2 of UV light using a Stratalinker.  
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Figure 6.1 – Construction of the rad16Δ base strain. A PCR product was created using primers designed to amplify loxP-
ura4+-loM3 in pAW1. Primers also incorporated 100bps of sequence upstream and downstream of rad16. Homologous 
recombination between the PCR product and rad16 in the wild type strain, EH238, allowed for successful knock out of rad16 and 
incorporation of lox sites to aid future recombination events. 
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 6.2.1.5 Colony PCR of UV sensitive transformants 
We carried out colony PCR (Section 2.5.13.5) on transformants that displayed 
UV sensitivity using primers A, B and C (Appendix 15). Primer A was designed to 
hybridise to the sequence upstream of the integration site, whereas B and C were 
designed to be specific to the rad16 and ura4+ gene insert respectively. 10pmol of 
primers A, B and C were all added to the colony PCR reaction mixture and results 
analysed on 1.5% agarose gels (Section 2.5.5). Successful colonies were 
transferred to liquid media and frozen at -80˚C. 
 6.2.1.6 PCR and sequencing of lox sites 
PCIA extraction (Section 2.5.13.6) was carried out to isolate genomic DNA to 
allow for PCR and Sanger sequencing of lox sites to ensure integrity. PCR, 
verification by agarose gel electrophoresis, product purification, Sanger sequencing 
and sequencing clean up were subsequently carried out (Sections 2.5.4 to 2.5.8). 
Sequences were analysed using Sequencer v4.6. Primers used are given in 
Appendix 16.  
6.2.2 Cloning of rad16+ (Fig. 6.2) 
6.2.2.1 Construction of the loxP-rad16+-loxM3 PCR product 
PCR was carried out using MMG (Section 2.5.4). Primers, rad16-Forward and 
rad16-Reverse, incorporating the relevant lox sites were designed with the 5’ and 3’ 
ends of the ORF of rad16 incorporated. Additionally, in rad16-Forward, nucleotides 
encoding an N-terminal histidine tag ([His]6) were integrated (Appendix 17). Primers 
were from MWG and of HPLC purity. Using previously extracted genomic DNA from 
S.pombe, thermocycling conditions consisted of an initial denaturation of 95˚C for 2 
minutes, followed by 30 cycles of 95˚C for 20 seconds, 51˚C for 30 seconds and 
72˚C for 3 minutes and 30 seconds. This was completed by a final elongation step of 
72˚C for 10 minutes. The reaction was repeated ten times, reaction mixtures pooled 
and ethanol precipitation carried out. The pellet was resuspended in dH2O and an 
aliquot was run on a 1.5% agarose gel. 
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6.2.2.2 Lineralisation of pAW8-ccdB 
Lineralisation of pAW8-ccdB was required for a more efficient in vitro Cre 
recombinase reaction by relaxing supercoiled plasmid. 500ng of pAW8-ccdB was 
lineralised with 2 units of SpeI (New England Biolabs) in the supplied buffer. The 
reaction mixture was incubated for 1 hour at 37°C and an aliquot run on an agarose 
gel alongside an aliquot of undigested plasmid to confirm lineralisation. 
6.2.2.3 In vitro Cre recombinase reaction between loxP-rad16+-loxM3 
and pAW8-ccdB 
 Recombination of loxP-rad16+-loxM3 was carried out with pAW8-ccdB, 
allowing for switching of rad16+ at the ccdB locus via corresponding lox sites. Molar 
ratios of 1:4, plasmid to insert were calculated in order to aid a more efficient Cre 
recombinase reaction. A standard Cre reaction was carried out (Section 2.5.12.8) 
and consisted of 100ng pAW8-ccdb and 150ng loxP-rad16+-loxM3 PCR product.  
  6.2.2.4 Transformation of electrocompetent E.coli cells with Cre 
recombinase reaction product. 
  Electroporation was used for transformation of DH5α E.coli electrocompetent 
cells with 1µl of Cre recombinase reaction product mixture and 25µl of cells (Section 
2.5.12.10). 100μl of transformation reaction was plated out onto LB plates with 
100µg/ml amplicillin and incubated at 30˚C for approximately 24 hours. Successful 
transformants were established in LB with 100µg/ml amplicillin and left to grow at 
30˚C overnight with shaking. Following this, plasmid extraction was carried out by 
Rebecca Williams (PhD student, Fleck group, Bangor) using the Machery-Nagel 
Nucleospin® plasmid extraction kit. 
  6.2.2.5 Verification of successful cloning 
Verification that loxP-rad16+-loxM3 had been successfully inserted into pAW8 
in place of ccdB was determined by restriction digest with BamHI by Rebecca 
Williams. 5µl of extracted plasmid was digested with 2 units of BamHI (New England 
Biolabs) with the supplied buffer and incubated for 1 hour at 37˚C. Following this, an 
aliquot of digestion product was run on a 1% agarose gel alongside an aliquot of 
undigested plasmid (Section 2.5.5). 
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6.2.3 Construction of rad16+ strain (Fig.6.2) 
6.2.3.1 Transformation of pAW8-rad16+ into rad16Δ base strain 
For homologous integration of the rad16+ cassette at the genomic locus, 
pAW8-rad16+ was transformed into the rad16Δ base strain using the LiAc method 
(Section 2.5.13.7). Reaction products were plated out on EMM supplemented with 
thiamine (EMM+thi) to induce expression of Cre recombinase through activation of 
the no message in thiamine (nmt41) promoter of pAW8. Cells were allowed to grow 
at 30˚C for approximately 4 days, at which point they were streaked out onto 
EMM+thi masterplates. The following steps were carried out by Oliver Fleck. 
Individual colonies were propagated in YEL to allow for removal of the plasmid and 
subsequently prevent further Cre recombinase action. Following 2 days of incubation 
at 30°C, cells were streaked out on YEA+5-FOA to allow for adequate selection for 
ura4- strains (5-FOA resistant, 5-FOAR; leu-). After incubation for 2 days at 30˚C, 
YEA masterplates were produced.  
6.2.3.2 Enrichment by high dose UV sensitivity 
The 5-FOAR transformants were further analysed by assaying for restored 
DNA damage repair capacity by treating a replica of the masterplate with 200J/m2 of 
UV using a Stratalinker. The wild type strain, EH238, and the rad16Δ strain were 
also treated in the same manner to act as a comparison for repair proficient and 
deficient strains, respectively. 
6.2.3.3 Enrichment by UV and MMS spot test treatment 
Transformants showing resistance to high dose UV were further analysed for 
sensitivity by spot tests treatment of 50-100J/m2 of UV and 0.01-0.015% MMS. The 
wild type strain, EH238, and the rad16Δ strain were also treated in the same manner 
to act as a comparison for repair proficient and deficient strains, respectively. 
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6.2.3.4 Colony PCR of UV and MMS resistant transformants 
Those colonies verified as insensitive to UV and MMS were analysed further 
by colony PCR (Sections 2.5.13.5 and 6.2.1.5, Appendix 15). 
6.2.3.5 PCR and sequencing of the ORF of rad16+ 
Genomic DNA was extracted using the PCIA method (Section 2.5.13.6). The 
rad16+ ORF and lox sites were amplified by PCR in order to gauge their integrity by 
Sanger sequencing (Section 6.2.1.6). Primers used are given in Appendix 18. 
6.2.4 SDM of pAW8-rad16+ 
6.2.4.1 Mutant plasmid synthesis (rad16MT) 
 Mutant strand synthesis and transformation of electrocompetent cells was 
carried out using the QuikChange Lightning SDM kit (Section 2.5.12.9), utilising 
pAW8-rad16WT and primers designed to create the variant amino acids. Primers 
were designed between 30-37 nucleotides in length, <40% GC content and with the 
mutation of interest in the centre of the primer with at least 10 bases either side to 
allow for adequate binding to the template. Primers used are given in Appendix 19. 
6.2.4.2 Extraction of rad16MT plasmids 
Successfully growing colonies were added to liquid LB with 100µg/ml of 
amplicillin. Following incubation for 16-18 hours at 30°C, plasmid extraction was 
carried out with Qiagen miniprep plasmid extraction kits following the manufacturers’ 
protocol (Section 2.5.12.7). 
6.2.4.3 PCR and Sanger sequencing of the ORF of rad16MT  
The ORF and flanking lox sites of the extracted plasmids were analysed by 
Sanger sequencing of an independent PCR product (Section 6.2.1.6, Appendix 18) 
to verify the integrity of the gene and lox sites, as well as ensuring that the 
appropriate mutation had been introduced. 
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 Figure 6.2 – Construction of pAW8-rad16+. A PCR product consisting of the entire rad16 gene with flanking lox sites was 
produced by amplification of EH238 wild type genomic DNA. In vitro RMCE was carried out between pAW8-ccdB and loxP-rad16+-
loxM3 PCR product, allowing for successful integration of rad16+ into the vector. 
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6.2.5 Construction of rad16MT strains (Fig. 6.3) 
6.2.5.1 Transformation of pAW8-rad16MT into rad16Δ base strain 
For homologous integration of the rad16MTcassette, pAW8-rad16MT was 
transformed into the rad16Δ base strain using the LiAc method (Section 2.5.13.7). 
Reaction products were plated out on EMM+thi. Cells were allowed to grow at 30˚C 
for approximately 4 days, at which point they were streaked out onto EMM+thi 
masterplates. Individual colonies were propagated in YEL to allow for removal of the 
plasmid and subsequently prevent further in vivo Cre recombinase action. Following 
growth for 2 days at 30°C, colonies were streaked out on YEA+5-FOA to allow for 
adequate selection for ura4- (5-FOAR; leu-) colonies and allowed to grow for 2 days, 
followed by production of YEA masterplates.  
6.2.5.2 Colony PCR of UV and MMS resistant transformants 
The 5-FOAR colonies were further analysed by colony PCR (Sections 2.5.13.5 
and 6.2.1.5, Appendix 15). 
6.2.5.3 PCR and sequencing of the ORF of rad16MT 
The rad16MT ORF and lox sites were amplified by PCR and sequenced in 
order to gauge integrity and incorporation of the relevant mutations. PCIA extraction 
of genomic DNA was carried out (Section 2.5.13.6), followed by PCR and Sanger 
sequencing (Section 6.2.1.6, Appendix 18).  
6.2.6 Construction of uve1Δ strains  
 Strain crossing was carried out by Oliver Fleck. The available uve1Δ strain 
(J129) is a different mating type to the strains used in this study, we first created the 
correct mating type. To do this, we crossed J129 (h- uve1::LEU2 leu1-32 ura4-D18) 
with 503 (h+leu1-32 ura4-D18 [ade6-704]). Strains were mixed on sporation media 
(MEA) and incubated for two days at 30˚C. After this time, the cells were placed 
under a microscope to identify asci with 4 spores each; a sign that the crossing of 
strains had been successful. These were then treated with 30% ethanol to kill the 
cells; the spores survive. The successful spores were grown on MMA with 
appropriate 
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Figure 6.3 – Construction of rad16MT strains. The various mutations of interest were introduced into the rad16Δ base strain 
by in vivo RMCE 
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supplements; in this case, uracil. After approximately 4 days growth, individual 
colonies were streaked onto plates of the same media and left to grow at 30˚C for a 
further 4 days to create the masterplate. The masterplate was replica plated onto 
YEA without adenine to cross out the redundant ade6-704 (a nonsense mutation that 
results in adenine auxotrophy). Selection of colonies of white colour (strains with 
ade6-704 are red in colour) was made. The successful cross was named OL2112 
(h+uve1::LEU2 leu1-32 ura4-D18). 
Cross 2 was carried out to combine OL2112 and the rad16Δ base strain (smt-
0 rad16::URA4 leu1-32 ura4-D18). The mating types, h+ and smt-0, will readily cross 
with one another. Strains were crossed in the same manner as described previously. 
Strains were grown on MMA. The produced strain was named uve1Δ-rad16Δ 
(h+rad16::URA4 uve1::LEU2 leu1-32 ura4-D18). 
Cross 3 was carried out to cross uve1Δ into the rad16+ and rad16MT strains 
(smt-0 rad16+leu1-32 ura4-D18 and smt-0 rad16MTleu1-32 ura4-D18). Strains were 
grown on MMA+ura. The strains produced were named uve1Δ-rad16+ and uve1Δr-
ad16MT (Fig. 6.4). 
6.2.7 Long term storage of bacterial colonies 
 Liquid cultures with successfully mutated plasmids were stored in equal 
volumes of 50% glycerol at -80˚C. 
6.2.8 Long term storage of S.pombe cultures 
 Liquid cultures of the rad16Δ base strain and successfully mutated strains 
were stored in 60% glycerol at -80°C. 
 6.2.9 In silico analysis 
 Alignment of amino acids between species was carried out using Clustal 
Omega. Restriction enzymes were chosen based on recognition sites within DNA 
sequence of plasmids using the New England Biolab Cutter, v 2.0. 
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 Figure 6.4 – Schematic of strain crosses carried out in order to knock out the 
uve1 gene in our previously constructed rad16Δ, rad16+ and rad16MT strains. The 
final strain is selectable by its ability to grow without leucine but not in the absence of 
uracil 
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6.3 Results 
 6.3.1 Analysis of conservation between species 
Percentage overall amino acid homology between XPF and the yeast 
homologs, Rad16 (S.pombe) and Rad1 (S.cerevisiae), was 36% and 31%, 
respectively. We observed conservation between all residues predicted to 
functionally affect the protein in XPF (Pro379, Arg576, Ser613 and Glu875) and 
Rad16 (Pro361, Arg548, Ser585 and Glu844, respectively). Additionally, the residue 
affected by a variant unlikely to affect function and not associated with PNAO, 
Arg415 (Rad16 - Arg399) was also conserved. 
 For XPF and Rad1 we observed conservation between the residues Pro379 
and Ser613 only (Rad1 - Pro469 and Ser747, respectively; Fig. 6.5). 
6.3.2 Construction of the rad16Δ base strain 
The rad16Δ base strain was successfully constructed by incorporation of the 
PCR product loxP-ura4+-loxM3 at the rad16 genomic locus (Fig. 6.7A). 
Recombination was made possible by the integration of 100bp regions at the 5’ and 
3’ end of the PCR product which was homologous to the upstream and downstream 
regions at the rad16 genomic locus. UV sensitivity enrichment allowed for 
identification of colonies likely to have rad16 replacement by ura4+ (Fig. 6.6). 
Following recognition of UV sensitive transformants, verification of replacement of 
rad16 with ura4+ was confirmed by colony PCR; the presence of a 537bp band 
indicated successful integration (Fig. 6.7B). Sanger sequencing on amplified 
products from extracted DNA confirmed that both lox sites were present and without 
mutation. However, 75% (3/4 colonies sequenced) contained mutations in the 50 
base pairs immediately upstream of the gene. 
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XPF Pro379 and Arg399 
 
Homo sapiens - NP_005227.1         EGEETKKELVLESNPKWEALTEVLKEIEAENKE--SEALGGPGQVLICASDDRTCSQLRD 
S.pombe - NP_587855.2              -GPNMDAIPILEEQPKWSVLQDVLNEVCHETMLADTDAETSNNSIMIMCADERTCLQLRD 
S.cerevisiae - NP_015303.1         -------EYTLEENPKWEQLIHILHDISHERMTNH-----LQGPTLVACSDNLTCLELAK 
                                             **.:***. * .:*.::  *               :: .:*: ** :* . 
 
XPF Arg576 
 
Homo sapiens - NP_005227.1         FGILKEPLT-IIHPLLGCSDPYALTRVLHEVEPRYVVLYDAELTFVRQLEIYRASRPGKP 
S.pombe - NP_587855.2              FEVIDDFNSIYIYSYNGE----RDELVLNNLRPRYVIMFDSDPNFIRRVEVYKATYPKRS 
S.cerevisiae - NP_015303.1         YEYVDRQDEILISTFK----SLNDNCSLQEMMPSYIIMFEPDISFIRQIEVYKAIVKDLQ 
                                   :  :.      *               *.:: * *::::: : .*:*::*:*:*       
 
XPF Ser613 
 
Homo sapiens - NP_005227.1         LRVYFLIYGGSTEEQRYLTALRKEKEAFEKLIREKASMVVPEEREGR--DETN--LDLVR 
S.pombe - NP_587855.2              LRVYFMYYGGSIEEQKYLFSVRREKDSFSRLIKERSNMAIVLTADSERFESQE--SKFLR 
S.cerevisiae - NP_015303.1         PKVYFMYYGESIEEQSHLTAIKREKDAFTKLIRENANLSHHFETNEDLSHYKNLAERKLK 
                                    :***: ** * *** :* ::::**::* :**:*.:.:      :    .  :     :: 
 
XPF Glu875 
 
Homo sapiens - NP_005227.1         AATALAITADSETLP-------ESEKYNPGPQDFLLKMPGVNAKNCRSLMH-HVKNIAEL 
S.pombe - NP_587855.2              PASAASIGLEA-GQD-------STNTYNQAPLDLLMGLPYITMKNYRNVFYGGVKDIQEA 
S.cerevisiae - NP_015303.1         PSNAVILGTNKVRSDFNSTAKGLKDGDNESKFKRLLNVPGVSKIDYFNLRK-KIKSFNKL 
                                    :.*  :  :             .:  * .  . *: :* :.  :  .:    :*.: :  
 
Figure 6.5 – Alignment of residues implicated in PNAO in XPF (Homo sapiens), Rad16 (S.pombe) and Rad1 (S.cerevisiae). 
Amino acids highlighted in green are residues of interest.  
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Figure 6.6 – UV enrichment for rad16Δ colonies. Wild type EH238 and a rad13Δ strain were also added to the plate for 
comparison as an NER proficient and deficient strain, respectively. Colonies identified as sensitive and analysed further are 
numbered on the plate treated with 150J/m2. 
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6.3.3 Construction of loxP-rad16+-loxM3 and cloning into pAW8-ccdB 
The production of the loxP-rad16+-loxM3 cassette was achieved by PCR and 
verified by the presence of a ~3kb band on an agarose gel (Fig. 6.7C). In vitro Cre 
recombinase was carried out with pAW8-ccdB and introduced into bacteria cells via 
electroporation. Subsequently, individual colonies were isolated and plasmid 
extraction was carried out using a Qiagen miniprep kit (Fig. 6.7D). A restriction digest 
was carried out using BamHI to verify that the rad16+ had been successful 
recombined into the plasmid (Fig. 6.7E). The ORF and lox sites were amplified and 
Sanger sequenced and integrity confirmed in all extracted plasmids. 
6.3.4 Transformation of pAW8-rad16+ into rad16Δ base strain, and 
genetic and phenotype testing 
pAW8-rad16+ was transformed into the rad16Δ base strain. Following growth 
of transformed cultures, enrichment by UV was carried out to confirm successful 
integration; those with restored rad16 had restored ability to repair UV damage. We 
identified four transformants with restored DNA damage repair capacity and further 
analysed these by spot test treatment with 50-100J/m2 of UV treatment and MMS 
treatment (Fig. 6.8). The transformants selected displayed a similar capacity for 
repair as EH238 wild type strain (Fig. 6.9). Following identification of insensitive 
colonies, colony PCR was carried out, with a band at 888 bps indicative that there 
had been successful incorporation at the rad16 genomic DNA locus of rad16+ from 
the plasmid. Additionally, genomic DNA from identified colonies was extracted, and 
Sanger sequencing of amplified products displayed that the entire ORF was intact in 
all colonies extracted. 
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 Figure 6.7 A) Production of a loxP-ura4+-loxM3 PCR product from targeted amplification of pAW1 (in duplicate). B) Colony PCR of colonies 
transformed with loxP-ura4+-loxM3 chosen as a result of increased UV sensitivity. Colony 26 acted as a no recombination control  (Fig. 6.6). C) Production of 
loxP-rad16+-loxM3 from genomic DNA. D) Extracted pAW8-rad16+ from five isolated colonies created by RMCE between pAW8-ccdB and loxP-rad16+-loxM3  
E) BamHI digestion of extracted pAW8-rad16+ from the 5 colonies isolated in D. Figures C-E were produced by Rebecca Williams. 
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Figure 6.8- UV enrichment for rad16+ colonies. The wild type EH238 strain and rad16Δ were 
also added to the plate for comparison as NER proficient and deficient strains, respectively. Colonies 
identified as insensitive and analysed further are numbered.  
 
Figure 6.9 – Spot tests on four strains identified from sensitivity analysis to be insensitive to 
UV treatment and therefore more likely to have successful recombination of rad16+. Treatment 
included various doses of MMS and UV light. 
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6.3.5 SDM of pAW8-rad16+ 
Following SDM on pAW8-rad16+, plasmids were analysed by Sanger 
sequencing of amplified PCR products of the entire ORF and flanking lox sites to 
allow for Sanger sequencing, ensuring integrity and successful incorporation of 
mutations (Fig. 6.10). 
In the first instance we had successful integration of Pro361Ser, Arg399Gln, 
Ser585X and Glu844Gly with no additional mutations in the ORF. However, we failed 
to integrate Arg548Thr. Following repeat of the SDM process with new primers, we 
identified colonies with the Arg548Thr with the mutation successfully incorporated, 
without additional mutations in the ORF. 
6.3.6 Transformation of pAW8-rad16MT 
Mutated plasmids were transformed into rad16Δ base strain. Successful 
colonies were selected and colony PCR was carried out, with a band at 888 bps 
indicative that there had been successful incorporation at the rad16 genomic DNA 
locus of rad16MT from the plasmid. Additionally, genomic DNA was extracted, 
amplified and Sanger sequenced, showing that the entire ORF was intact in all 
colonies extracted, and all colonies contained their respective introduced mutation. 
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Figure 6.10 – Chromatogram data of successfully introduced mutations in the pAW8-rad16+ plasmid using SDM 
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6.4 Discussion 
6.4.1 Species conservation 
We attempted to create a model system in order to test effects of various 
residue changes identified in patients with PNAO in the DNA repair gene ERCC4. 
We observed conservation of all amino acids of interest between XPF and the 
S.pombe homolog, Rad16. Despite S.cerevisiae being the better studied model for 
NER, complete conservation of residues of interest in the XPF homolog, Rad1, was 
not observed; only two of the five variants were conserved. This meant that S.pombe 
was the ideal candidate for modelling the residue changes of interest. 
6.4.2 RMCE 
We used PCR based methods to create the loxP-ura4+-loxM3 cassette that 
was used to successfully create the rad16Δ strain by recombination into a wild type 
strain. By replacement of rad16 with a selectable marker, ura4+, we could easily 
identify successfully recombined strains. 
The Cre/lox recombination system is a powerful tool and is used in the genetic 
manipulation of many organisms. The use of the site specific topoisomerase 
enzyme, Cre recombinase, allows for efficient and accurate cassette exchange 
between lox sites. By introduction of flanking loxP and loxM3 sites at the rad16 
locus, we were provided with a useful tool for site specific and accurate 
recombination at the rad16 genomic locus with various constructed cassettes. 
Differences in the spacer region of these two lox sites means that they recombine 
inefficiently with one another (Langer et al. 2002; Watson et al. 2008), preventing 
undesirable recombination events from occuring. Reinstatement of rad16+ and 
introduction of mutations was easily achieved by introducing a plasmid with the 
desired cassette into the rad16Δ base strain. This has advantages over PCR based 
methods of recombination, where homologous integration at a locus of interest can 
be used for gene deletion or insertion of mutations of interest (Bähler et al. 1998). 
PCR based method can suffer from low recombination efficiency and require the 
homologous integration process to be repeated if a different gene modification is 
required (Krawchuk and Wahls, 1999). The incorporation of lox sites that recombine 
with any lox flanked cassette efficiently at the locus of interest can overcome this 
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problem (Watson et al. 2008) and requires only one homologous recombination 
event. However, the insertion of the lox sites into genomic DNA could be a 
disadvantage in itself as they could potentially affect gene expression and/or protein 
function.  
6.4.3 SDM 
By carrying out SDM on pAW8-rad16+, we successfully produced a vector 
with our mutations of interest incorporated into the rad16 gene. In the first instance 
we failed to introduce the mutation that results in Arg548Thr. We theorised this could 
be due to a high TA content at the 5’ end of the original forward primer and therefore 
replaced this primer (Appendix 19). Following repeat of the SDM process with the 
new primers, we identified colonies with Arg548Thr successfully incorporated, 
without additional mutations in the ORF.  
6.4.4 Analysis of functionality 
In the construction of our model system we tested for functionality of the 
constructed strains at several points. Firstly, in the construction of the rad16Δ base 
strain, we considered that knockout of an essential NER gene would result in a UV 
sensitivity phenotype. Therefore we treated transformed cells with UV light to 
ascertain any heightened sensitivity. Similarly, following reintroduction of rad16+, we 
considered that reinstatement of the functional gene should restore a cells ability to 
repair UV and MMS induced damage. This constituted an efficient screening method 
when selecting for constructed strains of particular phenotypes. 
Secondly, following reintroduction of rad16+, we attempted to ascertain that 
the insertion of incorporated lox sites and a [His]6 tag did not affect expression of the 
gene, or function of the protein product. By treating with low dose UV, we confirmed 
that no effect on rad16+ role in NER was seen. By comparison to an unaltered strain, 
we demonstrated that there was no phenotypic effect on the strains ability in the 
repair of DNA damage. 
Additionally an essential gene, mis18, lies immediately upstream of rad16. 
Mis18 is involved in the control and regulation of centromeric chromatin and cell 
division by correct loading of the histone H3 variant, Cnp-1; an essential kinetochore 
(Hayashi et al. 2004; Williams et al. 2009). The region that falls between rad16 and 
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mis18 is likely to be involved in the transcription of the gene. Parts of this region 
were involved in the homologous recombination of loxP-ura4+-loxM3 during the 
production of the rad16 base strain. It is possible that mutations could have been 
incorporated into this PCR product during amplification, of particular relevance in the 
100bps upstream of rad16 required for homologous integration. Additionally, in the 
production of the rad16Δ, we incorporated lox sites at the 5’ genomic region of rad16. 
Following recombination of the loxP-ura4+-loxM3, the integrity of the loxP site and 
the region immediately upstream was checked by analysing sequence data. Of the 
colonies analysed, 75% contained a mutation in this region. We therefore used an 
error free strain as our base strain. 
Additionally, it was important to ascertain that introduction of lox sites did not 
affect the strains function. By observing normal colonies on growing plates and 
survival of the rad16Δ base strains in normal physiological conditions in comparison 
to the unaltered EH238 strain, we were confident that there was no effect due to the 
incorporation of loxP-ura4+-loxM3 at the rad16 genomic locus. 
We ensured the functionality of the lox sites at several stages by confirming 
their integrity by amplifying and Sanger sequencing extracted DNA and plasmids. 
We carried this out on genomic DNA following recombination of loxP-ura4+-loxM3 
and following the production of pAW8-rad16+ and pAW8-rad16MT. By verifying their 
integrity in this manner, we were satisfied that there would be no downstream 
problems when carrying out the various RMCE. 
6.4.5 Knockout of alternative UV repair pathways 
 Although it is typically and predominantly the role of the NER pathway in the 
repair of DNA adducts that occurs as a result to UV light, S.pombe possesses a 
distinct, alternative pathway that has also been shown to participate in this type of 
DNA repair (McCready et al. 1993). The UV damaged DNA endonuclease (Uve1) –
dependent excision repair pathway (UVER) has been shown to excise both 6,4PP 
and CPD’s. It has also been shown to excise platinum adducts, although at a 
reduced efficiency (Avery et al. 1999). Uve1 activates the pathway by first nicking the 
DNA 5’ to the adduct, at which point a BER like process will repair the damage much 
more rapidly than the NER pathway (Yonemasu et al. 1997). In order to rule out this 
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pathway in the repair of DNA damage following UV treatment, we knocked out uve1 
in all strains. This was carried out by crossing of strains with an uve1Δ with all rad16 
strains created for this project. 
The production of S.pombe strains with mutations of interest incorporated into 
rad16 provides a useful tool to study the potential of these variants to affect the 
proteins function. This can allow us to ascertain if the variants, originally identified in 
ERCC4, could affect the repair processes associated with various DNA damaging 
agents (Chapter 7). 
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Chapter Seven – Investigating the functional effects of variants introduced into 
rad16 
 
7.1 Introduction 
UV light causes direct DNA damage, producing CPD and 6-4,PP lesions. Both 
result in distortion of DNA, hindering transcription and replication, which can 
ultimately result in cell cycle arrest and apoptosis (Sinha and Hader, 2002). It is the 
role of NER to recognise, excise and repair the damaged strand (Section 1.3.3). 
S.pombe has an alternative UV repair system; UVER, which is governed by the 
endonuclease Uve1 (Section 6.4.5). In chapter 6, we successfully knocked out uve1 
in all constructed rad16 strains in order to truly assay for the effect of the variants of 
interest in the repair of UV damage by the NER pathway. 
MMS is an alkylating agent that adds methyl groups to nitrogen in purines. 
Despite the NER pathway being chiefly involved in the repair of bulky DNA adducts 
and not alkylated bases, mutations in NER genes in S.pombe have previously been 
shown to be sensitive to the actions of MMS (Kanamitsu and Ikeda, 2011). In 
S.pombe, this is believed to be due to the actions of the DNA repair sensor 
alkytransferase like protein (Atl1), responsible for the repair of alkylation of guanine 
residues (Pegg, 2000). Atl1 is responsible for recognising alkylation damage of 
guanine residues and shaping the lesion into what appears to be a bulky adduct, 
which subsequently recruits NER machinery to the area of damage (Pearson et al. 
2006; Tubbs et al. 2009). 
HU inhibits the production of new nucleotides by inhibiting ribonucleotide 
reductase. It therefore inhibits DNA synthesis and repair by depleting the dNTP pool. 
This results in replication fork stalling and cell-cycle arrest by inhibiting the build-up of 
nucleotides that normally occur during S phase (Koç et al. 2004; Petermann et al. 
2010). Previously, NER deficient strains (rad13Δ) have been shown to be sensitive to 
HU (unpublished data; Rolf Kraehenbuehl, Bangor University). 
Here, we sought to identify the functional consequences of variants introduced 
into rad16 in Chapter 6. By administration of a combination of treatments, we tested 
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DNA repair pathways that XPF/Rad16 are associated with (Section 6.1). In addition to 
oxaliplatin, we treated with UV light, MMS and HU. 
7.2 Materials and methods 
7.2.1 Spot tests 
  7.2.1.1 Primary cultures 
 Primary cultures were established by inoculating colonies of strains isolated 
from a YEA plate in YEL at 30°C with shaking overnight. 
  7.2.1.2 Cell counts and dilutions 
Cell counts of primary cultures were carried out and cells diluted in ten-fold 
serial dilutions in dH2O to the appropriate concentrations (ranging from 1 x 104-
107cells/ml). Either 5μl (uve1Δ strain UV spot tests plates) or 7μl (uve1+ strain UV, 
MMS and HU spot test plates) spots of each concentration was pipetted directly onto 
the plate in ascending order. For all treatments, untreated spot tests with the same 
cell concentration were used as controls.  
7.2.1.3 UV treatment 
Once dry, plates were treated with a range of UV doses using a Stratalinker 
(10, 50 and 100J/M2 for uve1+ strains and 10, 20, 40 and 60J/M2 for uve1Δ strains). 
Plates were stored at 30°C for four days, at which point photos of cell growth were 
taken. The experiment was repeated in triplicate for each concentration. In addition 
to the constructed uve1Δ strains, we also tested an uve1Δ strain with unaltered rad16 
(J129). 
7.2.1.4 MMS and HU treatment 
Spot tests with MMS (0.01, 0.015, 0.0175 and 0.02%) and HU (6 and 8mM) 
were carried out on plates with the desired concentration of reagents incorporated 
(Section 2.5.13.8). Plates were stored at 30°C for four days at which point photos of 
cell growth were taken. The experiment was repeated in triplicate for each 
concentration. 
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 7.2.2 Acute treatments 
  7.2.2.1 Primary cultures 
Primary cultures were established as described in section 7.2.1.1. 
7.2.2.2 Oxaliplatin  
 Cell counts of primary cultures were taken and acute treatment was carried 
out by incubation of 1x107 cells in YEL with and without 1mM of oxaliplatin for 18 
hours at 30°C. In the non-treatment groups, an equivalent volume of DMSO was 
added in place of oxaliplatin.  
 Following incubation, cells were counted and ten-fold dilutions were made to a 
range of appropriate concentrations. Approximately 100µl of the appropriate 
concentration was plated out in duplicate onto YEA plates, spread sterilely and 
allowed to dry. For all untreated cells, 1x102 cells were plated out; for treated rad16Δ 
and rad16Ser585X 1 x 104 and 1 x 103 cells were plated out and, for all other strains,    
1 x 103 and 1 x 102 cells were plated out. Plates were then stored at 30°C for four 
days, at which point counts of all growing cultures were made and percentage 
survival determined by comparison with untreated cells.  
7.2.2.3 UV treatment of uve1Δ strains 
 Cell counts of primary cultures were carried out and ten-fold dilution of cells to 
a range of appropriate concentrations were made. 
Approximately 100µl of each concentration was plated out in duplicate onto 
YEA plates, spread sterilely and allowed to dry. For all untreated cells, 1x102 cells 
were plated out. Once dry, plates were treated with the appropriate dose of UV using 
a Stratalinker. A range of UV treatments at various cell concentrations were used 
dependant on the sensitivity phenotype associated with the strain (Table 7.1). Plates 
were then stored at 30°C for four days, at which point counts of all growing cultures 
were made and survival determined by comparison with untreated cells. In addition 
to all constructed strains, we also plated and treated J129. 
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  7.2.2.4 Statistical analysis 
Average survival data for acute exposure experiments were analysed with the 
ANOVA test using the statistical programme IBM SPSS statistics 20 following 
transformation using the arcsine function. Correction for multiple testing was carried 
out using the Bonferroni technique. 
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A. 
 Dose 1 Dose 2 
                                   UV Dose (J/m2) 
Strain 
5 10 
uve1Δ-rad16Δ; 
uve1Δ-rad16Ser585X 
1x104 and 1x105 1x106 and 5x106 
 
B. 
 Dose 1 Dose 2 
                                   UV Dose (J/m2) 
Strain 
20 40 
J129 
uve1Δ-rad16+; 
uve1Δ-rad16Pro361Ser; 
uve1Δ-rad16Arg399Gln; 
uve1Δ-rad16Arg548Thr; 
uve1Δ-rad16Glu844Gly 
1x102 
1x102 (J129 only) 
and 1x103 
 
Table 7.1 – Amount of cells plated for each strain with dose of UV treatment administered. 
Amount of cells plated were dependant on sensitivity phenotype previously demonstrated by the 
strains in UV treatment spot tests 
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7.3 Results 
7.3.1 Spot test 
  7.3.1.1 UV treatment of UVER proficient strains 
 We observed at all doses of UV an increase in sensitivity of the rad16Ser585X 
and rad16Δ strain. There were no apparent differences in sensitivity between all 
strains with nonsynonymous variants and rad16+ (Fig. 7.1A). 
  7.3.1.2 UV treatment of UVER deficient strains 
We observed heightened sensitivity of uve1Δ-rad16+ in comparison to J129. 
Similar to the results of UV treatment of UVER proficient strains, we observed a 
heightened sensitivity of the uve1Δ-rad16Ser585X and uve1Δ-rad16Δ strains at all 
doses of UV treatment. There were no apparent differences in sensitivity between 
strains with nonsynonymous variants introduced and uve1Δ-rad16+ (Fig. 7.1B). 
  7.3.1.3 MMS treatment  
 We observed a heightened sensitivity at all concentrations of MMS for the 
rad16Ser585X and rad16Δ strain. There were no apparent differences in sensitivity 
between all strains with nonsynonymous variants and rad16+ (Fig. 7.1C) 
  7.3.1.4 HU treatment 
 We observed a slight sensitivity phenotype of rad16Ser585X and rad16Δ 
following HU treatment. There were no apparent differences in sensitivity between all 
strains with nonsynonymous variants and rad16+ (Fig. 7.1D). 
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Figure 7.1 – Spot test results for; A. UV treatment of proficient UVER rad16 strains. B. UV treatment of J129 and uve1Δ-rad16 strains. C. MMS 
treatment of rad16 strains. D. HU treatment of rad16 strains. Concentration of cells plated on every plate is displayed on the ‘no treatment’ plate in Fig7.1A. 
No treatment plates in Fig7.1A, C and D are identical. Further repeats of each experiment are given in Appendices 26-29. 
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7.3.2 Acute treatments 
Percentage survival for all strains following treatment was calculated in 
comparison to untreated plates (for oxaliplatin - Table 7.2; for UV – Table 7.3). 
Percentages were transformed using the arcsine function and comparisons with 
rad16+ (oxaliplatin) or uveΔ-rad16+ (UV) were carried out using ANOVA. Data was 
corrected for multiple testing using the Bonferroni technique. 
7.3.2.1 Oxaliplatin treatments 
 We observed a statistically significant decrease in survival for the rad16Ser585X 
strain only. However, when plotted separately, a consistent pattern of survival 
between strains with the introduced nonsynonymous variants was observed for 
experiments one, three and four (Fig. 7.2A, C and D). Due to variability of values 
between repeats, data from each experiment was normalised to rad16+, 
subsequently averaged and plotted (Appendix 30; Fig. 7.2E). We were unable to 
apply statistics to the normalised data due to no standard deviations for rad16+ 
(treated as 100%). In the normalised plot, the rad16Ser585X and rad16Δ strains had 
less than 20% of the overall survival displayed by rad16+, whilst all strains with 
nonsynonymous variants had less than 60% survival compared to rad16+ (Fig. 7.2E). 
Experiment two was excluded from the average for the normalised graph due to 
what appeared to be an outlying data point (rad16+; Table 7.3; Fig. 7.2B) 
7.3.2.2 UV treatments 
For the UV treatment, at dose one, we observed a statistically significant 
decrease in survival for both the uve1Δ-rad16Δ and uve1Δ-rad16Ser585X. This was not 
replicated at dose two. Due to variability of values between repeats, data was 
normalised to uve1Δ-rad16+, subsequently averaged and plotted at both doses 
(Appendices 31-32; Fig. 7.3A-B). In both normalised plots, we observed high 
sensitivity with the uve1Δ-rad16Ser585X and uve1Δ-rad16Δ strains (less than 1%) in 
comparison to uve1Δ-rad16+. For the nonsynonymous variants, at dose one the 
survival was similar to that observed to rad16+ (between 80-120%; Fig. 7.3A). This 
was mirrored at dose two for all strains except uve1Δ-rad16Glu844Gly (Fig.7.3B). We 
observed heightened sensitivity of uve1Δ-rad16+ compared to J129. 
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  Experiments       
  Strains 1 2 3 4 Average SD P 
Survival of 
treated 
strains in 
comparison 
to untreated 
controls (%) 
rad16+ 9.22 16.4 55.7 59.4 35.18 (41.44) 26.04 (28) - 
rad16Δ 0.64 7 16.5 8.1 8.06 (8.41) 6.52 (7.93) 0.142 (1) 
rad16-Pro361Ser 5.09 28.2 28 19.7 20.25 (17.6) 10.85 (11.6) 1 (1) 
rad16-Arg399Gln 3.4 14.3 25.9 23.7 16.83 (17.67) 10.27 (12.4) 1 (1) 
rad16-Arg548Thr 3.63 19.7 16 25.6 16.23 (15.08) 9.29 (11.01) 0.914 (1) 
rad16-Ser585X 0.28 3.3 4.5 5.6 3.42 (3.46) 2.29 (2.80) 0.046 (1) 
rad16-Glu844Gly 6.64 17.1 32.4 28.7 21.21 (22.58) 11.7 (13.93) 1 (1) 
  
Table 7.2 –Percentage survival of cells following treatment with 1mM of oxaliplatin. Averages 
and standard deviations (SD) were calculated for the four experiments. This was also calculated with 
experiment two excluded due to an outlying data point (rad16+; in parenthesis). Data was transformed 
using the arcsine technique and ANOVA was used to assess for differences in survival for each strain 
in comparison to rad16+. Bonferroni corrected P values (P) are given.
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  Figure 7.2 – Percentage survival (Table 7.2) for experiments 1 (A), 2 (B), 3 (C) and 4 (D). E. 
Average normalised percentage survival (for experiments 1, 3 and 4; Appendix 30) of constructed 
strains in comparison to untreated controls following oxaliplatin treatment. Experiment 2 was not 
included in the average due to an outlying data point. Standard deviations are displayed as vertical 
lines. 
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A. 
    Experiment       
  Strains 1 2 3 Average SD P 
Dose 1 
J129 116 87.69 62.04 88.58 26.99 - 
uve1Δ-rad16+ 58.70 70.39 66.11 65.07 5.92 - 
uve1Δ-rad16Δ 0.0116 0.0003 0.0044 0.0054 0.0057 4.2x10-4 
uve1Δ-rad16-Pro361Ser 74.58 55.26 61.08 63.64 9.91 1 
uve1Δ-rad16-Arg399Gln 56.30 86.96 70.48 71.25 15.34 1 
uve1Δ-rad16-Arg548Thr 82.96 82.17 54.35 73.16 16.3 1 
uve1Δ-rad16-Ser585X 0.0096 0.0011 0.0019 0.0042 0.0047 4.2x10-4 
uve1Δ-rad16-Glu844Gly 46.59 58.42 58.94 54.65 6.98 1 
 
B. 
    Experiment       
  Strains 1 2 3 Average SD P 
Dose 2 
J129 60.32 38.96 36.75 45.34 13.02 - 
uve1Δ-rad16+ 8.70 4.41 7.78 6.96 2.26 - 
uve1Δ-rad16Δ 0.0114 0 0.0004 0.003933 0.006469 1 
uve1Δ-rad16-Pro361Ser 17.03 1.68 9.22 9.31 7.68 1 
uve1Δ-rad16-Arg399Gln 12.61 2.54 4.76 6.63 5.29 1 
uve1Δ-rad16-Arg548Thr 8.67 4.65 5.54 6.29 2.11 1 
uve1Δ-rad16-Ser585X 0.0025 0.0001 0.0002 0.000933 0.001358 1 
uve1Δ-rad16-Glu844Gly 7.61 1.79 1.69 3.70 3.39 1 
 
Table 7.3 – Percentage survival of cells following treatment with A. Dose 1 B. Dose 2 of UV 
(Table 7.1). Averages and standard deviations (SD) were calculated for the three repeats. Data was 
transformed using the arcsine function and ANOVA was used to assess for differences in survival for 
each strain in comparison to uve1Δ-rad16+. Bonferroni corrected P values (P) are given.
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Figure7.3 – A. Average survival normalised to uve1Δ-rad16+ of constructed strains in 
comparison to untreated controls for dose 1 (Appendix 31). B. For dose 2 (Appendix 32). Standard 
deviations are displayed as vertical lines. 
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7.4 Discussion 
Untreated control plates for all conditions showed that all constructed strains 
were viable and grew normally (in comparison to rad16+ or uve1Δ-rad16+) under 
normal physiological conditions indicating that there was no functional impact of 
incorporated lox sites and/or [His]6 tag. 
 7.4.1 UV treatment of uve1+ strains 
 We observed, even at low doses of UV (10J/m2), extreme sensitivity of the 
rad16Δ strain and rad16Ser585X. This suggests that the introduction of the truncation 
mutation, Ser585X, severely impedes the ability of rad16 to act normally in the repair 
of UV induced damage, indicative of an NER deficiency.  
 All nonsynonymous variants introduced displayed a similar UV sensitivity as 
rad16+ indicating no significant effect on rad16 in the repair of UV damage. We saw 
no difference between the three predicted to be damaging variants associated with 
PNAO and Arg399Gln, not associated with PNAO. 
 7.4.2 UV treatment of uve1Δ strains 
  7.4.2.1 Spot tests 
 To compensate for the increased sensitivity as a result of the loss of the 
alternative UVER pathway, we treated uve1Δ strains with lower doses (10, 20, 40 
and 60J/m2) of UV than administered to the UVER proficient strains. 
 In addition to the rad16 constructed strains, we also treated J129. We 
observed a slightly heightened sensitivity of the uve1Δ-rad16+ strain in comparison to 
the J129 strain for all doses of UV, suggesting that there may be an effect of the 
introduced [His]6 tag and/or lox sites. However, since all constructs of rad16 created 
here contain the same genetic modification; this deems any associated phenotype 
comparable. 
 As displayed by the UVER proficient strains, we observed a heightened 
sensitivity of both the uve1Δ-rad16Δ and uve1Δ-rad16Ser585X. Again, all strains with 
nonsynonymous variants displayed sensitivity similar to that observed with uve1Δ-
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rad16+. We saw no difference between the three predicted to be damaging variants 
associated with PNAO and Arg399Gln, not associated with PNAO. 
  7.4.2.2 Acute treatment 
 We carried out an acute UV treatment on all uve1Δ strains. At dose one, as 
observed with the UV treatment spot tests, a statistically significant increase in 
sensitivity of the rad16Δ and rad16Ser585X was observed in comparison to rad16+. This 
was despite compensation for increased sensitivity as a result of UVER deficiency by 
lowering the dose of UV administered. Similarly, there were no significant differences 
between all nonsynonymous variant in comparison to rad16+. 
 We did not see a statistical difference in survival following treatment with dose 
2, despite normalisation graphs displaying a clear decrease in survival of both the 
rad16Ser585X and rad16Δ. Our inability to prove statistically that there was a difference 
at this dose could be due to large variability between the repeats. 
 As with the UV spot tests treatments, we observed a heightened sensitivity of 
the uve1Δ-rad16+ strain in comparison to J129 at all doses. 
 7.4.3 MMS treatment 
 We observed, at all concentrations of MMS, sensitivity of the rad16Δ and 
rad16Ser585X similar to the heightened sensitivity observed with UV treatment. Since 
the repair of MMS induced alkylation employs NER proteins indirectly through the 
actions of Atl1, this reinforces the concept of a deficiency of NER proteins in strains 
with the Ser585X variant. 
 As observed with the UV treatment, all introduced nonsynonymous variants 
displayed a similar sensitivity to MMS to that observed for rad16+, indicating no 
observable effect of these variants on DNA repair. Similarly, we saw no difference 
between the three predicted to be damaging variant associated with PNAO and 
Arg399Gln, not associated with PNAO. 
7.4.4 HU treatment 
Although some sensitivity of rad16Δ and rad16Ser585X was observed with HU 
treatment in comparison to rad16+, the degree of sensitivity observed was not as 
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severe as that seen in MMS and UV treatments. Since HU depletes dNTPs, it 
predominantly stalls replication forks which ultimately results in DSB when these 
forks collapse following prolonged or excessive dosing at the site (Petermann et al. 
2010). Previous research suggests that Rad16 and the human XPF-ERCC1 complex 
could have a role in the repair of such DSBs (Sargent et al. 2000; Prudden et al. 
2003; Ahmad et al. 2008; Al-Minawi et al. 2009; Kikuchi et al. 2013). The degree of 
sensitivity following HU treatment is mirrored between the rad16Δ and the 
rad16Ser585X strain, suggesting that rad16 has some role in the repair of HU specific 
DNA damage and that the truncation strain is unable to function adequately in the 
repair of such damage. 
7.4.5 Oxaliplatin treatment 
We were unable to mimic spot tests treatments for oxaliplatin due to low stock 
concentration of the drug. Oxaliplatin is only soluble in DMSO at a maximum 
concentration of 40mM, meaning that to reach concentrations in a 25ml YEL plate 
required we would have needed to add a high volume, reducing the amount of YEL 
and possibly affecting the ability of strains to grow normally.  
In order to assay for the effects of oxaliplatin, we carried out an acute 
oxaliplatin treatment. Statistically, we observed a heightened sensitivity of 
rad16Ser585X only. We thought that variability between repeats could be influencing 
the statistics and our ability to observe statistical significance between the other 
strains. Therefore, we normalised data to rad16+ to account for variability between 
repeats. Since the percentage survival of rad16+ in experiment two appeared to be 
an outlying data point, we removed the experiment from the average normalisation. 
Following normalisation, we observed a clear decrease in survival for rad16Δ also. In 
the normalised plot, unlike the acute UV and various spot test treatments, a 
heightened degree of sensitivity was also observed with all nonsynonymous variants 
introduced in comparison to rad16+.  
 
 In summary, we have shown that the introduction of Ser585X (Ser613X) into 
rad16 sensitises strains to MMS, HU and UV treatments to the same degree as that 
seen in the rad16Δ strain. Sensitivity was also observed following treatment with 
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oxaliplatin. This suggests that this truncating mutation is as detrimental to the role of 
the protein in various DNA repair pathways as deletions of the gene in its entirety. 
Although not statistically significant, we also observed an oxaliplatin specific 
decrease in survival for all strains with nonsynonymous variants (discussed further in 
Chapter 8). 
 
  
 206 
 
Chapter Eight – General discussion 
 
8.1 CRC predisposition 
Genetics has been shown to have an important role in CRC. Highly penetrant 
mutations have been shown to result in multiple hereditary CRC syndromes, whilst a 
variety of low penetrance alleles are believed to act in concert with one another to 
significantly alter an individual’s risk. Our training phase cohort has been used in the 
identification and validation of low and moderate penetrance risk alleles. Although 
not substantial enough to be presented in this thesis, I helped identify novel low 
penetrance alleles by GWAS meta-analysis (Appendix 33) and a moderate risk allele 
in the DNA repair gene OGG1 (Appendix 34). 
Better understanding of the genetics of CRC has led to the realisation that there 
are multiple proteins in particular pathways that are implicated in CRC risk. For 
example, multiple high and low penetrance alleles in genes that encode proteins 
involved in the TGFβ signalling pathway have been shown to be important in 
inherited forms of the disease. These include high penetrance mutations in SMAD4 
and BMPR1A, which are known to predispose to JPS (Section 1.2.1.4.2). Similarly, 
overexpression of GREM1 as a result of an upstream 40kb duplication has recently 
been shown to cause HMPS (Section 1.2.1.4.4). Interestingly, two low penetrance 
variants (rs16969681 and rs11632715) that fall within this region have been shown, 
following analysis of a GWAS risk locus, to be associated with disease risk (Section 
3.4.2.2). Similarly, a low penetrance risk variant, rs4939827, again identified by 
GWAS, is associated with over-expression of SMAD7 (Section 3.4.2.1). In addition, 
GWAS has also uncovered CRC risk loci associated with RHPN2 (19q13.1, 
[rs10411210]), BMP2 (20p12.3, [rs961253]) and BMP4 (14q22.2, [rs4444235]; 
Section 1.2.1.2), all part of the TGFβ signalling pathway. 
In addition to hereditary syndromes, the TGFβ pathway is important in CRC 
tumourigenesis. Complete loss of chromosome 18q is seen in approximately 75% of 
colorectal adenocarcinomas. This region is known to contain both SMAD2 and 
SMAD4 (Mehlen and Fearon, 2004). Additionally, TGFβR2 contains a microsatellite 
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repeat that is prone to MSI in MMR deficient cells, such as that seen in HNPCC or in 
approximately 12% of sporadic cancers (Lu et al. 1995; Fig. 8.1). 
As well as the TGFβ pathway, various DNA repair pathways are implicated in the 
genetics of CRC. Recently the identification of high penetrance mutations in POLE 
and POLD1, both important in DNA synthesis following excision of damage in 
multiple DNA repair pathways, were shown to predispose to multiple CRA and CRC 
(Section 1.7.2.2).  
High penetrance mutations in MUTYH, involved in the excision of adenine bases 
erroneously incorporated opposite 8-oxo-G that has formed due to oxidative 
damage, cause MAP (Section 1.2.1.2). Recently a variant in the oxidative repair 
protein OGG1, which encodes a protein which has roles in the direct repair of 8-oxo-
G, has also been shown to act as a low penetrance risk allele for CRC (Smith et al. 
2013). Other cancer types with an inherited component have been shown to be 
caused by both low and high penetrance mutations in genes involved in particular 
DNA repair pathways. For example, hereditary breast cancer is commonly a result of 
high penetrance mutations in BRCA1 and BRCA2 (Section 1.3.4.3.1). However, low 
penetrance inactivating mutations in BRIP1, which encodes a DNA helicase with 
known interactions with BRCA1 in HR and ICL repair, have also been shown to 
predispose to the disease (Seal et al. 2006). 
HNPCC is due to mutations in multiple genes in the MMR pathway (Section 
1.2.1.3). The MMR pathway is also important in CRC tumourigenesis. Up to 12% of 
sporadic tumours exhibit signs of MMR deficiency. This is most commonly as a result 
of inactivation of the MMR system via silencing of MLH1 via biallelic 
hypermethylation of the CpG islands in the promoter region, with tumours showing 
such methylation patterns being known as having a CpG island methylator 
phenotype (Kane et al. 1997; Toyota M et al, 1999). As a functional part of all three 
hMutL complexes, MLH1 is critical for functional MMR. 
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Figure 8.1 – The TGFβ signalling cascade. In TGFβ signalling, following binding of the TGFβ 
ligand to TGFβR1 and TGFβR2, there is receptor activation by phosphorylation (P). The activated 
intracellular domain of the proteins phosphorylate SMAD2 and SMAD3 and, following recruitment of 
SMAD4, relocate to the nucleus in order to regulate gene expression. Also, activated TGFβR 
activates RHPN2. SMAD7 is involved in the negative regulation of the SMAD2/SMAD3 complex. In 
the BMP signalling pathway, following binding of either BMP2 or BMP4 to BMPR1A or BMPR2, a 
dimeric complex involving combinations of the regulatory SMADS (R-SMAD; SMAD1, SMAD5 and 
SMAD8) is phosphorylated and activated. This complex recruits SMAD4 and relocates to the nucleus 
to regulate gene expression. This process is negatively regulated by SMAD6 and SMAD7, whilst 
GREM1 regulates BMP2/4 binding. Shown in green are proteins encoded by genes implicated by 
GWAS as associated with CRC risk; purple are involved in CRC tumourigenesis; red are involved in 
inherited forms of CRC. NOTE; GREM1 has been shown to have both high penetrance and low 
penetrance disease alleles. SMAD4 is associated with a hereditary CRC syndrome and is also 
involved in tumourigenesis. Adapted from Tenesa and Dunlop, 2009. 
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Here, we used our training phase cohort to help identify novel disease alleles 
associated with CRC. Given the importance of mutations in genes from DNA repair 
pathways in hereditary cancer syndromes, including various hereditary CRC 
disorders, we took a candidate gene approach focusing on DNA repair pathways. 
Despite our initial findings in the training phase cohort, we were unable to validate 
the apparent association between RAD1Glu281Gly and aCRC. We suggest that this 
could be due to the validation phase study being underpowered by the current 
sample size, and more aCRC and controls in the validation phase could be beneficial 
in ascertaining the effect of the allele on risk. 
 RAD1 is a component of the RAD9-HUS1-RAD1 (9-1-1) complex (Burtelow et 
al. 2000), which has roles in translesion synthesis, DSB repair and checkpoint 
activation in response to DNA damage (Parrilla-Castellar et al. 2004; Pichierri et al. 
2012). Additionally, roles in BER have also been proposed following the observation 
that the complex interacts with the DNA glycosylases MUTYH, TDG and NEIL1 (Shi 
et al. 2006; Guan et al. 2007a; Guan et al. 2007b), as well as interacting and 
regulating FEN1 (Friedrich-Heineken et al. 2005) and LIG1 (Song et al. 2009). 
Although there is no previous link to RAD1 in cancer predisposition, knockout in mice 
leads to an elevated rate on skin cancers (Han et al. 2010). With regards to CRC, 
the interaction with MUTYH is of particular interest, given the links between MUTYH 
and hereditary CRC. Inefficient binding of MUTYH to the 9-1-1 complex, as a result 
of nonsynonymous variants in MUTYH, has been shown to lead to a repair 
deficiency phenotype (Turco et al. 2013). Although the native RAD1 allele was 
mostly conserved throughout evolution and the amino acid change was predicted to 
be detrimental to protein function, it remains unclear how RAD1Glu281Gly could affect 
protein function. We postulate that potential disruption of protein-protein interactions 
could be key in the contribution of the RAD1 variant to the development of CRC. For 
example, the variant allele could disrupt complex formation by affecting the known C 
terminal binding of RAD1 to the N terminal of RAD9 (Doré et al. 2009). Alternatively, 
the variant could affect binding and localisation of the various other proteins that the 
complex has been associated with. 
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8.2 NGS of patients with adverse drug reactions 
Severe chemotherapeutic side effects can lead to a cessation of treatment or 
dose reductions which could be detrimental in the treatment of cancer. It is well 
known that there is variability between individuals in the severity of adverse effects 
experienced with the same treatments, for which genetics has the potential to play a 
role (Eichler et al. 2011). Improved understanding of underlying genetics could 
further understanding of cellular processes involved in drug reactions. This has the 
potential to allow clinicians to make better, informed choices when treating patients 
to improve the chance of treatment success whilst reducing debilitating side effects. 
For example, in the treatment of CRC, the FDA recommends genotyping for 
polymorphisms associated with UGT1A1 before administration of irinotecan. This 
allows for modifications of the dose administered, reducing the risk of severe 
diarrhoea and neutropenia in patients with these detrimental polymorphisms. 
Similarly, genotyping before treatment with the fluoropyrimidines for several variants 
associated with DYPD has been recommended to reduce severe side effects 
associated with polymorphisms that affect the rate of drug metabolism. 
Previously, candidate gene studies and GWAS have proved useful in the study of 
the pharmacogenetics of adverse events associated with many different drugs. 
However, candidate gene studies often fail to account for the various different 
mechanisms that are involved in toxic responses and GWAS of pharmacogenetics 
struggle to obtain sample sizes sufficient to validate an apparent association due to 
the often rarity of adverse events. NGS could prove to be useful in the 
pharmacogenetic study of adverse drug reactions due to its ability to identify rare 
variants, whilst sufficiently considering large proportions of the genome (Daly, 2010). 
Several studies have used NGS to study chemotherapy response and resistance. 
However, there are currently no published NGS studies investigating severe toxic 
responses 
Here, we used exome resequencing to uncover alleles associated with PNAO. 
One of the main limitations of exome resequencing is that by directly targeting the 
protein coding region a vast proportion of the genome is not analysed; up to 99% of 
the human genome is considered ‘non-coding’. A recent GWAS study of chronic 
PNAO uncovered nine variants in eight genes that appeared to be associated with 
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risk (Won et al. 2012). All of these variants were intronic. Additionally, a variant 
intronic to SCN4A has previously been associated with the severity and rate of onset 
of chronic PNAO (Argyriou et al. 2013). Due to high cost and time constraints, WGS 
is not as accessible as WES. It is anticipated that as the ‘third generation’ 
sequencing technology improves and competition between manufactures increase, 
there will be reductions in cost and time taken to acquire results. This will allow for 
WGS to be used more frequently in the discovery of alleles associated with particular 
phenotypes. 
 
8.3 PNAO  
PNAO remains a debilitating side effect in the treatment of aCRC for which, 
despite improved understanding of the underlying mechanisms of both the acute and 
chronic forms, there is currently no treatment to alleviate symptoms. In addition to 
impacting on cancer treatment due to dose modifications, it can affect the overall 
health and well-being of patients undergoing treatment (Tofthagen et al. 2013).  
 
 8.3.1 Exome resequencing of patients with PNAO 
We initially identified ten patients from the COIN trial and its translational study 
with extreme and dose limiting PNAO, In order to efficiently assess the exome 
resequencing data generated, we took two strategies to identify potential casual 
alleles. Firstly, we considered genes involved in the pharmacokinetics and cellular 
response to platinum drugs. Previously, variants in GSTP1, AGXT and ERCC1 have 
been shown to lead to an altered degree of PNAO, suggesting that altered cellular 
levels and/or effects of oxaliplatin can alter the sensitivity to treatment. We 
discovered a stop gain in the DNA repair gene, ERCC4, involved in the repair of 
DNA adducts such as that seen in oxaliplatin treatment. A decreased ability to repair 
DNA adducts could lead to an accumulation of lesions that has the potential to 
increase the rate of apoptosis. 
Secondly, we investigated genes involved in the neuronal function and/or 
peripheral neuropathy. Although in this thesis we did not find any association 
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between genes involved in neuronal function and/or neuropathy the recent finding 
that a nonsynonymous variant associated with the voltage gated sodium channel, 
SCN10A, was associated with an increased incidence of acute PNAO validates the 
analysis approach (Argyriou et al. 2013). Despite being beyond the scope of this 
project, a complete pathway analysis (much the same as carried out in this project 
for oxaliplatin) of genes involved in peripheral nerve function and/or neuropathy 
could be beneficial when considering future studies of PNAO. 
An alternative strategy not considered here includes the analysis of the data from 
the ten patients with PNAO without a prior hypothesis implied. This strategy would 
avoid any selection bias that comes with focusing on specific pathways such as that 
which can occur in candidate gene studies. To achieve this, filtering for all novel or 
low frequency stop gain or frameshifting indels in genes that are seen mutated in two 
or more of the ten patients could highlight potential genes involved in PNAO 
pathogenesis.  
 The avoidance of false positive and false negative results as a result of 
coverage issues is crucial in the analysis of exome resequencing data. In this study, 
we failed to validate a proportion of variants that were discovered through exome 
resequencing. Additionally, we found a small percentage of genes included in 
various analyses lacked sufficient coverage, potentially resulting in false negative 
results. An example of false negative results influencing WES studies was shown by 
Gilssen et al. (2012), whom demonstrated a failure to identify the causative gene 
associated with Kabuki syndrome (MLL2; at the time unknown) since it was not 
represented on the enrichment kit used and therefore was not sequenced. This 
highlights the need for stringent validations and consideration of coverage when 
analysing data generated. 
 
8.3.2 ERCC4 and PNAO 
In this thesis we report the discovery of the variant Ser613X in ERCC4 in one 
patient with PNAO. The patient was heterozygous for the variant. This variant would 
result in a truncated form of XPF, missing both the nuclease domain and the helix-
hairpin-helix (HhH2) domain, important for binding to ERCC1 (de Laat et al. 1998). 
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Since the DNA binding of the complex and stability of XPF is dependent on ERCC1 
(Tsodikov et al. 2005; Tripsianes et al. 2005; Arora et al. 2010), this would suggest 
that the haploinsufficiency seen in Patient 8 could be due to a decreased level of 
active XPF-ERCC1. This could potentially lead to inadequate DNA repair of 
oxaliplatin induced adducts and an increased rate of apoptosis, characterised by a 
heightened sensitivity.  
 We presented the identification of two rare nonsynonymous variants in 
ERCC4 which were shown to collectively contribute to PNAO. The rare variant 
hypothesis of disease aetiology states that individually rare but collectively common 
variants influence the likelihood of disease. We therefore theorised that these 
variants could be displaying varying but complementary effects on protein function. 
Both of these variants fall within proposed functional domains of XPF (McNeil and 
Melton, 2012). Recently, the Glu875Gly variant has been shown to alter the DNA 
binding ability of the XPF-ERCC1 complex, despite not effecting the protein-protein 
interaction between the two (Allione et al. 2013). Interestingly, the variant Pro379Ser 
has previously been identified as a pathogenic mutation in XPF when seen in a 
compound heterozygous state with other ERCC4 mutations (Gregg et al. 2011). 
Previously, analysis of XPF and ERCC1 in cells derived from XPE and XPF patients 
have revealed that there is cytoplasmic mislocalisation of both proteins that 
potentially contributes to a reduced capacity for DNA repair. In wild type cells, XPF 
and ERCC1 are never seen solely in the cytoplasm. Two cell lines from patients with 
one Pro379Ser allele, XP7NE and XP32BR, both displayed cytoplasmic localisation 
of XPF (Ahmad et al. 2010). Previously, cellular mislocalisation of proteins has been 
linked to other diseases including cystic fibrosis, where mislocalisation of mutant 
forms of the cystic fibrosis transmembrane conductance regulator (CFTR) chloride 
channel to the endoplasmic reticulum ultimately results in protein degradation (Welsh 
and Smith, 1993).  
Interestingly, previous research has suggested that altered expression of the 
sub units of the XPF-ERCC1 complex could affect the response and side effects to 
platinum treatment, presumably through an altered ability to repair damaged DNA 
(Section 1.6.2). Typically, increased expression of the subunits is correlated with an 
increased resistance to treatment, and a worse prognosis. On the contrary, a 
decreased level of expression leads to a heightened sensitivity to treatment. This 
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could result in an improved response, as well as potentially elevating the rate of 
adverse effects due to a reduced capacity for DNA repair, a build up of adducts and 
an increase in apoptosis. 
8.3.3 NER involvement in neuronal function and PNAO 
Since neurons are considered terminally differentiated, the need to replicate 
the genome is obsolete. However, the stability of DNA is paramount for adequate 
transcription. The various pathways of NER have been shown to be key in the 
maintenance of neuronal DNA, in particular TC-NER (Jaarsma et al. 2011). This is 
supported by the observation that approximately 20-30% of patients with mutations 
in several complementation groups of XP (XPA, XPD and XPG) have been reported 
to exhibit neurological symptoms, including peripheral neuropathy (Thrush et al. 
1974; Kanda et al. 1990; Robbins et al. 2002; Anttinen et al. 2008). Additionally, 
reduced capacity of the NER pathway has been linked to amplified adduct levels in 
the dorsal root ganglion of Xpa-/- and Xpc-/- mice following cisplatin treatment, 
implicating a role in the development of peripheral neuropathy (Dzagnidze et al. 
2007).  
With regards to mutations in ERCC4, XPF patients have previously exhibited 
symptoms of a milder neurological condition (Gregg et al. 2011), with signs of axonal 
polyneuropathy reported in one patient (Sijbers et al. 1998). This is supported by the 
findings that reduced expression of the XPF-ERCC1 complex mimicking that seen in 
XFE syndrome due to functional disruption of ERCC1 in mice has been shown to 
cause a distinct phenotype associated with peripheral neuropathy. The phenotype 
consisted of an accelerated aging related neuronal dysregulation and morphological 
loss of neurons (Goss et al. 2011).  
PNAO has previously been shown to be due to direct oxalate toxicity on neuronal 
cells by altering the action of voltage gated sodium channels (Grolleau et al. 2001). 
However, the genetic findings presented here suggest that DNA repair mechanisms 
could also contribute to neuropathy in the acute setting. The inability to repair DNA 
adducts that form following oxaliplatin treatment potentially increases the rate of 
neuronal apoptosis, synergistically contributing to an elevated rate of PNAO when 
the direct toxicity of oxalate is considered. 
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8.4 Assaying the effects of ERCC4 variants on DNA repair 
Using RMCE, we have successfully produced a model system in which to assay 
the functional effects of variants identified in ERCC4 in the S.pombe homolog, 
Rad16. We observed a heightened sensitivity with the rad16Ser585X strain to all forms 
of DNA damaging agents tested. The degree of sensitivity was similar to that 
observed with rad16Δ. Rad16 binds to the ERCC1 homolog, Swi10, via the C 
terminal domain (Carr et al. 1994) in much the same manner as XPF binds to 
ERCC1, and the sensitivity observed here highlights the importance of the C terminal 
interaction in complex formation for adequate DNA repair. 
The primary action of oxaliplatin as a chemotherapeutic is via the formation of 
inter and intrastrand crosslinks in DNA. The NER pathway is involved in the removal 
of intrastrand cross links but functions poorly in the removal of ICLs. However, XPF-
ERCC1 has NER independent roles in the repair of ICL by unhooking and HR 
(Niedernhofer et al. 2004). Interestingly, we observed between a 40 and 60% 
decreased survival of all strains constructed with nonsynonymous variants of interest 
following oxaliplatin treatment in comparison to the rad16+. However, this was not 
seen in the acute UV treatment, or mirrored in spot test treatments utilising MMS or 
UV treatment. This suggests that another mechanism distinct of NER was affected. 
We theorise that a heightened oxaliplatin sensitivity of strains with nonsynonymous 
variants could be due to a functional effect of the complex that hinders its ability to 
repair ICL. It is unclear what the exact effect of these variants on ICL repair could be. 
However, the recent findings that mutations in ERCC4 in two patients result in a FA 
phenotype as a result of an inability of the nuclease domain to properly process ICL, 
despite a relatively intact ability of the NER pathway, indicate that particular 
mutations could variably affect XPF in different mechanisms of DNA repair (Bogliolo 
et al. 2013). 
As mentioned previously, various ERCC4 mutations have been associated with a 
cellular mislocalisation of the complex. It could be possible the variants introduced 
into rad16 could be affecting localisation of the protein product. During the 
construction of rad16+, we incorporated a histidine tag at the 5’ genomic region of 
rad16. The histidine tag could therefore prove useful to assay for any mislocalisation 
effects of the introduced variants in S.pombe both before and after treatment with 
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oxaliplatin. This could be carried out by using antibodies to target the histidine tag in 
order to compare expression in separated nuclear and cytoplasmic cellular fractions 
or, alternatively, through immunofluorescence. 
 
8.5 Future directions 
 8.5.1 Analysis of ERCC4 variants in human cells 
 Although S.pombe acts as a good model for the variants discovered in 
ERCC4, it is desirable to investigate these variants further in human cells. There are 
many differences between the two organisms that could mean the effect of the 
variants observed may not be representative of human cells (Section 1.8). We have 
genotyped and identified HRC lymphoblastoid cell lines heterozygous for the ERCC4 
variants Pro379Ser, Arg576Thr and Glu875Gly. Work in our lab has begun to 
investigate the effects of these using various assays. This is being done by analysing 
the effect of these variants on survival following treatment with oxaliplatin and UV 
light, localisation by immunofluorescence, as well as assaying for the rate of repair of 
UV induced adducts. 
 
8.5.2 Functional analysis of ERCC6 
 In chapter five, we identified five predicted to be damaging rare 
nonsynonymous variants in ERCC6. Two of these were seen to collectively 
contribute to PNAO. This suggests that mutations in other components of the NER 
pathway could be playing a role in PNAO risk. If we are unable to validate these 
results in an independent cohort, it would be desirable to introduce these variants 
into a model organism, such as carried out here for rare variants in ERCC4. This 
could prove useful when assessing for any functional effects of the variants in the 
repair of oxaliplatin induced DNA damage. However, due to time constraints this is 
something that is beyond the scope of this thesis. 
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 8.5.3 NGS of patients with other adverse drug reactions 
 We have shown that NGS could potentially be used to uncover alleles 
associated with adverse drug reactions in the chemotherapeutic treatment of CRC. 
Therefore NGS could potentially be used as a tool to find genetic reasons for other 
adverse events in patients exhibiting severe forms of a given side effects 
(Summarised in table 1.6)  
 
 8.5.4 GWAS of severe adverse events 
 As well as taking an unbiased approach to disease gene discovery, GWAS 
encompass a large proportion of variation across the genome by genotyping SNPs in 
regions of high LD. Previously, GWAS has successfully been used to study severe 
adverse reactions to cancer treatments. With regards to CRC, a recent GWAS of 
toxicity associated with 5-FU or FOLFOX treatment uncovered and validated one 
SNP that was significantly associated with 5-FU associated diarrhoea (Fernandez-
Rozadilla et al. 2013). However, low statistical power due to problems’ reaching 
sufficient sample size in such studies and the need for adequate replication cohorts 
has meant that it can prove difficult to ascertain a specific association signal. It has 
been proposed that samples used in GWAS could be enriched in order to increase 
the chances of observing a given risk association. This could be done by 
concentrating on smaller cohorts that display an extreme form of a given phenotype 
to a given drug. By effectively enriching for a given phenotype we hope to increase 
the likelihood that a particular signal of high effect will be observed (Gurwitz and 
McLeod, 2013). Additionally there have been advances in genotyping chip design to 
cover regions not tagged by the common variants seen on traditional chips (Spencer 
et al. 2009). This means that some rare variants that would have otherwise been 
missed may now be successfully assayed. Association SNPs identified in GWAS can 
aid in assaying for the true casual SNP (as long as the association strength between 
the two is high) by guiding the researcher to the region that should be focused on 
during sequencing (Freedman et al. 2011). Taken together, these advances could 
prove useful in the discovery of alleles associated with severe adverse events in 
CRC treatment and broaden pharmacogenetic understanding. 
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Appendix 
Appendix 1 
Primers used in the amplification and Sanger sequencing of the ORF, flanking regions and 
5’UTR of RAD1 (tran – transcript) 
Region Forward primer (5’-3’) Reverse primer (5’-3’) 
Product 
size (bps) 
Tran 1 – 5’UTR ATGCAATCCAATCTGGCTCT AGCGCGGAGTAGGTGATAAG 501 
Tran 2 – 5’UTR-A TGGAAACAATCGCTCAAAAA TGATTGCGCCACTACATTTC 466 
Tran 2 – 5’UTR-B AGACAGGGTCTTGCTCCTTG AAGTTGGAGTCAGAGCCTATTTC 389 
Tran 3 – 5’UTR-A GCGAGAAATAACCAAGGAAAA GCAAGGTAGGAGGGGATGT 347 
Tran 3 – 5’UTR-B TCAAGTAAGTAACCCAAGAAAAGG GAAGGAGGCGGCACAGAC 361 
Exon 2 AGCCCCTTTCCACCTCTC TTGTCTACTGAAACCTTCCGATT 431 
Exon 3 TTCTCATGGGATTAGCACAGTA TGAACCAATGTTTATGTTCCAA 316 
Exon 4 AGGAGAAGCTGAACCCAGAA TGGGAAGATGGAGTACAGACC 372 
Exon 5 TGTGGTTTATTTTTGGATGAATG ACCTCCTCTTTATCACCAATGA 194 
Exon 6 TGGGAGTTCTGAGCAGTGTT GAAAATCCAATATGAAATGACAAA 339 
 
Appendix 2 
Primers used in the amplification and Sanger sequencing of the ORF, flanking regions and 
5’UTR of BRIX1. 
Region Forward primer (5’-3’) Reverse primer (5’-3’) Product 
size (bps) 
5’UTR CTCCTGGGGCCAACAACT GACCCCACCGCAAAGGTA 508 
Exon 1A TCCAACAAAACAGGCGATG TCGCTCCTATTTCCGATCTC 417 
Exon 1B GGAGGAAGTGAAGCCAGTCC TTAACACCCGGGCTACTCTG 513 
Exon2 CCTGGGCAACAGTGTGAGA TGAGAACACTGAACAAATGAAGA 299 
Exon3 TCTGGATAGCATATGTGGTTTGA TGGAAGACCAGTTATTGAAGAGT 273 
Exon4 AGCCTGGTTAGGTATTTTTGAGA TTTGCTTCATTCTCAACCCTTA 292 
Exon5 TGGTGAATAGGTGGTAAGCATT TTTGCACAACTATTTCAAAAGATTA 187 
Exon6 AAAAGTAATCTTTTGAAATAGTTGTGC AAGGTGGGGGTGAAACTAAA 243 
Exon7 GCCAAGTTATAGAAACAAATGAGC GGATGATACCGTGGTGTACTAAA 240 
Exon8 GGCTTTTGATGAATTACCACATT GGGCAACAAGAGCGAGAC 323 
Exon9 GGATTATCAATTATTTCAGGCACA GGCCAAAGGGTTCTGGTA 284 
Exon10 CACTGGCTGAAAGGATATATGG TTTTTCTTTCTTGTAAATGCTACACT 495 
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Appendix 3 
Primers used in the amplification and Sanger sequencing of the ORF, flanking regions and 
5’UTR of DNAJC21 (Tran-Transcript). 
Region Forward primer (5’-3’) Reverse primer (5’-3’) Product 
size (bps) 
5’UTR GCTCCTATCTCCCCCTTCAG GGCGGTGGTGTAGGTCAGT 463bps 
Exon 1 ACAGAGCCCACCCCTAGC GCCAGGTCCCTCTCTGCT 485bps 
Exon2 GTTTGTGGCATTTCTGATGG CCTATATTGATAACTGCTCCCAAC 242bps 
Exon3 TTCAAAAGGAGCAAGAAATCC GGCAATGCATCTTCAGTTTTC 332bps 
Exon4 CCCAAAATTCTTCAACATTAAAA GCCTGGGTGACAGAGTGAGA 327bps 
Exon5 GGTAAAAGATGTTTCGCATCAG GGCTGATGACTGAACCCAAC 493bps 
Exon6 GCTCTCTAGTGGGAATGGATTTT TTGGGAGATGTCAAATAAGCA 327bps 
Exon7 GCATATTTTAGATTTGTGCTCTGA ACTGTGCCACTGCACTCCT 229bps 
Exon8 TTGGTTGCAGTTATCCAGCA CCTGGGCAACAGAGTGATTC 338bps 
Exon9 CCATTGAACTACAGCCTTGTG CTGAATAAATAAGAGCACTGCAAC 311bps 
Exon10  
(Tran2-Exon11) 
TTGGCAACATAACATAAAAAGC TGGTCAGTCATGGGAAAGAA 347bps 
Exon11  
(Tran2-Exon12) 
AGAGAGCACTCAAATAATGATGG GGAATGGCTCACCAAATACA 245bps 
Exon12  
(Tran2-Exon13) 
ACAATTGTTTGATGCTTAATCTTG TGCAGATCACTGAAATTTTAACTC 353bps 
TRAN2-Exon10 TTGAATGTGGGTTGTGTAACAG CAATGGCAACAACAAACAGG 281bps 
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Appendix 4 
Primers used in the amplification and Sanger sequencing of the ORF, flanking regions and 
5’UTR of TTC23L. 
Region Forward primer  (5’-3’) Reverse primer  (5’-3’) Product 
size (bps) 
5’UTR - A TGCCAACGAAAGGGTAAGA AAAACTGGCCTCTGCATATTGT 423 
5’UTR - B CGCTCCCTTCCATCCTTG ACGTCCCCAGTTACCTTCC 322 
Exon 2 CAAACCAGAGGGGGAAAATAG AAAGCTCCTCACCCAGGTTT 238 
Exon 3 TGTCCCTATCCCCTAGTTGG AATCTGCATCGAAGGCAAAG 369 
Exon 4 TTCAGTCCTGTGTTCCAGTGA GTTGTGTGGGTCAGTTCAGC 273 
Exon 5 CCTCCCAGGAATGTTTTTGA ATCTCCCACCCTCCTGTATG 322 
Exon 6 TATCACCTGCTGTCCCTGTG CATGTAATTCCAAGCCTCATTC 250 
Exon 7 CAGTTCCTTTTGTGTCTGCAA TTCCAGCCCTTGTTCTTCTG 351 
Exon 8 GCTGGGACTCAAACTCACCT CCAATGTGCTTCCCTCATGT 253 
Exon 9 TGTCAATTGAGCCAAAGCTG TGCCTAGTTTTATCTGGGACCT 323 
Exon 10 CAGTGCAATGAAAGGAGAGACA TCCTCCATACACTGCCCTCT 184 
 
Appendix 5 
Primers used in the analysis of expression of specified genes in kidney and colon cDNA. 
Gene (exons covered) Forward primer (5’-3’) Reverse primer (5’-3’) Product 
size 
(bps) 
AGXT2 (Exons 3-7) CTTGGCTACAACCGTGTCCT CCACGAAAAACATCTGGACA 521 
AGXT2 (Exons 6-11) GAACTCCCTGGTGGGACA AGGCATTTCGCCAAAGATT 479 
BRIX1 (Exons 2-7) AACGGATTCTCATCTTTTCTTCC GCATAATGTGGTAATTCATCAAAA 358 
BRIX1 (Exons 6-10) CCCTCGCTGAACTGAAGATG CAGTGGGATCATGTGGAAGA 468 
DNAJC21 (Exons 2-5) ATCTGGATAATGCCGCAGAA TCATCTCTTCGGCTTTCCTC 612 
DNAJC21 (Exons 6-10) TGGTGGAGCAGTACAGAGAACA ACTCCTTCTCCAGGTCCATTT 492 
RAD1 (Exons 1-4) ACTTCCTCCGCGGTTCCT AGGCTTGTCAGGAGACATGG 719 
RAD1 (Exons 3-6) TCAGGAGTTTAAAGTTCAGGAAGA TCAAGACTCAGATTCAGGAACTT 640 
TTC23L (Exons 6-10) TGGCAGAGAAGCCTATTTCAA TCCTCCATACACTGCCCTCT 644 
TTC23L (Exons 3-6) TCATCCCAAAGAGAAATTAGCC AGCAAGTGTTAGGTCGTTCTCA 463 
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Appendix 6 
 Primers used for MLPA for CMT. 
Gene Forward primer (5' section of probe) Reverse primer (3' section of probe) Product 
size 
(bps) 
IL4 CTACATTGTCACTGCAAATCGACACCTAT TAATGGGTCTCACCTCCCAACTGCTTCCCCCT 130 
KCNJ6 TGACATGCCAAGCTCGAAGCTCCT ACATCACCAGTGAGATCCTGTGGGGTTACCGG 136 
PMP22 CAGTTACAGGGAGCACCACCAGGGAA CATCTCGGGGAGCCTGGTTGGAAGCTGCAGGCTTAGTCTGT 142 
PMP22 GCTACAGTTCTGCCAGAGATCAGTTGC GTGTCCATTGCCCACGATCCATTGCTAGAGAGAATCAGATA 148 
KIF1B TATGTCGGGAGCCTCAGTGAAGGT GGCTGTCCGGGTAAGGCCCTTCAATTCTCGAGAGACCAGC 154 
PRKCE CGAGTTCGTCACCGATGTGTG CAACGGACGCAAGATCGAGCTGGCTGTCTTT 160 
PMP22 CCTCTTCCTCAGGAAATGTCCACCACTGTT TCTCATCATCACCAAACGGTGAGGCTGGTTTTGTGCT 166 
PMP22 TGACAGGATCATGGTGGCCTGGA CAGACTGCAGCCATTCTGGGGGAAAGAGACACTTGGTTAGG 172 
CFTR CTTGTTCCATTCCAGGTGGCTGCTTCT TTGGTTGTGCTGTGGCTCCTTGGAAAGTGAGTATTCCATG 178 
BX089850 CTGCAGTTGGTTGAATCTGAAGAGCCCTT GGATACGGAAGGCTGACTGTGTATGGCTACTCTGAAGAATG 184 
HIPK3 CCTCAAGACCTATGTTACAGCATCCAACT TATAATATCTCCCATCCCAGTGGCATAGTTCACCAAGTCCC 193 
TEKT3 GCCTTGTTAACGAGGTACACGAGGTTG ACGACACCATCCAGACCCTGCAGCAGCGCCTGAGGGATGC 202 
IFNG TAAGTAGGAACTCATCCAAGTGATGGCTGAACT GTCGCCAGCAGCTAAAACAGGGAAGCGAAAAAGGTCTAGA 211 
KIF1B GGAGCACAAAGCACCGTGGGGTCCTT TTGCAGGCCCTCAATGACAAAGACATGAACGACTGGTT 219 
PMP22 GGGAGGGTCTTGCCTTAACATCCCTT GCATTTGGCTGCAAAGAAATCTGCTTGGAAGAAGGGGTTAC 229 
PMP22 TCTTCTCAGCGGTGTCATCTATGTGATC TTGCGGAAACGCGAATGAGGCGCCCAGACGGTCTGTCTGA 238 
STCH CAATGATGTATATGTGGGATATGAAAGCG TAGAGCTGGCAGATTCAAATCCTCAAAACACAATATAT 247 
PMP22 CCAGAATGCTCCTCCTGTTGCTGAGTA TCATCGTCCTCCACGTCGCGGTGCTGGTGCTGCTGTTCGT 256 
SFTPB GCTCATGCCCCAGTGCAACCAAGT GCTTGACGACTACTTCCCCCTGGTCATCGACTACTTCCAG 265 
LRRC48 CTGAGCTTGTTCAACAACCGGATCTCCAAG ATCGACTCCCTGGACGCCCTCGTCAAGCTGCAGGTGT 274 
DNAH5 GGCTTTCCTGGAGCTACTCAATACATTGAT AGACGTCACCACGAGGGATCTGAGTTCCACGGAACGA 283 
TEKT3 GGGACCGCTTTCCCCACTCCAATT TGACCCATAGCCTGAGCCTTCCTTGGAGACCCAGCAC 292 
NTNG1 CCATGAACATGGCAGTGCTATGACTTTTCT GACTACTCTTAACCAGTGAGGGCTACCTAGACTCAGGTGC 301 
PMP22 CTGTCTCTGTTCCTGTTCTTCTGCCAACT CTTCACCCTCACCAAGGGGGGCAGGTTTTACATCACTGGAA 310 
PTK2 CCAGGTTTCTGGCTACCCTGGTTCACATG GAATCACAGCCATGGCTGGCAGCATCTATCCAGGTCAGGCA 319 
BRCA1 GATGCACAGTTGCTCTGGGAGTCT TCAGAATAGAAACTACCCATCTCAAGAGGAGCTCATTAAG 328 
PMP22 CCGGAGTGGCATCTCAACTCGGAT TACTCCTACGGTTTCGCCTACATCCTGGCCTGGGTGGCCTTCC 337 
ELAC2 CTGACACCCAGCACTTGGTCCTGAAT GAGAACTGTGCCTCAGTTCACAACCTTCGCAGCCACAAGAT 346 
FLJ25830 GTGTAGCAGAACAGCTCAGGTGCTAGAAAT AGCCAGTCTCATTGACTCAACTGTGTTTCCTCAGAGAATCCCG 355 
APC GCTATGGGAAGTGCTGCAGCTTT AAGGAATCTCATGGCAAATAGGCCTGCGAAGTACAAGGATGCCA 364 
FLJ25830 GACTGTCGTCAGCTCGCCTCCATGGTT AGAGACTAGAATCGTGGAGCCCAATGTTTCCAACAGTGAG 373 
LIMK1 CGTTTCATCTGCCTCACGTGTGGGACCTTT ATCGGTGACGGGGACACCTACACGCTGGTGGAGCACT 382 
COX10 CATGGCCCTTCCCATCAATGCGT ACATCTCCTACCTCGGCTTCCGCTTCTACGTGGACGCAGAC 391 
SECTM1 GGTGGTCACTGCTGTCTTCATCCTCT TGGTCGCTCTGGTCATGTTCGCCTGGTACAGGTGCCGC 400 
ERBB2 TGCACCTTCTACCGCTCACTGCTGGAG GACGATGACATGGGGGACCTGGTGGATGCTG 409 
COX10 GGGAGGAATCCTCTACTCCTGGCAGTT TCCTCATTTCAACGCCCTGAGCTGGGGCCTCCGTGAAGAC 418 
EIF3S3 GCCAGAACATCAAGGAGTTCACTGCCCAA AACTTAGGCAAGCTCTTCATGGCCCAGGCTCTTCAAGAATA 427 
KCNQ1 GCTCTCGGGAATTTGAGGCCTGT GGCTGCTGTGGACCCTGGGAAAGAGCCTGTGCTTC 436 
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Appendix 7 
Primers used for validation by amplification and Sanger sequencing of various variants 
identified through exome resequencing 
Gene Variant Forward primer (5’-3’) Reverse primer (5’-3’) Product 
size 
(bps) 
ERCC4 Ser613X GCGCTCTAGGTTGCTGATTT CTTCCTTGCCCTATCCTTCC 287 
BRCA2 Lys3326X TGACGAAGAACTTGCATTGA TTCTTTTCTCATTGTGCAACATA 349 
STOML3 Arg164X CTGGGGAGAGGGGTATCAA GTGTTGGAATTCTCACCGTTT 410 
ANXA7 Tyr54X AACAAGCAGGAATGAAGAGGA TGTTCCTTATTTTTAGATGGGTCA 200 
APPL1 Phe472fs TCTGGGATTATGTTTGTACTGAAA GAAATGCAGACAGGGGATTA 389 
NEFM Tyr63fs TGAGCTACACGTTGGACTCG ATCTCCGCCTCAATCTCCTT 397 
NRP2 His906fs GTGCTGGTGCTGGTCTCC AACCAAAATGAACCCAAGGA 362 
SEMA4C Gly648fs CGGGTCCTTCCTCTACGA AGTAGCCTTGGCCCCTTTCT 304 
PPP1R13L Pro562fs CCCCCTACCCACAAGAAAC GGCTCTTTGCTACAGCTCCT 276 
SLC22A1 Pro425fs TTTCCTTTACTCCGCTCTGG TGATTACAGGCATGAGCCACT 314 
ERCC3 Arg283Cys TTTTTGACCATTGGACCTCTT TTGGCTTTTCAGCAAGGTGT 404 
ERCC6 Ser797Cys AAGAAGCTGGTGGAGAACTG ACTGCCACCTCAGCATCAG 459 
ERCC6 Gly929Arg CTCACCCTGTCAACCTCACC TCATCTCCACCAGAAGGTCA 358 
ERCC6 Phe1437Ile CCACTGGAATCAGATGTAGCTTT TCTTCCTTTTTGGCCAGGTT 465 
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Appendix 8 
Primers used for the amplification and Sanger sequencing of the ORF, flanking region and 
5’UTR of ERCC4  
Region Forward primer (5’-3’) Reverse primer (5’-3’) Product 
size (bps) 
5’UTR-A GGGGATGTGGAAACTCAAAA TGTTGAGCACCAGCACCA 559 
5’UTR-B AGCCTGGGCAACATATCAAC AGAGAGCCGAGCCTGAGAA 399 
Exon 1A CTCTCGGACTCGGCTCTCT GTGCAGCTGGAGAAAGTGG 252 
Exon 1B CCGCTGCTGGAGTACGAG TGTCATCGCGTAGTGTCAGG 433 
Exon 2 TCAGAGAAAGACAGCACATTATTT TGGAGAAAAATAAAATGGAAATTG 357 
Exon 3 CTCTGTTCTGTGCGTGGCTA CCATCAAATTGCTCTCGACTT 547 
Exon 4 TTTGTTGTTTTGCTTTTCGTG GCTATGTTTTTAAGTGACCTCCA 425 
Exon 5 GATACACAGGAAATAATCCTTTTGA CACACCTGATTCCCCCTAAA 354 
Exon 6 CGGTGTGGTTGGTAGGAAGA TTTCACATGGCCAAAGAAGAC 348 
Exon 7 TGATGCTCGTGTTATCTGTTG AAATAGAGACAGGGTTTCACCA 327 
Exon 8A ATGTCTTCCCTTCGGGTGA AGCCCGTTCTTTGTTTTGG 314 
Exon 8B GAGCGGAGGCCTTCTTATTG AGTGAGGGGTTCTTTCAGGA 377 
Exon 8C AAGGAGATGTCGAGGAAGGA AAGCAGCATCGTAACGGATA 401 
Exon 9 GCGCTCTAGGTTGCTGATTT CTTCCTTGCCCTATCCTTCC 287 
Exon 10 TCCTTGTTTTTGTTTTTGTTTTTC CCAACCCCCATTTTTAAGAG 361 
Exon 11A CCATCCATCAGAGTTAACAACA CCTCGGGAAGTGAGAGAGAA 403 
Exon 11B TGGAGCGCAAGAGTATCAGT ATCAAGGAGCGGCAGTTTTT 430 
Exon 11C CTGAAACAAAGCAAGCCACA TCTGGTCCACCGTACAATCA 442 
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Appendix 9 
Primers used for the amplification and Sanger sequencing of the ORF, flanking regions and 
5’UTR of ERCC1 
 Region Forward primer (5’-3-) Reverse primer (5’-3’) Product 
size (bps) 
5’UTR-A GCTGTCGTTGGTCACTGCT AGACTGCAGAGGGATCGAG 463 
5’UTR-B CCTGCTCTATGCTCTACTCTCC AGAGCTCCATAGCGTCAGGT 482 
Exon 1 TGCGGGATGAGAACGTAGAC CCCCATCCTATCCTCTTCGT 237 
Exon2 AAAGGGGAGAGGAACTCACA GGAGAACAAAGTGGCTGGAA 405 
Exon3 GTGCAAGAAGAGGTGGAGGA TCCAGAACACTGGGACATGA 263 
Exon4 ATTCCAGTGAGAGGGAAAAGG CTGCATTTCCTCTTGGAAGG 265 
Exon5 CCACCACGCCTGGCTAAT ACAGGAAGGAGAAGGGAAGG 241 
Exon6 GGCAATTCTTATGACTGACCA TGGAACTGAAGCTCAACCAC 255 
Exon7 CAGGCAGTCTGGGGACAC CAGGGAGATGGAAGGAAATG 260 
Exon8 CCCTGGGGAATATCTGAGG AGGCTGGTCTCCAACTTCTG 351 
Exon9 TAAAGAACCAAAACCCCACTC CAGAATCCCTCCCCAGAGAC 238 
TRAN5Ex3 AAGTGATCCTCCTGCCTCAG CTGGCTACAGGCCAGCTCTT 169 
 
Appendix 10 
Primers used for the amplification and Sanger sequencing of the ORF, flanking regions and 
5’UTR of STOML3 
Region Forward  primer (5’-3’) Reverse primer (5’-3’) Product 
size (bps) 
5’UTR-A TCGAGATTGCAGTGAGCTGT AAAGACCAAACTCCTAAGTGTCC 209 
5’UTR-B GCTTTGGAGGCACTGATAGG GCAGTGAGTGAGCTTTTGAAA 397 
Exon 1A TTTCAAAAGCTCACTCACTGC TGTGAAGAACAGGCAGCAAC 419 
Exon 1B CTTCCCTCACCAGGGTAACT TGCTACAACTCCTGCTTTGC 293 
Exon 2 TTCTATGCAGCCACATCAGG CCAGACGGAATACAACAGCA 342 
Exon 3 CATTACCTTCCCCATCTCCA AATAGGCACCACCAGGAAAA 281 
Exon 4 CATGTATCGCCCCATGTAAA GCGGGTACTCAGCTCATCTT 302 
Exon 5 GCCAGGACAGGTTTTAGGTG GTGGGGGATGCTTTGAACT 441 
Exon 6 TCACTCCAAATGCTGTAAATGC AACCCCTTTCTCATGCAAAT 381 
Exon 7 CTGGGGAGAGGGGTATCAA GTGTTGGAATTCTCACCGTTT 410 
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Appendix 11 - Primers used for the amplification and Sanger sequencing of the ORF and flanking 
regions of ERCC6  
Region Forward primer (5’-3’) Reverse primer (5’-3’) Product 
size (bps) 
5’UTR-A CTCTCCATCCTTCCCGTGTT CACAAGGAAACAGAGACGCT 517 
5’UTR-B TTCCTAGTCCCCTTTCCGAC AACCCTGCAGAGAAAGTCAG 555 
Exon 2A TCTTTTGAGAAATCAGTCTGCTC CATAGACGTCCACACCCAAA 410 
Exon 2B CCTCTCCTTTCGTTCTGTGG AAGGGCTGGGACTCAAAGAT 462 
Exon 3 GGGACATGTTTTTAGCATTTTTC CAAAAGAAACCCAAAATTTCTC 350 
Exon 4 ACAATAAATCACTTCATTGCTGTT CTCAAAACCCAGGCAAAGAC 258 
Exon 5A TTCTTTTGTACCCTCGGAAA TGGGGCTGGAGCTTTTCTA 312 
Exon 5B CCAGATCCCTCAGAAACAGG CAGAGGCTTCAGCTCATAGTCA 472 
Exon 5C AGGGAGACTCTGAGGGTGAAG GCTGCAGAAATCCAACCTCT 443 
Exon 6 TTTGGGTAATAATGGCAGCA AGTACCTTCAGGGCCCACAG 370 
Exon 7 ATCCCGCATGTTTCTCTGAC ATTCACAAGACCCTCCTCCA 373 
Exon 8 TTGTTTTGGGGGATCTTTTG CATGGATCAGAGAAAAACCAAA 295 
Exon 9 TGTGTCATGATTGAAAGGGTGT GCAGTTGGCACAAGGAAAG 349 
Exon 10 GCAGAGGAGCGTTTTAGGG CCTGGCCATCTTTCTCACAT 364 
Exon 11 AAGGAATGGAAGCAATTGAGAG AAGAATCCACTGAGGGCAGA 359 
Exon 12 ATCGCATGCATTGTGCTCT ATCTACCATGCGGGACTTCA 343 
Exon 13 AAGAAGCTGGTGGAGAACTG ACTGCCACCTCAGCATCAG 459 
Exon 14 CTGTTGGGGAAGGTGTTACC ATGCTGCTTTGGTGGGTAAG 301 
Exon 15 GAGGCAGAGGCTGAGAACTG TGAAGCCAACCAGAACATCA 284 
Exon 16 CTGGCTGTTCATCTTCCTGA CAAAACAAAAACCAAAGCCTTA 397 
Exon 17 TTCCAAGGCTGAAAGTTTGG CAAAGGCTGGTTGAATCCTT 434 
Exon 18A AAGTGCAATTTTTGCAGGTATTA TTTGAACATTCCCCATTTCC 424 
Exon 18B AGCAATGATAGGCTTGGAGAA AGGCTTTTGCTTTGGTCTCA 194 
Exon 18C GCCAGGCTCAAACAGAAGC ACAGCCCTCTATGCACCATC 362 
Exon 19 TTGATTCTCTAGGGTTTTCTAAGTG CCACACCTGCCCTGATTTTA 415 
Exon 20 AGCATGCAGATGGAAATGTT TGACCATTTTCTTCACATCCA 285 
Exon 21A CTCACCCTGTCAACCTCACC TCATCTCCACCAGAAGGTCA 358 
Exon 21B TCGCTTCCTCCTCACTCTTG ATCAAGTGCAGCCAACTTCC 439 
Transcript 2    
Exon6A TGCTATTGTGCGGTAAAAAGA TTTCCTCCTCCTTGATGGTG 465 
Exon6B TCAAGATGGCTCTGATGCTG TTCCCAAAACATACGCCTTC 415 
Exon6C CATCTTGGCTTGACTAGCTCTG CAGCAAATGTAGCCCAGACA 413 
Exon6D TCACGGGTGCAAACAATTTA ACCAGATGAGGCAACAGTGA 439 
Exon6E CCACTGGAATCAGATGTAGCTTT TCTTCCTTTTTGGCCAGGTT 465 
Exon6F TGGATTTTCTGGAGTTTCGTC TGGAACACTAGGCAAAACCA 290 
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Appendix 12 
Schematic of pAW1 with corresponding primer sequences. Primer sequence specific to 
plasmid are given. These allow for adequate amplification of ura4+ with flanking lox sites from pAW1 
for the construction of the base strain (adapted from Watson et al. 2008). 
 
Appendix 13 
Primers used in the amplification of loxP-ura4+-loxM3 from the pAW1 plasmid. In the forward 
primer, 100bp region upstream of the rad16 gene, ending immediately 5’ to the start codon, was 
incorporated in the 5’ region of the primers. Conversely, in the reverse primers, the 100bp region 
downstream of the rad16 gene, ending immediately 3’ at the stop codon, was incorporated in the 5’ 
region of the primer.  
Primer Sequence (5’-3’) 
ura4+F Primer (100bp upstream of 
rad16 + F from Appendix 12) 
TCCATCCAAATTGGAAAATTTTCGCATCAAAGTATTTAACAGCTTTCAG
AAATCAAAATTGCAAATTGGAAAATCTCTACGAATAACACCACCATTAA
ATcggatccccgggttaattaa 
ura4+R Primer (100bp downstream  
of rad16 + R from Appendix 12) 
TTATTAATTAGGTGCGCTTAACATTCTATATATGGTGAACCAATATATAT
CAGATGTAGAAGCAAAAATTAAATATATTACAAAATTATAAAAAAATAAA
gaattcgagctcgtttaaac 
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Appendix 14 
Sequences of the loxP and loxM3 recombination sites. Cre recombinase catalyses 
recombination effects at these specific sites. Two 13bp inverted repeats act as the binding sequence 
for Cre recombinase, whilst the 8bp spacer region helps in the replacement of strands. loxP and 
loxM3 differ in the spacer region only, allowing for specific directional recombination (Hoess et al. 
1986; Langer et al. 2002). 
 
Appendix 15 
Primers used for colony PCR 
Primer name Sequence (5’-3’) Product size with A(bps) 
A TCACGATCCGCCTAAATTCC -  
B (rad16 specific primer) TCAAGGGACTCTGCCACAAC 888 
C (ura4+ specific primer) TAAAGCAAGGGCATTAAGGC 537 
 
Appendix 16 
Primer sequences used in the amplification and Sanger sequencing of lox sites from 
extracted genomic DNA 
Primer set A and D (5’-3’) C and F (5’-3’) Product 
size 
(bps) 
A and C (5’-3’) - 
loxP site 
TCACGATCCGCCTAAATTCC CTAAAGCAAGGGCATTAAGGC 537 
D and F (5’-3’) – 
loxM3 site 
CCCAAGCATTAGAATCACCAA TGTACAAAGCCAATGAAAGATG 440 
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Appendix 17 
 Composition and structure of primers used in the construction of loxP-rad16+-loxM3 by PCR 
 
 
Appendix 18 
Primers used in the amplification and Sanger sequencing of the ORF of rad16 from extracted 
genomic DNA and constructed plasmids 
Primer 
set 
Forward primer (5’-3’) Reverse primer (5’-3’) Product 
size (bps) 
1 For pAW8-rad16 (pAW8-BF); 
ATTAGGCACCCCAGGCTTTA; 
For genomic DNA; 
TCACGATCCGCCTAAATTCC 
TGTGTTTTATGGAGGCGTGA  879 
 
537 
2 TGCGATTGTATCGTGAAACC TGCATTAGATGGGTAGCTGGA 568 
3 TCAGGTTCGTCTTTTCTTTCC TGGAAGGCTCTGGTTTCTTG 582 
4 CGTGATTATTTGAGTACGGTGA TTTGCTCCTCAATCGATCCT 592 
5 TTCGATTCTGATCCCAATTTT TGTAAAAGATTGGTGTTGTTCG 642 
6 GCCGTCTTTATTCCCAATGT TCACGCCTCCATAAAACACA 436 
7 CTGGGCAAGACTCAACGAA For pAW8-rad16 (rad16-R); 
GGGATAACTTCGTATATAATAC
CATATACGAAGTTATTTACTCA
TAGTCCTTTAACTGTTTTCGG 
For genomic DNA; 
CCCAAGCATTAGAATCACCAA 
224 
 
 
 
538 
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Appendix 19 
Primers used for SDM of pAW8-rad16+. Codons of interest are highlighted in grey, whilst 
nucleotide change/s shown in lower case and bold 
Variant in 
S.Pombe 
Rad16 
Equivalent  
XPF 
Native 
codon 
in rad16 
Forward primer (5’-3’) Reverse primer (5’-3’) 
Pro361Ser Pro379Ser 
(rs1799802) 
CCG GGAGGAACAGtCGAAATGG
TCTGTCTTGCAAGACG 
CGTCTTGCAAGACAGACCATT
TCGaCTGTTCCTCC 
Arg399Gln Arg415Gln 
(rs1800067) 
CGT TGTGCGCAGATGAGCaaACT
TGTTTACAGTTACGTGA 
TCACGTAACTGTAAACAAGTtt
GCTCATCTGCGCACA 
Arg548Thr Arg576Thr 
(rs1800068) 
CGG ATTTAAGACCTacGTACGTT
ATTATGTTCGAT 
(Replacement; 
TTAAATAATTTAAGACCTacG
TACGTTATTATGTTCG) 
ATCGAACATAATAACGTACgtA
GGTCTTAAAT  
(Replacement; 
CGAACATAATAACGTACgtAG
GTCTTAAATTATTTAA) 
Ser585SX Ser613Stop TCG GTACTATGGAGGATaGATTG
AGGAGCAAAA 
TTTTGCTCCTCAATCtATCCTC
CATAGTAC 
Glu844Gly Glu875Gly 
(rs1800124) 
GAA GAAAGATATTCAAGgAGCTT
CCGAAACCTCAGA 
TCTGAGGTTTCGGAAGCTcCT
TGAATATCTTTC 
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Appendix 20 - Scientific and common name of all mammalian species used in sequence alignments  
Scientific name Common name 
Ailuropoda melanoleuca  Giant panda 
Bos taurus  Cattle 
Callithrix jacchus  Common marmoset 
Canis lupus familiaris  Domestic dog 
Cavia porcellus Guinea pig 
Ceratotherium simum simum  White rhinoceros 
Condylura cristata  Star nosed mole 
Cricetulus griseus  Chinese hamster 
Dasypus novemcinctus  Nine banded armadillo 
Echinops telfairi  Lesser hedgehog tenric 
Equus caballus  Horse 
Felis catus  Domestic cat 
Gorilla gorilla gorilla  Western lowland gorilla 
Homo sapiens   Human 
Jaculus jaculus Lesser Egyptian jerboa 
Loxodonta africana  African elephant 
Macaca mulatta  Rhesus monkey 
Monodelphis domestica Opossum 
Mus muscularis Mouse 
Nomascus leucogenys  White cheeked gibbon 
Ochotona princeps  American pika 
Octodon degus Degu 
Odobenus rosmarus divergens  Walrus 
Orcinus orca Killer whale 
Ornithorhynchus anatinus  Platypus 
Oryctolagus cuniculus  European rabbit 
Otolemur garnettii  Greater galago 
Ovis aries  Sheep 
Pan paniscus  Bonobo 
Pan troglodytes  Chimpanzee 
Papio anubis Olive baboon 
Pongo abelii  Sumatran orang-utan 
Rattus norvegicus Norwegian rat 
Saimiri boliviensis boliviensis Black capped squirrel monkey 
Sarcophilus harrisii Tasmanian devil 
Sorex araneus  Common shrew 
Sus scrofa  Wild boar 
Trichechus manatus latirostris  West Indian manatee 
Tursiops truncatus  Bottle nosed dolphin 
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Appendix 21- Species conservation of the glutamic acid residue at position 281 in RAD1 (highlighted in grey). Alignment produced with Clustal Omega. A list 
of common names for species is given in Appendix 20. An asterisk (*) indicates complete conservation of a residue; a colon (:) indicates conservation 
between residues that are have very similar properties; a period (.) indicates conservation between residues which have weakly similar properties. 
Homo sapiens - NP_002844.1                            KVSIRTDNRGFLSLQYMIRNEDGQICFVEYYCCPDEEVPESES-- 
Bos taurus - NP_001179419.1                           KVSIRTDNRGFLSLQYMIRNEDGQICFVEYYCCPDEEVPDS---- 
Callithrix jacchus - XP_002745099.1                   KVSIRTDNRGFLSLQYMIRNEDGQICFVEYYCCPDEEVPESESSI 
Canis lupus familiaris - XP_536505.3                  KVSIRTDNRGFLSLQYMIRNEDGQICFVEYYCCPDEEVSESES-- 
Cavia porcellus - XP_003470270.1                      KVSIRTDNRGFLSLQYMIKNEDGQISFVDYYCCPDEDIPESES-- 
Ceratotherium simum simum - XP_004422775.1            KVSIRTDNRGFLSLQYMIRNEDGQICFVEYYCCPDEELPESEP-- 
Condylura cristata - XP_004678143.1                   KVSIRTDNRGFLSLQYMIRNEDGQVCFVEYYCCPDEEVSESES-- 
Dasypus novemcinctus - XP_004453398.1                 KVSIRTDNRGFLSLQYMIRNEDGQICFVEYYCCPDEVVPESES-- 
Echinops telfairi - XP_004698420.1                    KVSIRTDNRGFLSLQYMIRNEDGQISFVEYYCCPDEEEVSKSEP- 
Felis catus - XP_003981515.1                          KVSIRTDNRGFLSLQYMIRNEDGQICFVEYYCCPDEEVPESES-- 
Gorilla gorilla gorilla - XP_004059017.1              KVSIRTDNRGFLSLQYMIRNEDGQICFVEYYCCPDEEVPESES-- 
Macaca mulatta - NP_001248089.1                       KVSIRTDNRGFLSLQYMIRNEDGQICFVEYYCCPDEEVPES---- 
Mus musculus - NP_035362.2                            KVSIRTDNRGFLSLQYMIRNEDGQICFVEYYCCPDEEVPES---- 
Nomascus leucogenys - XP_004088254.1                  KVSIRTDNRGFLSLQYMIRNEDGQICFVEYYCCPDEEVPESES-- 
Ochotona princeps - XP_004583824.1                    KVSIRTDNRGFLSLQYMIKNEDGQICFVEYYCCPDEEVPESESGV 
Odobenus rosmarus divergens - XP_004412959.1          KVSIRTDNRGFLSLQYMIRNEDGQICFVEYYCCPDEEVPESES-- 
Orcinus orca - XP_004266062.1                         KVSIRTDNRGFLSLQYMIRNEDGQICFVEYYCCPDEEVPES---- 
Otolemur garnettii - XP_003792981.1                   KVSIRTDNRGFLSLQYMIRNEDGQICFVEYYCCPDEVVPESES-- 
Ovis aries - XP_004017107.1                           KVSIRTDNRGFLSLQYMIRNEDGQICFVEYYCCPDEEVPDS---- 
Pan paniscus - XP_003806716.1                         KVSIRTDNRGFLSLQYMIRNEDGQICFVEYYCCPDEEVPESES-- 
Pan troglodytes - XP_517813.2                         KVSIRTDNRGFLSLQYMIRNEDGQICFVEYYCCPDEEVPESES-- 
Papio anubis - XP_003899614.1                         KVSIRTDNRGFLSLQYMIRNEDGQICFVEYYCCPDEEVPES---- 
Pongo abelii - NP_001126246.1                         KVSIRTDNRGFLSLQYMIRNEDGQICFVEYYCCPDEEVPESES-- 
Rattus norvegicus - NP_001099889.1                    KVSIRTDNRGFLSLQYMIRNEDGQICFVEYYCCPDEEVPES---- 
Saimiri boliviensis boliviensis - XP_003925987.1      KVSIRTDNRGFLSLQYMIRNEDGQICFVEYYCCPDEEVPESESRI 
Sarcophilus harrisii - XP_003759996.1                 KVSIRTDNRGFLSLQYMIKNEDGQICFVEYYCCPDEDVSDSES-- 
Sorex araneus - XP_004605611.1                        KVSIRTDNRGFLSLQYMIRNEDGQICFVEYYCCPDEEVPESES-- 
Trichechus manatus latirostris - XP_004385297.1       KVSIRTDNRGFLSLQYMIRNEDGQISFVEYYCCPDEV-PESES-- 
Tursiops truncatus - XP_004323605.1                   KVSIRTDNRGFLSLQYMIRNEDGQICFVEYYCCPDEEVPES---- 
                                                      ******************:*****:.**:*******   ..     
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Appendix 22- Species conservation of the glutamine residue at position 1236 in POLG (grey). Alignment produced with Clustal Omega. A common key is 
given in Appendix 21. A list of common name for species is given in Appendix 20. 
Homo sapiens - NP_001119603.1                     ALDIYQIIELTKGSLEKRSQPGP------------------------------------- 
Bos taurus - XP_002696610.1                       ALDIYQIIELTKGSLEKXSQPGL------------------------------------- 
Callithrix jacchus - XP_002749184.1               ALDIYQIIELTKGSLEKRSQPGP------------------------------------- 
Cavia porcellus - XP_003475296.1                  ALDIYQIIELTKGSLEKXSQPGP------------------------------------- 
Ceratotherium simum simum - XP_004431996.1        ALDIYQIIELTKGSLEKRSQPGP------------------------------------- 
Condylura cristata - XP_004693042.1               ALDIYQIIELTKGSLERHSQSGL------------------------------------- 
Dasypus novemcinctus - XP_004455270.1             ALDIYQIIELTKGSLEKRSQPGP------------------------------------- 
Echinops telfairi - XP_004709933.1                ALDIYQIIERTKGSLGR------------------------------------------- 
Equus caballus - XP_001503097.1                   ALDIYQIIELTKGSLDKRNQPGP------------------------------------- 
Felis catus - XP_003986860.1                      ALDIYQIIELTKGSLEKXSPPGP------------------------------------- 
Gorilla gorilla gorilla - XP_004056785.1          ALDIYQIIELTKGSLEKRSQPGP------------------------------------- 
Jaculus jaculus - XP_004658240.1                  ALDIYQIIELTKGSLDKRSQPGP------------------------------------- 
Loxodonta africana - XP_003413940.1               ALDIYQIIELTKGSLEKRSQPGP------------------------------------- 
Macaca mulatta - XP_001092360.1                   ALDIYQIIELTKGSLEKRSQPGP------------------------------------- 
Mus musculus - NP_059490.2                        ALDIYQIIELTKGSLEKRSQPGP------------------------------------- 
Nomascus leucogenys - XP_003268536.2              ALDIYQIIELTKGSLEKRSQPGP------------------------------------- 
Ochotona princeps - XP_004578377.1                ALDIYQIIELTKGSLEKRSQPGP------------------------------------- 
Octodon degus - XP_004623348.1                    ALDIYQIIKLTKGSLEKRSQPGP------------------------------------- 
Odobenus rosmarus divergens - XP_004398363.1      ALDIYQIIELTKGSLEPXSQPGP------------------------------------- 
Orcinus orca - XP_004278297.1                     ALDIYQIIELTKGSLEKXSQPGP------------------------------------- 
Otolemur garnettii - XP_003788714.1               ALDIYQIIELTKGSLEKXSQRGP------------------------------------- 
Ovis aries - XP_004023438.1                       ALDIYQIIELTKGSLEKXSQPGLYPCLEALYLLPWSFIGAAKAPKTQAFSSAFCKRAGPR 
Pan paniscus - XP_003820468.1                     ALDIYQIIELTKGSLEKRSQPGP------------------------------------- 
Pan troglodytes - XP_523149.2                     ALDIYQIIELTKGSLEKRSQPGP------------------------------------- 
Papio anubis - XP_003901414.1                     ALDIYQIIELTKGSLEKRSQPGP------------------------------------- 
Pongo abelii - XP_002825850.2                     ALDIYQIIELTKGSLEKRSQPGP------------------------------------- 
Rattus norvegicus - NP_445980.1                   ALDIYQIIELTKGSLEKRSQPGP------------------------------------- 
Saimiri boliviensis boliviensis - XP_003921677.1  ALDIYQIIELTKGSLEKRSQPGP------------------------------------- 
Sus scrofa - XP_001927099.1                       ALDIYQIIELTKGSLEKRSQPGP------------------------------------- 
Trichechus manatus latirostris - XP_004370680.1   ALDIYQIIELTKGSLEKRSQPGP------------------------------------- 
                                             ********: *****                                         
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Appendix 23 - Species conservation of the valine residue at position 138 in REV1 (grey). Alignment produced with Clustal Omega. A common key is given in 
Appendix 21. A list of common name for species is given in Appendix 20. 
Homo sapiens - NP_001032961.1                         PEWIVESIKAGRLLSYIPYQLYTKQSSVQKGLSFNPVCRPEDPLPGPSNIAKQLNNRVNH 
Ailuropoda melanoleuca - XP_002920000.1               PEWIVESIKAGRLLSCIPYQLYSKPSNMQKGLNFNPACKAEESVPGPSSVAKQLNNRVNH 
Bos taurus - XP_003586659.1                           PEWIVESIKAGRLLSCIPYQLYSKPSSVQKSLNFNPVCKPEDPLPGPSSITKQLNDRVNH 
Canis lupus familiaris - XP_538458.3                  PEWIVESIKAGRLLSCIPYQLYSKQSNMQKGLNFNPACKAEEPVPGPSSVAKQLNNRVNH 
Cavia porcellus - XP_005004513.1                      PEWIVESIKAGRLLSYIPYQLYTKQSNAQRSLNFNPVCKPEDPVPGPSHVAKQPNNKVNH 
Ceratotherium simum simum - XP_004435909.1            PEWIVESIKAGRLLSYIPYQLYSKQSSVQKGLNFNPVCQPEDPVPGPSNIARQLNDRVNH 
Condylura cristata - XP_004686221.1                   PEWIVESIKAGRLLSYIPYQLYNKQSSVQKGLNFNPVCKPEDPVPGPSDIAKQLNNRVNH 
Dasypus novemcinctus - XP_004458115.1                 PEWIVESIRAGRLLSHVPYQLYTKQPSAQRGLTFHAVCKPEEPAPGPSSVAKPLNNRVNH 
Echinops telfairi - XP_004704398.1                    PEWIVESIKAGRLLSCIPYQLYTKQSTVQRALNFNPVCKPEDSMPGPSNISKQLNNRVNH 
Equus caballus - XP_001490149.1                       PEWIVESIKAGRLLSYIPYQLYTKQSNVQKGLNFTPVCKPEDPVPGPSNITKQLNNRVNH 
Gorilla gorilla gorilla - XP_004031548.1              PEWIVESIKAGRLLSYIPYQLYTKQSSVQKGLSFNPVCRPEDPLPGPSNIAKQLNNRVNH 
Macaca mulatta - XP_002799407.1                       PEWIVESIKAGRLLSYIPYQLYTKQSSVQKGLSFNPVCRPEDPVPGPSNIAKQFNNRVNH 
Monodelphis domestica - XP_001363717.1                PEWIVESIKAGRLLSYIPYQLYTKQSSVQKSLNFNPICKPEDSMPGPSNIAIELNNRVNQ 
Mus musculus - NP_062516.2                            PEWIVESIKAGRLLSSAPYQLYTKPSAAQKSLNFNPVCKPEDPGPGPSNRAKQLNNRVNH 
Nomascus leucogenys - XP_003274893.2                  PEWIVESIKAGRLLSYIPYQLYTKQSSVQKGLSFNPVCRPEDPLPGPSNIAKQLNNRVNH 
Ochotona princeps - XP_004594269.1                    PEWIVESIKAGRLLSCLPYQLYSRQSSVQKSLNFNAVCKPEEPLPGPSNTAKQLNNRVNH 
Odobenus rosmarus divergens - XP_004400175.1          PEWIVESIKAGRLLSCIPYQLYSKQSNMQKGLNFNPACKAEEPGPGPSSVAKQLNNRVNH 
Orcinus orca - XP_004277800.1                         PEWIVESIKAGRLLSYIPYQLYSKQSSTQKGLNFNPVCKPEDPVPGPSSITKQLNDRVNH 
Ornithorhynchus anatinus - XP_001507264.2             PEWIVESIKAGRLLPSIPYQLYTKQPGVPKGLNFNTICKPEDPLPGPSNRAKQLNQRVNH 
Oryctolagus cuniculus - XP_002709984.1                PEWIVESIKAGRLLSCIPYQLYNKQSAVQKSLTFSAACKPEDPLPGPSSIAKQFNNRVNH 
Otolemur garnettii - XP_003794384.1                   PEWIVESIKAGRLLSYIPYQLYTKQSSVQKGLNFNPVCKPEDPVPGPSNIAKQFNNRVNH 
Ovis aries - XP_004006184.1                           PEWIVESIKAGRLLSCIPYQLYSKQSSVQKSLNFNPVCKPEDPLPGPSSITKQLNDRVNH 
Pan paniscus - XP_003805448.1                         PEWIVESIKAGRLLSYIPYQLYTKQSSVQKGLSFNPVCRPEDPLPGPSNIAKQLNNRVNH 
Pan troglodytes - XP_001160264.1                      PEWIVESIKAGRLLSYIPYQLYTKQSSVQKGLSFNPVCRPEDPLPGPSNIAKQLNNRVNH 
Papio anubis - XP_003909074.1                         PEWIVESIKAGRLLSYIPYQLYTKQSSVQKGLSFNPVCRPEDPVPGPSNIAKQFNNRVNH 
Pongo abelii - NP_001126930.1                         PEWIVESIKAGRLLSYIPYQLYTKQSSVQKGLSFNPICRPEDPLPGPSNIAKQLNNRVNH 
Rattus norvegicus - NP_001101683.1                    PEWIVESIKAGRLLSSVPYQLYTKPSTAQKSLNFTPVCKPEEPVPGPSEIAKQLTNRVNH 
Saimiri boliviensis boliviensis - XP_003941371.1      PEWIVESIKAGRLLSYIPYQLYTKQSNVQKGLSFNPVCRPEDPVPGPSNIAKQLNNRVNH 
Sarcophilus harrisii - XP_003765700.1                 PEWIVESIKAGRLLSYIPYQLYTKQSSVQKSLNFNPICKPEDPMPGPSNIAIELNNRVNQ 
Sorex araneus - XP_004615851.1                        PEWIVESIKAGRLLSCIPYQLYSKQSNAQKGLSFNPVCKPGDPVPGPSNITKQFTNRVNH 
Sus scrofa - XP_003481195.1                           PEWIVESIKAGRLLSYIPYQLYSKQSTLQKGLNFNPVCKPEDSLPGPSSIAKQLNNRVNH 
Trichechus manatus latirostris - XP_004369371.1       PEWIVESIKAGRLLSYIPYQLYTKQSSVQKGLNFNPVCKPEDPMPGPSNIAKQLNNRVNH 
Tursiops truncatus - XP_004323487.1                   PEWIVESIKAGRLLSYIPYQLYSKQSSTQKGLNFNPVCKPEDPVPGPSSITKQLNDRVNH 
                                                      ********:*****   ****:.:     :.*.*   *:  :  ****      .::**: 
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Appendix 24 - Species conservation of variants in ERCC4. A. Pro379 (highlighted in grey); B. Arg415 (grey); C. His466 (grey) D. Arg576 (grey) and Ser613 
(yellow) E. Glu875. A common key is given in Appendix.21. A list of common name for species is given in Appendix 20. 
A. 
Homo sapiens - NP_005227.1                         RVYHLPDAKMSKKEKISEKMEIKE------GEETKKELVLESNPKWEALTEVLKEIEAEN 
Ailuropoda melanoleuca - XP_002918113.1            RVYHLPDAKMNKKGKMSEKMEIKE------EQETKKELVLESNPKWEALTEVLKEIEAEN 
Bos taurus - NP_001192289.1                        RVYHVPDAKMSKKSRLPEKLEIKE------EQETKKDLVLESNPKWAALTEVLKEIEAEN 
Callithrix jacchus - XP_002755959.2                RVYHLPDAKISKKGKISEKMEVKE------GQETKKELVLESNPKWEALTEVLKEIEAEN 
Canis lupus familiaris - XP_536967.3               RVYHLPDAKMNKKGKMSEKMEIKE------DQEAKKELVLESNPKWEALTEVLKEIEAEN 
Cavia porcellus - XP_003477812.1                   RVYHIPDAKMSKKSKMSEKMEIKE------GQETKKELVLESSPKWEALTEVLKEIEAEN 
Ceratotherium simum simum - XP_004441913.1         RVYHVPDAKMSKKDKMSEKMEIKE------EQETKKELVLESNPKWEALTEVLKEIEAEN 
Condylura cristata - XP_004692174.1                RVYQIPDAKASKKGKVSEKTEIKE------GQETKRELVLESNPKWEALTEVLKEIEAEN 
Cricetulus griseus - NP_001230961.1                RVYRVPDVKLNKKAKMSES---AE------GQETKKELVLESNPKWEALSEVLKEIEAEN 
Dasypus novemcinctus - XP_004466678.1              RVYHVPDAKMSKRSKMSEKMEIEE------GQETQKELVLESNPKWEALSEVLKEIEAEN 
Echinops telfairi - XP_004705920.1                 RVYHVPDAKMSKKSKRSEKTEVKE------GQETKKELVLESNPKWEALSEVLKEIEAEN 
Equus caballus - XP_001490470.2                    RVYNVPDDKMSKKGKMSEKMEIKE------EQETKKELVLESNPKWEALTEVLKEIEAEN 
Felis catus - XP_003998897.1                       RVYHLPDAKMNKKGKVSEKTEIEQ------VQETKKELVLESNPKWEALTEVLKEIEAEN 
Gorilla gorilla gorilla - XP_004057285.1           RVYHLPDAKMSKKEKVSEKMEIKE------GQETKKELVLESNPKWEALTEVLKEIEAEN 
Jaculus jaculus - XP_004652331.1                   RVYHVPDAKTSKTGKTSEILEIKE------GQETKKELVLENNPKWEALTEVLKEIEAEN 
Loxodonta africana - XP_003417763.1                RVYHVPDAKMSKKSQMSEKMEIKE------GQDTKKELVLESNPKWEALTEVLKEIEAEN 
Macaca mulatta - XP_001107209.1                    RVYHLPDAKMSKKGKISEKMEIKE------GQEAKKELVLESNPKWEALTEVLKEIEAEN 
Monodelphis domestica - XP_001375532.1             RVYHIADTRMNKKCKMTEKTNIKE------NQEMKRELVLESNPKWEALTEVLKEIETEN 
Mus musculus - NP_056584.2                         RVYRVPDVKLNKKAKTSEKTSSPE------VQETKKELVLESNPKWEALTDVLKEIEAEN 
Nomascus leucogenys - XP_004091351.1               RVYHLPDAXMSKKEKISEKMEIKERARYLVGLKTKKELVLESNPKWEALTEVLKEIEAEN 
Ochotona princeps - XP_004586829.1                 RVYRVPDAKLMKKGKMSENMEIKE------GQETRKELVLECSPKWEALTEVLKEIEAEN 
Octodon degus - XP_004644276.1                     RVYHIPDAKMSKKSKIPEKMEIKE------GQEAKKELVLESNPKWEALTEVLKEIEAEN 
Odobenus rosmarus divergens - XP_004408974.1       RVYHLPDAKMNKKGQMSEKMEMKE------EQETKKELVLESNPKWEALTEVLKEIEAEN 
Orcinus orca - XP_004270213.1                      RVYHVPDAKMSKKGKLPEKLEIKE------EQETRKELVLENNPKWEALSEVLKEIEAEN 
Oryctolagus cuniculus - XP_002711804.1             RVYHVPDSKMSKKGKMSEKMEIKE------EQETKKELVLECNPKWEALTEVLKEIEAEN 
Otolemur garnettii - XP_003802775.1                RVYHVPDAKINIKGKISEKMEVKE------GQETKKELVLESNPKWEALTQVLREIEAEN 
Ovis aries - XP_004021225.1                        RVYHVPDAKMTRKSKLPEKLEIKE-------QETKKELVLESNPKWAALTEVLKEIEAEN 
Pan paniscus - XP_003832737.1                      RVYHLPDAKMSKKEKISEKMEIKE------GQETKKELVLESNPKWEALTEVLKEIEAEN 
Pan troglodytes - XP_510831.2                      RVYHLPDAKMSKKEKISEKMEIKE------GQETKKELVLESNPKWEALTEVLKEIEAEN 
Papio anubis - XP_003916616.1                      RVYHLPDAKMSKKGKISEKMEIKE------GQEAKKELVLESNPKWEALTEVLKEIEAEN 
Pongo abelii - XP_002826187.1                      RVYHLPDAKMSKKEKISEKMEIKE------GQETKKELVLESNPKWEALTEVLKEIEAEN 
Saimiri boliviensis boliviensis - XP_003928795.1   RVYHLPDAKISKKGKISEKMEIKE------GQETKKELVLESNPKWEALTEVLKEIEAEN 
Sarcophilus harrisii - XP_003761738.1              RVYHIPDIRMNKKCKMTEKTD-QE------GQELKRELVLESNPKWEALTEVLKEIEIEN 
Sorex araneus - XP_004604386.1                     RVYHIPDTKLSKKDKIPEKVETKE------KQETKRELVLENSPKWEALTEVLKEIEAEN 
Trichechus manatus latirostris - XP_004373324.1    RVYHVPDAKMSTKSKMSEKMEIKE------EQETKKELVLESNPKWEALTEVLKEIEAEN 
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B. 
Homo sapiens - NP_005227.1                         KESEALGGPGQVLICASDDRTCSQLRDYITLGAEAFLLRLYRKTFEK--DSKAEEVWMKF 
Ailuropoda melanoleuca - XP_002918113.1            KESEALGGPGQVLICASDDRTCSQLREYITVGAEAFLLRLYRKTFEK--DTKAEEVWMKF 
Bos taurus - NP_001192289.1                        KESEVLGGPGQVLICASDDRTCSQLREYLTVGAEVFLLRLYRKTFEK--DSKAEDVWMRL 
Callithrix jacchus - XP_002755959.2                KESEALGGPGQVLICASDDRTCSQLRDYLTLGVEAFLLRLYRKTFEK--DSTAEEVWMKL 
Canis lupus familiaris - XP_536967.3               KESEALGGPGQVLICASDDRTCSQLREYITIGAEAFLMRLYRKTFEK--DSKAEEVWMKL 
Cavia porcellus - XP_003477812.1                   KESEALGGPGQVLICASDDRTCAQLKDYLTAGAEAFLLQLYRKTFEK--DSKAEEVWMKF 
Ceratotherium simum simum - XP_004441913.1         KESEALGGPGQVLICASDDRTCSQLREYIAIGAEAFLLRLYRKTFEK--DSKAEEVWMTF 
Condylura cristata - XP_004692174.1                KESEALGGPGRVLICASDERTCSQLREYLTGGAEAFLLRLYRKAFEK--DGKAQEVWAPP 
Cricetulus griseus - NP_001230961.1                KESEALGGPGQVLICASDDRTCCQLRDYLTAGAEAFLLRLYRKTFEK--DSKAEEVWVNL 
Dasypus novemcinctus - XP_004466678.1              KESEALGGPGQVLICASDDRTCSQLREYITIGAEAFLLRLYRKTFEK--DSKAEEVWMKF 
Echinops telfairi - XP_004705920.1                 KESEALGGPGQVLICASDDRTCIQLREYITSGAEAFLLALYRKTFEK--DSKAEEVWMKF 
Equus caballus - XP_001490470.2                    KESEALGGPGQVLICASDDRTCSQLREYIAVGAEAFLLRLYRKTFEK--DSKAEEVWMKF 
Felis catus - XP_003998897.1                       KESEALGGPGQVLICASDERTCSQLREYITIGAEAFLLRLYRKTFER--DSKAEDVWVQF 
Gorilla gorilla gorilla - XP_004057285.1           KESEALGGPGQVLICASDDRTCSQLRDYITLGAEAFLLRLYRKTFEK--DSKAEEVWMKF 
Jaculus jaculus - XP_004652331.1                   KESEALGGPGQVLICASDDRTCSQLKDYLTAGAEAFLLRLYRKTFEK--DSKAEEVWMQL 
Loxodonta africana - XP_003417763.1                KESEALGGPGQVLICASDDRTCSQLRECITTGAEAFLLRLYRKSFEK--DSKAEEVWMKF 
Macaca mulatta - XP_001107209.1                    KESEALGGPGQVLICASDDRTCSQLRDYVTLGAEAFLLRLYRKTFEK--DSKAEEVWMKF 
Monodelphis domestica - XP_001375532.1             NNSEALGGPGQVLICASDDRTCAQLREYITIGAKAFLLKIYTKTFGK--DNKAGEVKVKF 
Mus musculus - NP_056584.2                         KESEALGGPGRVLICASDDRTCCQLRDYLSAGAETFLLRLYRKTFEK--DGKAEEVWVNV 
Nomascus leucogenys - XP_004091351.1               KESEALGGPGQVLICASDDRTCSQLRDYITLGAEAFLLRLYRKTFEK--DSKAEEVWMTF 
Ochotona princeps - XP_004586829.1                 KQSEALGGPGQVLVCASDDRTCSQLKDYLTAGPEAFLLRLYRQAFEK--DSLAEEVWVRL 
Octodon degus - XP_004644276.1                     KESEVLGGPGQVLICASDDRTCSQLKDYLTTGAEDFLLQLYRKTFEK--DSKAEEVWMKF 
Odobenus rosmarus divergens - XP_004408974.1       KESEALGGPGQVLICASDDRTCSQLREYITVGAEAFLLRLYRKTFEK--DSKAEEVWMKF 
Orcinus orca - XP_004270213.1                      KESEALGGPGHVLICASDDRTCSQLRECIAVGAEAFLLRLYRKTFEK--DSKAEDVWMRF 
Oryctolagus cuniculus - XP_002711804.1             KESEVLGGPGQVLICASDDRTCSQLQGYLTAGAEAFLLGLYRQAFDK--DSRAEEVWARL 
Otolemur garnettii - XP_003802775.1                KESEALGGPGQVLICASDDRTCSQLRDYITLGTEAFLLRLYRKTFEK--DSKAKEVWMKF 
Ovis aries - XP_004021225.1                        KESEVLGGPGQVLICASDDRTCSQLREYLTVGAEVFLLRLYRKTFEK--DSKAEDVWMRL 
Pan paniscus - XP_003832737.1                      KESEALGGPGQVLICASDDRTCSQLRDYITLGAEAFLLRLYRKTFEK--DSKAEEVWMKF 
Pan troglodytes - XP_510831.2                      KESEALGGPGQVLICASDDRTCSQLRDYITLGAEAFLLRLYRKTFEK--DSKAEEVWMKF 
Papio anubis - XP_003916616.1                      KESEALGGPGQVLICASDDRTCSQLRDYITLGAEAFLLRLYRKTFEK--DSKAEEVWMKF 
Pongo abelii - XP_002826187.1                      KESEALGGPGQVLICASDDRTCSQLRDYITLGAEAFLLRLYRKTYEK--DSKAEEVWMKF 
Saimiri boliviensis boliviensis - XP_003928795.1   QESEALGGPGQVLICASDDRTCSQLRDYLTLGVEAFLLRLYRKTFEK--DSKAEEVWMKL 
Sarcophilus harrisii - XP_003761738.1              NNSEALGGPGKVLICASDDRTCAQLREYLTIGAKTFLLKLYTKTFGK--D-KAGEVKMKF 
Sorex araneus - XP_004604386.1                     QESEALGGPGQVLICASDDRTCTQLREYLSCGAEAFLLRLYRKTFEKEKDGPAEEDWARF 
Trichechus manatus latirostris - XP_004373324.1    KESEALGGPGQVLICASDDRTCSQLREYITTGAEAFLLRLYRKTFEK--DSKAEEVWMKF 
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C. 
Homo sapiens - NP_005227.1                         RKEDSSKRIRKSHKRPKDPQNKERASTKE-RTLKKKKRKLTLTQMVGKPE-ELEEEGDVE 
Ailuropoda melanoleuca - XP_002918113.1            RHEDGPKRMAKSNKRPKDPQNKQRAATKE-RTLKKKKRRLTLTQMMGKSE-EPEEEGDVK 
Bos taurus - NP_001192289.1                        RKEDDSKRIMKSSKRPKDLRDKDRPPAKE-KALRKKKPRLTLTQMMGRTE-ELEGEAGVE 
Callithrix jacchus - XP_002755959.2                RKEDSSNRIMKSHRRPKDPQNKERASTKQ-RTLKKKKRKLTLTQMVGKSE-ELEGEGDVE 
Canis lupus familiaris - XP_536967.3               RHEDSPKRMARSNKRPKDPQNKQRAATKE-RTLKKKKRRLTLTQMVGKSE-EPDEEQDVK 
Cavia porcellus - XP_003477812.1                   RKEDGSKRTIKSNKRPKDLQHKERGSIKE-RIPKKKKRRLTLTQMKGKSE-EVEEEEDVK 
Ceratotherium simum simum - XP_004441913.1         RKEDTSKRRMKSTKRPKDPQNKERTSTKE-KTRKKKKRKLTLTQMMGKSE-ELAEEGDAK 
Condylura cristata - XP_004692174.1                PREDCARRTTKARRRPADRPP------AQGRALKKKPRGLTLTQMVGAAG---PAGGDAP 
Cricetulus griseus - NP_001230961.1                RKGDGPKRTMKSDKRPKDTKNKERASTKKGAPK-RKKRELTLTQVMGTAEEP-PEEGAAE 
Dasypus novemcinctus - XP_004466678.1              RKEDNAKRRMKSNKRLKNPQNRERASTKE-RTLKKKRRRLTLTQMIGKSE-ELEAEPGIE 
Echinops telfairi - XP_004705920.1                 RKEDRSRRAMRANKRPKGHPSLERASGKG-RPLKRQKQRLTLPQMMGHPE-ELEGQGEAE 
Equus caballus - XP_001490470.2                    RQEDSSKRMAKSNKRPKDPHNKEKPSTKE-RTLRKKKRRLTLTQMIGKPE-ELEEEEDVK 
Felis catus - XP_003998897.1                       RNEDSAKRMAKSHKRPKDPHSKQRAAPKE-RTLKKKKRRLTLTQMIGKPE-EPEEEGDAK 
Gorilla gorilla gorilla - XP_004057285.1           RKEDSSKRIRKSHKRPKDPQNKERASTKE-RTLKKKKRKLTLTQMVGKPE-ELEEEGDVE 
Jaculus jaculus - XP_004652331.1                   RKDDSSKRPVKSHKRPKDTHNKDWASNKD-KALKRKRRRLTLTQMMGNSR-ELEGEGDVE 
Loxodonta africana - XP_003417763.1                RKEDSSKRIMKPNKRPKDPQNKERASNKE-RTLKRKKRRLTLTQMMANSE-EHEGEGKVE 
Macaca mulatta - XP_001107209.1                    RKEDSSKRIRKSHKRPKDPQNKERASAKE-RTLKKKKRKLTLTQMVGKPE-ELREEGDVE 
Monodelphis domestica - XP_001375532.1             KKEDNSKGNQKSSKESKVSKAKVRTSK---R-PPKKKQELTLAQMITKIEDESE------ 
Mus musculus - NP_056584.2                         RKGDGPKRTTKSDKRPKAAPNKERASAKRGAPLKRKKQELTLTQVLGSAEEP-PEDKALE 
Nomascus leucogenys - XP_004091351.1               RKEDSSKSIRKSHKRPKDPQNKEQSSTKE-RTLKKKKRKLTLTQMVGKPE-ELEEEGDVE 
Ochotona princeps - XP_004586829.1                 RKEDSSRRTRRSQKRPKDPPVKERPA-KE-RAGRKKKPKLTLTQMMGRPEDELEEEGEAE 
Octodon degus - XP_004644276.1                     RKEDGSKRTGKSNKRPKDLQHKEQSSLKE-RIPKKKKRRLTLTQMIGKSE-E---EEEVE 
Odobenus rosmarus divergens - XP_004408974.1       RCEDRPKRMAKSNKRPKDPPNKQRAATKE-RTLKKKKRRLTLTQMMRQSE-EPEEAGDVK 
Orcinus orca - XP_004270213.1                      RKEDGSKRIMKSNRRPKGLRNKDRASAKE-RAVKKKKPRLTLTQMMEQSE-ELEEEGGVE 
Oryctolagus cuniculus - XP_002711804.1             RKADGSSRTRRSDKRPRARA------ARE-RALKKKKPKLTLTQMVGKPEE-PAEEGDVE 
Otolemur garnettii - XP_003802775.1                RKEDSSREIMKSKKRPKNPQNKERSSTKG-RTLKKKKRRLTLTQMIEKSE-ELEEDGDVE 
Ovis aries - XP_004021225.1                        RKEDDSKRIMKSNKRPKDLQDKDRPPAKE-KALRKKKPRMTLTQMVGRAE-ALEGEAGAE 
Pan paniscus - XP_003832737.1                      RKEDSSKRIRKPHKRPKDPQNKERASTKE-RTLKKKKRKLTLTQMVGKPE-ELEEEGDVE 
Pan troglodytes - XP_510831.2                      RKEDSSKRIRKPHKRPKDPQNKERASTKE-RTLKKKKRKLTLTQMVGKPE-ELEEEGDVE 
Papio anubis - XP_003916616.1                      RKEDSSKRIRKSHKRPKDPQNKERASAKE-RTLKKKKRKLTLTQMVGKPE-ELREEGDVE 
Pongo abelii - XP_002826187.1                      RKEDSSKRIRKSHKRPKDPQNKERASTKE-RTLRKKKRKLTLTQMVGKPE-ELEEEGDVE 
Saimiri boliviensis boliviensis - XP_003928795.1   RKEDSSKRIMKSHKRPKDPQNKERASTKE-RTLKKKKRKLTLTQMVGKSE-ELEEEGDVQ 
Sarcophilus harrisii - XP_003761738.1              SKEDNSKGNLKSSKESKVSKAKIRTSK---KQRPTKKQELTLTQMVTKIEDEAE------ 
Sorex araneus - XP_004604386.1                     RKEDCARRGVKSGKGPKGRARAK-------ERTAKKKKKLTLTQMVAKTEEPEGEEGEAP 
Trichechus manatus latirostris - XP_004373324.1    RKEDNSKRIMKSNKRPKDPQNKEKASTKE-RTLKRKKRRLTLTQMMGNSE-EHKGEEQVE 
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D. 
Homo sapiens - NP_005227.1                         EVEPRYVVLYDAELTFVRQLEIYRASRPGKPLRVYFLIYGGSTEEQRYLTALRKEKEAFE 
Ailuropoda melanoleuca - XP_002918113.1            EVEPRYVVLYDAELTFVRQLEIYRASRPGKPLRVYFLIYGGSTEEQRYLTALRKEKEAFE 
Bos taurus - NP_001192289.1                        EVEPRYVVLYDAELTFVRQLEIYRASRPGKPLRVYFLIYGGSTEEQRYLTALRKEKEAFE 
Callithrix jacchus - XP_002755959.2                EVEPRYVVLYDAELTFVRQLEIYRASRPGKPLRVYFLIYGGSTEEQRYLTALRKEKEAFE 
Canis lupus familiaris - XP_536967.3               EVEPRYVVLYDAELTFVRQLEIYRASRPGKPLRVYFLIYGGSTEEQRYLTALRKEKEAFE 
Cavia porcellus - XP_003477812.1                   EVEPRYVVLYDAELTFVRQLEIYRASRPGKPLRVYFLIYGGSTEEQRYLTALRKEKEAFE 
Ceratotherium simum simum - XP_004441913.1         EVEPRYVVLYDAELTFVRQLEIYRASRPGKPLRVYFLIYGGSTEEQRYLTALRKEKEAFE 
Condylura cristata - XP_004692174.1                EVEPRYVVLYDAELTFVRQLEIYRASRPGRPLRVYFLIYGGSTEEQRYLTALRKEKEAFE 
Cricetulus griseus - NP_001230961.1                EVEPRYVVLYDAELTFVRQLEIYRASRPGKPLRVYFLIYGGSTEEQRYLTALRKEKEAFE 
Dasypus novemcinctus - XP_004466678.1              EMEPRYVVLYDAELTFVRQLEIYRASRPGKPLRVYFLIYGGSTEEQRYLTALRKEKEAFE 
Echinops telfairi - XP_004705920.1                 EVEPRYVVLYDADLTFVRQLEIYRASRPGKPLRVYFLIYGGSTEEQRYLTALRKEKEAFE 
Equus caballus - XP_001490470.2                    EVEPRYVVLYDAELTFVRQLEIYRASRPGKPLRVYFLIYGGSTEEQRYLTALRKEKEAFE 
Felis catus - XP_003998897.1                       EVEPRYVVLYDAELTFVRQLEIYRASRPGKPLRVYFLIYGGSTEEQRYLTALRKEKEAFE 
Gorilla gorilla gorilla - XP_004057285.1           EVEPRYVVLYDAELTFVRQLEIYRASRPGKPLRVYFLIYGGSTEEQRYLTALRKEKEAFE 
Jaculus jaculus - XP_004652331.1                   EVEPRYVVLYDAELTFVRQLEIYRASRPGKPLRVYFLIYGGSTEEQRYLTALRKEKEAFE 
Loxodonta africana - XP_003417763.1                EVEPRYVVLYDAELTFVRQLEIYRASRPGKPLRVYFLIYGGSTEEQRYLTALRKEKEAFE 
Macaca mulatta - XP_001107209.1                    EVEPRYVVLYDAELTFVRQLEIYRASRPGKPLRVYFLIYGGSTEEQRYLTALRKEKEAFE 
Monodelphis domestica - XP_001375532.1             EVEPRYVVLYDAELTFVRQLEIYRASRPGKPMRVYFLIYGGSTEEQRYLTALRKEKEAFE 
Mus musculus - NP_056584.2                         EVEPRYVVLYDAELTFVRQLEIYRASRPGKPLRVYFLIYGGSTEEQRYLTALRKEKEAFE 
Nomascus leucogenys - XP_004091351.1               EVEPRYVVLYDAELTFVRQXEIYRASRPGKPCRVYFLIYGGSTEEQRYLTALRKEKEAFE 
Ochotona princeps - XP_004586829.1                 EVEPRYVVLYDAELTFVRQLEIYRASRPGKPLRVYFLIYGGSTEEQRYLTALRKEKEAFE 
Octodon degus - XP_004644276.1                     EVEPRYVVLYDAELTFVRQLEIYRASRPGKPLRVYFLIYGGSTEEQRYLTALRKEKEAFE 
Odobenus rosmarus divergens - XP_004408974.1       EVEPRYVVLYDAELTFVRQLEIYRASRPGKPLRVYFLIYGGSTEEQRYLTALRKEKEAFE 
Orcinus orca - XP_004270213.1                      EVEPRYVVLYDAELTFVRQLEIYRASRPGKPLRVYFLIYGGSTEEQRYLTALRKEKEAFE 
Oryctolagus cuniculus - XP_002711804.1             EVEPRYVVLYDAELTFVRQLEIYRASRPGKPLRVYFLIYGGSTEEQRYLTALRKEKEAFE 
Otolemur garnettii - XP_003802775.1                EVEPRYVVLYDAELTFVRQLEIYRASRPGKPLRVYFLIYGGSTEEQRYLTALRKEKEAFE 
Ovis aries - XP_004021225.1                        EVEPRYVVLYDAELTFVRQLEIYRATRPGKPLRVYFLIYGGSTEEQRYLTALRKEKEAFE 
Pan paniscus - XP_003832737.1                      EVEPRYVVLYDAELTFVRQLEIYRASRPGKPLRVYFLIYGGSTEEQRYLTALRKEKEAFE 
Pan troglodytes - XP_510831.2                      EVEPRYVVLYDAELTFVRQLEIYRASRPGKPLRVYFLIYGGSTEEQRYLTALRKEKEAFE 
Papio anubis - XP_003916616.1                      EVEPRYVVLYDAELTFVRQLEIYRASRPGKPLRVYFLIYGGSTEEQRYLTALRKEKEAFE 
Pongo abelii - XP_002826187.1                      EVEPRYVVLYDAELTFVRQLEIYRASRPGKPLRVYFLIYGGSTEEQRYLTALRKEKEAFE 
Saimiri boliviensis boliviensis - XP_003928795.1   EVEPRYVVLYDAELTFVRQLEIYRASRPGKPLRVYFLIYGGSTEEQRYLTALRKEKEAFE 
Sarcophilus harrisii - XP_003761738.1              EVEPRYVVLYDAELTFVRQLEIYRASRPGKPMRVYFLIYGGSTEEQRYLTALRKEKEAFE 
Sorex araneus - XP_004604386.1                     ELEPRYVVLYDAELTFVRQLEIYRASRPGRPLRVYFLIYGGSTEEQRYLTALRKEKEAFE 
Trichechus manatus latirostris - XP_004373324.1    EVEPRYVVLYDAELTFVRQLEIYRAGRPGKPLRVYFLIYGGSTEEQRYLTALRKEKEAFE 
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E. 
Homo sapiens - NP_005227.1                         SETLPESEKYNPGPQDFLLKMPGVNAKNCRSLMHHVKNIAELAALSQDELTSILGNAANA 
Ailuropoda melanoleuca - XP_002918113.1            SDTLPESEKYNPGPQDFLLRMPGVNAKNCRTLMHHVKNIAELASLSQDKLAGILGNPGNA 
Bos taurus - NP_001192289.1                        SETLPEAEKYNPGPQDFLLKMPGINAKNCRSLMNHVKNIAELASLPFDELASMLGNTASA 
Callithrix jacchus - XP_002755959.2                SETLPESEKYNPGPQDFLLKMPGVNAKNCRSLMHHVKSIAELATLSQEELTSILGNAANA 
Canis lupus familiaris - XP_536967.3               SETLPESEKYNPGPQDFLLKMPGVNAKNCRALMHHVKNIAELASLSQDQLVGVLGNAGNA 
Cavia porcellus - XP_003477812.1                   SEALPESEKYNPGPQDFLLKMPGVNAKNCHSLMNHVKNIAELATLSQDKLTSILGHAANA 
Ceratotherium simum simum - XP_004441913.1         SETLPESEKYNPGPQDFLLKMPGVNAKNCRSLMSRVKNIAELASLSQDELAGILGNAAHA 
Condylura cristata - XP_004692174.1                SDTLPESDRYRPGPQDFLLKMPGVNAKNCHALMNQVGSLAELARLSQAELAAVLGNSANA 
Cricetulus griseus - NP_001230961.1                SETLPESDKYNPGPQDFVLKMPGINAKNCHSLMNHVKNIAELASLSQERLTSILGHAGNA 
Dasypus novemcinctus - XP_004466678.1              SETLPEAEKYNPGPQDFLLKMPGVNAKNRRSLMNHVKNIAELATLSQDKLTSILGNAANA 
Echinops telfairi - XP_004705920.1                 SATLPESEKYNPGPQDFLLKMPGISAKNCRALMTHVKNMVELATLSQERLTGILGNAANA 
Equus caballus - XP_001490470.2                    SETLPESEKYNPGPQDFLLKMPGVNAKNCRSLMNHVKTIAELASLSQDQLAGVLGNAANA 
Felis catus - XP_003998897.1                       SETLPESEKYNPGPQDFLLKMPGVNAKNCRALMHHVKNIAELASLSQDKLAGILGNASNA 
Gorilla gorilla gorilla - XP_004057285.1           SETLPESEKYNPGPQDFLLKMPGVNAKNCRSLMHHVKNIAELAALSQDELTSILGNAANA 
Jaculus jaculus - XP_004652331.1                   SETLPESEKYSPGPQDFLLKMPGVNAKNCRSLMNHVKNIAELATLPQDKLASILGNTGNA 
Loxodonta africana - XP_003417763.1                SETLPESEKYNPGPQDFLLKMPGVNAKNCRSLMNHVKNMAELATLSQDKLTSILGNAANA 
Macaca mulatta - XP_001107209.1                    SETLPESEKYNAGPQDFLLKMPGVNAKNCRSLMHHVKNIAELATLSQDKLTSILGNAANA 
Monodelphis domestica - XP_001375532.1             AETLPDSEKYNPGPQDFLLKMPGVNAKNCCSLMNHVKSIAELTTLSQDNLSSILGNAANA 
Mus musculus - NP_056584.2                         SETLPESDRYNPGPQDFVLKMPGVNAKNCRSLMNQVKNIAELATLSLERLTTILGHSGNA 
Nomascus leucogenys - XP_004091351.1               SEALPESEKYNPGPQDFLLKMPGVNAKNCRSLMHHVKNIAELTTLSQDKLASILGNAANA 
Ochotona princeps - XP_004586829.1                 SETLPESDKYNPGPQDFLLKMPGVNAKNCRSLMNRVKNIAELASLSQEELTSILGNAANA 
Octodon degus - XP_004644276.1                     SEALPESEKYNPGPQDFLLKMPGVNAKNCHSLMNHVKNIAELATLSQDKLTGILGHAANA 
Odobenus rosmarus divergens - XP_004408974.1       SETLPESEKYNPGPQDFLLKMPGVNAKNCRPLMQHVQNIAELASLSQDKLAGILGNAGNA 
Orcinus orca - XP_004270213.1                      SETLPEAEKYNPGPQDFLLKMPGVNAKNCRSLMTNIKNIAELASLSLDKLVLLLGNAANA 
Oryctolagus cuniculus - XP_002711804.1             SESLPESEKYNPGPQDFLLKMPGVNAKNCRSVMNHVKNIAELATLSQDELARILGNAVNA 
Otolemur garnettii - XP_003802775.1                SETLPESDKYNPGPQDFLLKMPGVNAKNCRSLMNHVKNIAELATLSQDKLSSVLGNAANA 
Ovis aries - XP_004021225.1                        SETLPEAEKYNPGPQDFLLKMPGINAKNCHSLMNHVKNIAELASLSFDKLASMLGNTASA 
Pan paniscus - XP_003832737.1                      SETLPESEKYNPGPQDFLLKMPGVNAKNCRSLMHHVKNIAELAALSQDELTSILGNAANA 
Pan troglodytes - XP_510831.2                      SETLPESEKYNPGPQDFLLKMPGVNAKNCRSLMHHVKNIAELAALSQDELTSILGNAANA 
Papio anubis - XP_003916616.1                      SETLPESEKYNAGPQDFLLKMPGVNAKNCRSLMHHVKNIAELATLSQDKLTSILGNAANA 
Pongo abelii - XP_002826187.1                      SETLPESEKYNPGPQDFLLKMPGVNAKNCRSLMHHVKNIAELATLSQDELTSILGNAANA 
Saimiri boliviensis boliviensis - XP_003928795.1   SETLPESEKYNPGPQDFLLKMPGVNAKNCRSLMHHVKSIAELATLSQEELTSILGNAANA 
Sarcophilus harrisii - XP_003761738.1              TETLPDSEKYNPGPQDFLLKMPGVNAKNCCSLMNHVKSIAELTTLSQDKLSSILGNAANA 
Sorex araneus - XP_004604386.1                     SDTLPESDRYNPGPQDFLLRMPGVSAKNCRALMNRVRSIAELAGLSQAQLADVLGNAASA 
Trichechus manatus latirostris - XP_004373324.1    SETLPESEKYNPGPQDFLLKMPGVNAKNCRSLMNHVKNIAELATLAQDKLTSILGNAANA 
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Appendix 25- Alignment of 300 base pairs in the 5’UTR of ERCC4 (5’ of exon1 highlighted in grey; start of ORF highlighted in green). A heptamer sequence 
(TTCGGC(C/T)) is seen repeated ten times in Homo sapiens (yellow), with apparent varying conservation between several species. Rs1799797 was found in 
the final nucleotide of the penultimate repeat in humans (blue). A common key is given in Appendix 21. A list of common species names is given in Appendix 
20. 
Homo sapiens - NG_011442.1                         GTGACTC-----------CATGAATCTTCGGCTCCACTCGGCTCTTCTTCGGCTGAGTTC 
Bos taurus - AC_000182.1                           CGGACTC-----------CACGAATCTTCGATTCTTCTAGGTTCCTCTTCGGCTGCGTTC 
Callithrix jacchus - NC_013907.1                   GTGACTC-----------TACGAACCTTCGGCTCCACTCGGCTCCTCTTCGGCTGAGTTC 
Dasypus novemcinctus - NW_004482259.1              GAATCTT-----------CGGCCCGCGCGCTTTCGGATTCGGCCTTCTTCGGCTTCCTTC 
Equus caballus - NC_0091562                        GTGGCTC-----------TATTAATCTTCGGCTCTGCTCGGCTCCTCTTCGTCTGTGTTC 
Gorilla gorilla gorilla - NC_018440.1              GTGACTC-----------TATGAATCTTCGGCTCCACTCGGCTCTTCTTCGGCTGAGTTC 
Oryctolagus cuniculus - NC_013674.1                CTCTTCG-----------GATCATCCTCTTCTCGGCCTCGGCTCCTTTTCGGCTATTTCC 
Otolemur garnettii - NW_0038526652                 TTAACTTTTTCCGTTTTTGATGTCCTTCGGGTTACTCCCCTCTCCTTGGTGGATGGTGGC 
Pan paniscus - NW_00870645.1                       GTGACTC-----------TATGAATCTTCGGCTCCACTCGGCTCTTCTTCGGCTGAGTTC 
Pan troglodytes - NC_006483.3                      GTGACTC-----------TATGAATCTTCGGCTCCACTCGGCTCTTCTTCGGCTGAGTTC 
Pongo abelii - NC_012607.1                         GTGACTC-----------TATGAATCTTCGGCTCCACTCGGCTCTTCTTCGGCTGAGTTC 
Saimiri boliviensis boliviensis - NW_003943634.1   GTGACTC-----------TACGAACCTTCGGCTCTACTCGTCTTCTCTTCGGCTGAGTTC 
Trichechus manatus latirostris - NW_004443960.1    GTGACTT-----------TGCGAATCTTTAGC---TCTCGGCTTCTCTTCGGCTGCGTTC 
                                                                      .                .        *    * .*     * 
Homo sapiens - NG_011442.1                         GGCCAACGCTTGCCTTCTCAGGCTCGGCTCTCTTCGGCTTTCTGAGAGCGC-GCCTGTCG 
Bos taurus - AC_000182.1                           GGCCGGCTCCCGTCCTGTCGGGCTCGGCTCTCTTCGGCTACGTTCGGCGGC-TTTCGTCC 
Callithrix jacchus - NC_013907.1                   GGCCGACGCTTGCCTCCTCAAGCTCGGCTCTCTTCGGCTTTCTGAGAGCAC-GCTCGTCC 
Dasypus novemcinctus - NW_004482259.1              GGCCAGAGCGAGACTTCTCGGCCTCGGCTCTCTTCGGCCGTCTTTGGCCAGCGCTCGTCC 
Equus caballus - NC_0091562                        GGCCAGCGCTCGCCTTCTCGGGCTCGGCTCTCTTCGGCTTCCTTCGGCCAG-CGCGCGCC 
Gorilla gorilla gorilla - NC_018440.1              GGCCAACGCTTGCCTTCTCAGGCTCGGCTCTCTTCGGCTTTCTGAGAGCGC-GCCTGTCG 
Oryctolagus cuniculus - NC_013674.1                GGCTATCTCTCGTCTCCTCAGAACCGGCGCTCCTCGGCCGCCTTCGGTCTC--GCTCGTC 
Otolemur garnettii - NW_0038526652                 AGGCGGAGGAGGTGTAG--AGCGCCCGAGGACTTGGAAGCACAGAAACAGGGTTCAGGCC 
Pan paniscus - NW_00870645.1                       GGCCAACGCTTGCCTTCACAGGCTCGGCTCTCTTCGGCTTTCTGAGAGCGC-GCCTGTCG 
Pan troglodytes - NC_006483.3                      GGCCAACGCTTGCCTTCTCAGGCTCGGCTCTCTTCGGCTTTCTGAGAGCGC-GCCTGTCG 
Pongo abelii - NC_012607.1                         GGCCAACGCTCCCCTTCTCAGGTTCGGCTCTCTTCGGCTTTCTGAGAGCGC-GCCTGTCC 
Saimiri boliviensis boliviensis - NW_003943634.1   GGCCGAAGCTTGCCTTCTCAGGCTCGGCTGTCTTCGGCTTTCTGAGAGCAA-GCTCGTCC 
Trichechus manatus latirostris - NW_004443960.1    GGCCCGCGCTCGTCT---CAAACTCGGCTCTTTT-------------------------- 
                                                   .*    .            ..   * *.  :  *                           
Homo sapiens - NG_011442.1                         TGGCCTCGGCTCCTCTTCGGCTGCGTTCGGCCCACGAT---------------------- 
Bos taurus - AC_000182.1                           ------------------------------------------------------------ 
Callithrix jacchus - NC_013907.1                   TGGTCTCGGCTCCTCTTCGGCTGCGTTCGCCCCACGAT---------------------- 
Dasypus novemcinctus - NW_004482259.1              CCTGTTCGACTCCTCTTCGGCTTCCTTCGGCCGGCGCT---------------------- 
Equus caballus - NC_0091562                        TTC--------------------------------------------------------- 
Gorilla gorilla gorilla - NC_018440.1              TGGCCTCGGCTCCTCTTCGGCTGCGTTCGGCCCACGAT---------------------- 
Oryctolagus cuniculus - NC_013674.1                AGGACTCGGCTCCTCTTCGGCTGCGTTCAGCCCGCCCTCTCGGGGTCGGCTTTCTTCGGG 
Otolemur garnettii - NW_0038526652                 TGC--AGGAGACAACCGCGGGTCGG-TAGCTCCAGCAT------------------CGCG 
Pan paniscus - NW_00870645.1                       TGGCCTCGGCTCCTCTTCGGCTGCGTTCGGCCCACGAT---------------------- 
Pan troglodytes - NC_006483.3                      TGGCCTCGGCTCCTCTTCGGCTGCGTTCGGCCCACGAT---------------------- 
Pongo abelii - NC_012607.1                         TGGCCTCGGCTCCTCTTCGGCTGCGTTCGGCCCACGAT---------------------- 
Saimiri boliviensis boliviensis - NW_003943634.1   TGGCCTCGGCTCCTCTTCGGCTGCATTCGCCCCACGAT---------------------- 
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Trichechus manatus latirostris - NW_004443960.1    -----------------CGTCTGCGTTCGGCCGGTGCT---------------------- 
Homo sapiens - NG_011442.1                         ----CA----TCTCAGTCTCAGCTCTCCTCGGCTACGTTCGGCTGGCT-GCCGTCCTCTC 
Bos taurus - AC_000182.1                           --------------GGACTCGGCTCCCTT--------------------------CGGCC 
Callithrix jacchus - NC_013907.1                   ----CG----TCTCAGTCTCGGCTCTCCTTGGCTTTTTTCGGCTGGAT-TTCGTCCTTTC 
Dasypus novemcinctus - NW_004482259.1              ----CGTTTTTC--GGGCTCGGCTCTCTTCG---GCTATCTTCGGCCA-AAGCTCGTCTG 
Equus caballus - NC_0091562                        ------------TCGGGCTCGGCTCTCTTCGGCTCCCTTCG---GCTT-ACGTTCGTCTC 
Gorilla gorilla gorilla - NC_018440.1              ----CT----TCTCAGTCTCAGCTCTCCTCGGCTACGTTTGGCTGGCT-GCCGTCCTCTC 
Oryctolagus cuniculus - NC_013674.1                TGATTCTCGTCACGGCCTCGGCTCCTCTTCGGCTGCGGTCGGTCGGCTATCGTCGGATCC 
Otolemur garnettii - NW_0038526652                 CGGAGGGCCTATGAATCTTCGGCTCCACTCGGCTCCACTCGGCT-----CCACTCGGCTC 
Pan paniscus - NW_00870645.1                       ----CA----TCTCAGTCTCAGCTCTCCTCGGCTACGTTCGGCTGGCT-GCCGTCCTCTC 
Pan troglodytes - NC_006483.3                      ----CA----TCTCAGTCTCAGCTCTCCTCGGCTACGTTCGGCTGGCT-GCCGTCCTCTC 
Pongo abelii - NC_012607.1                         ----CA----TCTCAGTCTCGGCTCTCCTCGGCTACGTTCGGCTGGCT-GTCGTTCTCTC 
Saimiri boliviensis boliviensis - NW_003943634.1   ----CG----TCTCAGTCTCGGCTCTCCACGGCTGCGTTCGACTATAT-TTCGTTGTCTC 
Trichechus manatus latirostris - NW_004443960.1    ----CCACTTACCGGACCTGTTTTCTCTTCG---GCTCCGTTCGGCCT-ACGTTAGTCTC 
                                                                 .         * . :                                
Homo sapiens - NG_011442.1                         GGACTCGGCTCTCTTCGGTTGAGTTCGGCCTAC---TCTCCACTAGGAGT---------- 
Bos taurus - AC_000182.1                           ACACTCGGCTCTCTTCGGCATGGTCCGGCCCAC---TCTCGTCTCAGACT---------- 
Callithrix jacchus - NC_013907.1                   GGACTCGGCTCTCTTCGGTTAAGTTCGGCCTAC---TCTCGTCTCGGACT---------- 
Dasypus novemcinctus - NW_004482259.1              GGCTCGGTTCCTCTTCGGCTCCCTTCGGCCGAC---GCTCGCCTCGGACT---------- 
Equus caballus - NC_0091562                        AGCCTCGGCTCTCTTCGGCTCCCCTCGGCTTAC---GCTCGTCCGGGTTT---------- 
Gorilla gorilla gorilla - NC_018440.1              GGACTCGGCTCTCTTCGGTTGAGTTCGGCCTAC---TCTGCACTGGGAGT---------- 
Oryctolagus cuniculus - NC_013674.1                GACTCGGGTGCTCTTCGGCTGCGTTCGGCCCGT---GCTCGTCTCGGACT---------- 
Otolemur garnettii - NW_0038526652                 CACTCGGCTCCTCTTCGGCTGAGTTCGGCCGGCCTTCGTCCTCTCCGACTCGGCTTTCCT 
Pan paniscus - NW_00870645.1                       GGACTCGGCTCTCTTCGGTTGAGTTCGGCCTAC---TCTCCACTCGGAGT---------- 
Pan troglodytes - NC_006483.3                      GGACTCGGCTCTCTTCGGTTGAGTTCGGCCTAC---TCTCCACTCGGAGT---------- 
Pongo abelii - NC_012607.1                         GGACTCGGCTCTCTTCGGTACAGTTCGGCCTAC---TCTCATCTCGGAGT---------- 
Saimiri boliviensis boliviensis - NW_003943634.1   GGACTCGGCTGTCTTCGGTTAAGTTCGGCCAAC---TCTCGTCTCGGACT---------- 
Trichechus manatus latirostris - NW_004443960.1    GGACTCGGCTCTCTTCGGTTGCGTTCGGCCCAC---GCTCGTCTCAGACT---------- 
                                                     .   *    ******* :     ****  .      *   *   *: *           
Homo sapiens - NG_011442.1                         CGGCTTCCTTCGGCTGCGTTCGGCTGC-GACCCGGAAGAGCTTCCATG 
Bos taurus - AC_000182.1                           CGGCTTCCTTCGGCTACGTTTCGCCGCCGCCCCGGAAGGGCGCCCATG 
Callithrix jacchus - NC_013907.1                   CGGCTCCTTTCGGCTGCATTCGGCTGC-GCCCCGGAAGAGCCTCCATG 
Dasypus novemcinctus - NW_004482259.1              CGGCTCTCTTCGGCTACGTTCGGCCGCGGCCCCGGAAGGGCGTGCATG 
Equus caballus - NC_0091562                        CGGCTCTCTTCGGCTGCGTTCGGCCGCGGCCCCGGAAGGGCGCCCATG 
Gorilla gorilla gorilla - NC_018440.1              CGGCTTCCTTCGGCTGCGTTCGGCTGC-GACCCGGAAGAGCTTCCATG 
Oryctolagus cuniculus - NC_013674.1                CG----------GCTCTCTCCGGCTGCGGCCCCGGAAGAGCGCCCATG 
Otolemur garnettii - NW_0038526652                 CGGCGACGTTCGGCTGCGTTCG-GCGGCGCCCCGGAAGAGCTTCCATG 
Pan paniscus - NW_00870645.1                       CGGCTTCCTTCGGCTGCGTTCGGCTGC-GACCCGGAAGAGCTTCCATG 
Pan troglodytes - NC_006483.3                      CGGCTTCCTTCGGCTGCGTTCGGCTGC-GACCCGGAAGAGCTTCCATG 
Pongo abelii - NC_012607.1                         CGGCTTCCTTCGGCTGCGTTCGGCCGC-GACCCGGAAGAGCTTCCATG 
Saimiri boliviensis boliviensis - NW_003943634.1   CGG--------------------CTAC-GCCCCGGAAGAGCCTCCATG 
Trichechus manatus latirostris - NW_004443960.1    CGGCTCTCTTCGGCTACGTTAGGCCGCGGACCCGGAAGAGCATCCATG 
                                                   **                       .  *.********.**   **** 
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Appendix 26  
Two additional repeats of UV spot test treatment of UVER proficient strains. 
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Appendix 27 
Two additional repeats of UV spot test treatment of J129 and constructed uve1Δ-rad16 strains 
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Appendix 28 
Two additional repeats of MMS spot test treatment of UVER proficient strains. No treatment plates are the same as given in Appendix 26. 
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Appendix 29 
Two additional repeats of HU spot test treatment of UVER proficient strains. No treatment plates are the same as given in Appendix 26. 
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Appendix 30 
Percentage overall survival, normalised to rad16+, of strains treated with 1mM of oxaliplatin in 
comparison to survival of untreated control. Experiment 2 has been omitted due to outlying data. 
     Experiment 
  Strains 1 3 4 Average SD 
Percentage 
survival 
normalised to 
rad16+ (%) 
rad16+ 100 100 100 100 0 
rad16Δ 6.91 29.62 13.64 16.72 11.66 
rad16-Pro361Ser 55.17 50.27 33.16 46.20 11.56 
rad16-Arg399Gln 36.83 46.5 39.9 41.08 4.94 
rad16-Arg548Thr 39.37 28.73 43.1 37.07 7.46 
rad16-Ser585X 3.08 8.08 9.43 6.86 3.35 
rad16-Glu844Gly 72.03 58.17 48.32 59.51 11.91 
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Appendix 31 
Percentage overall survival, normalised to uve1Δ-rad16+, of strains treated with ‘dose one’ of 
UV treatment (Table 7.1) in comparison to survival of untreated control plates. 
  Experiment   
 Strains 1 2 3 Average SD 
Dose 1 
uve1Δ-rad16+ 100 100 100 100 0 
uve1Δ-rad16Δ 0.020 0.000 0.007 0.009 0.010 
uve1Δ-rad16-Pro361Ser 127.056 78.505 92.387 99.316 25.006 
uve1Δ-rad16-Arg399Gln 95.923 123.540 106.612 108.692 13.926 
uve1Δ-rad16-Arg548Thr 141.344 116.735 82.207 113.429 29.707 
uve1Δ-rad16-Ser585X 0.016 0.002 0.003 0.007 0.008 
uve1Δ-rad16-Glu844Gly 79.377 82.995 89.149 83.840 4.940 
 
Appendix 32 
Percentage overall survival, normalised to uve1Δ-rad16+, of strains treated with ‘dose two’ of 
UV treatment (Table 7.1) in comparison to survival of untreated control plates. 
  Experiment   
 Strains 1 2 3 Average SD 
Dose 2 
uve1Δ-rad16+ 100 100 100 100 0 
uve1Δ-rad16Δ 0.131 0 0.005 0.045 0.074 
uve1Δ-rad16-Pro361Ser 195.889 38.113 118.540 117.514 78.893 
uve1Δ-rad16-Arg399Gln 144.957 57.624 61.185 87.922 49.426 
uve1Δ-rad16-Arg548Thr 99.667 105.492 71.272 92.143 18.309 
uve1Δ-rad16-Ser585X 0.029 0.002 0.003 0.011 0.015 
uve1Δ-rad16-Glu844Gly 87.556 40.598 21.738 49.964 33.894 
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Appendix 33 
Dunlop MG, Dobbins SE, Farrington SM, Jones AM, Palles C, Whiffin N, Tenesa A, 
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L, Grimes G, Gorman M, Semple C, Ma YP, Barclay E, Prendergast J, Cazier JB, 
Olver B, Penegar S, Lubbe S, Chander I, Carvajal-Carmona LG, Ballereau S, Lloyd 
A, Vijayakrishnan J, Zgaga L, Rudan I, Theodoratou E; Colorectal Tumour Gene 
Identification (CORGI) Consortium, Starr JM, Deary I, Kirac I, Kovacević D, Aaltonen 
LA, Renkonen-Sinisalo L, Mecklin JP, Matsuda K, Nakamura Y, Okada Y, Gallinger 
S, Duggan DJ, Conti D, Newcomb P, Hopper J, Jenkins MA, Schumacher F, Casey 
G, Easton D, Shah M, Pharoah P, Lindblom A, Liu T; Swedish Low-Risk Colorectal 
Cancer Study Group, Smith CG, West H, Cheadle JP; COIN Collaborative Group, 
Midgley R, Kerr DJ, Campbell H, Tomlinson IP, Houlston RS (2012). Common 
variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. 
Nat Genet.; 44(7): pp 770-776 
Appendix 34 
Smith CG, West H, Harris R, Idziaszczyk S, Maughan TS, Kaplan R, Richman S, 
Quirke P, Seymour M, Moskvina V, Steinke V, Propping P, Hes FJ, Wijnen J, 
Cheadle JP (2013). Role of the Oxidative DNA Damage Repair Gene OGG1 in 
Colorectal Tumorigenesis. J Natl Cancer Inst ; 105(16): pp 1249-1253 
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